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Abstract 
The Ketogenic diet (KD) is an alternative treatment option for people with drug-resistant 
epilepsy. It can reduce seizure frequency, but it is resource-intensive and may cause 
adverse side effects. Predictors of response – which, in the absence of specific metabolic 
disorders, are unknown – would improve patient selection and may enhance 
understanding of how the KD exerts its antiseizure effect. This project is concerned with 
identifying possible genetic markers of response to the KD. DNA was extracted from 
capillary blood taken from individuals who were following the KD for their epilepsy, or who 
had done so in the past. Individuals were classed as responders if they achieved ≥50 seizure 
reduction. Response was classified at various follow-up points, as well as a summary of 
response over time. Association studies were conducted using candidate gene (KCNJ11 and 
BAD) sequencing, genome-wide single nucleotide polymorphism array, and whole exome 
sequencing data to determine whether there was an over-representation of specific gene 
variants in KD responders, compared to non-responders.  
Common variation in KCNJ11 and BAD was not significantly associated with KD response. 
rs12204701 reached significance in the array-based genome-wide association study 
including common variants, with 3-month diet response as the phenotype. No significant 
results were obtained when summary diet response was taken as the phenotype. Using the 
gene-based c-alpha test with the exome sequencing data, including all exonic and splicing 
variants, ANKRD36C reached significance; using a pathway-based count of case-unique 
alleles test, the ‘ERBB1 Internalisation’ pathway reached significance. No further significant 
results were obtained from the exome sequencing data when using other gene- and 
pathway-based tests or when variants were further filtered according to predicted 
functional consequence. Other genes with large differences in responder/non-responder 
minor or alternative allele counts are also of interest. It is unknown how these may 
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contribute to variability in KD response. Some common themes were identified amongst 
the genes and pathways of significance and suggestive significance: cell cycling, apoptosis, 
glucose homeostasis, neurological processes and triglyceride biosynthesis. It is biologically 
plausible that these processes influence KD response, although it is likely that many genes 
play a role. 
A larger sample size is needed in order to improve power to detect genotypic-phenotypic 
associations and increase confidence in the importance of the genes of interest. 
  
7 
 
Table of Contents 
Declaration ....................................................................................................................................... 2 
Statement of contribution ................................................................................................................. 3 
Abstract ............................................................................................................................................ 5 
List of Tables ....................................................................................................................................14 
List of Figures ...................................................................................................................................16 
List of abbreviations .........................................................................................................................19 
Acknowledgements ..........................................................................................................................22 
1 Background: Epilepsy, the Ketogenic diet and Genetics ............................................................23 
1.1 Epilepsy ............................................................................................................. 23 
 Definitions ................................................................................................................23 1.1.1
 Burden ......................................................................................................................24 1.1.2
 Treatment and management .....................................................................................25 1.1.3
1.2 The Ketogenic diet and Epilepsy ......................................................................... 27 
 The Ketogenic diet – clinical reports of effectiveness .................................................30 1.2.1
 Effects of the Ketogenic diet beyond seizure frequency .............................................40 1.2.2
 Tolerability ................................................................................................................42 1.2.3
 Retention ..................................................................................................................43 1.2.4
 Biochemical response to the Ketogenic diet and putative mechanisms of 1.2.5
action 46 
 Are we able to predict response to the Ketogenic diet? .............................................66 1.2.6
1.3 The Ketogenic diet and Genetics ........................................................................ 78 
 Differential response to the Ketogenic diet ...............................................................79 1.3.1
 Differential regulation of gene expression .................................................................83 1.3.2
1.4 Research questions and hypotheses .................................................................. 92 
2 Methodology ............................................................................................................................95 
2.1 Ethics and recruitment ....................................................................................... 95 
8 
 
2.2 Phenotypic data collection ................................................................................. 99 
2.3 Genotypic data collection ................................................................................ 101 
 Research questions 1 and 2 .....................................................................................101 2.3.1
 Research question 3 ................................................................................................104 2.3.2
3 Phenotypic results ..................................................................................................................107 
3.1 Introduction..................................................................................................... 107 
3.2 Methods .......................................................................................................... 109 
3.3 Results ............................................................................................................. 112 
 An overview ............................................................................................................112 3.3.1
 Compliance .............................................................................................................117 3.3.2
 Ketogenic diet response: seizure frequency at specific follow-up points ..................119 3.3.3
 Factors beyond seizure frequency ...........................................................................123 3.3.4
 Ketogenic diet response over time ..........................................................................125 3.3.5
 Factors affecting Ketogenic diet response ...............................................................128 3.3.6
3.3.6.1 Demographic and clinical parameters ................................................... 128 
3.3.6.2 Epilepsy syndrome or cause ................................................................. 133 
3.3.6.3 Biochemical parameters ....................................................................... 134 
 Use of phenotypic data for genetic analyses ............................................................136 3.3.7
3.4 Discussion ........................................................................................................ 138 
 Cohort demographics ..............................................................................................139 3.4.1
 Compliance .............................................................................................................140 3.4.2
 Diet response ..........................................................................................................143 3.4.3
 Factors affecting Ketogenic diet response ...............................................................148 3.4.4
 Factors beyond seizure frequency ...........................................................................149 3.4.5
 Conclusion ..............................................................................................................151 3.4.6
4 Candidate gene analysis .........................................................................................................153 
4.1 Introduction..................................................................................................... 153 
9 
 
 The candidate gene approach .................................................................................153 4.1.1
 Candidate genes: background information ..............................................................156 4.1.2
 Rationale for selection of candidate genes ..............................................................160 4.1.3
4.2 Methods .......................................................................................................... 163 
 Phenotypic data ......................................................................................................163 4.2.1
 Genetic data ...........................................................................................................165 4.2.2
4.2.2.1 Quality control ..................................................................................... 167 
4.2.2.2 Association analysis .............................................................................. 167 
4.2.2.3 Population structure ............................................................................ 169 
4.2.2.4 Information on variants found .............................................................. 170 
 Power calculations ..................................................................................................171 4.2.3
4.3 Results ............................................................................................................. 172 
 Quality control ........................................................................................................172 4.3.1
 Common variation in KCNJ11 and BAD ....................................................................172 4.3.2
4.3.2.1 Overview .............................................................................................. 172 
4.3.2.2 Population genetics .............................................................................. 178 
 Association analysis .................................................................................................180 4.3.3
 Previously unreported variants or SNPs with minor allele frequency <0.01 ..............182 4.3.4
 Haplotype analyses .................................................................................................187 4.3.5
 Power calculations ..................................................................................................187 4.3.6
4.4 Discussion ........................................................................................................ 189 
 Potential consequences of SNPs with lowest p-values .............................................192 4.4.1
 Rare and novel variation in KCNJ11 and BAD ...........................................................196 4.4.2
 Conclusions and future work ...................................................................................196 4.4.3
5 Common genetic variation and response to the Ketogenic diet: a Genome-wide 
Association Study ...........................................................................................................................198 
5.1 Introduction..................................................................................................... 198 
 The genome-wide association study approach ........................................................198 5.1.1
10 
 
 Quality control ........................................................................................................199 5.1.2
 Population stratification ..........................................................................................201 5.1.3
 The multiple testing burden ....................................................................................202 5.1.4
 Interpreting results .................................................................................................203 5.1.5
 Alternative approaches to the single-SNP method ...................................................204 5.1.6
5.2 Methods .......................................................................................................... 209 
 Phenotypic data ......................................................................................................209 5.2.1
 Genetic data ...........................................................................................................210 5.2.2
 Quality control ........................................................................................................213 5.2.3
5.2.3.1 Per-individual quality control exclusion criteria .................................... 213 
5.2.3.2 Per-SNP quality control exclusion criteria ............................................. 215 
 Covariates and population structure .......................................................................216 5.2.4
 GWAS......................................................................................................................221 5.2.5
 Correction for multiple testing ................................................................................221 5.2.6
 Visualisation of GWAS results ..................................................................................222 5.2.7
 Power calculations ..................................................................................................224 5.2.8
 Gene- and pathway-based analyses.........................................................................224 5.2.9
5.3 Results ............................................................................................................. 226 
 Quality control ........................................................................................................226 5.3.1
 Covariates and population structure .......................................................................227 5.3.2
 Correction for multiple testing ................................................................................229 5.3.3
 GWAS results ..........................................................................................................229 5.3.4
 Power calculations ..................................................................................................234 5.3.5
 Gene- and pathway- based analyses ........................................................................236 5.3.6
5.4 Discussion ........................................................................................................ 246 
 Significant results ....................................................................................................246 5.4.1
 Potential sources of error ........................................................................................249 5.4.2
11 
 
5.4.2.1 Phenotypic ........................................................................................... 249 
5.4.2.2 Genotypic ............................................................................................. 250 
 SNPs of suggestive significance................................................................................252 5.4.3
 Gene- and pathway-based analyses.........................................................................254 5.4.4
 Conclusions and future work ...................................................................................259 5.4.5
6 Rare genetic variation and response to the Ketogenic diet: Illumina exome chip ....................261 
6.1 Introduction..................................................................................................... 261 
 The common disease/rare variant hypothesis .........................................................261 6.1.1
 Variant prioritisation: variant class ..........................................................................262 6.1.2
 Variant prioritisation: bioinformatics tools ..............................................................268 6.1.3
 Extreme phenotypes ...............................................................................................272 6.1.4
6.2 Methods .......................................................................................................... 273 
 Phenotypic data ......................................................................................................273 6.2.1
 Genetic data ...........................................................................................................275 6.2.2
 Quality control and variant filtering .........................................................................275 6.2.3
 Covariates and population structure .......................................................................279 6.2.4
 Association analyses................................................................................................279 6.2.5
 Gene- and pathway-based analyses.........................................................................280 6.2.6
6.3 Results ............................................................................................................. 281 
 Quality control and variant filtering .........................................................................281 6.3.1
 Association analyses................................................................................................282 6.3.2
6.3.2.1 Single variant approach ........................................................................ 282 
6.3.2.2 Gene and pathway-based approaches .................................................. 286 
6.4 Discussion ........................................................................................................ 287 
 Power: study design and variant prioritisation .........................................................288 6.4.1
 Results of interest ...................................................................................................292 6.4.2
 Rare variant detection with arrays versus sequencing .............................................296 6.4.3
 Rare variant/common disease hypothesis ...............................................................298 6.4.4
12 
 
 Conclusions and future work ...................................................................................299 6.4.5
7 Exonic variation and response to the Ketogenic diet: whole exome sequencing......................301 
7.1 Introduction..................................................................................................... 301 
 Accurate variant detection ......................................................................................303 7.1.1
7.1.1.1 Avoiding errors generated in the library ............................................... 304 
7.1.1.2 Avoiding base-calling error ................................................................... 304 
7.1.1.3 Avoiding alignment (or mapping) error ................................................. 305 
7.1.1.4 Calling variants ..................................................................................... 306 
7.1.1.5 Variant filtering .................................................................................... 310 
 Strategies for identifying susceptibility variants or genes in exome 7.1.2
sequencing data .....................................................................................................................311 
 Pathway analysis .....................................................................................................317 7.1.3
 Population stratification ..........................................................................................318 7.1.4
 Interpretation and utility of results..........................................................................320 7.1.5
7.2 Methods .......................................................................................................... 321 
 Phenotypic data ......................................................................................................321 7.2.1
 Genotypic data ........................................................................................................327 7.2.2
7.2.2.1 Quality control ..................................................................................... 329 
7.2.2.2 Per-variant quality control .................................................................... 329 
7.2.2.3 Per-individual quality control................................................................ 330 
 Population structure ...............................................................................................336 7.2.3
 Association analyses................................................................................................337 7.2.4
7.2.4.1 Single variant approach ........................................................................ 337 
7.2.4.2 Gene-based approach .......................................................................... 337 
7.2.4.3 Correction for multiple testing ............................................................. 341 
7.2.4.4 Pathway-based analysis ........................................................................ 341 
7.3 Results ............................................................................................................. 342 
 Quality control and population structure.................................................................342 7.3.1
 Association studies ..................................................................................................346 7.3.2
7.3.2.1 Single variant approach ........................................................................ 346 
13 
 
7.3.2.2 Gene-based approach .......................................................................... 348 
7.3.2.3 Pathway analyses ................................................................................. 358 
7.4 Discussion ........................................................................................................ 360 
 An overview of strategies adopted to increase power .............................................361 7.4.1
 Potential sources of error ........................................................................................364 7.4.2
 Results of interest ...................................................................................................368 7.4.3
7.4.3.1 Single variant and gene-based approach .............................................. 368 
7.4.3.2 Pathway-based approach ..................................................................... 373 
 Conclusions and future work ...................................................................................378 7.4.4
8 Conclusions, study limitations and future work.......................................................................380 
8.1 Conclusions...................................................................................................... 380 
 Comments on phenotypic results ............................................................................380 8.1.1
 Comments on genotypic results ..............................................................................382 8.1.2
8.2 Study limitations .............................................................................................. 392 
 Classification of KD response ...................................................................................392 8.2.1
 Compliance to treatment ........................................................................................393 8.2.2
 Prospective versus retrospective recruitment .........................................................394 8.2.3
 Sample size .............................................................................................................395 8.2.4
 Population structure ...............................................................................................396 8.2.5
 Replicates and batch effect .....................................................................................397 8.2.6
8.3 Future work ..................................................................................................... 397 
 Continuing recruitment and further analyses ..........................................................397 8.3.1
 Gene expression analyses........................................................................................399 8.3.2
 Follow-up studies ....................................................................................................400 8.3.3
 Clinical translation ...................................................................................................401 8.3.4
8.4 Final words ...................................................................................................... 401 
9 References .............................................................................................................................403 
10 Appendices .........................................................................................................................461 
14 
 
Appendix 1.1 ............................................................................................................... 461 
Appendix 1.2 ............................................................................................................... 462 
Appendix 2.1 ............................................................................................................... 464 
Appendix 2.2 ............................................................................................................... 467 
Appendix 2.3 ............................................................................................................... 469 
Appendix 2.4 ............................................................................................................... 487 
Appendix 4.1 ............................................................................................................... 489 
Appendix 4.2 ............................................................................................................... 490 
Appendix 4.3 ............................................................................................................... 491 
Appendix 5.1 ............................................................................................................... 492 
Publications arising from this work .................................................................................................493 
 
List of Tables 
Table 1.1: Composition of Ketogenic diets and variants ..................................................... 29 
Table 1.2: Studies detailing response to the Classical Ketogenic diet with 3-24 months 
follow-up .......................................................................................................................... 34 
Table 1.3: Studies detailing response to the Medium Chain Triglyceride, Ketogenic diet, 
Modified Atkins diet and Low Glycaemic Index Treatment ................................................ 38 
Table 1.4: Conditions caused by genetic factors that have a ‘probable’ benefit from the 
Ketogenic diet ................................................................................................................... 80 
Table 1.5: Conditions caused by genetic factors that have a ‘suggested' benefit from the 
Ketogenic diet ................................................................................................................... 81 
Table 3.1: Cohort clinical and demographic data (for cases with diet response data, n=253)
 ....................................................................................................................................... 114 
Table 3.2: Reported benefits on seizures, aside from reduced total seizure frequency, from 
the Ketogenic diet ........................................................................................................... 123 
Table 3.3: Reported benefits, independent of seizures, from the Ketogenic diet ............. 124 
Table 3.4: Results from Chi-square tests assessing independence of diet response at 
different time points ....................................................................................................... 126 
15 
 
Table 3.5: Putative factors affecting 3-month Ketogenic diet response ............................ 129 
Table 3.6: Putative factors affecting summary Ketogenic diet response ........................... 130 
Table 3.7: Putative factors affecting extreme summary Ketogenic diet response ............. 132 
Table 3.8: Putative factors affecting diet response at 3-month follow-up: biochemical 
parameters ..................................................................................................................... 135 
Table 3.9: Putative factors affecting diet response at 6-month follow-up: biochemical 
parameters ..................................................................................................................... 135 
Table 3.10: Putative factors affecting diet response at 12-month follow-up: biochemical 
parameters ..................................................................................................................... 136 
Table 4.1: Previously reported SNPs found in KCNJ11 and BAD in Ketogenic diet cohort.. 174 
Table 4.2: R2 values between pairs of previously reported KCNJ11 and BAD SNPs found in 
Ketogenic diet cohort ...................................................................................................... 177 
Table 4.3: Observed and expected population genetics data for KCNJ11 and BAD SNPs (from 
the 1000 Genomes Project) and results from Chi-square test of independence ............... 178 
Table 4.4: Breakdown of Ketogenic diet responders and non-responders by ethnicity, n=303
 ....................................................................................................................................... 179 
Table 4.5: Results of association analysis: common and intermediate variation in KCNJ11 
and BAD in Ketogenic diet responders and non-responders (n=303 for KCNJ11 and n=246 
for BAD) .......................................................................................................................... 181 
Table 4.6: Results of association analysis: common and intermediate variation in KCNJ11 
and BAD in Ketogenic diet responders and non-responders, including ethnicity as a 
covariate (n=303 for KCNJ11 and n=246 for BAD) ............................................................ 182 
Table 4.7: KD response in cases with previously unreported variants or variants with 
MAF<0.01 (in this cohort) in KCNJ11 and BAD ................................................................. 184 
Table 4.8: Top 10 most significant results for haplotype association analysis: variation in 
KCNJ11 and BAD in Ketogenic diet responders and non-responders (n=303 for KCNJ11 and 
n=248 for BAD) ............................................................................................................... 187 
Table 4.9: Results of association analysis, not accounting for ethnicity: common and 
intermediate variation in KCNJ11 and BAD in Ketogenic diet overall responders and non-
responders (summary KD response, n=216) .................................................................... 489 
Table 4.10: Results of association analysis, including ethnicity as a covariate: common and 
intermediate variation in KCNJ11 and BAD in Ketogenic diet overall responders and non-
responders (summary KD response, n=216) .................................................................... 490 
16 
 
Table 4.11: Top 10 most significant results for haplotype association analysis: variation in 
KCNJ11 and BAD in Ketogenic diet overall responders and non-responders (summary KD 
response, n=216) ............................................................................................................ 491 
Table 5.1: Genes with lowest p-values in 3-month and summary KD response gene-set 
analysis ........................................................................................................................... 238 
Table 5.2: Known regions of long-range linkage disequilibrium (identified by Price et al 
[686]) excluded from Identity-by-State calculations ........................................................ 492 
Table 6.1: Function of variants included in the Group 0 MAF<5% and MAF<0.5% analyses 
(prior to per-SNP quality control filtering) ....................................................................... 281 
Table 7.1: Description of Ketogenic diet response in 45 samples who had whole exome 
sequencing ...................................................................................................................... 323 
Table 7.2: Mean performance metrics for responders and non-responders as measures of 
ancestry matching ........................................................................................................... 337 
Table 7.3: Function of variants included in the exome sequencing analyses .................... 343 
Table 7.4: Performance metrics for all exonic variants for all samples included in analyses, 
n=36 ............................................................................................................................... 344 
Table 7.5: Genes that reached significance or suggestive significance in c-alpha analyses: 
Groups 0 and 1 ................................................................................................................ 349 
Table 7.6: Genes of most interest from exome sequencing analyses................................ 355 
List of Figures 
Figure 1.1 ‘Metabolic pathways involved in Ketogenic diet treatment’, taken from Masino 
and Rho (2012) ................................................................................................................. 49 
Figure 1.2: ‘Hypothetical pathways leading to the anticonvulsant effects of the ketogenic 
diet’, taken from Bough and Rho (2007) [166] ................................................................... 52 
Figure 1.3: The KATP-glycolysis hypothesis, taken from Ma et al., 2007 ............................... 62 
Figure 1.4:  Genes shown to be upregulated by the Ketogenic diet in animal models ........ 86 
Figure 1.5: Genes shown to be downregulated by the Ketogenic diet in animal models ..... 87 
Figure 2.1: Phenotype proforma...................................................................................... 100 
Figure 3.1: Flowchart of cases recruited and included in final analysis ............................. 113 
Figure 3.2: Distribution of diet compliance scores, n=66 .................................................. 117 
17 
 
Figure 3.3: Scatter plot of compliance scores and length of time on diet when questionnaire 
was completed, for 66 individuals ................................................................................... 118 
Figure 3.4: 3-month diet response, n=257 (n=252 with classifiable diet response data) ... 120 
Figure 3.5: 6-month diet response, n=171 (n=160 with classifiable diet response data) ... 120 
Figure 3.6: 12-month diet response, n=119 (n=111 with classifiable diet response data) . 121 
Figure 3.7: 18-month diet response, n=77 (n=69 with classifiable diet response data) ..... 121 
Figure 3.8: 24-month diet response, n=49 (n=46 with classifiable diet response data) ..... 121 
Figure 3.9: Line graph showing trend of Ketogenic diet responder/non-responder status 
over time for five cases ................................................................................................... 125 
Figure 3.10: Summary diet response, n=253 (n=221 with classifiable diet response data) 128 
Figure 3.11: Extreme summary diet response, n=253 (n=108 with classifiable diet response 
data) ............................................................................................................................... 128 
Figure 4.1: Flow-chart of cases with diet response data and included in final candidate gene 
analyses .......................................................................................................................... 166 
Figure 4.2: Detectable relative risk and disease allele frequency curves for 3-month KD 
response cohort, with 80% power, assuming a disease prevalence of 0.5%, alpha=0.007, 
126 cases and control:case ratio of 1.4. Black line=recessive model; purple line=dominant 
model; orange line=co-dominant model .......................................................................... 188 
Figure 4.3: Power and sample size curves, using a co-dominant model, disease and marker 
allele frequencies of 0.017, assuming a disease prevalence of 0.5%, control:case ratio of 1.4 
and alpha of 0.007. Black line=relative risk of 2.0; orange line=relative risk of 1.5; purple 
line=relative risk of 1.4. ………………………………………………………………………………………………… 189 
Figure 5.1: Illustration of the concept of direct or indirect association in GWAS .............. 199 
Figure 5.2: Flowchart of cases recruited and included in final GWAS ............................... 212 
Figure 5.3: Mean heterozygosity rates per individual, separated by ethnicity .................. 214 
Figure 5.4: For all individuals with Ketogenic diet response data: plot of values of the first 
and second vectors obtained by multidimensional scaling of pairwise identity-by-state 
values, with ethnicity highlighted .................................................................................... 218 
Figure 5.5: For all individuals with Ketogenic diet response data: plot of values of the first 
and second vectors obtained by multidimensional scaling of pairwise identity-by-state 
values, with 3-month response highlighted ..................................................................... 219 
Figure 5.6: Scree plot for the first 10 eigenvalues of the Multidimensional scaling matrix 220 
18 
 
Figure 5.7: Quantile-quantile plots of GWAS results from Fisher’s exact test, using 
unadjusted p-values. A) 3-month diet response, λ=1.00; B) Summary diet response, λ=1.00
 ....................................................................................................................................... 228 
Figure 5.8: Quantile-quantile plots of GWAS results from logistic regression, using 
unadjusted p-values. A) 3-month diet response, λ=1.008; B) Summary diet response, 
λ=1.0002 ......................................................................................................................... 229 
Figure 5.9: Regional association plot and linkage disequilibrium (LD) map for rs12204701+/-
500Kb. In the association plot, the left y-axis represents -log10 (P-values) for association 
with 3-month KD response; the right y-axis represents the recombination rate; the x-axis 
represents base-pair positions along the chromosome (human genome build 37). The top 
variant, rs12204701, is shown in purple, the rest of the variants are coloured according to 
their linkage disequilibrium r2 value with rs12402021. In the LD map, LD is indicated as 
D’/LOD. The colour white = LOD < 2, D' < 1; blue = LOD < 2, D' = 1; shades of pink/red = LOD 
≥ 2, D' < 1; bright red = LOD ≥ 2, D' = 1. LD pattern is based on genotype data obtained for 
this study. Confidence interval minima for strong LD: lower: 0.7, upper 0.98; Upper 
confidence interval maximum for strong recombination: 0.9; Fraction of strong LD in 
informative comparisons are at least 0.95; markers with <0.05 MAF are excluded .......... 231 
Figure 5.10: Regional association plot and linkage disequilibrium (LD) map for 
rs12402021+/-500Kb. In the association plot, the left y-axis represents -log10 (P-values) for 
association with 3-month KD response; the right y-axis represents the recombination rate; 
the x-axis represents base-pair positions along the chromosome (human genome build 37). 
The top variant, rs12402021, is shown in purple, the rest of the variants are coloured 
according to their linkage disequilibrium r2 value with rs12402021. In the LD map, LD is 
indicated as D’/LOD. The colour white = LOD < 2, D' < 1; blue = LOD < 2, D' = 1; shades of 
pink/red = LOD ≥ 2, D' < 1; bright red = LOD ≥ 2, D' = 1. LD pattern is based on genotype 
data obtained for this study. Confidence interval minima for strong LD: lower: 0.7, upper 
0.98; Upper confidence interval maximum for strong recombination: 0.9; Fraction of strong 
LD in informative comparisons are at least 0.95; markers with <0.05 MAF are excluded . 232 
Figure 5.11: HapMap figure of rs12204701 +/-500Kb, including nearby Entrez genes and 
dbSNP SNPs .................................................................................................................... 234 
Figure 5.12: Detectable relative risk and disease allele frequency curves for 3-month KD 
response cohort, with 80% power, assuming r2  of 0.9 between genotyped marker and 
causal variant, a disease prevalence of 0.5%, alpha=1.00x10-7, 116 cases and control:case 
ratio of 1.01. Black line=recessive model, orange line=dominant model, purple line=co-
dominant model ............................................................................................................. 235 
Figure 5.13: Power and sample size curves, using a recessive model (black line), dominant 
model (orange line) and co-dominant model (purple line), assuming r2=0.9 between 
genotyped marker and causal variant, a disease prevalence of 0.5%, disease and marker 
allele frequencies of 0.2 and relative risk of 1.4, alpha=1.00x10-7 and a control to case ratio 
of 1.4 .............................................................................................................................. 236 
19 
 
Figure 5.14: A Snapshot of the Protein Interaction Database PRL Signalling events pathway, 
taken from http://pid.nci.nih.gov. ................................................................................... 245 
Figure 6.1: Extreme responders and non-responders, n=106 (out of 250 individuals with 
diet response data and genotyped with the Illumina chip) .............................................. 274 
Figure 6.2: The Pathway Interaction Database S1P4 pathway, taken from 
http://pid.nci.nih.gov ...................................................................................................... 287 
Figure 7.1: Proportion of exonic bases achieving ≥2X coverage ....................................... 331 
Figure 7.2: Proportion of exonic bases achieving ≥10X coverage ..................................... 332 
Figure 7.3: Proportion of exonic bases achieving ≥20X coverage ..................................... 332 
Figure 7.4: Proportion of exonic bases achieving ≥30X coverage ..................................... 333 
Figure 7.5: Ti/Tv ratio of all exonic variants per individual ............................................... 333 
Figure 7.6: Mean genotype quality score per individual ................................................... 334 
Figure 7.7: Proportion of singletons per individual .......................................................... 334 
Figure 7.8: Proportion of heterozygous genotypes per individual .................................... 335 
Figure 7.9: Identity-by-state matrix: genotypic similarity between all pairs of individuals 336 
Figure 7.10: BIOCARTA PTC1 Pathway, taken from http://www.biocarta.com/pathfiles .. 359 
Figure 8.1: Diagram of the insulin/insulin-like growth factor 1/insulin receptor substrate 
signalling cascade, taken from Tao et al. 2007 [1140] ...................................................... 385 
 
List of abbreviations 
 
2DG 2-deoxy-D-glucose  
ACA acetoacetate  
ADAS-cog Alzheimer’s Disease Assessment Scale-Cognitive subscale 
ADP adenosine diphosphate  
AED anti-epileptic drug 
ATP adenosine triphosphate  
BCH Birmingham Children's Hospital 
BDNF brain-derived neurotrophic factor 
BHB beta-hydroxybutyrate  
BMI body mass index 
BRHSC Bristol Royal Hospital for Sick Children  
BWA Burrows-Wheeler Aligner  
20 
 
CI confidence interval 
CNS central nervous system  
CNV copy number variant 
CSF cerebrospinal fluid 
DEND developmental delay, epilepsy, and neonatal diabetes 
DNA deoxyribonucleic acid  
ECH Evelina Children's Hospital 
EDTA ethylenediaminetetraacetic acid 
EEG electroencephalography 
ESP Exome Sequencing Project  
GABA gamma-aminobutyric acid 
GERP Genomic Evolutionary Rate Profiling 
GLUT1 glucose transporter 1 
GO Gene Ontology 
GOSH Great Ormond Street Hospital for Children  
GWAS genome-wide association study 
HDL high-density lipoprotein 
HIE Hypoxic ischemic encephalopathy  
HWE Hardy-Weinberg equilibrium 
IBD identity-by-descent 
IBS identity-by-state 
ILAE International League Against Epilepsy 
ION Institute of Neurology 
IQ intelligence quotient  
IQR interquartile range 
KD Ketogenic diet 
LCT long-chain triglyceride 
LD linkage disequilibrium 
LDL low-density lipoprotein 
LGIT low-glycaemic index treatment 
LGS Lennox-Gastaut syndrome 
LOD logarithm of the odds 
LRT likelihood ratio test 
MAD Modified Atkin's diet 
MAF minor allele frequency 
MARS Medication Adherence Report Scale  
MCM minichromosome maintenance  
MCT medium-chain triglyceride 
MDS multidimensional scaling 
NCBI National Center for Biotechnology Information 
NHLBI National Heart, Lung, and Blood Institute  
NHNN National Hospital for Neurology and Neurosurgery 
NHS National Health Service 
NICE National Institute for Health and Clinical Excellence 
21 
 
mRNA messenger ribonucleic acid  
PCA principal component analysis 
PCR polymerase chain reaction 
PDD pyruvate dehydrogenase deficiency 
PHHI hyperinsulinaemic hypoglycaemia of infancy  
PID Pathway Interaction Database 
PNDM permanent neonatal diabetes  
PUFA polyunsaturated fatty acids  
RCHM The Royal Children's Hospital in Melbourne 
RCT randomised controlled trial 
RNA ribonucleic acid 
ROS reactive oxygen species 
SIFT Sorting Intolerant From Tolerant 
SJS Stevens-Johnson syndrome  
SNP single nucleotide polymorphism 
SNV single nucleotide variant 
TENS toxic epidermal necrolysis  
UCL University College London 
UK United Kingdom 
UTR untranslated region 
VNS vagus nerve stimulation  
YE Young Epilepsy 
 
  
22 
 
Acknowledgements 
First and foremost, I would like to thank my supervisors, Professors Sanjay Sisodiya and 
Helen Cross, for giving me the opportunity to have this academic experience. It has been a 
steep learning curve, which I have truly enjoyed and appreciated.  
To the clinicians and health care professionals at all study sites, especially those at Great 
Ormond Street Hospital, Evelina Children’s Hospital and Matthew’s Friends: thank you for 
allowing me to invade your clinics and for putting up with my incessant pestering. The Keto 
dietitians, more than anybody, have propelled my love for all things high-fat, low-carb.  
I am extremely grateful to Dr Jon White and Dr Costin Leu for many insightful discussions 
and helpful advice regarding genetics and programming. Also to my friends and colleagues 
at the Institute of Neurology and Institute of Child Health for showing me the ropes and 
making me feel very welcome. 
Finally, I would like to say a massive thank you to my husband, Andreas, for your patience 
and words of encouragement. I know you will be delighted to see the back of this thesis, 
not least because it will mean an exponential rise in the baked goods produced from our 
kitchen.   
This work is dedicated to the memory of those who, very sadly, are no longer with us. 
 
 
  
23 
 
1 Background: Epilepsy, the Ketogenic diet and 
Genetics 
 
1.1 Epilepsy 
 Definitions 1.1.1
Epilepsy is defined by the International League Against Epilepsy (ILAE) and the International 
Bureau for Epilepsy as:  
a disorder of the brain characterized by an enduring predisposition to generate 
epileptic seizures and by the neurobiologic, cognitive, psychological, and social 
consequences of this condition. The definition of epilepsy requires the occurrence of 
at least one epileptic seizure [1]. 
The brain dysfunction may result from a variety of causes, and thus epilepsy is not thought 
to be a ‘singular disease entity’ [1]. 
A seizure, the clinical manifestation of epilepsy, is defined as ‘a transient occurrence of 
signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the 
brain’ [1]. Based on mode of onset and termination, and clinical manifestation [1], seizures 
may be classified as generalised (‘originating at some point within, and rapidly engaging, 
bilaterally distributed networks’), focal (‘originating within networks limited to one 
hemisphere’) or unknown [2]. Epileptic spasms are classified as unknown, as there is 
‘inadequate knowledge to make a firm decision regarding whether spasms should be 
classified as focal, generalised, or both’ [2].  
The epilepsies may be categorised according to their aetiology: genetic, where the epilepsy 
is ‘the direct result of a known or presumed genetic defect(s) in which seizures are the core 
24 
 
symptom of the disorder’, structural/metabolic, where there is a ‘distinct other structural 
or metabolic condition or disease’ associated with epilepsy, or unknown [2].  
Epilepsy syndrome, or electroclinical syndrome, refers to ‘a group of clinical entities that are 
reliably identified by a cluster of electroclinical characteristics’ and other features, such as 
age of onset, EEG (electroencephalography) characteristics and seizure type; constellations 
refer to entities that are ‘clinically distinctive’ to electroclinical syndromes due to specific 
lesions or other causes; epilepsies associated with structural or metabolic conditions do not 
fit a ‘specific electroclinical pattern’ and may be organised by factors such as type of lesion, 
age of onset, localisation, seizure type, and specific ictal and interictal EEG patterns; other 
epilepsies are termed of unknown cause [2].  
 Burden 1.1.2
There are an estimated 70 million people worldwide who live with epilepsy [3, 4], of which 
approximately 10.5 million are aged under 15 years [5]. The median prevalence of active 
epilepsy (in which the last seizure occurred in the previous 12 months) is thought to be 7 
per 1,000 for people of all ages [3]; the median prevalence for under-15s is estimated at 4.7 
per 1,000. 20-40% of people with epilepsy worldwide are thought to have a drug-resistant 
condition [6], defined as ‘failure of adequate trials of two tolerated and appropriately 
chosen and used AED [antiepileptic drug] schedules (whether as monotherapies or in 
combination) to achieve sustained seizure freedom’ [7]. 
The total cost of epilepsy (including direct healthcare costs, direct non-medical costs and 
indirect costs) in Europe in 2010 was €13.8 billion [8]; a strong association has been 
identified between seizure frequency and cost in the USA [9] and Europe [10]. 
Financial burden is only one of the many costs of epilepsy. Adults with epilepsy have 
reported increased dissatisfaction with their education, family life, health, friends, social 
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life, achievement of their goals, and energy levels than adults without epilepsy [11]. 
Increased seizure frequency and severity have been associated with reduced health-related 
quality of life (QoL) [12]; seizure severity and seizure frequency may independently affect 
QoL [13]. Children with epilepsy have a relatively compromised QoL, in particular older 
children, those with a higher seizure frequency, those receiving polytherapy, those with 
partial seizures, and those who have been receiving treatment for longer [14-17]. In 
children, pharmacoresistance to seizures has been associated with lower full-scale 
intelligence quotient (IQ) [18] and has been identified as a significant risk factor for 
mortality [19]. 
 Treatment and management 1.1.3
As outlined in the National Institute for Health and Clinical Excellence (NICE) guidelines 
[20], the ‘mainstay’ of epilepsy treatment is AEDs, which are usually recommended after a 
second epileptic seizure. Which AED(s) are used depends on the individual’s seizure type, 
epilepsy syndrome, co-medication and co-morbidity, lifestyle, and the preferences of the 
person and their family and/or carers [21]. AEDs may cause adverse side effects, including 
dizziness, drowsiness, weight gain, visual field defects, nephrolithiasis, and movement and 
behavioural disorders [22, 23]. 
Epilepsy surgery may be considered in certain patients, when the potential benefits of the 
procedure outweigh the risks (including potential side effects, such as memory problems 
and visual field defects [24, 25]) and surpass chances of remission with further drug 
manipulation [26]. 
For the drug-resistant population, particularly (but not exclusively) for individuals not 
eligible for or who are opposed to epilepsy surgery, non-pharmacological treatments need 
consideration. Psychological interventions, such as relaxation therapy, cognitive behaviour 
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therapy and bio-feedback, the Ketogenic diet (KD) and vagus nerve stimulation (VNS) are 
alternative treatment options. 
Although psychological interventions have not been shown to affect seizure frequency, 
they have improved QoL in some adults and may be suitable for use in children and young 
people with drug-resistant focal epilepsy [21].  
VNS may be considered as an adjunctive therapy in children, young people and adults with 
drug-resistant epilepsy and who are not suitable for surgery [21]. VNS has been shown to 
reduce seizure frequency by ≥50% in 26% participants aged <18 years [27]; a statistically 
significant improvement in seizure severity has also been reported, along with improved 
mood (independent of seizure frequency) [28]. Side effects previously reported with long-
term VNS treatment include voice alteration, coughing, paresthesia and headaches [29].    
Guidelines created in ‘resource-rich’ countries, such as those from NICE, may not be 
appropriate or feasible in ‘resource-poor’ countries [30], due to, for example, limited 
funding, infrastructure and ethical issues [31]. Epilepsy care guidelines, such as the World 
Health Organisation mental health Gap Action Programme [32], created for use in non-
specialist health settings, may not underline (or even mention) the importance of non-
pharmacological treatment options for people with epilepsy. 
The continuing prevalence of epilepsy, despite the (theoretical) availability of over 20 AEDs, 
highlights the need for improved outcomes for people with this condition: management of 
seizures without a reduction in QoL. Although they may also cause adverse side effects, 
non-pharmacological interventions may help drug-resistant cases. This study focuses on the 
KD; its role in epilepsy treatment is outlined in the following section. 
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1.2 The Ketogenic diet and Epilepsy   
Following preliminary reports concerning the effects of fasting on seizure cessation [33], 
Wilder [34] aimed to mimic the state of starvation and produce ketosis with a high-fat, low-
carbohydrate diet. This led to the introduction of the so-called ‘Classical Ketogenic diet’, 
typically with a 4:1 ratio of fat (grams) to protein and carbohydrate (grams), for people with 
drug-resistant epilepsy.  
The initial enthusiasm for the KD was ousted by the discovery of diphenylhydantoin in 1938 
and the advent of new, easy-to-administer AEDs. Although widely used, concerns were 
quickly raised regarding adverse side effects of these drugs, such as gingival hyperplasia 
from diphenylhydantoin [35].  
In the 1970s, in an attempt to make the diet more palatable, Huttenlocher introduced the 
Medium Chain Triglyceride (MCT) KD on the premise that MCTs are more ketogenic per 
calorie, and the diet therefore allows a greater bulk of protein and carbohydrate [36, 37]. 
The MCT KD originally derived 60% of its calories from MCT oil. A modified MCT KD, 
designed to decrease gastrointestinal side effects, derived 30% of its calories from MCT oil 
and 30% from long-chain fats [38]. Nowadays, the proportion of energy from MCT fats is 
dependent on individual requirements and tolerance.  
The classical KD was established as the treatment of choice for a) pyruvate dehydrogenase 
deficiency (PDD), where deficiencies in a catalytic component of the mitochondrial enzyme 
PD complex (which catalyses the conversion of pyruvate to acetyl CoA and thus plays a 
crucial role in energy metabolism), are overcome by the provision of an alternative source 
of acetyl CoA by the KD [39, 40]; and b) glucose transporter 1 (GLUT1) deficiency syndrome 
[41], where impaired glucose transport across the blood-brain barrier is overcome by the 
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use of ketone bodies (which don’t rely on the glucose transporter system to enter the 
brain) as fuel by the brain. 
The KD experienced a reemergence when a programme was aired on NBC-TV’s Dateline in 
October 1994, based on Charlie Abrahams and his response to the diet [42]. Charlie’s father 
founded The Charlie Foundation to facilitate the availability of information regarding the 
diet for other parents. Other charities dedicated to the KD cause have subsequently been 
created, such as Matthew’s Friends and The Daisy Garland. 
Since the early 2000s, the KD repertoire has expanded to include more ‘relaxed’ variant 
forms of the diet, including the Modified Atkins diet (MAD) and the Low Glycaemic Index 
Treatment (LGIT), aiming to provide increased flexibility and palatability. The MAD is based 
on a ratio of approximately 1:1, although this is not necessary in all meals, and includes 10-
30g of carbohydrate/day with no restriction of fluids, calories or protein. It allows users 
more flexibility and does not require the weighing of food portions or an initial hospital 
stay [43]. The LGIT includes a higher proportion of carbohydrates (approximately 40-
60g/day) than the classical KD, with 60% of calories taken from fat, but only permits 
carbohydrates with a Glycaemic Index of <50 relative to glucose. In this project, the 
acronym ‘KD’ will be used to refer to all KD types, unless otherwise specified. 
A summary of the composition of the KD and variant diets is given in Table 1.1. Fine-tuning 
by the dietitian is customary. 
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Table 1.1: Composition of Ketogenic diets and variants 
 
 
KD, Ketogenic diet; MCT, Medium Chain Triglyceride; MAD, Modified Atkins diets LGIT, Low 
Glycaemic Index Treatment; LCT, Long Chain Triglyceride 
 
Nowadays, the classical KD, MCT KD and MAD are offered in approximately 15 NHS 
(National Health Service) hospitals across the UK to children with drug-resistant epilepsy. 
Two centres have a service dedicated to adults. Prior to commencing KD treatment, 
individuals are screened (with biochemical testing of blood and/or urine) for disorders of 
fatty acid metabolism and organic acidurias that may lead to deterioration when lipids are 
used as the primary energy source or when dietary intake of protein or certain amino acids 
is not restricted. For example, an individual with medium chain acyl-CoA dehydrogenase 
deficiency would present with low serum and urine carnitines and elevated serum levels of 
medium-chain-length fatty-acid-derived acylcarnitines, such as octanoyl carnitine 
(http://www.fodsupport.org/mcad.htm). Many other factors also lead to caution being 
taken when considering whether to commence KD, such as a family history of 
hyperlipidaemia, nephrolithiasis, or severe gastro-oesophageal reflux. 
Unless seizures worsen after starting the KD, it is customary to follow dietary treatment for 
approximately three months before considering discontinuation [151]. Follow-up clinics 
occur approximately every three months for the first year, although contact with a dietitian 
is more frequent). If effective and tolerated, the diet is usually followed for two years 
Diet Ketogenic ratio % Carbohydrate % Protein % Fat (LCT) % Fat (MCT) 
Classical KD 4:1 (or 3:1, 2:1 and so on) 4 6 90 0 
MCT KD equivalent to 3:1 19 10 11 60 
Modified MCT KD equivalent to 3:1 19 10 41 30 
MAD equivalent to 0.9-1:1 ~10 ~25 65 0 
LGIT n/a 10 30 60 0 
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before discontinuation is considered, although the diet may be continued for much longer 
[44].  
Modern clinical studies demonstrating the diet’s effectiveness have fuelled the continuing 
interest in the KD among scientific and clinical communities. 
 The Ketogenic diet – clinical reports of effectiveness 1.2.1
In the first systematic review of KD response, it was estimated that ≥50% seizure reduction 
is achieved in 56% children and seizure freedom is achieved in 16% [45]. In a subsequent 
systematic review, the estimated rate for achieving seizure freedom was 15.6% with 33% 
achieving ≥50% seizure reduction [46]. In a meta-analysis, the pooled odds ratio of 
achieving >50% seizure reduction among patients who followed the KD until the end point 
of the study (this varied between studies) relative to those who had discontinued the diet 
before the end point was 2.25 [47]; 52% of individuals who remained on the diet for 
variable periods of time (up to 24 months) were reported to have achieved ≥90% seizure 
control and 24% achieved complete seizure control.  
The systematic reviews and meta-analysis consisted entirely of uncontrolled and 
predominantly retrospective studies, as highlighted by the authors. It was unclear whether 
studies had been screened independently by more than one researcher for inclusion in 
either systematic review, which may have introduced bias; in the meta-analysis, studies 
were rated for strength of evidence by one of three neurologists. Authors of both 
systematic reviews claimed to be investigating use of the KD in childhood epilepsy, but 
some of the studies included participants aged >18 years. Aside from the need for 
prospective, controlled trials, the authors also underlined the fact that primary outcomes 
were not uniform across all studies, long-term follow-up was limited and the clinical 
characteristics of dropouts were seldom described.  
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Since the aforementioned reviews and meta-analysis, a randomised controlled trial (RCT) 
assessing effectiveness of the KD for drug-resistant epilepsy has been conducted. Children 
aged 2-16 years with at least daily seizures or more than seven seizures per week, who had 
not responded to at least two AEDs were included in the study. 38% of participants treated 
with a classical KD or MCT KD achieved >50% seizure reduction at three month follow-up, 
compared with 6% of controls; 7% of treated participants experienced a >90% seizure 
reduction compared with no controls [153]. There was no significant difference in the 
number of children who achieved >50% or 90% reduction between the classical KD and 
MCT KD groups [98]. Responder rates are thought to be lower than those previously 
reported due to the intent-to-treat approach adopted in the RCT.  
An RCT evaluating the effectiveness of the MAD in children has also been conducted [48]. 
52% of 50 children who received the MAD achieved >50% seizure reduction at 3-month 
follow-up, compared to 11.5% of 52 controls; 30% of the treatment group achieved >90% 
seizure reduction, compared to 7.7% of controls. 
In a blinded RCT, 20 children with Lennox-Gastaut syndrome were fasted and randomised 
to receive a KD plus a saccharin drink, or a KD plus a glucose drink (designed to act as a 
non-ketogenic diet) [49]. After six days, participants were fasted and then they received the 
KD with the alternative drink. There was no significant difference in improvement seen 
between the two groups, although a median of 1.5 fewer seizures per day were reported in 
the saccharin arm. The lack of statistically significant results is thought to be because 
ketosis was not completely eliminated in the group who received the glucose drink and 
baseline seizure frequency was measured following the fasting period, which may have 
reduced seizure frequency more effectively than the KD.    
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Other randomised trials have been conducted, but they compared the effects of different 
levels of carbohydrate intake [50], ketogenic ratios [51], or introduction of the KD with or 
without a fasting period [52], as opposed to randomising patients to KD treatment or no 
change in treatment.  
A PubMed search was conducted to identify other studies (prospective or retrospective 
cohort studies, or uncontrolled studies) assessing the effectiveness of the KD, with 3-, 6-, 
12- and/or 24-month follow-up data. The keywords ‘ketogenic diet’ were used and articles 
published in English, Spanish and French were included. Studies reporting on the KD for 
status epilepticus and metabolic disorders were excluded, as were abstracts.   
The results for studies on the classical KD can be found in Table 1.2, and for the MCT KD, 
MAD and LGIT in Table 1.3. The percentage of participants classed as ‘responders’ (≥50% 
seizure reduction or seizure-freedom) in each study has been calculated with an intent-to-
treat approach. Diet response rates are similar to those calculated in meta-
analyses/systematic reviews [45-47], although seizure-freedom rates may be higher than 
calculated here, as not all studies provided this information. There are a higher proportion 
of responders in cohorts following the classical KD compared to other diet types; this may 
be reflective of the population demographics – younger patients are often more likely to 
follow the classical KD, due to the soft texture of the foods that tend to be used and the 
perceived ease of compliance in this age group, compared to, for example, adolescents. 
There are too few studies on the other diet types (in particular the MCT KD and LGIT) to 
permit comparison of response rates.     
58 further studies were found in which participants had followed the diet for varying 
lengths of time and response was summarised independent of follow-up time. These were 
excluded, as they do not allow for inter-study comparison. 
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Responder rates in studies with fixed follow-up points of <3 months (range 12 days-10 
weeks) were similar to 3-month response rates: 102/176(58.0%) achieved ≥50% seizure 
reduction, of which 34(19.3%) became seizure-free [49, 53-62].  
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Table 1.2: Studies detailing response to the Classical Ketogenic diet with 3-24 months follow-up 
Study Design 
Number 
recruited 
Age range at 
diet onset 
(years) 
Participants with ≥50% seizure reduction, n(% of original number recruited); of which seizure-
free, n(%)¥ 
 
3 months 6 months 12 months 24months 
[63] Prosp 45 21-52 - 
20(44%) with ‘reduction 
in number of fits’; 2(4%) 
- - 
[64] Prosp 100 0.3-16 54(54%); NR 48(48%); NR 32(32%); NR - 
[65] 
 
Prosp 150 1-16 85(57%); 4(3%) 72(48%); 5(3%) 64(43%); 11(7%) - 
[66] Prosp 51 1-8 28(55%); 6(12%) 27(53%); 6(12%) 20(39%); 5(10%) - 
[67] Prosp 41 1-18 13(32%); 6(15%) 10(24%); 3(7%) 3(7%); NR - 
[68] Prosp 74 NR 24(32%); 14(19%) 39(53%); 19(26%) 52(70%); 23(31%) - 
[69] (also 
reported in 
[70]) 
Prosp 13 1-19 10(77%); 4(31%) 9(69%); 3(23%) 8(62%); 4(31%) 5(38%); 2(15%) 
[71] 
 
Prosp 35 0.2-13 17(49%); 5(14%) 15(43%); 4(11%) 10(29%); 3(9%) - 
[72] Retro 143 0.3-29 59(41%); 21(15%) 60(42%); 24(17%) 54(38%); 23(16%) - 
[73] Prosp 56 1-23 21(38%); 6(11%) 15(27%); 4(7%) 5(9%); 0(0%) - 
[74] Retro 24 1-15 - 17(71%); 4(17%) 11(46%); 4(17%) - 
[75] Retro 23 0.4-2 14(61%); 3(13%) 13(57%); 3(13%) 13(57%); 3(13%) - 
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[76] Retro 45 12-19 - 14(31%); NR 13(29%); NR - 
[77] Retro 124 
Mean=4.1±1.5 
in one group; 
5.3 ±1.6 in the 
other 
94(76%); 43(35%) - - - 
[78] Retro 53 0.5-15 
25(47%) with >90% 
seizure reduction 
29(55%) with >90% 
seizure reduction 
- - 
[52] Prosp 48 1-14 30(63%); 10(21%) - - - 
[79] Retro 20 3-9 - - 13(65%); 2(10%) - 
[80] Prosp 12 0.6-6 - - 10(83%); NR β - 
[81] Retro 199 0.5-17 123(62%); 70(35%) 115(58%); 66(33%) 82(41%); 50(25%) - 
[82] Retro 12 0.7-18 - 11(92%); 3(25%) - - 
[83] Retro 71 0.6-20 44(62%); NR 33(46%); NR 23(32%); NR - 
[84] Retro 26 2-13 7(27%); NR 4(15%); NR 8(31%); NR - 
[85] Retro 13 0.33-4. 11(85%); NR 8(62%); NR 6(46%); NR - 
[86] Retro 43 0.5-3 30(70%); 15(35%) 23(53%); 17(40%) - - 
[87] Retro 57 1-26 - - 31(54%); NR - 
[88] Prosp 48 1-12 30(67%); NR - - - 
[89] Prosp 25 1-18 16(64%); 2(8%) 15(60%); 3(12%) 12(48%); 2(8%) - 
[90] Retro 70 1-12 - 44(63%); NR 38(54%); NR 29(41%); NR 
[91] (also 
reported in 
[92]) 
Prosp 18 2-15 12(67%); 4(22%) - - - 
[93] Retro 106 0.3-14.8 - 67(63%); NR 60(57%); NR - 
[94] Prosp 76 0.3-16 60(79%); 33(43%) - - - 
[95] Retro 25 0.5-15.8 - 13(52%); 0(0%) - - 
[96] Retro 47 
Mean 47.2 
±33.7months 
29(62%); 21(45%) - - - 
36 
 
Prosp - prospective; Retro - retrospective 
¥ number of seizure-free participants is included in the number with ≥50% seizure reduction 
NR - not reported 
[97] Retro 118 0.3–15 89(75%); NR 84(71%); NR - - 
[98]* Prosp 
73 on 
classical 
diet 
2-16 18(25%); 1(1%) 18(25%); 1(1%) 13(18%); 4(5%) - 
[99] Prosp 30 1-15 16(70%); 3(13%) - - - 
[100] Prosp 8 25-36 2(25%); NR - - - 
[101]* Retro 
17 on 
classical 
diet 
0.11-12 11(65%); NR 7(41%); NR 4(24%); NR - 
[102] Prosp 27 0.75-5 16(59%); 3(11%) 13(48%); 4(15%) 10(37%); 5(19%) - 
[103] Retro 50 1-14 33(66%); 9(18%) - - - 
[104] Prosp 38 0.3-5 27(71%); 11(29%) 28(74%); 12(32%) 20(53%); 9(24%) - 
[105] Prosp 104 Mean 1.2±0.1 66(63%); 19(18%) 67(64%); 29(28%) 80(77%); 31(30%) 80(77%); 34(33%) 
[106] Prosp 12 24-65 5(42%); 2(17%) √ - - - 
[107] Prosp 48 1.3-12.2 26(54%); 10(21%) - - - 
[108] Prosp 15 4-11 8(53%); NR 8(53%); NR 5(33%); 1(7%) - 
[109] Retro 26 
19.5±2.2 
months 
22(85%); 9(35%) ≠ 21(81%); NR ≠ 16(62%); NR ≠ - 
[110] Prosp 38 0.7-5 23(61%); 9(24%) - - - 
[111] Prosp 26 1.3-15.8 17(65%); 5(19%) - - - 
[112] Prosp 61 Median 4.8 29(48%); 2(3%) 24(39%); 2(3%) 19(31%); 2(3%) - 
[113] Retro 71 1.5-18 36(51%); 3(4%) 20(28%); 1(1%) 17(24%); 1(1%) - 
[114] Prosp 317 
2 months to 17 
years 8 months, 
111(35%); 66(21%) 83(26%); 43(14%) 59(19%); 34(11%) - 
[115] Prosp 17 
mean age of 
9.4±1.1 months 
14(82%); 11(65%) 14(82%); 5(29%) - - 
[116] Prosp 31 0.6-7 22(71%); 14(45%) - - - 
TOTAL (not including [78] or 
[63] 
3020 - 1402(46%); 441(15%) 1059(35%); 263(9%) 
811(27%); 
217(7%) 
114(4%); 36(1%) 
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* studies assessing effectiveness of more than one type of Ketogenic diet. Response rates given for participants on classical KD only 
√ Response rate at 4 months 
≠ Response rates at 1-3months, 5-7months, 10-13months 
β Response rates at 12 and 18 months compared to baseline  
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Table 1.3: Studies detailing response to the Medium Chain Triglyceride Ketogenic diet, Modified Atkins diet and Low Glycaemic Index Treatment with 3-24 
months follow-up 
Study Design Diet type 
Number 
recruited 
Age range 
Participants with ≥50% seizure reduction, n(% of original number 
recruited); of which seizure-free, n(%)¥ 
3 months 6 months 12 months 24months 
[117] Prosp MCT 15 1.5-9 9(60%); 1(7%) 6(40%); 2(13%) 
3(20%); 
1(77%) 
- 
[98]* Prosp MCT 72 on MCT 2-16 21(29%); 1(1%) 14(19%); 0(0%) 
16(22%); 
3(4%) 
- 
[118] Prosp MAD 20 3-16 14(70%); 3(15%) 
12(60%); 
3(15%) 
- - 
[119] Prosp MAD 14 2-14 7(50%); 4(29%) 5(36%); 3(21%) - - 
[50] Prosp MAD 20 3-16 7(35%); NR 
10(50%); 
2(10%) 
- - 
[120] Prosp MAD 8 30-54 - 
1(12.5%); 
0(0%) 
- - 
[121] Prosp MAD 30 18-53 14(47%); 1(3%) 7(23%); 1(3%) - - 
[101]* Retro MAD 10 on MAD 0.4-15.2 2(20%); NR 2(20%); NR 1(10%); NR - 
[122] Prosp MAD 15 2-17 6(40%); NR - - - 
[123] Prosp MAD 5 4-18 3(60%): 1(20%) 3(60%); 1(20%) - - 
[124] Prosp MAD 51 1-16 16(31%); 5(10%) - - - 
[125] Prosp MAD 38 1-15 17(45%); 5(13%) 13(34%); 0(0%) 9(24%); 0(0%) - 
[126] Prosp MAD 18 18-55 2(11%); 0(0%) 4(22%); 0(0%) 3(17%); 0(0%) - 
[127] Retro MAD 87 <18 - 36(41%); NR 28(32%); NR 8(9%); NR 
[48] Prosp MAD 
102 (50 in diet 
group) 
2-14 26(52%); 5(10%) - - - 
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[128] (includes 
data from 
[129]) 
Retro LGIT 76 1.5-22 
50% of ‘the 
population’; NR 
54% of ‘the 
population’; NR 
66% of ‘the 
population’; 
NR 
- 
[130] Retro LGIT 15 1-20 4(27%); NR 7(47%); NR 6(40%); NR 4(27%); NR 
[131] Prosp 
Classical and 
MCT 
15 18-41 1(7%); 0(0%) √ 1(7%); 0(0%) 2(13%); 0(0%) - 
[132] Prosp 
Classical, MCT 
and MAD 
33 1-40 5(15%); NR 6(18%); NR - - 
TOTAL (not including [128] 542  154(26%); 26(4%) 
127(23%); 
12(2%) 
68(13%); 
4(1%) 
12(2%); NR 
Prosp – prospective; Retro - retrospective 
¥ number of seizure-free participants is included in the number with ≥50% seizure reduction 
* studies assessing effectiveness of more than one type of Ketogenic diet. Response rates given for participants on specified diet type only 
√ Response rate at 4 months 
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As for studies with fixed long-term follow-up points: 2/2 participants following a KD for 36 
months achieved ≥50% seizure reduction, one of whom was seizure-free [70]; of 15 people 
following the diet for >48 months, 13(86.7%) were responders, one of whom was seizure-
free [133].  
Evidence suggests that a favourable response to the KD may be sustained after 
discontinuation of dietary treatment. From the nine studies identified with follow-up after 
diet discontinuation in participants who had achieved seizure-freedom on the KD, 
154/199(77.4%) remained seizure-free [96, 133-138]. Follow-up after discontinuation of 
the diet (not stated in three studies) ranged from 0-7 years. 
Only one study looked into response following discontinuation of the KD in adolescents and 
adults: all three subjects who achieved >75% seizure reduction on the diet returned to pre-
treatment frequency 1-7 months following cessation of treatment [106]. This may 
represent a disparity between dietary therapy in children and older people.  
 
This review highlights the fact that dietary treatment, although effective in terms of seizure 
reduction in many patients with drug-resistant epilepsy, is not a panacea. Further trials of 
the MCT KD, MAD and LGIT with clearly defined follow-up times are needed. Studies with 
clearly-defined long-term follow-up times are also needed for all KD types. 
It is unknown why the KD can have potential long-lasting effects on seizure control. 
Additional studies are warranted to determine whether the antiepileptic effects of the diet 
outlast treatment, particularly in adolescents and adults. 
 Effects of the Ketogenic diet beyond seizure frequency 1.2.2
Other measures of treatment response that may lead to improved quality of life, 
independent of seizure reduction, must be considered.  
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The KD may lead to improvements in seizure severity in children and encourage 
continuation of dietary treatment despite inadequate seizure control [92, 118]. Seizure 
severity was not affected in one study involving adults following the KD [131], although 
anecdotal reports suggest otherwise (personal communication with metabolic dietitians 
from the National Hospital for Neurology and Neurosurgery, and Susan Wood, adult 
dietitian at Matthew’s Friends Clinics for Ketogenic Dietary Therapies). 
The KD has contributed to improved psychological function and quality of life in adults 
[100, 131, 139]; improvements were often independent of seizure control achieved on the 
diet and have also been reported in subjects without epilepsy [140-142]. Children following 
the KD may also have positive side effects, such as improved behaviour, sleep, 
alertness/attention, comprehension and motor skills [48, 73, 92, 143-148], or simply 
improved QoL [91, 149]. Improvements may be unrelated to seizure reduction [92, 143, 
146, 148] or decreases in concomitant AED usage [146] and can result in a higher 
probability of continuing on the diet, more so than reduced seizures or medication [147].  
The KD has been shown to slightly worsen psychosocial adjustment and mood (particularly 
anger/hostility and fatigue/inertia) in school-aged children and adolescents [148]. The 
authors attributed the decrease in psychosocial adjustment to the higher mean age of diet 
onset of patients in their cohort, compared to other studies. There are reports of dietary 
treatment interfering with social interaction in adolescents [76, 150]. 
The effects of the KD may reach further than solely seizure control, providing additional 
motivation for initiation or continuation of treatment. Such benefits are not consistently 
reported in studies investigating KD effectiveness, and further work is required to assess 
the proportion of patients that may profit from dietary treatment in this way. Equally, 
negative psychosocial effects from the diet should be reported in order to facilitate 
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prospective identification of patients at risk. Perhaps diet effectiveness should be defined 
by parameters other than seizure reduction alone.  
 Tolerability 1.2.3
Like most medical treatments, the KD may cause adverse side events. Such effects include 
gastrointestinal symptoms, hyperuricaemia, hypocalcaemia, hypomagnesaemia, acidosis, 
hypercholesterolaemia, renal stones and stunted growth [151].  
In a meta-analysis of studies assessing the effectiveness of the KD in paediatric patients, 
the most frequently reported side effects were constipation (occurring in 14% of children 
remaining on the diet for at least three months); weight loss, growth problems, or anorexia 
(13%); nausea and vomiting (5%); behavioural problems or irritability (4%); increased 
serum cholesterol or triglycerides (4%); lethargy (4%); hypercalciuria (2.5%); increased liver 
enzymes (2.4%); renal stones (1.9%); diarrhoea (1.6%) and hypoglycaemia (1.3%) [152]. 
In the only RCT of the classical KD and MCT KD in a paediatric population, the most 
common side effect was constipation, reported by 33% of participants during the first three 
months of treatment [153]. One child had haematuria and renal echogenic debris whilst on 
the diet, which was successfully managed with potassium citrate. Other side effects 
included vomiting (24%), diarrhoea (13%), abdominal pain (9%), lack of energy (24%) and 
hunger (22%). There were no significant differences in tolerability between the classical KD 
and MCT KD groups [98]. 
In the RCT of the MAD, the most common side effect was constipation, reported by 46% of 
participants [48]. Other side effects included anorexia (18%), lethargy (6%) and vomiting 
(10%). Two children developed frequent chest infections, and another developed 
hyperammonaemic encephalopathy one week after starting the diet.  
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No direct comparison between adolescents or adults and children has been made of diet 
tolerability. From the limited data, side effects appear similar in all age groups [154].  
Long-term complications of the KD are relatively unknown. A higher risk of fractures, renal 
stones and stunted growth has been found in children who followed the diet for >6 years 
[155]. Evidence appears most consistent for a negative effect on height and/or weight 
during KD implementation, particularly when the diet is started at a young age [137, 156-
160]; some studies, however, have reported little or no effect on growth parameters [143, 
158, 161]. Patients who follow the KD long-term may experience catch-up growth (height 
and weight) after discontinuation of dietary treatment, with most improvement in weight 
observed in ambulatory individuals, and most improvement in height and weight in 
individuals who achieved seizure-freedom on the KD. Abnormal lipid values may also 
gradually return to normal over time (2+ years) [44, 137, 162]. 
It has been recommended that signs of hyperlipidaemia, cardiac disease, linear growth 
failure, gastrointestinal disorders, nephrolithiasis, electrolyte/vitamin/ mineral/trace 
element deficiencies, and osteoporosis/osteopenia/fractures are monitored closely in 
patients following the KD long-term [163].  
Adverse effects from short-term use of the KD are common, but mostly non-critical and/or 
transient. The risks associated with long-term use, however, are largely unknown.  
 Retention  1.2.4
46 studies from Table 1.2 and Table 1.3 gave initial study recruitment figures and retention 
rates at fixed follow-up points (including prospective and retrospective studies). 79% of the 
total number of participants who started the classical KD were still following the diet at the 
3-month point; for studies that gave 6-month point retention figures, 63% remained on the 
diet, 43% remained at the 12-month point and 43% at the 24-month point (only two 
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studies). Retention rates for the MAD were 76% at the 3-month point, 64% at 6 months, 
44% at 12 months and 18% at 24 months (one study). Only two studies provided retention 
information for the MCT diet: 70% continued on the diet at the 3-month point, 53% at 6 
months, and 39% at 12 months. Only one study provided retention information for the 
LGIT: 67% continued on the diet at the 3-month point, 60% at 6 months, 47% at 12 months, 
and 40% at 24 months.   
In adolescents and adults, retention rates may be even lower, although reports are 
inconsistent and sample sizes limited. Up to 78% of participants have discontinued dietary 
treatment even before three months [100]. Many may refuse to start the diet in the first 
place; in one study, only 18 out of 130 eligible adults consented to begin the KD [126]. 
Reasons for discontinuation of the KD are not consistently reported. In the RCT of the 
classical KD and MCT KD, of the 10 children who discontinued dietary treatment before the 
3-month point, 9(90%) of these withdrew due to lack of tolerability: three because of 
parental unhappiness with the restrictions, two with behavioural food refusal, one with 
extreme drowsiness, and three due to gastrointestinal side effects; the remaining child 
withdrew due to increased seizures [98, 153]. In the RCT of the MAD, treatment was 
discontinued in the two children who developed frequent chest infections and one who 
developed hyperammonaemic encephalopathy [48]. Only one other child discontinued 
treatment prior to the 3-month point; this was due to the perceived restrictiveness of the 
diet by the child and family.  
In a study exploring the reasons for discontinuation of dietary treatment prior to the 6-
month point, 10/19(52.7%) children withdrew from the diet for medical reasons (lack of 
efficacy, complications or unrelated hospitalisation), and 9/19(47.4%) withdrew for non-
medical reasons (caregiver issues or patient issues, such as food refusal) [150]. 
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Discontinuation for medical reasons was more common in children <6 years of age, 
whereas non-compliance was more common in older children.  
Other reports outline similar reasons for diet discontinuation: in one study with long-term 
follow-up, 33/67(49.3%) families discontinued the diet before 12 months due to 
ineffectiveness, 12/67(17.9%) due to intercurrent illness unrelated to the diet, and 
20/67(29.9%) found it to be too restrictive [133]; in another study, of 183 patients who 
discontinued the diet after 0.03–12.3 years, 23% discontinued due to seizure freedom, 23% 
due to prolonged KD use with limited continued benefit, 20% due to diet ineffectiveness, 
12% due to reduced efficacy over time, 11% due to medical illness, 8% due to perceived 
restrictiveness, and 3% due to worsening seizures [164]. 
Levels of compliance must also be considered alongside retention rates, as it may not 
always be easy or even possible for a patient to consistently adhere to a restrictive regime, 
depending on food preference, social circumstance and caregiver understanding of the KD. 
There is a tendency for studies to simply provide numbers/proportions of patients who are 
(allegedly) following the diet and of those who have discontinued. Levels of compliance 
have been noted in two studies, measured by communication with parents/patients [73] or 
using serum beta-hydroxybutyrate (BHB) or urine acetoacetate (ACA) [106]. Inter-individual 
variability in ketone body production and maintenance may be high [165], and response to 
the diet may not solely depend on ketosis per se [166]. Continual recording of food intake, 
as previously undertaken in a case report [167], may provide more accurate levels of 
compliance with the diet but would not be feasible on a wider scale or in outpatient 
settings. Alternative ways of assessing compliance are needed. 
KD retention levels seem poor, although studies with long-term KD retention data are 
limited. The most common reason for discontinuation of treatment may be lack of 
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effectiveness, but the restrictiveness of the regime also affects dropout rates. This 
highlights the need for an improved selection process for the KD and for further study into 
the mechanisms underlying its treatment effects. 
 Biochemical response to the Ketogenic diet and putative mechanisms of action 1.2.5
The biochemical changes induced in response to the KD are similar to those induced by 
starvation: principally, a change in metabolism from ‘glucocentric’ (use of glucose as an 
energy substrate) to ‘adipocentric’ (where ketone bodies and fatty acids act as energy 
substrates) metabolism [168]. The principal difference is that lean body mass and blood 
glucose levels are maintained with the KD (although blood glucose levels may drop below 
normal, they are then maintained at this level and should not continue to fall), whereas 
they are diminished with prolonged starvation.  
During the early stages of starvation, or the post-absorptive state, in response to lower 
blood glucose levels, insulin concentrations decrease and glucagon increases. This has 
three main consequences: hepatic glycogenolysis and gluconeogenesis are stimulated and 
fatty acid synthesis from acetyl CoA and hepatic glycolysis are inhibited. All these effects of 
glucagon are mediated through activation of the cyclic AMP cascade.  
Triacylglycerol from adipose tissue is broken down to give fatty acids and glycerol. Fatty 
acids are used by the liver and muscle as an energy source and glycerol is converted to 
glucose.   
The glucose formed from glycogenolysis is transported for use in muscle and adipose 
tissue, although hepatic glycogen stores are depleted after approximately a day of fasting. 
Uptake of glucose is reduced due to low insulin levels and glucose oxidation is inhibited in 
muscle and adipose tissue, which causes increased release of lactate, pyruvate, and alanine 
for gluconeogenesis. As previously mentioned, fatty acids become the main energy 
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substrate for muscle and liver. These processes (glycogenolysis and the release of glucose 
by the liver, the mobilisation of fatty acids from adipose tissue, and the shift in the fuel 
used by muscle and the liver from glucose to fatty acids) help to stop blood glucose levels 
from falling any further. 
The body also reduces its need for glucose. When fatty acids are oxidised, the acetyl CoA 
formed during this process is converted to HMG-CoA (via HMG-CoA Synthase, a rate-
limiting enzyme that is only found in the liver) and then into ACA (which breaks down to 
acetone) and BHB. This is thought to occur several days after starvation begins. Ketogenesis 
is also thought to occur in the kidneys [169]. Normally, the acetyl CoA is oxidized to CO2 
and H2O in the citric acid cycle but, due to the large quantities generated from the 
degradation of fatty acids, not all can be oxidised in the citric acid cycle, partially because 
the process of gluconeogenesis depletes the supply of oxaloacetate, which is essential for 
the entry of acetyl CoA into the citric acid cycle. Instead, the ketone bodies produced are 
transported to tissues that are able to use them as energy substrates, such as the brain. 
Most neurons do not contain enzymes to be able to oxidise fatty acids [170].  
A certain level of glucose is still needed (red blood cells, for example, can only use glucose 
for energy as they lack mitochondria containing the enzymes of fatty acid/ketone body 
oxidation) and, although some glucose is provided by hepatic and renal gluconeogenesis, 
the process of converting glycerol to glucose is limited. If ketone bodies were not produced 
and used as fuels by some tissues, lean body mass would be broken down to obtain amino 
acids for conversion to glucose [171].  
As starvation is prolonged, the brain begins utilising more ketones and less glucose until 
ACA and BHB become the primary fuels of the brain. After 3.5 days of starvation, the 
amount of glucose consumed by the human brain is approximately 75% less than normal 
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[172]. After 5-6 weeks of starvation, approximately 60% of the brain’s energy supply is from 
ketone bodies [173]. At the same time, muscles use progressively more fatty acids as 
energy substrates, and hepatic gluconeogenesis and hepatic urea production (produced 
from the nitrogen released from amino acid breakdown for excretion) decrease. From 
clinical observation, this process of keto-adaptation is thought to take 2-4 weeks [168, 
174]. The performance of trained endurance athletes was not found to differ after four 
weeks of following a low-carbohydrate diet [175], whereas earlier studies showed 
performance to be limited in the early periods of adaptation to such diets. Although studies 
of long-term consumption of low-carbohydrate (with or without additional fat intake) have 
been studied in healthy individuals [176], those who are overweight [177, 178] and those 
with Type II diabetes [179-181], no studies were found that systematically documented the 
process of keto-adaptation over a long period of time.   
The KD aims to replicates this state of starvation, encouraging the production of ketone 
bodies with high dietary fat intake. The speed at which keto-adaptation occurs depends on 
the rate at which the diet is introduced, the ketogenic ratios used, and whether it is 
preceded by a fasting period. 
The hallmark features of the KD, focusing on the effects of energy substrate utilisation in 
the brain, are outlined in Figure 1.1. 
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Figure 1.1 ‘Metabolic pathways involved in Ketogenic diet treatment’, taken from Masino and Rho 
(2012) 
This figure serves to show the complexity of the physiological changes that occur in 
response to the KD; this is only a snapshot, which does not include potential downstream 
effects of ketones or fatty acids in the brain. This network could be expanded to the entire 
body: without lipolysis from adipose tissue, the liver and kidneys would have insufficient 
energy to produce ketones or for amino acid oxidation for use for glucose synthesis, and if 
muscles did not preferentially use fatty acids as an energy source instead of glucose, less 
glucose would be available for tissues that are (partially or completely) dependent on it as 
an energy substrate. Theoretically, genetic variants affecting any one of these processes 
may influence KD response. The need to treat individuals with damaging mutations in 
SLC2A1 (the gene encoding the glucose transporter protein type 1, which transports 
glucose across the blood-brain barrier) with the KD is well-documented, but there are many 
other potential candidate genes. It makes sense that the ability to transport ketone bodies 
across the blood brain barrier would be a predominant factor in determining the rate at 
which the brain can use ketone bodies. Thus, variants affecting the amount or function of 
the monocarboxylate transporters, MCT1 and MCT2, which are responsible for the transfer 
of ketone bodies across the blood-brain barrier and for their access to astroglial and 
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neuronal cells [182], would be of interest. However, considering that the capacity of ketone 
body transporter proteins is also dependent on plasma ketone concentration, variants 
affecting any link in the network that brings about an increase in ketone body production 
could also be relevant. Variants that influence the breakdown of BHB and ACA to acetyl 
CoA for entry into the tricarboxylic acid cycle (via D-β-hydroxybutyrate dehydrogenase and 
succinyl-CoA:acetoacetate-CoA transferase), or that influence levels of free fatty acids or 
blood glucose/glycolytic flux could also influence KD response, independent of ketone body 
levels. It is unknown exactly which of the physiological responses induced by the KD are 
most relevant for seizure control. If this was known, it would be easier to pinpoint 
potentially relevant genes. 
Despite decades of endeavours to elucidate the underlying mechanisms of the KD, no 
definitive theory as to what causes its antiepileptic effects has been accepted. Having been 
designed to mimic the effects of starvation on the body, it may be assumed that the 
mechanisms underlying the antiepileptic/neuroprotective effects of calorie 
restriction/starvation are also responsible for those underlying the KD. Many postulated 
mechanisms of action do overlap, such as reduction of reactive oxygen species (ROS), 
antiinflammatory effects, increased mitochondrial biogenesis and neurotrophic factor 
activity [183], AMP kinase activation and subsequent inhibition of mammalian target of 
rapamycin (mTOR) [184], and reduced blood glucose and energy made from glycolysis 
[185]. Indeed, some studies suggest that calorie restriction alone is enough to have an 
antiepileptic effect [186-188] and that the effectiveness of the KD is improved when 
administered with fasting or calorie restriction [189, 190]. 
However, evidence suggests that there may be different underlying mechanisms of action. 
Only calorie-restricted KD-fed rats (as opposed to normal calorie-restricted or ad libitum 
diets) were protected against prolongation of ‘kindling-like afterdischarges’ in a maximal 
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dentate activation test [187]. Calorie restriction and the KD have had different effects on 
seizure thresholds in various seizure tests: the KD protected from 6 Hz-induced seizures 
and failed to protect against kainic acid-induced seizures, whilst the calorie-restricted diet 
caused increased seizure activity in the 6 Hz test, but protected juvenile mice against kainic 
acid-induced seizures [191]. KD-fed mice displayed a pattern of hepatic gene expression 
distinct from those fed a calorie-restricted diet [192]. 
Putative theories regarding how the KD exerts its antiepileptic effects, culminating in a 
network of complex interrelationships, are illustrated in Figure 1.2.  
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Figure 1.2: ‘Hypothetical pathways leading to the anticonvulsant effects of the ketogenic diet’, 
taken from Bough and Rho (2007) [166] 
Postulated mechanisms of action of the KD are outlined below: 
i) Ketone bodies  
In an individual following the KD, a shift occurs in hepatocytes: the high level of acetyl CoA 
generated from fat metabolism is converted to the ketone body ACA and its derivatives, 
BHB and acetone. These ketone bodies serve as a cellular energy source, and can cross the 
blood-brain barrier. 
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Given elevated serum ketones levels in patients [193] and animals [194] following the KD, 
and the rapid reversal of seizure protection with glucose infusion [36], it is not surprising 
that much work has concentrated on the role of ketosis in the therapeutic mechanisms of 
the KD. 
ACA [195, 196] and acetone [196-198] have been shown to have direct antiepileptic effects 
in animal models. In vitro studies have also revealed potential antiepileptic properties of 
ketone bodies: BHB and ACA slowed the firing rate of substantia nigra pars reticulata 
neurons [199]; ACA inhibited vesicular glutamate release in cultured neurons and sliced 
brain tissues, but not in astrocytes, reduced the amplitude of miniature excitatory 
postsynaptic currents in hippocampal slices, and suppressed the 4-aminopyridine-evoked 
seizures and glutamate release [200]; a combination of ACA and BHB prevented glutamate 
excitotoxicity in both acutely dissociated neocortical neurons and in isolated neocortical 
mitochondria [201], and protected against glutamate toxicity in hippocampal cell lines and 
primary hippocampal neurons [202]; presence of BHB increased the open probability of 
single KATP channels in mouse dentate gyrus granule cells [203], the implications of which 
will be discussed in the Energy metabolism section.  
Using proton magnetic resonance spectroscopy, cerebral acetone has been detected in 5/7 
individuals with either ‘partial’ or ‘full’ seizure control on the KD [204].  
Evidence is, however, conflicting:  BHB and ACA did not alter synaptic transmission in rat 
hippocampal-entorhinal cortex slices and cultured hippocampal neurons [205], nor did they 
modulate gamma-aminobutyric acid-a (GABAA) or ionotropic glutamate receptors in 
cultured neocortical neurons [206]. Chronic treatment with BHB failed to suppress evoked 
and spontaneous epileptiform activity in hippocampal slice cultures, despite protecting the 
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cultures against chronic hypoglycaemia, oxygen-glucose deprivation, and NMDA-induced 
excitotoxicity [207]. 
Furthermore, blood BHB or urinary ACA levels are not always associated with improved 
seizure control in humans [50, 51, 55, 80, 93, 100, 109, 119, 121, 122, 124, 126, 128, 132, 
208-213] or animals [186, 194, 214-219] following a KD. 
Although inconsistent, in vivo and in vitro evidence suggests that ketones have antiepileptic 
properties, but they may not directly mediate these effects [166]. Ketones may also be 
neuroprotective (for example, protection against glutamate excitotoxicity), but this does 
not necessarily translate into increased seizure protection. 
ii) Reduced glucose usage and reduced glycolysis 
The KD, by its very nature, makes use of energy substrates (ketone bodies) that are directly 
metabolised by mitochondria and thus bypass, and possibly even inhibit [199, 220] 
glycolysis. 
The proposal that reduced glucose and glycolysis is another mechanism by which the KD 
exerts its antiepileptic properties is supported by several facts: glucose uptake, glucose 
metabolism and glycolysis increase during seizures [221, 222], glycolytic energy is needed 
to maintain synaptic activity [223], and the effects of the KD can be rapidly reversed upon 
infusion of glucose [224]. 
Cultured hippocampal neurons and astrocytes from Bad-knockout mice, which have 
reduced cellular glucose metabolism [225], showed reduced mitochondrial utilisation of 
glucose and elevated utilisation of BHB, consistent with KD-induced changes in metabolism 
[226]. Bad -/- mice displayed resistance to behavioural and electrographic seizures and 
seizure severity was diminished. BadS155A (non-phosphorylatable) mice, which have 
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opposite effects on BAD’s apoptotic activity, displayed the same phenotype, highlighting 
the role of glucose metabolism.   
Other experimental studies have yielded conflicting results. Mice fed a KD or a calorie-
restricted diet were found to have lower blood glucose levels than those fed a control diet, 
but the two dietary interventions had different effects on seizure thresholds in 6 Hz- and 
kainic acid-induced seizure tests [191]. These findings that blood glucose levels are not 
correlated with KD response have been supported [216, 217, 219, 227] and contradicted 
[185, 228] in other KD rodent models.  
Clinical reports are similarly inconclusive: a correlation has been reported between lower 
blood glucose levels and increased KD effectiveness [128, 229], but others have found that 
blood glucose levels were not correlated with diet response [109, 230]. The association 
may be clouded due to varying accuracy and comparability between different methods of 
blood glucose measurement [231], and high variability in blood glucose levels, even in 
normal individuals [165].   
Despite these inconsistencies, experimental studies have continued to implicate low 
glucose levels and reduced glycolysis in the antiepileptic effects of the KD. 
Glucose restriction in neurons from rat hippocampal slices, with sufficient or high levels of 
adenosine triphosphate (ATP), resulted in significant hyperpolarisation and decreased 
neuronal excitability [232]. The authors reported that this was due to increased 
extracellular adenosine acting at adenosine A1 receptors (A1R) and opening KATP channels.  
2-deoxy-D-glucose (2DG), a glucose analogue that transiently inhibits glycolysis by blocking 
phosphoglucose isomerase [233], has reduced seizures induced by 6 Hz [234, 235], 
audiogenic stimulation [235] and pilocarpine [236] in rodents. 2DG has also reduced 
interictal epileptiform bursts in rat hippocampal slices [235] and increased the post-
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discharge threshold in kindled rats [237]. It has not, however, protected against maximal 
electroshock [235, 236], pentylenetetrazole-induced [235, 236], kainic acid-induced [236], 
or amygdala-kindled seizures [234]. In one study, 2DG decreased seizure threshold in 
pentylenetetrazole, kainic acid and electroshock seizure threshold tests [234].  
2DG has been shown to increase [238] and decrease [237] hippocampal expression of 
genes encoding brain-derived neurotrophic factor (BDNF) and to decrease expression of 
the gene encoding its receptor, TrkB tyrosine kinase [237] in rodents. 2DG also prevents or 
reduces the seizure-induced upregulation in expression of Bdnf and Ntrk2 [237].   
Diverting glucose metabolism from glycolysis to the pentose phosphate pathway with 
fructose-1,6-bisphosphate provides protection against seizures induced by pilocarpine, 
kainic acid or pentylenetetrazole in rats [236].  
iii) Fatty Acids 
The antiepileptic properties of fatty acids, in particular polyunsaturated fatty acids (PUFAs), 
have made them prime candidates in the search for underlying mechanisms of action of 
the KD. 
Animal studies have demonstrated that PUFAs have antiepileptic activity [239-247], 
although others have not found this to be true for eicosapentaenoic and docosahexaenoic 
acid [248], or linoleic acid and alphalinolenic acid [249]. Clinical studies have supported the 
idea that docosahexaenoic acid has antiepileptic properties [250, 251], but findings are 
conflicting [252, 253].  
Supplementation of a standard diet with linoleic and alphalinolenic acid can exert 
anticonvulsive properties comparable to a KD [243]. 
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One potential way in which PUFAs may exert an antiepileptic effect is through peroxisome 
proliferator-activated receptor (PPAR) activation. These nuclear receptor hormones are 
transcription factors that bind to DNA and regulate gene expression, and also serve as 
intracellular receptors by binding lipids [254]. Dietary PUFAs, in particular alphalinolenic 
acid and linoleic acid, are thought to be potent PPARα ligands [255]. PPARα-activated 
promotion of transcription of genes, such as that encoding mitochondrial 3-hydroxy-3-
methylglutaryl-CoA synthase (Hmgcs2) in the brain and liver, is thought to be at least partly 
responsible for the rise in blood ketone levels with the KD [256, 257].  
Hepatic PPARα is also involved in the regulation of a variety of genes encoding enzymes of 
intermediary metabolism and neurotransmitters, such as the glutamic-oxaloacetate 
transaminases, cyclooxygenase 2 and inducible nitric oxide synthase [256]. This adaptation 
mimics the transcriptional response to fasting [258] and mirrors one proposed mechanism 
of some AEDs, such as valproate: the alteration of neurotransmitter concentrations 
implicated in epilepsy [259]. 
Fatty-acid-stimulated PPARα, PPARδ and PPARγ (together with the co-activator, 
peroxisome proliferator-activated receptor γ co-activator 1) have been implicated in the 
control of gene expression of uncoupling proteins (UCPs) [260, 261]. These are 
mitochondrial transporters present in the inner mitochondrial membrane that dissipate the 
proton gradient generated by the respiratory chain so that heat is generated, instead of 
ATP [262, 263]. In vitro experiments show that increased expression of Ucp2 protects 
against neuronal cell death in the face of toxicity [264-267]. Levels and activity of Ucp2, 
Ucp4 and Ucp5 were increased in the hippocampi of mice fed a KD, compared to those fed 
a standard diet [268]; this was also associated with decreased ROS production. Decreased 
ROS is just one of the numerous consequences of increased UCPs, which may be (in part) 
responsible for the neuroprotective/antiepileptic effects of the KD; others include 
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increased mitochondrial biogenesis, increased ATP levels, decreased lipid peroxidation, 
regulation of mitochondrial calcium flux and heat generation in presynaptic nerve terminals 
[264, 269].    
Other proposed mechanisms for the modification of seizure threshold by PUFAs include the 
inhibition of voltage-gated sodium and calcium channels, activation of specific K2P channels 
[166], a combined effect on A-type potassium channels, sodium channels and resting 
membrane potential [270], and antiinflammatory actions [271]. 
Clinical evidence regarding the significance of PUFAs in the KD is conflicting. Serum PUFAs 
were significantly increased in children following a KD, and a positive correlation between 
reduction in seizure frequency and elevation in serum total arachidonic acid was reported 
[212]. The change in total plasma fatty acids during KD treatment has been shown to mirror 
the effectiveness of the diet [272]. Others have found that changes in fatty acids levels in 
plasma phospholipids did not correlate with likelihood of >90% seizure reduction at the 6-
month point, compared to prior to starting the diet [89]. Responders to the KD have been 
found to have a significant increase of serum palmitoleic acid and a significant decrease of 
arachidonic acid compared to non-responders, although no difference was found in levels 
of linoleic acid or alphalinolenic acid [101]. 
The medium chain saturated fatty acid, decanoic acid, has been implicated in the 
mechanism of the MCT KD: it improved seizure control in an in vitro pentylenetetrazol 
model compared to valproate [273] and it has been shown to increase mitochondrial 
proliferation in a neuronal cell line [274]. Decanoic acid is elevated in patients during 
dietary treatment [275, 276], although levels were not found to differ between responders 
and non-responders. 
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Despite these theories regarding different types of fatty acids, KDs containing either MCT, 
flaxseed oil (rich in alphalinolenic acid), butter, or an equal combination of the three, 
conferred a similar amount of seizure protection in rats, independent of differences in 
ketosis [215, 277]. Response rates in people following a classical KD or an MCT KD were 
found not to differ significantly [98, 278, 279]. Diet responders have been found to have 
larger absolute decreases in plasma phospholipid fatty acid 18:0 (number of carbons: 
number of double bonds) and lesser increases in 24:1 during dietary treatment, compared 
to non-responders [89]. No difference was found in levels of the fatty acids 14:0, 16:0, 16:1, 
18.1, 18.2, 18.3, 20.0, 20.3, 20.4, 20.5, 22.0, 22.5, 22.6 and 24.0, measured pre-diet and 
during dietary treatment, between responders and non-responders. 
There is little evidence to suggest that one particular type of fatty acid is required for the 
antiepileptic effects of the KD. The importance of the quantity of fatty acids is unclear.   
iv) Reduced oxidative stress 
In addition to the effects of UCPs on ROS (discussed in Fatty Acids section), there is 
evidence that ketone bodies reduce ROS generation [201, 268, 280-283]. This may be 
important, as ROS have been implicated in seizure generation and epileptogenesis [284, 
285], and oxidative stress generated by ROS is associated with neuronal loss in 
neurodegenerative diseases [286]. 
Other measures taken from KD-fed animals are indicative of enhanced mitochondrial 
antioxidant status: elevated mitochondrial glutathione (increased activity and up-regulated 
protein levels of glutamate cysteine ligase indicated de novo glutathione synthesis), 
reduced hippocampal (but not in the frontal cortex) CoA and lipoic acid [282], and 
increased hippocampal (but not cerebellar) glutathione peroxidase activity [287], compared 
to controls. 
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Tumour tissue from animals fed a KD displayed a differential expression of specific genes 
involved in the regulation of ROS levels, to mirror that seen in non-tumour brain tissue 
[283]. Although this study was not concerned with the antiepileptic effects of the KD, 
neuroprotective changes seen in tumours, such as reduced Cox2, increased glutathione 
peroxidase 7, and increased serine peptidase inhibitor, may also be relevant for protection 
against seizures.   
Treatment of human embryonic kidney cells with BHB was found to inhibit class I histone 
deacetylases and, in mouse kidney, it lead to increased transcription of oxidative stress 
resistance genes, such as those in the FOXO3A network (Foxo3a, Mt2, Lcn2, Lemd3 and 
Hbp1), Mn-SOD, and catalase [270].  
v) Energy metabolism  
Neuronal energy consumption is substantial, predominantly in order to maintain resting 
potentials and for neuronal signalling [288]. One might expect more efficient/increased 
energy metabolism to lead to stabilised synaptic function, limited neuronal 
hyperexcitability and fewer seizures.   
It has been shown that rats fed a high-fat diet for three weeks had increased ‘cerebral 
energy reserve’, with an increased cerebral ATP/ADP (adenosine diphosphate) ratio and 
lower concentrations of other substrates such as creatine [289]. Gene expression patterns 
in the hippocampus of rats fed a KD revealed an upregulation of many (but not all) 
transcripts encoding energy metabolism enzymes and mitochondrial proteins, compared to 
controls [290, 291].  
Rodents fed a KD also showed increased number of hippocampal mitochondria [291, 292], 
a trend for increased skeletal muscle mitochondrial biogenesis (measured as citrate 
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synthase activity) [293], elevated glutamate levels, decreased glycogen levels and an 
elevated phosphocreatine:creatine ratio [291].  
Concordant with these rodent studies, improved energy metabolism has been observed in 
humans following a KD, with increased phosphocreatine-ATP and 
phosphocreatine:inorganic phosphorus ratios in the grey matter compared to prior to 
starting the diet [294].   
How exactly enhanced energy reserves may lead to improved seizure control is unclear. 
One interpretation is that increased ATP concentration enhances or prolongs activity of 
Na+/K+ ATPase pumps, contributing to neuronal stability [233]. Increased power for ion 
pumps may lead to changes in the resting membrane potential and an increased capacity 
to produce inhibitory neurotransmitters [165].   
The ‘KATP-glycolysis hypothesis’ [295] is another putative explanation for the acute 
antiepileptic properties of the KD. According to this theory, the reduced glycolysis (and thus 
reduced glycolytic ATP production) brought about by low glucose/high ketone body 
concentrations triggers the opening of KATP channels (most importantly in the brain), 
depressing neuronal excitability. Although it is unknown how glycolysis is regulated in 
neurons in an individual following the KD, there is evidence that supports the KATP-glycolysis 
hypothesis. Ketone bodies (BHB or ACA) were found to reduce spontaneous firing rate in 
neurons in the substantia nigra pars reticulata, an effect that was seen to be even larger in 
faster firing cells [199]; this slowing was eliminated in the presence of KATP blockers, or in 
Kir6.2 knockout mice, suggesting that KATP channels are activated/opened in the presence 
of ketone bodies. Consistent with this work, in the presence of BHB, basal channel and 
stimulus-elevated open probability were increased in mouse dentate granule neurons 
[203]. 
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The authors suggested that reduced glycolytic production of ATP in the submembrane 
compartment could activate plasma membrane KATP channels, reducing electrical activity 
[199, 295]. High electrical activity, such as that produced by a seizure, increases Na+/K+ 
ATPase pump activity and ATP utilisation near the plasma membrane. This may in turn 
activate KATP channels in a process of negative feedback. Supporting this theory, the spike-
dependent increase in KATP channel open probability in mouse dentate granule neurons was 
reduced or abolished in the presence of a blocker of the Na+-K+ ATPase [203].  
Figure 1.3 depicts this negative feedback mechanism. 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: The KATP-glycolysis hypothesis, taken from Ma et al., 2007 
The role of ATP in the KATP-glycolysis hypothesis may seem contradicted by observations 
from animal studies that the KD is associated with normal or raised hippocampal [291, 292] 
or whole brain [289] ATP levels [296]. Considering the role of glucose/glycolysis in seizures, 
it may be specifically (depleted) glycolytic energy, rather than overall increased energy 
reserves, that is important for seizure management, as this reduces energy reserves 
necessary for seizure initiation and spread [165]. 
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Linked with this is the theory that the release of ATP associated with glucose restriction 
leads to elevated extracellular adenosine levels and the activation of adenosine A1R, which 
open KATP channels [232]. This link between activation of A1R and opening of KATP channels 
has been made elsewhere [232, 297-299] and its significance for the antiepileptic effect of 
the KD is complemented by other factors:  
a) adenosine signalling via A1R can reduce neuronal excitability [300] and suppress 
seizures [301].  
b) Adk-knockout mice, with seizures associated with deficient adenosine/A1R 
signalling, had no change in seizure frequency or duration when fed a KD [302]; seizures 
were nearly abolished in mice with intact A1R/adenosine deficiency (Adk-Tg) and were 
reduced by around 50% in mice with reduced A1R(A1R+/–), suggesting that KD-induced 
seizure control depends on A1R. 
c) the presence of BHB has been associated with increased open probability of single 
KATP channels in dentate granule neurons [203]. Taken with findings that ketones slow 
neuronal firing rate via opening of KATP channels [199], this suggests that KATP channels may 
act as a ‘link between metabolism and neuronal excitability’ [203]. 
Evidence behind the theory of energy metabolism and the KD appears strong, and provides 
a plausible connection between various components of the KD and their contribution to its 
antiepileptic mechanism.   
vi) GABAergic Inhibition 
Alteration in brain handling of glutamate, glutamine and GABA (a major inhibitory 
neurotransmitter), has been proposed as another mechanism by which the KD exerts its 
antiepileptic effect. Data suggest that ketosis intensifies mitochondrial metabolism and flux 
through the tricarboxylic acid cycle, increasing the availability of glutamine and the GABA 
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precursor glutamate in astrocytes [303, 304]. Elevated levels of GABA are expected to 
dampen hyperexcitability throughout the brain [166]. 
In vivo and in vitro studies have provided evidence both for and against the GABAergic 
hypothesis. Rats fed a calorie-restricted KD, or a normal calorie-restricted diet, have 
exhibited greater paired-pulse inhibition, which may reflect enhanced GABA-ergic 
inhibition via enhancement of GABAA receptors, than ad-libitum controls [187]. Calorie-
restricted diets have also been associated with increased mRNA (messenger ribonucleic 
acid) expression of Gad-67 and -65 in several regions of the brain, which encode the rate-
limiting enzyme in GABA synthesis, glutamic acid decarboxylase, [305]; increased Gad67 
mRNA in the striatum was an effect specific to KD-fed rats. BHB-treated astrocytes have 
displayed decreased GABA-transaminase and GABA transporter GAT-1 mRNA expression 
[306]. This has been contradicted by findings that there was no difference in regulation of 
transcripts encoding GABAB receptors, metabotropic glutamate receptors, or subunits of N-
methyl-D-aspartate in hippocampi from rats fed a KD, compared to controls [291].   
Similar inconsistencies are found in studies regarding brain GABA levels, which may be 
lower [307] or unchanged [308-310] in animals fed a KD, compared to controls.   
There are clinical reports that support the GABAergic hypothesis: strengthened short-
latency cortical inhibition, measured by transcranial magnetic stimulation, and enhanced 
peri-rolandic beta activity, measured by quantitative EEG, was found in healthy volunteers 
following a KD for two weeks [311]. This may be a reflection of cortical GABAA inhibition. 
Two of three participants with epilepsy showed increased cerebral GABA concentration, 
measured by magnetic resonance spectroscopy, when following a KD for two weeks [312]; 
one participant also showed increased GABA levels when following the KD for three 
months. Cerebrospinal fluid GABA was significantly increased in children with epilepsy at a 
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mean of four months after KD initiation, with higher levels in those who achieved >50% 
seizure reduction compared to non-responders [313].    
vii) Norepinephrine and neuropeptides 
There is evidence that norepinephrine, which protects against seizures in many animal 
models of epilepsy [314], is required for the antiepileptic effect of the KD. KD-fed rats had 
two-fold higher extracellular norepinephrine levels than rats fed a standard diet [315]. 
Latency to flurothyl-induced seizure was not increased in dopamine β-hydroxylase 
knockout mice, which are unable to synthesis norepinephrine; latency was increased in 
controls with normal norepinephrine levels [316]. 
Neuropeptide-Y and galanin, which are expressed together with norepinephrine by the 
majority of locus coeruleus neurons [317] and have antiepileptic properties [318, 319], are 
also likely candidates for the antiepileptic effects of the KD. However, the KD had no effect 
on the expression of genes encoding neuropepeptide-Y (in the brain or liver) [192, 320] or 
galanin (in the brain) [320] in mice.   
Leptin, which regulates the activity of these neuropeptides, has been shown to regulate 
hippocampal and hypothalamic neuron excitability [321] and reduce neuronal injury 
associated with kainic acid-induced status epilepticus [322]. Serum leptin is increased in 
KD-fed rats [323, 324], although hypothalamic leptin signalling may be impaired, indicated 
by decreased phosphorylation of STAT3 (signal transducer and activator of transcription), a 
downstream mediator of leptin receptor signalling. This was not due to ketones 
themselves, as leptin resistance was not observed with intraperitoneal injection of BHB 
[323]. 
viii) Anaplerosis 
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Another putative mechanism of action of the KD is based on the observation that seizures 
cause a deficiency in tricarboxylic acid cycle intermediates, leading to increased excitability 
[233, 325]. It has been hypothesised that replenishing these intermediates (a process 
known as ‘anaplerosis’) may prevent seizures.  
The anaplerotic compound, triheptanoin, has been shown to affect seizure susceptibility in 
mouse models [326]. Triheptanoin supplementation of a KD reduced memory impairment 
in a mouse model of familial Alzheimer's disease [327]. 
Supplementation with the branched chain amino acids leucine, isoleucine and valine, which 
provide precursors to replenish tricarboxylic acid cycle intermediates [328], may increase 
the effectiveness of the KD [329].  
 
This snapshot of the various hypothetical mechanisms of action of the KD highlights that a) 
we are still uncertain exactly how dietary treatment exerts an antiepileptic effect – there is 
evidence that mechanisms may be distinct/additional to those behind 
antiepileptic/neuroprotective effects of calorie restriction, and b) not all putative 
mechanisms are mutually exclusive – they may co-exist and even complement each other. 
This is especially true for the theory of energy metabolism, which encompasses reduced 
glycolysis, KATP channel modulation, enhanced adenosine transmission and improved 
mitochondrial function. An awareness of these (and indeed all) theories will influence 
decisions regarding genetic analyses, including the selection of candidate genes, and 
potentially the interpretation of results.   
 Are we able to predict response to the Ketogenic diet? 1.2.6
The KD is the treatment of choice for GLUT1 deficiency syndrome [330] and PDD [40, 331, 
332], as it provides an alternative fuel source, relieving blocks in metabolism upstream 
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from the tricarboxylic acid cycle [333]. The KD has also been found to be particularly useful 
for the following conditions/syndromes: 
- epilepsies with structural causes, such as lissencephaly, hypoxic-ischemic encephalopathy, 
cerebrovascular accident, intraventricular hemorrhage [334] or focal malformation of 
cortical development [96]. 
- status epilepticus [335] and epilepsies with immune causes, such as fever-induced 
refractory epileptic encephalopathy in school age children [336, 337]. 
- certain epilepsy syndromes, often with genetic causes, such as epilepsy with myoclonic 
atonic seizures [338-340], infantile spasms [57, 115, 341, 342], mitochondrial respiratory 
chain defects [343], Lennox-Gastaut [82, 113] and Dravet syndrome [79, 344-347]. It is of 
interest that 5% of a cohort of children with epilepsy with myoclonic atonic seizures were 
found to have GLUT1 deficiency with mutations in SLC2A1 [348]. Increasing numbers of 
patients with early-onset absence epilepsy are being found to have SLC2A1 mutations [349, 
350]; these individuals may not necessarily be drug-resistant or have developed a 
movement disorder. 
This list acts merely as an indication of likelihood of KD response; it does not rule out a 
favourable response to the KD in patients with other epilepsy syndromes or epilepsies of 
different/unknown causes.  
The question remains whether other patient demographics or clinical parameters allow 
response to the KD to be predicted. Such an exploration of potential predictors of response 
is essential for this study, as it may allow potential confounding factors in this cohort to be 
identified and enhance understanding of the mechanisms behind dietary therapy for 
epilepsy. 
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A PubMed search of the English- and Spanish-language literature was performed, with the 
keywords ‘ketogenic diet’ and ‘epilepsy’. Articles regarding the KD for metabolic disorders 
and refractory status epilepticus were excluded, as were case reports, abstracts, letters and 
papers published pre-1970.  
No single factor was consistently shown to predict response (favourable or unfavourable) 
to the KD, as outlined in a recent review [351].  
i) The following factors have (almost) consistently demonstrated no effect on KD 
response: 
Gender: gender has been found to have no effect on response to the KD in children [57, 66, 
71, 75, 79, 86, 93, 105, 107, 113, 118, 119, 123, 124, 127, 208, 211, 213, 279, 339, 344, 352-
360], adolescents [76, 93, 113, 118, 119, 123, 211, 279, 344, 352, 353, 355, 356, 359, 360] 
or adults [100, 121, 355, 360]. 
Others have found that male children and adolescents were slightly more likely to respond 
to the KD after one month, compared to females [55]. In contrast, female gender has 
predicted a favourable response after 12 months in adults [126].  
Intellectual status: developmental delay and cognitive impairment have been found not to 
influence KD effectiveness [72, 76, 103, 208, 354, 361], although individuals with less 
severe mental delay who have achieved seizure reduction on the KD may be more likely to 
maintain this reduction at the 12-month point [361].  
ii) Evidence regarding the effects of other factors on KD response is mixed: 
Age at diet initiation: no difference has been found when comparing age at diet initiation 
with KD response in children [54, 55, 66, 71, 79, 84, 86, 90, 93, 96, 105, 107, 113, 118, 119, 
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124, 127, 208, 211, 213, 279, 339, 347, 354-360, 362-364], adolescents [54, 55, 76, 93, 113, 
118, 119, 279, 355, 356, 359, 360, 363] or adults [100, 121, 126, 355, 360].  
Others have found KD response to be more favourable in children under one year of age 
[75], under 3 [365], under 5 [366], under 8 [352], under 10 [367], under 12 years [72], and 
with a ‘lower average age’ [123] compared to older children in each cohort, and in those 
with a mean age of 8 compared to non-responders with a mean age of 12 years [37]. 
Improved response has also been found in those aged between 3 or 4 - 10 years, compared 
to toddlers and older children [130, 353].   
Age at seizure onset: age at seizure onset has been found not to affect response to the KD 
in children [54, 55, 57, 86, 107, 109, 118, 124, 127, 208, 344, 360, 362], adolescents [54, 55, 
118, 344, 360] or adults [121, 360].  
Others have found an association between lower age at epilepsy onset with a favourable 
response to the KD in children [211, 364] and adolescents [211]. Higher age at onset of 
infantile spasms has been associated with increased likelihood of spasm reduction with 
dietary therapy [105].   
Anti-epileptic drugs: no correlation has been found between KD response and number of 
AEDs previously tried [55, 118, 121, 123, 124, 127, 208, 360], or number of AEDs exposed 
to at the time of diet initiation [55, 107, 118, 121, 126, 127, 355, 360, 362]. Differences in 
AEDs used or drug combinations [211], changes in AEDs [93], early/late reduction of 
medication during dietary treatment [78], or time to initial treatment of spasms with 
medication [109] may also not affect diet response.  
Current or previous use of valproic acid seems not to affect KD response [83, 113]. 
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Others have found a favourable response to the KD in children exposed to fewer AEDs prior 
to diet initiation [75, 105] and at diet initiation [105], compared to non-responders. A 
higher likelihood of response may also be found in children with no prior steroid use [105]. 
Children receiving phenobarbital in conjunction with the KD have been found to be less 
likely to respond to dietary treatment than those receiving valproic acid, topiramate, 
levetiracetam, lamotrigine or zonisamide; those receiving zonisamide may be more likely to 
respond [368].  
Body Mass Index (BMI): no relationship has been found between KD response and BMI 
[118, 127, 208, 358] or body weight [121] at diet initiation. Response to the KD may also be 
independent of the following factors during dietary treatment: BMI changes [93, 128, 358]; 
weight loss [55, 126], reduction in BMI [126]; growth [369]. 
Others have found an association between increased likelihood of KD response with a 
lower weight-to-height z-score [109], a stable BMI [118] and with a greater decrease in BMI 
during dietary treatment [121]. 
Diet ratio: no difference has been found in KD response with different ketogenic ratios [57, 
75, 76, 83, 105, 123, 208, 370]. 
Individuals following a KD with a 4:1 ketogenic ratio had better seizure control than those 
following a 3:1 diet [51]. People who started a diet on 10g carbohydrate/day were found to 
be more likely to respond to treatment at 3-month follow-up (but not at other follow-up 
times) than those who started on 20g/day [50].  
Diet type: a ‘strong trend’ has been identified for higher responder rates in people 
following the classical KD compared to those following the MAD [125] and a higher 
proportion of children following the classical KD reported decreased (unknown to what 
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extent) seizure frequency and severity, compared to those following the MAD [371]; others 
have not found this comparing the classical KD with the MAD [101, 360], or with the MCT 
KD [98, 278, 279]. 
EEG: no relationship has been reported between KD response and EEG patterns in general 
[213, 358, 364], or any of the following parameters: classic hypsarrhythmia, focal versus 
non-focal EEG abnormalities, EEG slowing, spikes or polyspikes, presence of focal spikes or 
EEG changes, high voltage spike-wave or multifocal discharges, normal background, 
epileptiform discharges in frontal, central, parietal and occipital regions, bilateral 
synchrony, trains of epileptiform discharges, burst suppression patterns, or generalised 
spike-wave abnormalities, posterior delta/theta/alpha relative power, spike index, number 
of regions of epileptiform discharges, or effect of sleep on epileptiform discharges [57, 66, 
71, 103, 105, 107, 124, 208]. 
Others have found an unfavourable outcome to the KD to be associated with presence of 
epileptiform EEG discharges in the temporal region [103], electrographic bilateral 
synchrony [103], higher frequency EEG background activity [211], classic hypsarrhythmic 
patterns [75] and multifocal spikes [66] at diet onset. No authors specifically stated 
whether this was independent of epilepsy syndrome or not. 
Epilepsy cause or syndrome: of those studies that specifically looked at KD response in 
people with epilepsies of different causes or with different epilepsy syndromes, the 
majority found no difference between groups:  diet response may be unaffected by 
epilepsy cause [57, 72, 75, 80, 84, 90, 103, 113, 119, 124, 211, 356-358, 363, 372], epilepsy 
syndrome [119, 211, 355, 357, 358, 362], or by prior resective surgery [121, 126]. A 
favourable response to the KD has been found to be more likely in people without 
‘surgically-approachable epilepsy’ or a surgically-approachable focus [95, 133, 373] (this 
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may be a surrogate for epilepsy syndrome), although others have reported high response 
rates in individuals with surgically-remediable focal malformations of cortical development 
[96].  
Others have reported a more favourable response to the KD in individuals with 
symptomatic, as opposed to idiopathic or cryptogenic epilepsy [354, 355]. Better response 
rates have also been reported in those with ‘idiopathic’ or ‘cryptogenic’ epilepsy [84, 86]. 
A higher proportion of children with infantile spasms caused by pre/perinatal injury were 
found to respond to the KD, compared to those with infantile spasms caused by brain 
malformation or with cryptogenic spasms [109].  
Seizure-freedom whilst following the KD has been achieved in more people with epileptic 
encephalopathies than in those with localisation-related epilepsies [374].  
Children with myoclonic-astatic epilepsy were found to be more likely to respond to the KD 
than those with absence epilepsy, cortical dysplasia, Lennox-Gastaut syndrome, Sturge-
Weber syndrome, myoclonic absence epilepsy, juvenile myoclonic epilepsy, encephalitis, 
Angelman syndrome or Dravet syndrome [127].  
Ketosis: no correlation has been found between seizure control and blood BHB levels in 
children [51, 55, 56, 109, 119, 128, 210-213, 375], adolescents [51, 55, 56, 119, 128, 210-
212, 375] or adults [126, 128, 210, 375], nor between seizure control and urinary ketosis in 
children [50, 55, 80, 93, 122-124, 132, 209, 375], adolescents [50, 55, 93, 122-124, 132, 
209, 375] or adults [100, 121, 132, 209, 375].  
‘Large ketosis’ (unspecified whether ketones measured in blood or urine) has been found 
not to influence the likelihood of achieving seizure-freedom during the first two weeks of 
following the KD [208]. 
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No relationship has been found between breath acetone and seizure control in children, 
adolescents and adults following the KD [376].  
Others have reported a correlation between improved seizure control and higher blood 
BHB levels in children [36, 98, 132, 193], adolescents [98, 132] and adults [132] following 
the KD.  
A positive correlation has been found between seizure control and urinary ketone levels in 
children, [98, 118, 119, 354, 369], adolescents [98, 118, 119, 369] and adults [369]. 
Other biochemical markers: KD responders have been found to have larger absolute 
decreases in plasma phospholipid fatty acid 18:0 and lesser increases in 24:1 during dietary 
treatment [89] compared to non-responders. Positive correlations between reduction in 
seizure frequency and elevation in serum total arachidonic acid [212], increase in fat 
oxidation [377], increase in serum palmitoleic acid and decrease of serum arachidonic acid 
[101] have also been reported. 
In one cohort, the individual who achieved greatest seizure reduction on the KD also had 
the largest increase of total and low-density lipoprotein (LDL) cholesterol [120].  
No difference has been found in levels of the plasma phospholipid fatty acids 14:0, 16:0, 
16:1, 18.1, 18.2, 18.3, 20.0, 20.3, 20.4, 20.5, 22.0, 22.5, 22.6 and 24.0 (number of carbons: 
number of double bonds) [89], monoamine or HVA/5HIAA levels [378] between diet 
responders and non-responders, measured pre-diet and during dietary treatment. 
Responders and non-responders have displayed no difference in levels of carnitine, amino 
acids, organic acids or blood count [211], levels of linoleic acid or alpha-linolenic acid [101], 
or in levels of octanoic or decanoic acid [276].  
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Seizure frequency: pre-diet seizure frequency has been found not to affect KD response [55, 
75, 76, 100, 103, 105, 118, 126, 208, 352, 360]. 
Others have reported KD response to be more favourable in people with recently increased 
seizure frequency [54] or a higher pre-diet seizure frequency [121, 127]. 
Seizure type: a more favourable response to the KD has been reported in people with 
generalised seizures compared to partial seizures [72, 90, 95, 211, 366, 374].  
Focal seizures have been associated with decreased likelihood of a favourable response to 
the KD compared to other seizure types [50, 93, 103, 208]. In one cohort, dietary therapy 
was ineffective for ‘grand mal or focal motor seizures’ [37]. In another, children with ‘minor 
seizures’ showed a better response to the KD compared to those with ‘major seizures’ 
[379].  
Children with infantile spasms [354] or multiple seizure types [76, 93] have been found to 
respond more favourably to the KD than those with other specific seizure types. 
Others have found no differences in seizure control when comparing seizure types in 
people following the KD [55, 66, 71, 79, 80, 84, 85, 107, 113, 119, 121, 124, 128, 145, 153, 
213, 279, 339, 344, 352, 354, 355, 358, 359, 361, 363, 365, 380]. 
Time between seizure onset and initiation of dietary treatment: no difference has been 
found in response to dietary treatment with respect to time between epilepsy onset and 
dietary treatment [54, 57, 86, 100, 103, 109, 213]. 
Others have shown KD responders to have a shorter time from epilepsy onset to diet 
initiation than non-responders [99, 211]. 
iii) There are limited data (≤four studies per factor) regarding the effects of the 
following factors on KD response: 
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Blood glucose: a correlation has been reported between lower blood glucose levels and 
increased diet effectiveness [128, 229]. Others, however, have found that blood glucose 
levels were not correlated with diet response [109, 230]. 
Imaging: no difference in likelihood of achieving seizure freedom within two weeks of diet 
onset has been reported between people with or without a structural brain abnormality 
[208]. KD effectiveness may not be predicted by magnetic resonance imaging [107, 124] or 
computerised tomography findings [124]. 
Other: KD response has been found to be independent of ethnicity [93], having a family 
history of epilepsy or history of febrile seizure [103]. 
In summary, there is no evidence to suggest that KD response is affected by any of the 
factors identified. For the majority of factors, findings are inconsistent, which makes it 
difficult to draw conclusions. Some factors, such as differential response to the diet with 
age, may also be affected by environmental and/or social factors. Even the apparently most 
consistent evidence must be interpreted with caution. For example, only one of the studies 
that investigated the relationship between ketosis and effectiveness of the KD at various 
follow-up points found this correlation to be true at all times [159]; this may indicate that 
ketosis serves more as an indicator of dietary compliance, rather than effectiveness. 
Reports of improved response in very young children and adolescents may be due to better 
diet adherence in these age groups, and small numbers of participants in some age groups 
must be considered. Disease severity, referral bias and resource availability may also affect 
age at KD initiation. 
It must also be considered that each factor may not be a separate entity. For example, the 
following factors may be inextricable from epilepsy syndrome, or at least represent a 
greater or lesser degree of epilepsy severity: age at diet initiation, age at seizure onset, EEG 
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and imaging findings, intellectual status, pre-diet seizure frequency and surgery or 
surgically approachable epilepsy. Brain ketone utilisation depends on other factors, 
including blood ketone and glucose levels [221, 381], which may explain the variability in 
study findings with respect to the effect of these factors on KD response. Reports of 
improved response to the KD in people with more severe or recently-worsened epilepsy 
may simply reflect a regression to the mean. 
Evidence suggesting no effect on KD response is most consistent for gender and intellectual 
status. A large number of studies found no effect of gender on diet response and the two 
studies that do report a gender effect, which comprise different age groups and follow-up 
times, are conflicting. No studies have reported an effect of intellectual status on KD 
response; the finding that individuals with less severe mental delay who achieved seizure 
reduction on the KD were more likely to maintain this reduction at long-term follow-up 
may be due to increased likelihood of compliance with the diet, or may reflect epilepsy 
type. 
In the absence of sufficient or consistent evidence from human studies, in vivo and in vitro 
models may provide further clues. 
Many factors and their putative effect on KD response have been investigated in 
experimental studies; a variety of models have been used, so collated results must be 
interpreted with caution.  
The KD can be effective in both young and adult rodents [166], although some have shown 
a calorie-restricted KD to be most effective in young rats [382]. 
BHB levels have been shown to correlate [227, 383] and not correlate [186, 194, 214-219] 
with KD response in rodents. 
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Likewise, blood glucose levels have been shown to correlate [185, 228] and not correlate 
[191, 216, 217, 219, 227] with KD response in rodents. 
Seizure protection in rats may not be affected by fat composition of a KD [215], although 
PUFA supplementation of a standard diet can exert anticonvulsive properties comparable 
to the KD [243]. 
Studies have shown increased diet ratio to be associated with improved KD effectiveness 
[214, 217, 227, 384] in rodents. 
A calorie-restricted KD was found to induce a significant increase in seizure resistance in 
rats compared to an ad libitum KD [385].    
One study found that valproate, carbamazepine, lamotrigine, oxcarbazepine, and 
topiramate significantly decreased the concentration of free acetone in mouse brain [386].  
Experimental observations regarding the effects of certain factors on KD response tend to 
replicate their clinical correlates. For example, animal studies provide conflicting evidence 
with regards age at diet initiation and blood glucose. Experimental evidence indicating 
improved diet effectiveness with increased diet ratio does appear strong, which is 
inconsistent with most clinical findings. This may be due to the fact that the ketogenic 
ratios often used in animal studies are higher than those used (or that could be used in a 
palatable diet) in humans. Most animal studies have demonstrated a lack of correlation 
between ketosis and seizure protection, which may point towards an indirect effect of 
ketone bodies in the KD, such as optimising Krebs cycle function or inhibition of ROS 
production [296]; ketone body levels may be a surrogate for the real mechanism of the KD 
[273]. 
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Overall, the limited or conflicting evidence has not highlighted any specific patient 
demographics or clinical parameters to be mindful of in future analyses. It also provides 
little indication as to potential mechanisms of action of the KD in humans. This literature 
review highlights the need to look for predictors of response to the KD, as (with the 
exception of specific metabolic disorders) there is currently no consistent evidence for any 
one predictor. The rationale behind investigating potential genetic predictors of response 
will be explored in the following section. 
1.3 The Ketogenic diet and Genetics 
In the context of disease and pharmacotherapy (or perhaps, more appropriately in this 
case, ‘nutritherapy’), a comprehensive understanding of the interaction of genotype and 
phenotype holds immense potential. For example, the clinical utility of the discovery of the 
association of carbamazepine-induced Stevens-Johnson syndrome (SJS) and toxic 
epidermal necrolysis (TENS) with the HLA-B*1502 allele in Asians [387] has been 
demonstrated: prospectively screening Han Chinese individuals before initiating 
carbamazepine therapy, and withholding carbamazepine from those who were HLA-
B*1502–positive, reduced the incidence of carbamazepine-induced SJS/TENS [388]. Pre-
treatment screening may theoretically reduce the financial burden of drug-related adverse 
outcomes [389], but this has not been shown to be the case with HLA-B*1502 screening for 
people with epilepsy [390].  
Differences in gene expression may also be used as phenotypic predictors, such as drug-
response in cancer [391], weight maintenance following calorie restriction [392] and 
response to endurance exercise training [393].  
It seems prudent to investigate whether genetic variation influences KD response due to 
various factors. A particularly favourable response to the KD has been observed in 
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individuals with conditions mainly caused by single genetic factors and there are limited 
animal and human studies that suggest a genetic basis to KD response. As a period of time 
(up to some weeks) tends to be needed for the KD to exert its full anticonvulsant effects, it 
has been suggested that altered gene expression is involved [394]; the KD has been 
associated with gene expression changes in animal models, as will be discussed in the 
following section. One of the major influences on gene expression is gene variation [395-
397] and so it seems appropriate that individual genetic variation determines whether 
somebody responds favourably to the KD or not.  
An awareness of the literature associated with the KD, its putative antiepileptic 
mechanisms of action and the theoretical interaction of genetics has facilitated the 
selection of candidate genes for further study. Further detail will be given in Chapter 4. 
 Differential response to the Ketogenic diet 1.3.1
There is evidence that certain epilepsy syndromes and conditions in humans respond 
particularly well to the KD [151, 398]. Many of these conditions are caused predominantly 
by single genetic factors, which may lead to the postulate that there are other genetic 
factors, independent of epilepsy syndrome, that also influence response to the KD.  
Seven epilepsy syndromes have a ‘probable benefit’ (reported in at least two publications) 
from the diet [151]; these syndromes, along with their causative mutations, are outlined in 
Table 1.4. Several syndromes, as well as selected mitochondrial disorders, such as 
phosphofructokinase deficiency and mitochondrial respiratory chain complex disorders, 
have a ‘suggestion of benefit’ (only from case reports or series); these can be found in 
Table 1.5. Associated genes were found from Online Mendelian Inheritance in Man 
(http://www.omim.org), Genetics Home Reference (http://ghr.nlm.nih.gov), The 
MalaCards human disease database (http://www.malacards.org), and PubMed searches. 
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Table 1.4: Conditions caused by genetic factors that have a ‘probable’ benefit from the Ketogenic 
diet  
CONDITION ASSOCIATED GENE MUTATIONS 
Glucose transporter protein 1 (GLUT1) 
deficiency 
SLC2A1 
Pyruvate dehydrogenase deficiency 
PDHA1 
PDHB 
DLAT 
DLD 
PDHX 
PDP1 
Epilepsy with myoclonic atonic seizures 
(Doose syndrome) 
SCN1A 
SCN1B 
GABRG2 
GRIN2B 
SLC2A1 
Tuberous sclerosis complex 
TSC1 
TSC2 
Rett syndrome 
MECP2 
CDKL5 
FOXG1 
Severe myoclonic epilepsy in infancy (Dravet 
syndrome) 
SCN1A 
SCN1B 
SCN2A 
SCN9A 
PCDH19 
GABRG2 
GABRD 
West syndrome 
CDKL5 
ARX 
SCN1A 
SCN2A 
MAGI2 
LINC00581 
FOXG1 
SPTAN1 
ALDH7A1 
GLDC 
GCSH 
GCST 
KCNJ11 
POMC 
PNKP 
FLNA 
STXBP1 
IL1RN 
PHGDH 
TLE 
ARX 
PTCH1 
TSC1 
TSC2 
LIS1 
DCX 
SLC25A22 
ST3GAL3 
TUBA1A 
ATP7A 
TPH1 
IDUA 
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Table 1.5: Conditions caused by genetic factors that have a ‘suggested' benefit from the Ketogenic 
diet 
 
Few studies have reported on KD response in individuals screened for genetic mutations. 
2/4 people with SCN1A mutations and 1/1 with a 4p- deletion achieved >50% seizure 
reduction after following a KD for three months [334]. When following the diet for one 
CONDITION ASSOCIATED GENE MUTATIONS 
Phosphofructokinase deficiency  (Glycogen storage disease type VII) PFKM 
Myophosphorylase deficiency (Glycogen storage disease type V) PYGM 
Mitochondrial respiratory chain complex I 
ACAD9 
FOXRED1 
MT-ND1 
MT-ND2 
MT-ND3 
MT-ND4 
MT-ND4L 
MT-ND5 
MT-ND6 
NDUFA1 
NDUFA10 
NDUFA11 
NDUFA2 
NDUFAF1 
NDUFAF2 
NDUFAF3 
NDUFAF4 
NDUFAF5 
NDUFAF6 
NDUFS1 
NDUFS2 
NDUFS3 
NDUFS4 
NDUFS6 
NDUFS7 
NDUFS8 
NDUFV1 
NDUFV2 
NUBPL 
NDUFB3 
Mitochondrial respiratory chain complex II 
SDHAF1 
SDHA 
Mitochondrial respiratory chain complex IV 
(Cytochrome-c Oxidase Deficiency Disease) 
FASTKD2 
COX14 
COX6B1 
COA5 
MTTS1 
MTTL1 
C2ORF64 
C12ORF62 
COX20 
MTTN 
MTCO1 
MTCO2 
MTCO3 
COX15 
COX10 
SURF1 
SCO2 
SCO1 
TACO1 
LRPPRC 
Lafora body disease 
EPM2A 
NHLRC1 
NFU1 
CSTB 
CLN3 
GBE1 
PARK2 
PPP1R3C 
TRIM32 
PRDM8 
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month, 8/13 (61.5%) children with SCN1A mutations achieved ≥75% seizure reduction; at 3- 
and 6-month follow-up, 6/13 (46.2%) achieved ≥75% seizure reduction, as did 5/13 (38.5%) 
at 9-month follow-up [345]. Another study tested individuals with Dravet syndrome for 
SCN1A mutations (6/7 tested positive) and reported on the effectiveness of dietary 
treatment in six individuals (4/6 had improved seizure control), but it is unclear whether the 
KD was administered in those tested for mutations or not [346]. 
No studies have directly compared KD response with presence/absence of specific genetic 
mutations in humans.   
Animal studies have shown strain-specific responsiveness to the KD in terms of seizure 
threshold: FVB/NJ in-bred mice strains fed a KD showed increased latency to generalised 
tonic clonic seizure, compared to controls; A/J mice showed reduced latency [399].  
The KD has been shown to reduce seizure frequency in Kcna1-null mice [400] and elevate 
seizure threshold in Scn1a knockout mice [401]. 
The KD resulted in near seizure-freedom in Adk-Tg mice, ‘significantly’ reduced seizures in 
A1R
+/- mice, and had no effect in A1R
-/- mice, suggesting a role of adenosine A1R in KD-
induced seizure reduction [302].   
Genetic influences on biochemical parameters associated with the KD have been reported. 
Increased mitochondrial utilisation of BHB was found in Bad-null and BadS155A cortical 
neurons and astrocytes compared with wild-type cells, leading to increased open 
probability of KATP channels [226] (this will be discussed further in Chapter 4); higher activity 
levels of hepatic BHB dehydrogenase and acetoacetyl-CoA thiolase were found in Shc 
knockout compared to wild-type mice [402]. KD- or fasting-induced ketosis was suppressed 
in Prkce-null [403], Pparα-null [404] and Fgf21 knockout [405] mice compared to wild types, 
although evidence is conflicting for the latter [406]. Glucose levels have been found to be 
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lower in KD-fed Pparα-null mice [404] and higher in Fgf21 knockout mice [405], compared 
to wild types.   
Differential responsiveness to the KD with a genetic basis has also been shown in patients 
with Alzheimer’s disease. Daily administration of the ketogenic agent AC-1202 for 90 days 
resulted in significant differences in serum BHB levels and Alzheimer’s Disease Assessment 
Scale-Cognitive subscale (ADAS-cog) scores compared to placebo; effects were most 
notable in patients who did not carry the apolipoprotein E4 (APOE4) allele [407]. 
Consumption of an MCT drink, compared to placebo, has led to improved performance in 
ADAS-cog in APOE4- but not APOE4+ subjects [408]. 
 
Experimental work indicates that the KD is effective in Kcna1- and Scn1a-null mice and that 
responsiveness to the KD (in terms of seizure control) may be strain-specific, but further 
studies are needed. The following genes have been shown to play a potentially important 
role in the mechanisms of the KD: Bad, Kcnj11, Shc1, Pkcε, Pparα and Fgf21, but it is 
unknown whether this is relevant for humans. Genetic factors may influence efficacy of the 
KD, in terms of improved cognition, in humans. 
 
 Differential regulation of gene expression 1.3.2
Decades of research have led to the identification of many gene expression changes 
associated with calorie restriction [409]; one would expect similar changes from the KD. 
Indeed, many of the putative mechanisms of action of the KD involve an up- or down-
regulation of gene expression.  
A recent study showed that pilocarpine-injected, epileptic rats fed a KD had a distinct 
genomic methylation profile and gene expression patterns compared to untreated epileptic 
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rats – the KD seemed to ameliorate DNA methylation and subsequent gene expression 
changes associated with seizures [410]. A full list of differentially methylated or expressed 
genes was not provided. Only two candidate genes were mentioned: KD treatment 
attenuated the hypermethylation and decreased gene expression of Camkk2 
(calcium/calmodulin-dependent protein kinase kinase 2, beta) in the epileptic rat (Camkk2 
gene expression was decreased in non-KD-fed epileptic rats compared to controls), a 
difference which was statistically significant; the KD reversed the hypomethylation of the 
Il10rb (interleukin 10 receptor, beta) locus seen in non-KD-fed epileptic rats but it had no 
effect on Il10rb expression. 
A literature search was conducted to identify other genes that have been shown to be 
differentially regulated in animal models (both ‘healthy’ and epilepsy models were 
included) due to the KD. Only genes shown to be upregulated from feeding of a KD, not 
from the application of substances designed to mimic the effects of KD-feeding, such as 
2DG or BHB, were considered. This is to allow for a more accurate representation of KD-
feeding in humans, and allows for the (presumed) interaction of the many components of 
the KD. 
Figure 1.4 portrays a snapshot of genes, and the proteins they encode, that have been 
shown to be upregulated by the KD in animal models. Official full names and gene symbols 
are taken from the Gene database (www.ncbi.nlm.nih.gov/gene), searched for by Accession 
number or by the gene name used by study authors. Mouse Genome Informatics 
nomenclature guidelines have been followed (Guidelines for Nomenclature of Genes, 
Genetic Markers, Alleles, and Mutations in Mouse and Rat: 
http://www.informatics.jax.org/mgihome/nomen/gene.shtml).   
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KEY (for Figures 4 and 5) 
Black text with no 
symbol=shown in 
hippocampus 
ϴ=shown in whole brain 
¥=shown in hippocampus 
and liver 
§=shown in hippocampus 
and whole brain 
Ж=shown in liver 
∏=shown in lymph node 
and CNS 
$=shown in striatum 
The potential consequences of each gene upregulation are given in yellow boxes, where 
possible.  
Other genes shown to be upregulated by the KD include the following: 
Latexin (Lxn) [290] 
TIMP metallopeptidase inhibitor 2 (Timp2) [290] 
Bone morphogenetic protein receptor, type IA (Bmpr1a) [290] 
Nuclear receptor subfamily 3, group C, member 2 (Nr3c2) [290] 
Guanine nucleotide binding protein (G protein), alpha z polypeptide (Gnaz) [290] 
Myelin basic protein (Mbp) [290] 
Syntaxin 1B (Stx1b) [290] 
Synaptotagmin XI (Syt11) [290] 
Prion protein (Prnp)ϴ [283] 
Membrane protein, palmitoylated 4 (Mpp4) ϴ [283] 
Neuroglobin (Ngb) ϴ [283] 
Serine (or cysteine) peptidase inhibitor, clade E, member 1 (Serpine1) Ж [404] 
Glucose transporter 1 (Glut1) ϴ [411] 
Glucose transporter 3 (Glut3) ϴ [411] 
and 389 genes listed in Supplementary Table 1 in Bough et al., 2006 [291]. 
ϴ=shown in whole brain 
Ж=shown in liver 
 
The effects of these genes with regards to KD antiepileptic action have not been extensively 
investigated.  
Figure 1.5 portrays a snapshot of genes (and the proteins they encode) that have been 
shown to be downregulated by the KD in animal models.  The same criteria used for Figure 
1.4 have been applied.  
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[192, 256, 
283, 289-291, 305, 412-414] 
 
**Mitochondrial 
transcripts: 
See Appendix 1.2: 
transcripts that encode 
mitochondrial proteins, 
from Bough et al., 2006 
[291] 
 
***Peroxisome 
proliferator-activated α 
and δ have not been 
shown directly to be 
upregulated by KD-feeding 
 
*Energy metabolism genes 
Genes from Fig 3B Bough et 
al., 2006 [291] (Appendix 
1.1) 
ATP synthase, H+ 
transporting, mitochondrial 
Fo complex, subunit d 
(Atp5h)  
ATP synthase, H+ 
transporting, mitochondrial 
Fo complex, subunit 
B1(Atp5f1) 
Acyl-CoA synthetase long-
chain family member 1 
(Acsl1) 
aldolase A, fructose-
bisphosphate (Aldoa) 
NAD(P)H dehydrogenase, 
quinone (Nqo1) ϴ 
 
 
Figure 1.4:  Genes shown to be upregulated by the Ketogenic diet in animal models 
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[192, 290, 
291, 405, 
413, 415-
418]
Figure 1.5: Genes shown to be downregulated by the Ketogenic diet in animal models 
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Other genes shown to be downregulated by the KD: 
Cytochrome P450, family 17, subfamily a, polypeptide 1 (Cyp17a1) [290] 
Macrophage migration inhibitory factor (Mif) [290] 
Tachykinin 2 (Tac2) [290] 
Proopiomelanocortin (Pomc)Ø [192] 
Ras-related protein, (Rala) [290] 
Calponin 3 (Cnn3) [290] 
Fibrinogen  β chain (Fgb) [290] 
V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (Erbb3) [290] 
Casein kinase II β subunit (Csnk2b) [290] 
Apolipoprotein E (Apoe) ϴ [415] 
Amyloid beta (A4) precursor protein (App) ϴ [415] 
Heat shock protein 90α (Hsp90ab1) [290] 
and 274 genes listed in Supplementary Table 1 in Bough et al., 2006 [291]. 
Ø=shown in hypothalamus 
ϴ=shown in whole brain 
 
Figure 1.4 and Figure 1.5 emphasise the complexity of KD treatment and the fact that many 
of the gene expression changes have unknown consequences.  
In summary, the principal effects on gene expression induced by the KD are: 
In the hippocampus: 
- Upregulation of mitochondrial transcripts and genes associated with energy 
metabolism. This has led to an increased number of mitochondrial profiles and energy 
metabolites (although evidence is conflicting as to which metabolites are increased).   
- Upregulation of PPARs. Although only Pparγ has been shown to be upregulated 
with the KD (with effects on UCPs), Pparα and Pparδ are also assumed to be implicated 
[256].  
- Upregulation of Mct1, leading to increased transport of ketones into the brain. 
- Upregulation of genes encoding subunits of sodium and potassium channels. One 
would expect this to affect regulation of neuronal excitability and seizure susceptibility 
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[304] (many genes associated with epilepsy encode voltage-gated sodium channels [419] 
and Kcnn2 has been found to protect against kainate and glutamate excitotoxicity and 
increase neuron survival after sodium cyanide or staurosporine insult [420]) although this 
has not been shown directly by KD-feeding.  
- Differential regulation of genes leading to reduced ROS/oxidative stress.   
- Downregulation of protein kinase C-related genes. One would expect this to affect 
neuronal excitability, potentially through GABA receptor activation – there is evidence that 
the receptor for activated C kinase (Rack1) and protein kinase C bind to distinct sites on the 
GABAA receptor, potentially affecting neuronal excitability [421]. 
- Downregulation of genes encoding ion channels, and genes associated with protein 
transport, synaptic transmission, and cell signalling. How exactly this may exert an 
antiepileptic effect is unknown. 
- Downregulation of Ppp2ca, possibly due to reduced oxidative stress, leading to 
reduced apoptosis through the inactivation of BCL2 [422].   
- Downregulation of Rps6 and Akt1, potentially leading to an antiepileptic effect via 
inhibition of the mTOR pathway. 
 
In whole brain: 
- Upregulation of Hmgcs2, possibly via Pparα.  
- Upregulation of other genes associated with reduced ROS/oxidative stress.  
- Downregulation of Casp3, leading to antiapoptotic effects. 
 
In the liver: 
- Upregulation of Hmgcs2, possibly via Pparα, and downregulation of Hmgcr, leading 
to increased serum ketone bodies. Fasting/drug-activated Pparα upregulates expression of 
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many other genes, such as medium chain acyl dehydrogenase (Mcad), carnitine 
palmitoyltransferase 1a (Cpt1a) and long chain fatty acyl-CoA synthase (Acs1) [256]; these 
have not directly been shown to be affected by the KD.  
- Upregulation of Fgf21. PPARα-mediated expression of FGF21 in the liver stimulates 
gluconeogenesis, fatty acid oxidation and ketogenesis [423]. It is unknown how this may 
affect seizure susceptibility, but it is of interest that FGF21 can cross the blood brain barrier 
[424] and that rats treated with intracerebroventricular FGF21 had suppressed hepatic 
glucose production and gluconeogenic gene expression, and increased insulin sensitivity 
[425]. 
- Differential regulation of genes associated with fatty acid metabolism, consistent 
with increased fatty acid oxidation and decreased fatty acid synthesis.  
- Downregulation of G6pc, leading to decreased gluconeogenesis.  
 
In the lymph node and central nervous system (CNS): 
- Downregulation of genes encoding cytokines and chemokines, potentially leading to 
ROS reduction.  
 
In the striatum: 
- Increased expression of Gad1. This may be associated with increased GABA 
synthesis. 
 
There is conflicting evidence regarding the regulation of other genes from KD-feeding: 
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Tumor necrosis factor α (Tnfa): Hippocampal expression Tnfα has been shown to be 
increased in KD-fed mice, compared to controls, and kainic acid-induced increases in Tnfα 
were attenuated by KD-feeding [414]. Others have found no change in hepatic Tnfα 
expression [405], and reduced expression in the lymph node and CNS [417]. 
Prostaglandin-endoperoxide synthase 2 (Ptgs2) [often referred to as Cox2]: Increased 
expression of Ptgs2 has been found in whole brain from mice fed a KD, compared to those 
fed a standard diet [283]; in tumour cells, the KD has attenuated a tumour-induced increase 
in Ptgs2 [283] and in the hippocampus, the KD has attenuated a kainic acid-induced 
increase in Ptgs2 [414]. 
Other inflammatory markers: Evidence regarding expression of other genes that may also 
serve as inflammatory markers is conflicting. No change in hepatic expression of interleukin 
1 complex (Il1), Il6 and chemokine ligand 2 (Ccl2) was found [405], whilst others reported 
decreased expression of Il1b, Il6 and Ccl2 in the lymph node and CNS in KD-fed mice, 
compared to those fed a standard diet [417]. 
Considering the antioxidant effects of KD-feeding observed in several studies [183], 
expression of genes encoding proinflammatory cytokines may be expected to be reduced 
with the KD – for example, TNFα, IL1 and IL6, the related chemokine ligand 2 (expression 
induced by TNFα [426]), and COX2, which has been associated with excitotoxicity, ROS 
generation and neuronal death, [427, 428]. Seemingly contradictory findings may be 
explained by an initial induction of mild oxidative stress from the KD, in order to activate 
pathways that ultimately lead to an improved redox state (as may occur with activation of 
the Nrf2 pathway [412]), but this is just speculation.   
Insulin-like growth factor (IGF) system: Brain IGF1 receptor, Igf1r, and IGF binding protein 
Igfbp-3 mRNA levels were increased in rats fed a calorie-restricted KD, compared to those 
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fed a standard diet or a calorie-restricted diet [411]; Igfr, Igfbp-2 and -5 mRNA levels were 
unchanged. Others have reported increased expression of Igfbp1 with the KD [290]. 
The significance of these changes for epilepsy is unknown, although the improved insulin 
sensitivity associated with calorie restriction (through increased adiponectin and decreased 
TNFα) has been proposed as one of the mechanisms by which calorie restriction results in 
longevity [429]. Insulin/IGF1 are also thought to play a role in Alzheimer’s disease, through 
the regulation of APP and amyloid-β levels. [430]. 
Evidence regarding expression changes of mitochondrial DNA (mtDNA) is limited. The KD 
has been shown to increase mitochondrial biogenesis [291, 293] and upregulate transcripts 
encoding mitochondrial proteins [291]. The KD has also been associated with increased 
mtDNA copy number in skeletal muscle of wild type mice [293], as has a high-fat diet [431]. 
It must be noted, however, that ketosis has differing effects on skeletal muscle compared to 
brain [291, 432].  
This review of the literature has identified a plethora of genes that are differentially 
expressed in KD animal models, compared to controls. When evaluating the evidence, many 
factors must be considered: not all findings are consistent, not all animal models used are 
identical and the location of gene expression changes may be significant. 
No studies have been identified that have looked at gene expression changes in humans 
following a KD. 
1.4 Research questions and hypotheses 
This literature review has highlighted a need to improve targeting of the KD. KD treatment 
requires input from a neurologist, specialist dietitian and often a specialised nurse, it 
requires some level of dietary restriction (this varies according to the KD type) and can 
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cause adverse side effects. The ability to predict response to the KD would prevent 
unnecessary dietary restriction in those who are unlikely to respond and prioritise those 
who are more likely to respond – the KD may be used earlier in their natural history. In 
order to do this, predictors of response must be identified and knowledge regarding the 
mechanisms behind the antiepileptic/neuroprotective properties of the KD expanded. 
Aside from the presence of certain metabolic disorders, there is conflicting evidence 
regarding the influence of demographic, clinical and biochemical factors on KD response; 
the only really consistent finding is that neither gender nor intellectual status affect KD 
response. As such, in the majority of cases (those without GLUT1 or PDD), there is no 
mechanistic guide to KD use. 
This project will investigate the genetic basis behind differential response to the KD in 
humans. The rationale for this is based on several factors, as outlined earlier in this chapter:  
i) a genetic basis to response to the KD for epilepsy has been shown in animal 
models and for Alzheimer's disease in humans 
ii) there is evidence that certain epilepsy syndromes and conditions in humans 
respond particularly well to the KD, many of which are caused predominantly 
by single genetic factors 
iii) the KD causes changes in gene expression, even if the consequences of these 
changes are largely unknown. Genetic variation has a major influence on gene 
expression and so it seems appropriate that individual genetic variation 
determines whether somebody responds favourably to the KD or not.   
This project has two principal research questions:  
Research question 1 
Does common genetic variation affect response to the KD? 
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Research question 2 
Does rare genetic variation affect response to the KD? 
Work was completed in preparation for investigation of another research question 
(Research question 3): ‘what gene expression changes are induced in humans following a 
KD?’ Due to funding limitations, this analysis could not be completed. 
Project hypothesis: it is expected that there will be a differential distribution of common 
and/or rare gene variants, present in one or more genes, in responders of the KD compared 
to non-responders. 
Predictors with a clinical utility (potentially a group of common variants or one or more 
rare variants in a gene or a group of genes) may allow dietary treatment to be considered 
at an earlier stage for patients who are more likely to respond favourably; dietary 
treatment may be avoided, or other treatment options prioritised, for those less likely to 
respond favourably to the KD; of course, other factors would always be considered, such as 
the severity of the patient’s condition, treatments already trialled and the motivation of 
the patient and family. Even identification of genes/variants with small effect sizes on KD 
response would bring us one step closer to unravelling the mechanisms behind the 
antiepileptic effects of the KD, potentially with a view to optimising treatment in the 
future.  
A variety of genetic analyses will be conducted, including a candidate gene analysis, 
genome-wide association study and whole exome sequencing. This enables the advantages 
of various approaches to be harnessed, optimising the chances of detecting a genotype-
phenotype correlation, if one does exist.   
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2 Methodology 
2.1 Ethics and recruitment 
Ethical approval for the project was sought by the researcher and granted by the National 
Research Ethics Service Committee London - City Road & Hampstead (formerly East Central 
London Research Ethics Committee 1) (Appendix 2.1).  
Based on the limited pool from which to recruit participants, an initial sample size of 100 
was proposed. This was due to the small number of individuals following the KD (or who 
have previously followed the KD and are still under hospital follow-up) in the UK, together 
with the logistical difficulties in gaining ethnical approval for international collaboration 
and ensuring consistent, continued recruitment across multiple centres/countries. The 
proposed sample size was later increased to 200, based on the recruitment rate. For 
variants of large effect size, results have been obtained from genome-wide association 
studies with fewer than 100 patients [433]; genetic variants that increased risk of 
carbamazepine-induced hypersensitivity reactions were identified from 22 patients [434]. 
Only a few (4-5) people [435, 436], or indeed even one individual [437], may be required 
for identifying causal genes with exome sequencing. Having a comparable cohort size in 
this project as those used in successful studies to date gives a reasonable chance of finding 
relevant variants, if they have a sufficiently large effect size. The power to detect a 
genotypic-phenotypic association, if one exists, with this sample size, depends on various 
factors, such as the number of genes and variants being tested and whether sequencing or 
genotyping was performed. More detailed power calculations are provided in each chapter.  
A larger cohort would increase power to detect variants with smaller effect sizes. 
A favourable ethical opinion was also granted for an amendment (Appendix 2.2) to allow 
blood to be taken from participants prior to starting the diet (for new-starters), at one 
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point whilst on the diet, and when dietary treatment had been discontinued (if the 
participant was weaned off the diet while the study was still in operation). This would allow 
gene expression changes to be tracked pre-, during- and post- diet. 
Research and Development approval was sought and granted for each of the following 
sites: Great Ormond Street Hospital for Children (GOSH), National Hospital for Neurology 
and Neurosurgery (NHNN), Evelina Children’s Hospital (ECH), Young Epilepsy (YE), 
Birmingham Children’s Hospital (BCH), St George’s Hospital, Addenbrooke’s Hospital, Alder 
Hey Children’s Hospital, Bristol Royal Hospital for Sick Children (BRHSC) and The Royal 
Children's Hospital in Melbourne (RCHM). The researcher obtained honorary research 
contracts for each site, except for RCHM, where Jacinta McMahon provided phenotypic 
data.   
The researcher attended every KD clinic (both new patient and follow-up clinics) at GOSH, 
ECH and NHNN during the recruitment period. Patients who had previously followed the KD 
at these hospitals were also identified (from lists of past KD patients kept by dietitians, as 
well as from a list provided by Prof Helen Cross of participants from the GOSH RCT) and the 
researcher recruited from specialist clinic appointments attended by any of these 
individuals who were still under follow-up. The researcher sought permission from, or 
made the consultant aware that recruitment was taking place during his/her clinic. At 
several sites, potential participants were identified and recruited by specialist/research 
nurses (at BCH and BRHSC), a research assistant (at RCHM), keto-assistants (at Matthew’s 
Friends clinics, held at Young Epilepsy) or dietitians (at St George’s). 
Inclusion criteria: 
- Individuals aged ≥3months who were either following the KD, who were soon to be 
commencing the KD, or who had followed the KD in the past for his/her epilepsy.  
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Exclusion criteria: 
- Individuals who discontinued the diet before the 3-month point due to lack of 
tolerability (those who discontinued the diet before the 3-month point due to lack 
of response or seizure increase were not excluded). 
- Individuals with known GLUT1 deficiency, PDD or other metabolic disorders. 
- Individuals with progressive myoclonic epilepsies (as lack of response may be due 
to the progressive nature of the condition). 
Potential participants were approached by the researcher or other recruiter, either in the 
waiting room, prior to or following the clinic appointment, or during the actual clinic 
appointment. Parents/guardians/patients were politely asked if they would mind sparing a 
few moments and were offered to go to a quiet area (such as a free clinic room, or the 
nearby playroom) to discuss the study. Adult patients, parents/guardians, young people 
and children were provided with an age-specific, written information sheet, adapted to 
whichever facility in which the patient was receiving care, explaining the study and all 
procedures involved. It was emphasised that participation was entirely voluntary. The 
researcher or the patient's consultant took consent; parental consent was obtained for 
patients under 16 years of age and assent forms were also provided for children. Sample 
information sheets and consent/assent forms for adult patients at the NHNN and for 
parents/guardians, young people and children at GOSH are provided in Appendix 2.3. 
Everybody had the opportunity to discuss any issues pertaining to their/their child's 
participation in the study before signing the consent form. Consent was offered within the 
clinic, but people could wait until the subsequent clinic visit. The use of interpreters was 
made available where required. Participants received no compensation from having taken 
part in the study.  
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A breakdown of the number of participants obtained from each site, and whether they 
were recruited prospectively or retrospectively, is given below: 
- GOSH: n=93 of which 58 were prospective and 35 were retrospective. 77 were eligible for 
inclusion in the study. 
- NHNN: n=18 of which 15 were prospective and 3 were retrospective. 14 were eligible for 
inclusion in the study. 
- ECH: n=82 of which 57 were prospective and 25 were retrospective. 67 were eligible for 
inclusion in the study. 
- YE in conjunction with Matthew’s Friends: n=13 of which 8 were prospective and 5 were 
retrospective. 11 were eligible for inclusion in the study. 
- BCH: n=24 of which 23 were prospective and 1 was retrospective. 21 were eligible for 
inclusion in the study. 
- St George’s Hospital: n=11, all of which were prospective. 8 were eligible for inclusion in 
the study. 
- Addenbrooke’s Hospital: n=19 of which 7 were prospective and 12 were retrospective. 19 
were eligible for inclusion in the study. 
- Alder Hey Children’s Hospital: n=4, all of which were prospective. 4 were eligible for 
inclusion in the study. 
- BRHSC: n=2, all of which were prospective. 1 was eligible for inclusion in the study. 
- RCHM: n=35 of which 6 were prospective and 29 were retrospective. 31 were eligible for 
inclusion in the study. 
 
The researcher sat in every clinic for all patients at GOSH, ECH and NHNN who were 
recruited prospectively; with all retrospectively-recruited patients from GOSH, ECH and 
NHNN, the researcher discussed their previous experiences with the KD in a quiet place 
either before or after clinic. The researcher attended clinic for 4 participants from 
Matthew’s Friends, and contacted 4 participants by postal letter; the researcher attended 
clinic for 6 of the participants from BCH; the researcher attended two clinics at St George’s 
Hospital. The researcher attended no clinics at BRHSC, RCHM or Alder Hey Children’s 
Hospital. Dr Alasdair Parker and Dr Anna Maw from Addenbrooke’s Hospital, with 
assistance from the dietitian Helena Champion, provided the researcher with a list of 
contact details of patients who had previously followed the KD – the researcher was given 
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permission to contact the parent/guardian(s) of these patients to ask whether they wished 
to participate in the study. Following an initial telephone conversation, patient information 
sheets and consent forms were sent to parent/guardian(s) and, if they wished to 
participate, DNA stored at Addenbrooke’s was used for genetic analyses.   
Patients following the KD at the time of recruitment were asked to complete a 
questionnaire regarding compliance to the KD (patient and parent/guardian versions - used 
for patients unable to complete the questionnaire - are given in Appendix 2.4). This 
questionnaire was adapted from a validated questionnaire used to assess compliance with 
AEDs at The Epilepsy Society’s Chalfont Centre, Chalfont St Peter. It is based on the 
Medication Adherence Report Scale (MARS) developed by Professor Rob Horne from UCL 
School of Pharmacy. The MARS questionnaire was designed for measuring adherence to 
medicines used for psychiatric disorders, but it has been widely used for a range of 
conditions. It measures non-adherence using a five-item Likert scale, which accounts for 
the fact that non-compliant behaviour extends across a spectrum [438]. The questionnaire 
also attempts to address non-adherence in a non-threatening and non-judgemental 
manner, encouraging patients to answer truthfully [439]. The KD version of a questionnaire 
was registered as an audit at GOSH, NHNN, YE, BCH, Addenbrooke’s Hospital and St 
George’s Hospital, and as a service evaluation at ECH.  
2.2 Phenotypic data collection 
Phenotypic data collection was obtained from patient hospital records (paper and 
electronic versions, including main hospital records, Dietetic department records and 
Neurology department records), using a proforma created by the researcher (Figure 2.1). 
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Unique identification 
code 
 
Clinical history 
(including 
pregnancy/birth details, 
onset of seizures, 
history of head injury, 
history of status 
epilepticus)  
 
Height 
 
 
 
 
 
Weight 
Pre-diet: 3 month point: 
6 month point: 
12 month point: 
18 month point: 
24 month point: 
 
Pre-diet: 
 
3 month point: 
6 month point: 
12 month point: 
18 month point: 
24 month point: 
 
Epilepsy syndrome  
Seizure types (before 
and during KD) 
 
AEDs/drugs Pre-diet: 3 month point: 
6 month point: 
12 month point: 
18 month point: 
24 month point: 
Previous (start date, stop date, max dose, response and side effects): 
 
Family history 
(epilepsy and other) 
 
Neurodevelopment 
(including formal 
developmental 
assessments) 
 
Neurological findings  
EEG data  
Imaging data 
 
 
Date started KD and 
diet type 
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Date stopped KD (if 
retrospective) 
 
Response to KD 3 month point: 
6 month point: 
12 month point: 
18 month point: 
24 month point: 
Biochemical data 
 
 
Pre-diet: 3 month point: 
6 month point: 
12 month point: 
18 month point: 
24 month point: 
Side effects 
 
 
 
Long-term outcome Post-2 years: 
 
 
Figure 2.1: Phenotype proforma 
All data were pseudo-anonymised prior to entry into a database, with a unique 
identification number allocated and saved elsewhere. Only those directly involved in the 
study had access to information. All personal data were stored on a secure NHS computer 
and were password-protected. Hard copies were kept on NHS premises in a locked cabinet. 
2.3 Genotypic data collection 
 Research questions 1 and 2 2.3.1
(Does common or rare genetic variation affect response to the KD?) 
For participants who were following the KD or who had already weaned off the diet: 
participants had blood taken once, usually at the same time as blood taken for routine 
clinical monitoring. Anaesthetic cream or spray was used where appropriate and blood was 
taken by an experienced phlebotomist. 2-5ml was taken from children, 10ml from adults, 
and put into an EDTA (ethylenediaminetetraacetic acid) tube. 
EDTA samples were sent to the Molecular Genetics laboratory at GOSH, where DNA was 
extracted by clinical geneticists.  
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DNA was extracted by one of two methods, depending on workflow and the volume of 
blood obtained: for blood samples 1.5ml-4ml, Autogen (AutoGen Inc, Hollister, 
Massachusetts, USA) was used; for blood samples 0.5ml-2.5ml, Fujifilm (FUJIFILM 
corporation, Tokyo, Japan) was used. Autogen is an automated machine which uses 
Qiagen’s FlexiGene procedure – a protease digestion/DNA precipitation method, whereby 
the erythrocytes and leucocytes are lysed with a buffer while keeping the nuclei intact. A 
nuclei pellet is obtained by centrifugation and DNA precipitated by addition of isopropanol. 
Fujifilm uses pressured filtration technology, which is carried out using an 80μm thick 
porous membrane that immobilises the nucleic acid without need for centrifugation. 
DNA samples were also received from RCHM, where DNA had been extracted from blood 
using Maxi Qiagen kits, which use the FlexiGene procedure. 
All DNA samples were vertically stored in a -80oC freezer at UCL Institute of Neurology. 
DNA concentration and 260/280 ratios (a measure of DNA purity - for pure DNA, the ratio 
of the absorbance at 260 and 280nm is approximately 1.8 [TECHNICAL SUPPORT BULLETIN, 
NanoDrop® ND-1000 and ND-8000 8-Sample Spectrophotometers, www.nanodrops.com]) 
of all samples was measured with NanoDrop ND-1000 Spectrophotometer (Thermo Fisher 
Scientific Inc., USA). 
At each of the study sites, it is standard practice to test children with infantile-onset 
epileptic encephalopathy for GLUT1 deficiency (particularly if they have a very favourable 
response to the KD), either from SLC2A1 mutation, hypoglycorrhachia or low cerebrospinal 
fluid:blood glucose ratio. In case any individuals had not been tested, SLC2A1 was 
sequenced in all samples to be included in genetic analyses at the North East Thames 
Regional Genetics Laboratory by Dr Suzanne Drury to formally exclude the possibility of 
GLUT1 deficiency. DNA was quantified using a Qubit® Fluorometer (Life Technologies 
103 
 
Corporation). 250ng of DNA was used in the Illumina TruSeq Custom Amplicon Library 
Preparation protocol, according to manufacturer’s instructions (TruSeq Custom Amplicon 
Library Preparation Guide, © 2013 Illumina, Inc). This includes hybridisation of oligo probes 
(designed to target the 10 coding exons of SLC2A1), removal of unbound oligos, extension-
ligation of bound oligos to form DNA templates that consist of the regions of interest 
flanked by primer sequences, and finally polymerase chain reaction (PCR) amplification of 
the DNA templates, incorporating indexes to enable sample pooling. Libraries were 
normalised in order to ensure equal representation of each sample. Up to 96 samples were 
then pooled, prior to sequencing on an Illumina MiSeq® sequencing system. This uses 
‘sequencing by synthesis’ technology, where four fluorescently-labelled nucleotides are 
added in each sequencing cycle, one of which attaches to the chain of DNA; the emitted 
fluorescence (identified from laser excitation) identifies each base; the data are then 
aligned and compared to a reference genome. For each sample, paired-end sequencing 
reads were mapped to the February 2009 assembly of the human genome (Genome 
Reference Consortium Human Build 37) using the Burrows-Wheeler Aligner (BWA) and the 
default settings [440]. Sequence variants were called using VarScan2 (mpileup2cns) with a 
minimum total read depth requirement of 30, and the default settings [441]. Variants were 
limited to coding regions and 14 and 6 base pairs 5’ and 3’ respectively. Variants were 
annotated using the Ensembl Variant Effect Predictor Perl Script. 
No individual with unknown GLUT1 deficiency harboured a missense variant that was 
predicted to be damaging. Two individuals (one extreme non-responder who discontinued 
the KD immediately and one with a variable response to the KD, who remained on the KD 
long-term) harboured a missense variant in SLC2A1 but these were both predicted to be 
tolerated by functional prediction algorithms. All synonymous and non-coding variants with 
a minor allele frequency (MAF) <2% were analysed with Alamut (Interactive Biosoftware, 
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LLC), but none were predicted to affect splicing (removal of intronic regions located 
between exons for production of RNA).   
SLC2A1 sequencing failed in eight individuals due to low quantity or quality DNA. 
Samples were also prepared by the researcher to be sent to  
a) AROS Applied Biotechnology A/S, Denmark to be genotyped with the Infinium 
HumanOmniExpressExome Beadchip (Illumina Inc, San Diego, USA) (all cases with 
DNA samples eligible for inclusion as of January 2013) 
b) Royal Devon & Exeter Hospital for sequencing of KCNJ11 and BAD (all cases with 
DNA samples eligible for inclusion as of April 2013) 
c) Institute of Neurology Neurogenetics Unit for whole exome sequencing (45 
selected extreme responders and non-responders) 
Further information regarding Methodology, including sample selection and genetic 
analyses, will be described in Chapters 4-7. 
 Research question 3  2.3.2
(What gene expression changes are induced in humans following a KD?) 
For new starters: participants had blood taken at one point pre-diet and at one point when 
following the diet (preferably at the 3-month point). Samples were usually taken at the 
same time as blood taken for routine clinical monitoring and the same procedure was used 
as for Research questions 1 and 2. Although ethical approval was also obtained for post-
diet blood samples, the logistical difficulties of this quickly became clear – patients often 
weaned off the diet before their next clinic appointment.  
On each blood-letting occasion, 2.5ml blood was put into a PAXgene Blood RNA tube 
(PreAnalytix GmbH, Switzerland), for reduced RNA degradation and gene induction [442]. 
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On one of these occasions, an extra (approximate) 2.5ml blood was put into an EDTA tube 
for DNA extraction, as described above. 
PAXgene tubes were softly inverted 8-10 times to mix the sample with the preserving 
agent, kept at room temperature for 2-6 hours (in order to ensure complete lysis), then at 
4oC overnight. The following morning, tubes were put in a -80oC freezer at UCL Institute of 
Neurology until processing. 
Prior to RNA extraction, PaxGene tubes were left to defrost at room temperature overnight 
(approximately 14 hours). Total RNA was manually extracted by Dr Mar Matarin, following 
the PaxGene Blood RNA Kit protocol (Qiagen, USA; reference number: 762174). Samples 
were processed in two batches, both including an equal number of pre-diet and on-diet 
samples from randomly selected patients. Nucleic acid pellets in the PAXgene tube were 
isolated by centrifugation, washed, re-suspended by vortexing, and incubated with 
Proteinase K and lysis Buffer BR2 to bring about protein digestion. Following transferral of 
the supernatant to a fresh microcentrifuge tube and an additional centrifugation to remove 
residual cell debris, ethanol was added and the tube was loaded onto a PAXgene RNA spin 
column. When centrifuged, RNA selectively binds to the PAXgene silica-gel membrane and 
contaminants pass through. After removing contaminants with several wash spins, elution 
with Buffer BR5 pipetted directly onto the PAXgene column membrane was undertaken, 
followed by incubation. RNA was chilled on ice, ready for storage. RNA concentration and 
260/280 ratios (a measure of RNA purity - for pure RNA, the ratio of the absorbance at 260 
and 280nm is >1.8-2.0 [443]) was measured using NanoDrop ND-1000 Spectrophotometer 
(Thermo Fisher Scientific Inc., USA).  
RNA samples (n=42, one pre-diet and one on-diet for 21 individuals) are currently in 
storage at -80oC at UCL Institute of Neurology. Pending funding, it is planned to analyse 
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these samples with the Affymetrix Human Exon 1.0 Sense Target Array (or a similar array). 
This will allow investigation of gene expression levels and alternative splicing in individuals 
following the KD, compared to pre-diet levels, and to determine whether these differ in 
responders and non-responders.  
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3 Phenotypic results  
 
3.1 Introduction 
A phenotype is defined as the ‘observable traits of the organism’ [444], or often, in medical 
contexts, as ‘deviation from normal morphology, physiology, or behaviour’ [445]. 
Establishing the phenotype of a patient is a challenging, yet critical task, both for clinical 
management and observational and interventional research. The ability to detect an 
association of a phenotypic trait with another factor, and the confidence in the validity of 
this association, depends on the accurate delineation of the trait in question on a case-by-
case basis [446]; incorrect classification of cases/controls or, in this case, responders/non-
responders, may result in false negative or false positive findings. To this purpose, the 
definition of the phenotypic trait in question should be carefully considered and high 
quality standards should be adhered to in order to produce accurate and reproducible 
results, especially if inter-study comparison is desired at a later stage. The very nature of 
phenotypic information, which may change over time and can be subject to external 
influence, as well as the methods used to obtain this information, may hinder this accuracy. 
This highlights the importance of extending phenotypic measurements over time and 
including information regarding environmental factors and other biological systems aside 
from those that are obviously involved with the phenotypic trait in question [447]. A 
balance must be sought between what is thought to be relevant (although this is 
debatable, for example, in the context of the KD, where evidence regarding factors that 
affect response is conflicting), completeness of the data sources, and time available for 
phenotyping. 
Deep phenotyping, defined as the ‘precise and comprehensive analysis of phenotypic 
abnormalities in which the individual components of the phenotype are observed and 
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described’ [445], reflects the understanding that disease, or phenotypic traits, often 
represent a spectrum. Even if the principal outcome measured in a study is binary 
(affected/unaffected, or responder/non-responder), other factors may be involved. In the 
context of the KD, the effects on diet response of various factors, such as age at seizure 
onset, could be assessed and relevant covariates could be included in analyses. This could 
not be done without detailed documentation of demographic and clinical data for each 
participant. 
Deep phenotyping is especially important in genetic studies, where the functionality of 
variants with a genotypic-phenotypic association may be unknown. The extent of the 
effects of a particular genotype on a particular trait may be better understood; for 
example, whether homozygosity at a particular locus has a more mild or severe effect on 
the phenotype, compared to heterozygosity. Such detailed understanding may be 
especially challenging, but nevertheless important, with rare variants or those with small 
effect sizes. Elucidating influences on the phenotype may not necessarily lead to results 
with clinical utility, but will certainly further understanding of the network of genotypic-
phenotypic associations, including gene-gene or pathway interactions. 
Here, an overview of the cohort is presented. Information already obtained as part of the 
KD service provision, along with questionnaires handed out to participants recruited 
prospectively, were used to classify KD response, obtain rough measures of compliance and 
detailed clinical and demographic data. KD response was classified in terms of seizure 
frequency, both at specific time points and as a summary of longitudinal response; other 
potential contributors to what constitutes a clinically meaningful response were also 
considered. Potential correlations of clinical or demographic parameters with KD response 
were assessed. This allows comparison of response rates and demographics with other 
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published cohorts and encourages thought as to how phenotypic information can be used 
for genetic analyses. 
3.2 Methods 
As outlined in Chapter 2, clinical and demographic data were obtained from hospital notes, 
using a proforma created by the researcher.  
Where possible, it is important to assess compliance to the KD to ensure that cases are not 
classified as non-responders simply because they did not adhere to treatment in the first 
place, rather than due to a particular biological/genetic reason. The more patients with 
inadequate compliance that are included in a clinical trial, the lower the power [448], and 
so a larger sample size would be needed to obtain the same possibility of committing Type I 
(false positive) or II (false negative) error. This notion can feasibly be extended to 
association studies. In this study, compliance to the diet was measured by serum BHB (this 
is done anyway as part of standard KD monitoring and measurements were subsequently 
obtained from hospital records) and questionnaires, adapted from a validated 
questionnaire previously used to assess compliance with AEDs (a copy is given in Appendix 
2.4). Answers to questions 1-6, solely from patients who received the diet orally, were used 
to create a compliance score for each case: if the answer to a question was ‘never’, a score 
of 5 was given; ‘rarely’ = 4; ‘sometimes’ = 3; ‘often’ = 2; ‘very often’ = 1. The maximum 
compliance score was 30. Cronbach’s alpha, a measure of internal consistency for 
questionnaires (to determine whether questions that propose to measure a similar 
construct produce similar scores) expressed as a number between 0 and 1, was calculated 
using the ‘cronalpha’ function in Microsoft Excel 2010 (v. 14, Microsoft, Washington, USA). 
Urine and/or blood ketone levels (which are often checked on a daily basis by parents, 
particularly during the first few months of dietary treatment) would have been useful to 
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assess compliance, but data were seldom present in hospital records or dietetics notes; 
where data were available, measurements were often sporadic and not documented over a 
prolonged period of time.  
KD response was defined in terms of seizure-frequency. Seizure frequency was calculated 
in four week (28 day) epochs prior to starting the diet (baseline), prior to the 3-month 
point, 6-month, 12-month, 18-month and 24-month point, where applicable. These time 
points represent when follow-up with the consultant neurologist usually occurs after 
starting the KD; weaning of the diet is typically considered after two years. If clinic 
appointments fell >2 weeks before or after a specific follow-up point, diet response at that 
point was classified as unknown. Where seizure diaries were completed as part of 
monitoring for the KD service provision, these were used to calculate exact seizure 
frequency. Otherwise, clinic letters prior to starting the diet and at each KD follow-up clinic 
were used to gain a crude measure. Response to the diet after 24 months was noted for 
participants with long-term follow-up, solely from clinic letters. 
Cases were placed into a response category at each follow-up point. Cases with ≥50% 
seizure reduction were classified as ‘responders’; those with <50% seizure reduction were 
‘non-responders’. A ≥50% seizure reduction is viewed as clinically useful in this drug-
resistant cohort (personal communication with GOSH Paediatric Neurologist). Personal 
contact between many patients/parents/guardians and the researcher through attendance 
at clinic appointments aided diet response classification – the researcher witnessed, first-
hand, any visible changes in patients since starting the diet and heard detailed descriptions 
from parents/guardians regarding their experiences with the diet. Such details may not 
always be mentioned in clinic letters. 
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A Chi-square goodness of fit test was used to assess whether diet response at a single time 
point correlates with response at other time points. This tests the null hypothesis that the 
observed number of matches (responder-responder, or non-responder-non-responder) is 
different to the expected number of matches at two particular time points, given the 
proportions of responders/non-responders at these time points, and an assumption of 
independence. A significance threshold of 0.05 represents the probability that the 
observed distribution of data is due to chance. With a p-value of <0.05, the null hypothesis 
of independence (the observed number of matches is different to the expected number of 
matches) can be rejected, with a less than 1 in 20 chance of being incorrect.  
The merits of classifying diet response for each case at specific follow-up points, versus 
placing each case into a summary response category that summarised his/her diet 
response over time, were considered. Two summary response categories were created:  
i) Summary diet response, where cases are classified as responders or non-
responders, based on their response at all time points recorded 
ii) Extreme summary diet response, which aims to include those cases with the 
most extreme response to dietary therapy.  
Logistic regression was used to assess the effect of various demographic and clinical factors 
on diet response, based on the summary diet response phenotypes. Analyses were re-
conducted, using diet response at specific follow-up time points, for those factors with a 
statistically significant correlation with summary diet response. For categorical factors, 
pairwise combinations not reported from the original calculation (one category is 
automatically used as a base category) were analysed using the ‘relevel’ function, which 
redefines the base category. For example, in the original calculation comparing diet 
response and diet type, the classical KD was automatically defined as the base category and 
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so response in cases following the classical KD was compared to those following either the 
MCT KD or the MAD. By redefining the base category as either MAD or MCT KD, response 
in cases following these two diet types could be compared. All analyses assessing putative 
correlations between diet response and demographic/clinical factors will help indicate 
what variables, if any, to include in genetic analyses.  
To avoid the inflated likelihood of Type I error when testing multiple hypotheses, a 
Bonferroni-corrected significance threshold was calculated, based on an alpha of 0.05 and 
the number of tests conducted. This is a simple and widely-used method of correcting for 
multiple testing in statistical analyses, although (for non-genetic analyses) there is no 
accepted gold standard [449].   
Clinic letters and dietetics notes were used to extract information regarding diet response 
beyond seizure frequency, but these beneficial/adverse effects were not quantified. 
Microsoft Excel 2010 (v. 14, Microsoft, Washington, USA) and R: A Language and 
Environment for Statistical Computing (v. 3.0.0, R Foundation for Statistical Computing, 
Vienna, Austria) were used for descriptive and inferential statistics.  
3.3 Results  
 An overview 3.3.1
Figure 3.1 shows the number of cases recruited and included in final phenotypic analyses. 
This includes all cases, independent of quality control criteria employed in genetic analyses.  
The cohort clinical and demographic data are summarised in Table 3.1.  
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Figure 3.1: Flowchart of cases recruited and included in final analysis   
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Table 3.1: Cohort clinical and demographic data (for cases with diet response data, n=253) 
Gender Male n=132 (52%) 
Female n=121 (48%) 
Age at seizure onset (years) median(IQR) 0.67(1.86)  
(unknown for 1 case) 
Age at diet onset (years) median(IQR) 5.60(6.60)  
‘Developmental delay’ or ‘learning difficulties’ 
(as described in clinic letters) 
Cases described as having developmental delay n=168 (66%) 
Cases described as having learning difficulties n=37 (15%) 
No developmental delay/learning difficulties n= 18(7%) 
Unknown n=30 (12%) 
Cause of epilepsy * Genetic n=29 (11%) 
 
Mutation in SCN1A n=14 
Mutation in CDKL5 n=3 
Mutation in PCDH19 n=1 
Mutation in MECP2 n=3 
Mutation in STXBP1 n=1 
Chromosome translocation n=2 
17q22–q23.1  deletion n=1 
17p13.3 deletion (Miller-Dieker syndrome) n=1 
3p25 deletion n=1 
Chromosome q22 deletion n=1 
Cardio-facio cutaneous syndrome (unknown which gene) 
n=1 
Structural-metabolic 
n=72 (28%)  
Hypoxic ischemic encephalopathy (HIE) n=20 
Perinatal stroke (without HIE) n=1 
Haemorrhage n=4 
Neonatal hypoglycaemia n=2 
Polymicrogyria n=10 
Pachygyria n=1 
Infection n=6 
Periventricular leukomalacia n=1 
Cystic encephalomalacia n=1 
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Occipital lobe abnormality n=1 
Temporal lobe abnormality n=3 
Hypoplasia n=2 (1 with cerebellar hypoplasia and 1 with 
hypoplasia of the corpus callosum) 
Cortical dysplasia n=2 
Porencephaly n=1 
‘Lesions’ n=1 
Neurofibromatosis type 1 n=1 
Epidermal naevus syndrome n=1 
Tuberous sclerosis n=5 
Hippocampal sclerosis n=2 
Lissencephaly n=2 
Ohtahara syndrome n=1 
Unknown n=4 
Unknown cause n=152 (60%) 
Epilepsy syndrome * Dravet syndrome/severe myoclonic epilepsy of infancy n=15 (6%) 
Lennox-Gastaut syndrome/LGS-spectrum n=13 (5%) 
Childhood absence epilepsy n=3 (1%) 
Juvenile myoclonic epilepsy n=2 (1%) 
Juvenile absence epilepsy n=3 (1%) 
Epilepsy with myoclonic atonic (astatic) seizures (Doose syndrome) n=14 (6%) 
Epilepsy with myoclonic absences n=1 (1%) 
Epilepsy with myoclonic atonic seizures and myoclonic absences n=1 (1%) 
Myoclonic epilepsy (unspecified) n=7 (3%) 
Epilepsy of infancy with migrating focal seizures n=3 (1%) 
Ohtahara syndrome n=1 (1%) 
West syndrome n=15 (6%) 
Undiagnosed n=175 (69%) 
Seizure localisation based on EEG and clinical 
features 
 
Generalised n=78 (31%) 
Focal n=91 (36%) 
Focal with secondary generalisation n=7 (3%) 
Focal and generalised (cases with seizures that originate from a specific area in one hemisphere, as well as seizures 
that originate from bilateral hemispheres, as shown by EEG) n=71 (28%) 
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Spasms n=5 (2.0%) 
Unknown = 1 (0.4%) 
Number of AEDs at diet onset mean[95% CI] 2.34[2.22, 2.46] 
AEDs at diet onset ** Sodium valproate n=131 (52%) 
 Levetiracetam n=81 (32%) 
 Topiramate n=68 (27%) 
 Vigabatrin n=23 (9%) 
 Carbamazepine n=21 (8%) 
 Lamotrigine n=56 (22%) 
 Clobazam n=95 (38%) 
Number of failed AEDs prior to diet onset 
mean[95% CI] 
6.61[6.28, 6.94] 
(unknown for 3 cases) 
Diet type (at 3-month point) *** Classical Ketogenic diet n=166 (66%) 
Medium Chain Triglyceride Ketogenic Diet n=47 (19%) 
Modified Atkins Diet n=39 (15%) 
Unknown n=1 (0.4%) 
Feed Oral n=173 (68%) 
Gastrostomy/naso-gastric tube n=64 (25%) 
Oral and tube n=16 (6%) 
* Cause of epilepsy (genetic, structural/metabolic, unknown) and epilepsy syndromes have been classified according to Berg et al. (2010) 
** Only the most common AEDs taken in our cohort have been included in ‘AEDs at diet onset’; other AEDs (such as nitrazepam or gabapentin) were only taken 
by a small number of cases, which did not allow for stratification into responders and non-responders - there would be too few cases in each group for statistical 
analysis.    
*** no patients were following the Low Glycaemic Index Treatment, as this was not offered as a diet option at the study sites. If a patient transitioned to a 
different diet type before the 3-month point, the new/second diet type was considered this individual’s ‘diet type’.
117 
 
 Compliance 3.3.2
Compliance questionnaires were returned from 66 patients, either from patients 
themselves (five cases) or from parent/guardian(s). The mean [95% confidence interval] 
compliance score out of 30 was 26.5 [25.7, 27.3]; follow-up time ranged from 2-82 months. 
There is no standard cut-off point for high/low compliance from such questionnaires; the 
threshold is based on the frequency distribution for the particular dataset. As the 
distribution of compliance scores is positively skewed (shown in Figure 3.2) and there is no 
natural cut-off point where the group can be dichotomised, the lower 3rd was taken as the 
‘low compliance’ group. Approximately one quarter of patients with compliance 
questionnaire data scored ≤25/30 (the lowest score was 17/30).  
 
Figure 3.2: Distribution of diet compliance scores, n=66 
Cronbach’s alpha was 0.68. This means that the questions in the compliance questionnaire 
have an average intercorrelation of 0.68, or that 68% of the variance is consistent across 
the six questions.  
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Compliance score 
A coefficient of 0.68 may be viewed as low, considering that a value of 0.8 is generally 
accepted as reliable. This has, however, been disputed - values of 0.7 or below may be 
appropriate, depending on what is being measured [450]. Cronbach’s alpha depends on 
several factors, such as the number of items in the scale, especially when intercorrelation 
between items is low [451]. A low alpha value may also be attributed to heterogeneous 
question constructs [452] or skewed distribution of data scores [453]. The small number of 
items in the scale and the positively skewed distribution of compliance scores may have 
lowered the alpha value. 
As shown in Figure 3.3, there is no clear correlation between length of time on diet and 
compliance levels.  
 
 
 
 
Figure 3.3: Scatter plot of compliance scores and length of time on diet when questionnaire was 
completed, for 66 individuals 
Serum BHB levels were available for: 
122 cases (48% of those with 3-month diet response data) at 3-month follow-up: 
median(IQR) 2.74(2.61)mmol/L 
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70 cases (44% of those with 6-month diet response data) at 6-month follow-up: 
median(IQR) 3.06(2.58)mmol/L  
56 cases (52% of those with 12-month response data) at 12-month follow-up: median(IQR) 
2.89(2.66)mmol/L 
Data were not normally distributed at any time point.  
BHB was not recorded for 18- or 24-month follow-up, due to small sample sizes. 
Considering that the ‘recommended’ (in a handbook of Dietary Treatments for Epilepsy, 
but not supported by published studies) serum BHB level for individuals following the KD is 
4-6mmol/L [454], the median BHB levels in our cohort appears low. However, the 
interquartile ranges (a measure of dispersion and variability in observations) are wide, 
meaning that the middle 50% of observations are widely spaced apart [455]. 41(34% of 
122) cases had serum BHB levels ≥4mmol/L at 3-month follow-up, 24(34% of 70) cases at 6-
month follow-up and 20(36% of 56) cases at 12-month follow-up. The largest proportion of 
patients with BHB levels within the normal range (<0.6mmol/L) was 9/122(7%), at 3-month 
follow-up. Potential reasons for variability in serum BHB levels are outlined in the 
Discussion. 
 Ketogenic diet response: seizure frequency at specific follow-up points 3.3.3
The proportions of responders/non-responders at 3-month, 6-month, 12-month, 18-month 
and 24-month follow-up are given in Figure 3.4, Figure 3.5, Figure 3.6, Figure 3.7 and Figure 
3.8 respectively. A proportion of participants were unclassifiable at specific follow-up 
points (range 2-9%), either due to insufficient information provided in clinic letters or 
missed appointments. 
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9(4% of 252) participants were seizure-free at the 3-month point, 10(6% of 160) at 6-
months, 7(6% of 111) at 12-months, 3(4% of 69) at 18-months and 3(7% of 46) at 24-
months.  
Diet response was calculated from seizure diaries in 35/252(14%) participants at the 3-
month point, 23/160(14%) at the 6-month point and 14/111(13%) at the 12-month point. 
No participants had completed seizure diaries at the 18- and 24-month points. 
 
Figure 3.4: 3-month diet response, n=257 (n=252 with classifiable diet response data)  
 
 
Figure 3.5: 6-month diet response, n=171 (n=160 with classifiable diet response data)  
51% 47% 
2% 
Responders (≥50% 
seizure reduction) 
Non-responders (˂50% 
seizure reduction) 
Unclassifiable
63% 
30% 
6% Responders (≥50% 
seizure reduction) 
Non-responders 
(˂50% seizure 
reduction) 
Unclassifiable
121 
 
78% 
18% 
4% 
Responders (≥50% 
seizure reduction) 
Non-responders (˂50% 
seizure reduction) 
Unclassifiable
78% 
15% 
7% 
Responders (≥50% 
seizure reduction) 
Non-responders (˂50% 
seizure reduction) 
Unclassifiable
   
 
 
 
 
 
Figure 3.6: 12-month diet response, n=119 (n=111 with classifiable diet response data)  
 
Figure 3.7: 18-month diet response, n=77 (n=69 with classifiable diet response data)  
 
 
 
 
 
Figure 3.8: 24-month diet response, n=49 (n=46 with classifiable diet response data)  
75% 
14% 
9% 
Responders (≥50% 
seizure reduction) 
Non-responders (˂50% 
seizure reduction) 
Unclassifiable
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If an intent-to-treat type approach were adopted (to the extent that is possible in this 
study, as not all people who were referred for the KD at each centre were identified and 
approached), thus including individuals who were recruited but then decided not to start 
the KD (n=20), those who stopped the diet before the 3-month point due to non-
compliance or adverse side effects (n=4), or who died whilst following the KD (n=1), 
response rates are as follows: 
3-month point: 131/282(46%) achieved ≥50% seizure reduction, of which 9(3%) were 
seizure-free. 
6-month point: 108/282(38%) achieved ≥50% seizure reduction, of which 10(4%) were 
seizure-free. 
12-month point: 93/282(33%) achieved ≥50% seizure reduction, of which 7 (2%) were 
seizure-free.  
18-month point: 58/282(21%) achieved ≥50% seizure reduction, of which 3(1%) were 
seizure-free.  
24-month point: 38/282(13%) achieved ≥50% seizure reduction, of which 3(1%) were 
seizure-free.  
 
As may be expected, most cases who continue to follow the KD long-term are classified as 
responders. Some cases, however, defined as non-responders in terms of seizure 
frequency, remained on the diet, even up to 24 months after starting. Potential reasons for 
this are outlined in the following section.  
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 Factors beyond seizure frequency 3.3.4
Other benefits on seizures, aside from reduced frequency, reported at any time point, are 
given in Table 3.2.  
Table 3.2: Reported benefits on seizures, aside from reduced seizure frequency, from the 
Ketogenic diet 
Benefit 
Number of cases who reported benefit, 
n (% of 253[cases with diet response 
data]) 
Less severe seizures (defined as less ‘severe’ or 
‘milder’ in hospital records) 
n=36 (14%) 
Shorter seizures n=26 (10%) 
Reduced used of emergency medication n=17 (7%) 
Quicker recovery time n=15 (6%) 
Shorter clusters of seizures n=11 (4%) 
Fewer daytime seizures n=4 (2%) 
Fewer hospital admissions n=4 (2%) 
Fewer episodes of status n=4 (2%) 
Fewer convulsive seizures/seizures that lead to falls n=3 (1%) 
Fewer night-time seizures n=2 (1%) 
Now able to recognise warning signs before a seizure n=2(1%) 
Seizures don’t ‘progress’ to the same extent as 
before 
n=2 (1%) 
Seizure pattern changed to clusters n=1 (0.4%) 
 
40 individuals who reported one or more of these benefits were classified as non-
responders at the 3-month point. This represents 33% of the total number of non-
responders at this time point. 23/40(57.5% of the 40 who reported one or more seizure-
related benefits) cases remained on the diet at the 6-month point; 15/40(37.5%) cases 
remained on the diet at the 12-month point; 11/40(28%) cases remained on the diet at the 
18-month point; 5/40(12.5%) cases remained on the diet at the 24-month point. 
For those who followed a KD for six months or longer, 52/164(32%) patients were able to 
reduce their number or dose of AEDs without an adverse effect on seizures (AEDs are 
generally not changed before the 3-month point); seven of these 52 patients were weaned 
off all regular AEDs - this was still the case at the most recent follow-up (range: 1-9 years 
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since AED-free, whilst still following the KD), with the exception of one case who recently 
had an AED introduced due to worsening seizure control, with no effect (AED to be 
weaned). Four further patients are currently reducing AED dose, the effect of which is still 
unknown.  
Other non-seizure-related benefits reported at any time point, are given in Table 3.3. 38 
cases (31% of the total number of non-responders at the 3-month point) who reported one 
or more of these benefits were classified as non-responders at the 3-month point. 22(58% 
of 38) of these cases remained on the diet at the 6-month point (five were classified as 
responders at this point); 14(37% of 38) remained on the diet at the 12-month point (eight 
were classified as responders at this point); 10(26% of 38) remained on the diet at the 18-
month point (five were classified as responders at this point); 5(13% of 38) remained on the 
diet at the 24-month point (two were classified as responders at this point). 
Table 3.3: Non-seizure-related benefits from the Ketogenic diet 
Benefit 
Number of cases who reported benefit, 
n (% of 253[cases with diet response data]) 
More aware/alert/brighter/attentive n=141 (56%) 
More communicative/interactive/responsive n=61 (24%) 
More vocal/verbal/improved speech n=34 (13%) 
More active n=31 (12%) 
Improved school performance n=21 (8%) 
Improved concentration n=18 (7%) 
Improved sleep n=16 (6%) 
Improved behaviour n=10 (4%) 
Steadier/better balance n=8 (3%) 
Improved eye contact n=8 (3%) 
Happier n=7(3%) 
Improved head control n=5 (2%) 
Improved motor skills n=4 (2%) 
Calmer n=3 (1%) 
Improved eating n=2 (1%) 
Improved reflux n=1 (0.4%) 
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It is likely that such reported benefits are the reason why a proportion of participants 
remain on the diet past the 3-month point, despite being defined as non-responders in 
terms of seizure frequency.  
 Ketogenic diet response over time  3.3.5
As an example of how response to the KD can vary over time, KD responder/non-responder 
status over time is shown for five individuals in Figure 3.9. For some cases, responder 
status may be constant over time (Person 4 remained a non-responder from 3- to 18-
month follow-up), whilst for others this is not the case (for example, Person 2 was a non-
responder at 3-, 6- and 12-month follow-up, became a responder at 18-month follow-up 
and then a non-responder again at 24-month follow-up.  
Figure 3.9: Line graph showing trend of Ketogenic diet responder/non-responder status over time 
for five cases 
The inconsistency of KD response over time can be shown statistically. Chi-square goodness 
of fit tests demonstrate that response at different time points are not always correlated 
(p>0.05), as shown in Table 3.4. Response is more likely to be correlated at 3-month and 6-
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month follow-up than at later time points: the p-value for independence of response at 3-
month and 6-month follow-up is far lower than for any other pairwise test. 
Table 3.4: Results from Chi-square tests assessing independence of diet response at different time 
points  
 
3-month follow-
up: 
X2 value 
P value 
6-month 
follow-up: 
X2 value 
P value 
12-month 
follow-up: 
X2 value 
P value 
18-month 
follow-up: 
X2 value 
P value 
24-month follow-
up: 
X2 value 
P value 
3-month 
follow-up 
- 
48.11 10.52 4.16 7.11 
4.04x10
-12
* 0.009692* 0.087399 0.053992 
6-month 
follow-up 
- 
- 
48.86 3.98 3.19 
- 2.04x10-05* 0.109783 0.160186 
12-month 
follow-up 
- - 
- 
12.55 9.92 
- - 0.019647* 0.037707* 
18-month 
follow-up 
- - - 
- 
29.59 
- - - 0.005534* 
24-month 
follow-up 
- - - - 
- 
- - - - 
* p<0.05 
When looking at KD response rates and putative factors affecting response, it may be 
appropriate to consider an individual’s diet response over time, rather than concentrating 
on specific time points.  
Longitudinal response was accounted for by creating a summary diet response phenotype. 
Some cases were easily classified as ‘overall’ responders or non-responders. For example, 
those who achieved ≥50% seizure reduction at every time point recorded were classified as 
responders and those who achieved <50% seizure reduction at every time point recorded 
were classified as non-responders. Hospital notes were used, as well as communication 
with patients/parents/guardians at clinic appointments and with patients’ neurologists and 
dietitians. Individuals who consistently reported approximately 50% seizure reduction over 
time, or those with very fluctuating diet response over time were excluded from the 
summary diet response classification, as responder/non-responder status was ambiguous. 
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An extreme summary diet response category was also created. Extreme responders were 
cases who maintained ≥75% seizure reduction at all follow-up points, or who had ≥75% 
seizure reduction at all but one follow-up point (cases were not excluded if, at one time 
point, seizures were 50-75% reduced compared to baseline, as long as seizure frequency 
had reduced to ≥75% seizure reduction by the next time point). This was to allow for a 
degree of variability in seizure frequency. If ≥75% seizure reduction had been achieved but 
the diet was subsequently discontinued due to an increase in seizures, cases were 
excluded. Several cases, for example, reported ≥75% seizure reduction at the 3- or 6-month 
point but then, by the next time point, seizures were either no different or were occurring 
more frequently compared to baseline. Cases classified as responders at the 3-month point 
but with no further diet response data available were excluded, as it is unknown whether 
they will continue to be responders at the 6-month point and beyond (this could be said for 
any follow-up point, as seizure frequency may vary over time, but one has more confidence 
that a reduction in seizure frequency is due to treatment and not due to chance if seizure 
reduction is consistent over more than one time points). Individuals who reported no 
change in seizures or increases seizure frequency at the 3-month point and subsequently 
weaned off the diet were classified as extreme non-responders. Individuals who reported 
some reduction in seizure frequency but not quite 50% reduction were excluded from this 
category.  
The proportion of overall responders/non-responders, based on the summary response 
phenotype, is shown in Figure 3.10, and the extreme summary response phenotype is 
shown in Figure 3.11. 
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Figure 3.10: Summary diet response, n=253 (n=221 with classifiable diet response data) 
 
 
Figure 3.11: Extreme summary diet response, n=253 (n=108 with classifiable diet response data) 
Using an intent-to-treat approach, 116/282(41%) would be classified as overall responders 
(summary diet response); 41/282(15%) would be classified as overall extreme responders 
(extreme summary diet response). 
 Factors affecting Ketogenic diet response  3.3.6
3.3.6.1 Demographic and clinical parameters 
The summary response phenotypes, and 3-month KD response, were used to determine 
whether there was an influence of demographic/clinical factors on KD response. The 3-
16.2% 
26.5% 56.9% 
Extreme responders
Extreme non-
responders
Unclassified
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month KD response cohort has the largest sample size, compared to response classified at 
other time points and summary response classifications, and it represents the first time 
point at which response to dietary treatment is formally assessed. The summary 
phenotypes were also used because response is not always consistent over time – the 
same case may be classified differently at different time points (for example, as a 
responder at the 3-month point, but as a non-responder at the 6-month point).  
Results from logistic regression (see Table 3.5, Table 3.6 and Table 3.7) showed that the 
number of failed AEDs correlated (unadjusted p-value<0.05) with 3-month and summary 
diet response (the lower the number of failed AEDs, the increased likelihood of a 
favourable response) and use of topiramate correlated with both summary diet response 
classifications (use of topiramate was associated with increased likelihood of a favourable 
response). When applying a Bonferroni-corrected significance threshold, based on an alpha 
of 0.05 and 10 tests, no factors reached statistical significance (p-value<0.005). 
Table 3.5: Putative factors affecting 3-month Ketogenic diet response 
Factor 
Number of 
responders with 
data available 
Number of non-
responders with 
data available 
Estimate Z value P value 
Gender 131 121 0.20 0.78 0.43 
Age of seizure 
onset (years) 
130 121 0.01 0.42 0.68 
Age of diet 
onset (years) 
131 121 -0.02 -1.22 0.23 
Aetiology 131 121  
 
Genetic vs  Structural/Metabolic 0.05 -0.37 0.72 
Genetic vs  Unknown 0.33 0.11 0.91 
Structural/Metabolic vs Unknown (using 
relevel) 
0.28 0.98 0.33 
Seizure 
localisation 
131 120    
 
Focal vs Generalised 0.14 0.45 0.65 
Focal vs Focal+Generalised -0.24 -0.75 0.46 
Focal vs Focal with secondary generalisation 0.85 0.99 0.32 
Focal vs spasms 0.34 0.36 0.72 
Generalised vs Focal+Generalised (using -0.38 -1.14 0.25 
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relevel) 
Generalised vs Focal with secondary 
generalisation (using relevel) 
0.71 0.82 0.41 
Generalised vs spasms (using relevel) 0.20 0.21 0.83 
Focal+Generalised vs Focal with secondary 
generalisation (using relevel) 
1.09 1.25 0.21 
Focal+Generalised vs spasms (using relevel) 0.58 0.61 0.54 
Focal with secondary generalisation vs 
spasms (using relevel) 
-0.51 -0.41 0.68 
Number of 
AEDs taken at 
diet onset 
131 121 0.09 0.69 0.49 
AEDs taken at 
diet onset 
131 121  
 
Sodium valproate 0.35 1.37 0.17 
Levetiracetam 0.21 0.78 0.44 
Topiramate 0.46 1.60 0.11 
Vigabatrin -0.18 -0.42 0.68 
Carbamazepine -0.62 -1.31 0.19 
Lamotrigine -0.29 -0.94 0.35 
Clobazam 0.25 0.94 0.34 
Number of 
failed AEDs 
prior to diet 
onset 
130 120 -0.10 -2.06 0.04 
Diet type 130 120  
 
Classical Ketogenic diet vs Modified Atkins 
Diet 
-0.59 -1.65 0.10 
Classical Ketogenic diet vs Medium Chain 
Triglyceride Ketogenic diet 
-0.27 -0.83 0.41 
Modified Atkins Diet vs  Medium Chain 
Triglyceride Ketogenic diet  (using relevel) 
0.32 0.73 0.46 
Feed 131 121  
 
Oral vs Tube 0.27 0.93 0.35 
Oral vs Oral and Tube 0.53 0.99 0.32 
Tube vs  Oral and Tube (using relevel) 0.26 0.45 0.65 
 
Table 3.6: Putative factors affecting summary Ketogenic diet response 
Factor 
Number of 
responders with 
data available 
Number of non-
responders with 
data available 
Estimate Z value P value 
Gender 116 105 0.21 0.78 0.44 
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Age of seizure 
onset (years) 
116 105 0.03 0.81 0.42 
Age of diet 
onset (years) 
116 105 -0.01 -0.63 0.53 
Aetiology 116 105  
 
Genetic vs  Structural/Metabolic 0.01 0.20 0.84 
Genetic vs  Unknown 0.01 0.27 0.79 
Structural/Metabolic vs Unknown (using 
relevel) 
0.02 0.08 0.94 
Seizure 
localisation 
116 105    
 
Focal vs Generalised 0.13 0.39 0.70 
Focal vs Focal+Generalised -0.23 -0.66 0.51 
Focal vs Focal with secondary generalisation 0.57 0.63 0.53 
Focal vs spasms -0.53 -0.57 0.57 
Generalised vs Focal+Generalised (using 
relevel) 
-0.36 -1.01 0.31 
Generalised vs Focal with secondary 
generalisation (using relevel) 
0.44 0.49 0.63 
Generalised vs spasms (using relevel) -0.66 -0.70 0.48 
Focal+Generalised vs Focal with secondary 
generalisation (using relevel) 
0.79 0.88 0.38 
Focal+Generalised vs spasms (using relevel) -0.30 -0.32 0.75 
Focal with secondary generalisation vs 
spasms (using relevel) 
-1.10 -0.87 0.38 
Number of 
AEDs taken at 
diet onset 
116 105 0.08 0.58 0.56 
AEDs taken at 
diet onset 
116 105  
 
Sodium valproate 0.31 1.15 0.25 
Levetiracetam 0.03 1.05 0.30 
Topiramate 0.63 1.99 0.05 
Vigabatrin -0.31 -0.69 0.49 
Carbamazepine -0.79 -1.61 0.11 
Lamotrigine -0.23 -0.72 0.47 
Clobazam 0.02 0.08 0.94 
Number of 
failed AEDs 
prior to diet 
onset 
115 104 -0.10 -1.93 0.05 
Diet type 116 104  
 
Classical Ketogenic diet vs Modified Atkins 
Diet 
-0.37 -0.95 0.34 
Classical Ketogenic diet vs Medium Chain 
Triglyceride Ketogenic diet 
-0.13 -0.34 0.34 
Modified Atkins Diet vs  Medium Chain 
Triglyceride Ketogenic diet  (using relevel) 
0.24 0.49 0.62 
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Feed 116 105  
 
Oral vs Tube 0.29 0.32 0.37 
Oral vs Oral and Tube 0.24 0.45 0.65 
Tube vs  Oral and Tube (using relevel) -0.05 -0.08 0.94 
 
Table 3.7: Putative factors affecting extreme summary Ketogenic diet response 
Factor 
Number of 
responders with 
data available 
Number of non-
responders with 
data available 
Estimate Z value P value 
Gender 41 67 0.05 0.12 0.91 
Age of seizure 
onset (years) 
41 67 -0.02 -0.29 0.77 
Age of diet 
onset (years) 
41 67 -0.04 -1.09 0.28 
Aetiology 41 67  
 
Genetic vs  Structural/Metabolic -0.07 -0.10 0.92 
Genetic vs  Unknown -0.22 -0.35 0.73 
Structural/Metabolic vs Unknown (using 
relevel) 
-0.15 -0.34 0.73 
Seizure 
localisation 
41 67    
 
Focal vs Generalised 0.65 1.37 0.17 
Focal vs Focal+Generalised 0.49 0.97 0.33 
Focal vs Focal with secondary generalisation 16.44 0.01 0.99 
Focal vs spasms n/a n/a n/a 
Generalised vs Focal+Generalised (using 
relevel) 
-0.15 -0.29 0.77 
Generalised vs Focal with secondary 
generalisation (using relevel) 
15.79 0.01 0.99 
Generalised vs spasms (using relevel) n/a n/a n/a 
Focal+Generalised vs Focal with secondary 
generalisation (using relevel) 
15.94 0.01 0.99 
Focal+Generalised vs spasms (using relevel) n/a n/a n/a 
Focal with secondary generalisation vs 
spasms (using relevel) 
n/a n/a n/a 
Number of 
AEDs taken at 
diet onset 
41 67 0.05 0.21 0.84 
AEDs taken at 
diet onset 
41 67  
 
Sodium valproate 0.36 0.90 0.37 
Levetiracetam 0.06 0.14 0.89 
Topiramate 1.08 2.28 0.02 
Vigabatrin -0.97 -1.19 0.23 
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Carbamazepine -0.80 -1.16 0.25 
Lamotrigine -0.76 -1.47 0.14 
Clobazam -0.07 -0.19 0.85 
Number of 
failed AEDs 
prior to diet 
onset 
41 66 -0.09 -1.14 0.25 
Diet type 41 66  
 
Classical Ketogenic diet vs Modified Atkins 
Diet 
0.44 0.68 0.50 
Classical Ketogenic diet vs Medium Chain 
Triglyceride Ketogenic diet 
-0.32 -0.58 0.56 
Modified Atkins Diet vs  Medium Chain 
Triglyceride Ketogenic diet  (using relevel) 
0.12 0.15 0.88 
Feed 41 67  
 
Oral vs Tube -0.62 -1.39 0.16 
Oral vs Oral and Tube 0.41 0.51 0.61 
Tube vs  Oral and Tube (using relevel) -0.22 -0.26 0.80 
 
3.3.6.2 Epilepsy syndrome or cause 
Response rates were separated out according to groups of patients with the same epilepsy 
syndrome or aetiology. Those with epilepsy with myoclonic atonic seizures had higher 
response rates than expected (considering response rates in the cohort as a whole, 
although no statistical analyses were performed, as the sample size in each group was 
small; most participants do not have an epilepsy syndrome diagnosis or have epilepsy of 
unknown aetiology): 12/14(85.7%) cases with epilepsy with myoclonic atonic seizures 
groups were classified as responders at the 3-month point, and 10/14(71%) were classified 
as responders according to the summary diet response phenotype (one case was excluded 
from the summary response classification due to variable seizure frequency over time), five 
(36% of 14) of which were extreme responders.  
Response rates in other groups (those including ≥10 cases) are as follows: 
i) 7/15(47%) cases with Dravet syndrome (14 of which had a known 
mutation in SCN1A) were responders at the 3-month point; 7/15(47%) 
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were overall responders (summary diet response), of which three (20 % 
of 15) were extreme responders.   
ii) 10/15(62.5%) cases with West syndrome were responders at the 3-
month point (another patient with West syndrome was recruited [n=16] 
but KD response was unclassifiable in this case), and 8/15(53%) were 
overall responders (summary diet response), three (20% of 15) of which 
were classified as extreme responders. 
iii) 6/13(46%) cases with Lennox-Gastaut syndrome were responders at the 
3-month point; 3/13(23%) were overall responders (summary diet 
response), of which one (8% of 13) was an extreme responder. 
iv) 11/20(55%) cases with epilepsy due to hypoxic ischemic encephalopathy 
were responders at the 3-month point; 11/20(55%) were overall 
responders (summary diet response), of which seven (35% of 20) were 
extreme responders. 
v) 5/10(50%) cases with epilepsy due to polymicrogyria were responders at 
the 3-month point; 4/10(40%) were overall responders (summary diet 
response), of which one (10% of 10) was an extreme responder. 
3.3.6.3 Biochemical parameters   
Possible associations of selected biochemical parameters measured at 3-month, 6-month 
and 12-month clinic appointments with diet response at the corresponding follow-up time 
points were investigated by logistic regression, as shown in Table 3.8, Table 3.9 and Table 
3.10 respectively. The association of biochemical parameters was not assessed at the 18- or 
24-month points, due to small sample sizes.  
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A Bonferroni-corrected significance threshold, based on an alpha of 0.05 and 15 tests, was 
imposed. No factors reached statistical significance when adjusting for multiple testing (p-
value<0.003). 
Table 3.8: Putative factors affecting diet response at 3-month follow-up: biochemical parameters 
Biochemical parameter, 
measured in blood 
Estimate T value P value 
Number of cases with data  
(3-month diet response and 
biochemical measure) 
Free carnitine (µmol/L) 0.007 2.43 0.02 104 
Acetyl carnitine (µmol/L) 0.01 2.19 0.03 93 
Propionyl carnitine (µmol/L) -0.01 -0.09 0.93 76 
Butyryl carnitine (µmol/L) -0.44 -1.15 0.25 76 
Isovaleryl carnitine (µmol/L) 0.09 0.17 0.86 76 
Hexanoyl carnitine (µmol/L) 0.17 0.18 0.86 68 
Octanoyl carnitine (µmol/L) 0.36 0.64 0.52 76 
Tetradecenyl carnitine 
(µmol/L) 
0.62 0.88 0.39 61 
Palmitoyl carnitine (µmol/L) 0.25 2.01 0.04 67 
Creatinine (µmol/L) 0.0009 0.29 0.77 146 
Glucose (mmol/L) 0.02 0.20 0.84 86 
Non-esterified fatty acids 
(mmol/L) 
-0.01 -0.11 0.92 111 
Beta-hydroxybutyrate 
(mmol/L) 
0.04 1.29 0.20 122 
Cholesterol (total) (mmol/L) -0.003 -0.09 0.93 129 
Triglycerides (mmol/L) -0.01 -0.42 0.68 128 
 
Table 3.9: Putative factors affecting diet response at 6-month follow-up: biochemical parameters 
Biochemical parameter, 
measured in blood 
Estimate T value P value 
Number of cases with data  
(6-month diet response and 
biochemical measure) 
Free carnitine (µmol/L) 0.0008 0.25 0.80 77 
Acetyl carnitine (µmol/L) 0.007 1.54 0.13 59 
Propionyl carnitine (µmol/L) -0.13 -1.16 0.25 53 
Butyryl carnitine (µmol/L) -0.20 -0.37 0.71 53 
Isovaleryl carnitine (µmol/L) 1.38 1.81 0.08 52 
Hexanoyl carnitine (µmol/L) -0.53 -0.53 0.60 53 
Octanoyl carnitine (µmol/L) -0.99 -1.30 0.20 49 
Tetradecenyl carnitine 
(µmol/L) 
1.37 1.64 0.11 49 
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Palmitoyl carnitine (µmol/L) -0.03 -0.18 0.86 52 
Creatinine (µmol/L) 0.0002 0.04 0.97 91 
Glucose (mmol/L) -0.07 -0.83 0.41 71 
Non-esterified fatty acids 
(mmol/L) 
-0.15 -0.76 0.45 67 
Beta-hydroxybutyrate 
(mmol/L) 
0.03 1.03 0.31 70 
Cholesterol (total) (mmol/L) 0.06 1.45 0.15 87 
Triglycerides (mmol/L) 0.006 0.19 0.85 87 
 
Table 3.10: Putative factors affecting diet response at 12-month follow-up: biochemical 
parameters 
Biochemical parameter, 
measured in blood 
Estimate T value P value 
Number of cases with data 
(12-month diet response 
and biochemical measure) 
Free carnitine (µmol/L) -0.001 -0.32 0.75 44 
Acetyl carnitine (µmol/L) -0.005 -0.94 0.35 39 
Propionyl carnitine (µmol/L) 0.10 0.43 0.67 33 
Butyryl carnitine (µmol/L) 0.36 0.79 0.44 33 
Isovaleryl carnitine (µmol/L) 0.53 0.62 0.54 33 
Hexanoyl carnitine (µmol/L) -1.24 -0.82 0.42 33 
Octanoyl carnitine (µmol/L) -2.39 -2.81 0.01 33 
Tetradecenyl carnitine 
(µmol/L) 
-0.13 -0.17 0.87 33 
Palmitoyl carnitine (µmol/L) -0.08 -0.45 0.65 33 
Creatinine (µmol/L) -0.003 -0.75 0.46 61 
Glucose (mmol/L) -0.18 -1.76 0.09 41 
Non-esterified fatty acids 
(mmol/L) 
0.11 0.79 0.44 52 
Beta-hydroxybutyrate 
(mmol/L) 
-0.02 -0.58 0.56 56 
Cholesterol (total) (mmol/L) -0.02 -0.44 0.66 54 
Triglycerides (mmol/L) 0.04 0.82 0.42 53 
 
 Use of phenotypic data for genetic analyses 3.3.7
Seizure frequency will be the only parameter used to classify individuals as 
responders/non-responders for use in genetic analyses. This is not because other effects of 
dietary treatment are not considered clinically meaningful, but because they have not been 
137 
 
quantified in this study and therefore, classification of KD response that includes these 
parameters could not be reliably replicated in other cohorts.  
If there is there a genetic basis to KD response, it is unknown what architecture it takes. 
Different mechanisms may influence KD response at different time points, or (as in the case 
of SLC2A1 mutations), certain variants may influence KD response, no matter whether this 
is in the short- or long-term. Due to this uncertainty (this is an exploratory study), the 
following phenotypes will be used for genetic analyses: 
i) 3-month KD response 
This represents the largest cohort and so the maximum proportion of available data is 
used. Furthermore, in clinical practice, response to the KD is commonly judged at 3-month 
follow-up. Based on this judgement, a decision is taken whether to discontinue or continue 
treatment (if continued, the benefits of the KD are weighed up against any disadvantages, 
at each time point). Using 3-month KD response as a phenotypic measure is thus clinically 
useful. 
The number of individuals with diet response data falls over time (many people have 
weaned off the diet). Due to the small sample size, at least in terms of genetics studies, the 
3-month response cohort only provides limited power to detect an effect of the factor 
being investigated; the 6-, 12-, 18- and 24-month cohorts have even less power and non-
responders are under-represented at later time points. For these reasons, separate 
analyses will not be conducted using response at these time points, although they are used 
to classify individuals as overall responders and non-responders.  
ii) Summary KD response and extreme summary KD response  
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Using summary response classifications accounts for the fact that response at specific time 
points may not be representative of an individual’s overall experience with the KD (an 
individual may be classified as a responder at 3-month follow-up but as a non-responder at 
6-months). In this way, associations with genes affecting KD response in the broader sense 
are searched for. 
The summary diet response phenotype will be used for analyses investigating the putative 
influence of common genetic variation, which are assumed to have a small phenotypic 
effect. The extreme summary diet response phenotype will be used for analyses 
investigating the putative influence of rare genetic variation, which are thought, in general, 
to have a larger phenotypic effect compared to common variation. 
Comparisons may be made with 3-month KD response analyses; some genes may influence 
KD response in the short-term, whereas others influence response in the long-term, 
potentially due to longer-term gene expression changes. 
One individual was found to have GLUT1 deficiency after completion of this chapter 
(identified from whole exome sequencing) and so was excluded from all genetic analyses. 
3.4 Discussion  
Key findings: 
 All phenotypic data (except for compliance questionnaires) used in this study were 
taken from sources designed for clinical monitoring, not for research purposes. 
 Recognising the limits of the data available, the demographics of this cohort 
(predominantly young people with severely drug-resistant epilepsy), and KD 
response rates are similar to those reported in the literature. 
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 Compliance to the KD was assessed in a proportion of patients with use of 
questionnaires and serum BHB levels taken at clinic appointments. Most patients 
were thought to be compliant, but more objective measures of assessing 
compliance, which are more representative of the whole period of time between 
clinic appointments, are needed.  
 Seizure frequency was used to measure KD response. This was the only effect of 
the diet to be quantified (at least, to the extent possible when data is taken mostly 
from clinic letters). Response may be classified at specific follow-up points, or as a 
summary of response over time.  
 Other parameters, such as a reduction in seizure severity or increased alertness, 
are often clinically relevant to individuals following the KD – people may remain on 
the diet despite <50% reduction in seizure frequency. These parameters are not 
routinely quantified as part of routine clinical monitoring and so were not used to 
classify KD response in this study. Tools, such as seizure severity scales or quality of 
life questionnaires, may be useful in further studies.  
 None of the non-genetic factors evaluated were significantly associated with KD 
response (either at 3-month follow-up or when using summary diet response 
phenotypes) after adjusting for multiple testing.   
 Cohort demographics 3.4.1
The demographics of this cohort, which has one of the largest sample sizes reported, are 
typical of many KD groups presented in the literature. There is a tendency for patients to 
have an early age at seizure onset and diet initiation (this is also affected by the small 
number of centres offering KD treatment for adults), have failed multiple AEDs, and they 
often have some level of developmental delay. Many have unknown causes of epilepsy or a 
clinical presentation that does not easily fit into a particular epilepsy syndrome.   
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The difficulties in accurately phenotyping patients with epilepsy must be highlighted. 
Determination of seizure localisation, for example, even when based on EEG data and 
clinical seizure manifestation, may be open to interpretation. In these cases, one must trust 
in the experts (such as neurophysiologists) who interpreted the data in the first place. 
Patients are often classified under such umbrella terms as Idiopathic Generalised Epilepsy, 
particularly in older clinic letters, thus heterogeneity within groups may be wider than 
expected. When adopting a relatively new classification system, as is the case here, some 
interpretation is often required when extracting information from sources that have used 
previous systems.  
Even with deep phenotyping, some desired data will unavoidably be missing. There is, for 
example, (conflicting) evidence that measures of BMI are correlated with KD response; 
recordings of weight, weight-for-height z-score and BMI at diet onset, or changes in these 
variables during dietary treatment, could not be included here due to incompleteness and 
inconsistencies in the data. In most cases, patients’ weight and height were measured at 
diet information clinic sessions. However, the diet may not have been initiated until much 
later (over a year in some cases) and all measurements may not have been recorded again 
immediately before commencement of the diet. Missing values arose from unattended 
appointments or appointments when measurements were not taken. When considering 
growth in paediatric patients, such inconsistencies would make inter- and intra-patient 
comparison problematic. As many data sources were consulted as possible to avoid missing 
data for other variables.  
 Compliance 3.4.2
Compliance questionnaire scores indicated high compliance to the diet in approximately 
three quarters of patients for whom questionnaire data were available, although the 
definition of high compliance used here, which is based on the frequency distribution of 
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the data, might change if more questionnaires were collected. Notwithstanding the fact 
that compliance data are not available for all cases, scores calculated from the 
questionnaires assume, on the part of the patient or parent/guardian(s), complete honesty 
and a thorough understanding of the restrictions of the KD and of the questions being 
asked. Although it has been reported that people who admit non-compliance to medication 
tend to be telling the truth [456-458], indirect methods of measuring compliance, such as 
questionnaires, may lead to over-estimation of compliance levels [459]. Reactions to the 
statement ‘We alter the diet’ may depend on the type of KD followed, how often changes 
are made by the patient’s dietitians, and whether such changes were accounted for here. 
Despite the advantages of basing the questionnaire on a validated one, perhaps further 
adjustments could have made it more diet-specific.  
The moderate Cronbach’s alpha correlation coefficient may have been affected by the 
small number of items in the questionnaire, the positive distribution of scores or the small 
sample size. As a non-normal distribution of scores reduces the precision of the coefficient, 
underestimating the population reliability, a larger sample size (>100 for a moderate 
correlation coefficient or >1000 for small correlation coefficient) would help approximate 
the non-normal distribution towards normality and reduce the negative bias imposed on 
the alpha value [453]. This has been found to reduce bias to a greater extent than when the 
number of items/test length was increased.  
An alternative method of assessing reliability of the compliance questionnaire, ‘test-retest’, 
would have provided an indication of test reliability over time. Employing both Cronbach’s 
alpha and the ‘test-retest’ method to assess reliability of the compliance questionnaire may 
have yielded more easily interpretable results. The likelihood that participants would have 
completed and returned the same questionnaire on more than one occasion, however, is 
low. 
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Used as a measure of diet compliance, serum BHB levels are also hard to interpret. 
Although generally considered more accurate than urine ketones, which are influenced by 
fluid intake, urine volume and concentration [460], serum BHB may be affected by other 
medications, recently-completed exercise, constituents of recent meals/snacks, and time of 
day. Inter-individual variability in ketone body production and maintenance is high [165] 
and measures taken on one day may not be representative of the whole period of time 
between each follow-up point. It would have been preferable to use measures taken at 
home by parents on a twice-daily basis. However, whilst most parents claim to take these 
measurements, at least when dietary treatment has been recently commenced and dietary 
manipulation is still occurring, urine ketones are measured in most children (serum BHB 
would be preferable for research purposes) and these data were seldom available for the 
28 days prior to each follow-up point, when seizure frequency was determined. It is 
becoming increasingly common for parents to hand over ‘diaries’ of ketone levels 
measured at home over a prolonged period of time, although this varies among centres. If 
all participants were to be recruited prospectively, a higher proportion of these data may 
be obtained. Measurements taken by parents may be subject to a greater level of error 
than measurements taken in hospitals, but use of repeated measurements should be more 
representative of the period of time between each follow-up point. Measurement of 
breath acetone levels is an alternative way to assess ketosis on a regular basis (levels 
correlate with urinary and serum ACA and serum BHB [376, 461]), but the equipment 
needed to do this is not commonly available outside a laboratory setting.        
Reports from the literature assessing KD compliance have so far relied on urine and blood 
ketone testing [106], where 3/12(25%) patients were described as having ‘none’ or ‘mild’ 
compliance, or on communication with parents/patients [73], where 12/56(21.4%) patients 
had ‘poor’ compliance. It is unknown what threshold was adopted to define compliance 
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levels defined by ketone body measurements and so it is difficult to compare compliance 
levels in this cohort (also those derived from the questionnaires) to anything in the 
literature.    
Based on the fact that compliance data are not available for all participants, together with 
the realisation that many other (uncontrollable) factors may have influenced results, no 
participants were excluded from analyses based on compliance measures. One must be 
aware of potential misclassification bias if some participants were incorrectly classified as 
non-responders simply because they were non-compliers. Other methods, such as weighed 
food records, would have more accurately ensured that all participants were compliant, 
but this would have been difficult to achieve with a large sample size and would have 
required all participants to be recruited prospectively. The compliance data collected do, at 
least, provide some assurance that most patients were actually following the diet, 
something that is often neglected in drug response studies.  They do, at least, provide some 
assurance that most patients were actually following the diet, something that is often 
neglected in drug response studies.  
 Diet response 3.4.3
Responder rates in this cohort are consistent with those reported in the literature. The 
proportion of responders increases as time goes on, which is consistent with the fact that 
non-responders are less likely to remain on the diet long-term. The proportion of 
responders may be higher than those reported in prospective studies with an intent-to-
treat analysis; in this study, even if all participants who were approached for recruitment 
were included when calculating responder rates, a true intent-to-treat approach could not 
be used as some participants were recruited retrospectively. However, one would not 
expect responder rates to be too inflated, as the majority of participants have been 
recruited from tertiary referral centres, where particularly severe cases of intractable 
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epilepsy are seen. Only patients with hospital follow-up appointments could be recruited 
retrospectively, which may have resulted in a bias towards cases with multiple co-
morbidities, which may be harder to treat.  
Several difficulties with classifying response to the diet must be considered. For example, 
one is reliant on the patient or his/her parent/guardian/carer(s) for the recording of seizure 
frequency; this may lead to under- [462] or over-reporting [463], depending on the 
motivation, capability and priorities of the recorder. The proportion of participants with 
completed seizure diaries at baseline and four weeks prior to the next follow-up point was 
low, depending on the KD service protocol in each hospital, parental/patient commitment 
and whether the participant had previously taken part in research or schemes for which 
recording of seizures was required. This proportion decreased with time. Clinic letters, 
which essentially provide a second-hand report of information from 
patients/parents/guardians, were the most common source used to ascertain response to 
the diet; created primarily for patient care and administrative purposes (not for research) 
[464], they do not guarantee accuracy or reliability. Some cases remained unclassified due 
to inadequate documentation. For example, comments such as seizures were ‘better’ or 
‘reduced’ were deemed inadequate to determine response at that time point. In some 
cases, the most recent pre-diet clinic appointment was a substantial amount of time before 
the commencement of dietary treatment, for example due to the wait for funding approval 
or medication changes, and so baseline seizure frequency could not be ascertained. 
Classifying diet response was particularly difficult when patients were under the care of 
another centre when they started the KD, often quite some time prior to recruitment - 
obtaining hospital records from a site not directly involved in the study was problematic 
and so details regarding diet response were insufficient for accurate classification. Personal 
communication between the researcher and patients/parents/guardians and participants’ 
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consultants and dietitians aided response classification, both for cases recruited 
prospectively and retrospectively. The researcher was better able to judge, for example, 
whether the description of seizure frequency at each time point was accurate, depending 
on the reporter, seizure type, or seizure frequency itself (if the patient is having hundreds 
of seizures a day, it may be impossible to obtain an accurate number).  
More widespread use of seizure-diaries may further improve the data quality and provide 
documentation of the frequency of each seizure type, which the resolution of the data 
from clinic letters did not allow. In the future, it may be feasible that completion of seizure 
diaries for at least 28 days prior to starting the diet, and 28 days prior to each follow-up 
point, is stipulated as a requirement for involvement in the study, at least for participants 
recruited prospectively. Whereas parental reporting of seizures (for example, from phone 
interviews and mailed questionnaires) can poorly correlate with data from medical records 
[465], through use of diaries, parental reporting has been shown to have high concordance 
with objective methods (such as an actigraph to measure sleep schedules) [466]. However, 
considering that the act of observing or self-observation itself introduces bias, influencing 
the phenomenon being observed, seizure diaries may not be a panacea (although no 
reports were found that show the extent of bias introduced specifically by seizure diaries). 
Accurate reporting depends on awareness of seizures (over half of seizures, in particular 
focal seizures, may not be recognised by the patients themselves or carers [462, 467-469]) 
and the motivation and capabilities of the recorder. Recall bias may affect accuracy if the 
recorder forgets to input an entry around the time of an event. Electronic diaries and 
supervised diaries, where information inputted by the recorder is reviewed by a researcher, 
may lead to more consistent data entry, as recorders are reminded to fill in the diary, and 
potentially increase diary validity [470]. Having said this, for individuals whose seizures 
occur in weekly/monthly clusters, seizure reduction on the diet may not be accurately 
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reflected in seizure diaries (the cluster may occur just before the 28 days prior to baseline 
and so, according to the seizure diary, the patient would be seizure-free before starting the 
diet) and so clinic letters may be more appropriate for ascertaining diet response. For 
individuals with non-clinical seizures, even the use of seizure diaries may not help 
parents/guardians to ascertain seizure frequency; frequency counts may only be possible 
with an EEG recording. In this study, such cases were unclassifiable as responders or non-
responders.  
Even if the number of seizures documented were 100% precise, the pattern of seizure 
frequency may simply reflect the natural evolution and fluctuation of the seizure disorder. 
One may question whether changes in seizure frequency were due to initiation of the KD or 
whether they would have happened anyway and subsequently returned to baseline – 
regression to the mean [471]. One way to avoid such doubt and account for recent 
fluctuations in seizure frequency would be to take seizure-freedom (potentially measured 
by the ILAE definition of drug resistance [7] or ‘Rule of Three-to-Six’ [472]) as the measure 
of diet response. It has been reported that only seizure-freedom, or >90% seizure reduction 
[473] will result in measureable improvement in quality of life in adults [474], with seizure-
free adults reaching similar levels to those of the general population [475]. However, while 
it is true that seizure-freedom (or as close to seizure-freedom as possible) would be ideal, 
and has been associated with improved quality of life in children compared to those with 
persistent seizures [476], the probability of achieving this with any new treatment in a 
cohort with drug-resistant epilepsy is minimal [477, 478]. A ≥50% seizure reduction, a 
standard measure of treatment effectiveness used in clinical trials [479], was viewed as 
clinically useful in this cohort. An observed improvement in seizure control, defined as 
≥50% seizure reduction, from use of everolimus was accompanied by improved quality of 
life in children [480]. A ≥50% fluctuation in seizure frequency is also less likely to occur due 
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to chance, compared to lesser degrees of fluctuation [481]. Calculating seizure frequency in 
a defined epoch prior to baseline and each follow-up point seemed more appropriate than 
methods that rely on previous seizure-free intervals, as, in view of the severity of the 
condition of most participants (seen in tertiary, sometimes considered quaternary, care), 
many may continue to have daily seizures even after a dramatic seizure reduction. Clinic 
letters may also not provide detailed or accurate data regarding the longest seizure-free 
interval in the previous 12 months. 
By using repeated measures of response over time, confidence is further increased that 
changes in seizure frequency were due to dietary treatment and not the natural evolution 
of the seizure disorder. As shown by chi-squared tests, 3-month diet response is likely to 
correlate with 6-month or (to a lesser extent) 12-month diet response, but not with 18- or 
24-month response. Whilst calculating seizure frequency at various time points compared 
to baseline is another approach to classifying KD response, which may be useful in genetic 
analyses to ascertain whether different genes influence response at different time points, it 
is clear that response taken at one time point may not accurately reflect response at a later 
time point. Summary response phenotypes account for this variability in response over 
time. Difficulty arises with individuals who have been following the diet for a short period 
of time. As shown by individuals who have followed the diet long-term, response, for 
example, at the 3-month point, may not correlate with response at later time points. Thus, 
summary phenotypes for cases with data at few time points may not be accurate or may 
differ if more data were to be collected in the future. For this reason, in the extreme 
summary diet response category, individuals with only 3-month response data were 
excluded (unless, of course, they weaned off the diet due to lack of response). A 
disadvantage with this category is that the sample size is dramatically reduced and so the 
power to detect an association between response and demographic/clinical factors is low. 
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As this category includes only the most extreme responders and non-responders, however, 
it should have the most power to detect associations with rare variants with a large effect 
size on KD response. 
 Factors affecting Ketogenic diet response 3.4.4
Out of all factors assessed, the number of failed AEDs prior to diet onset and use of 
topiramate at diet onset were most closely associated with KD response. They did not 
reach statistical association when correcting for multiple testing, although it must not be 
forgotten that the Bonferroni adjustment is conservative; whilst it decrease the chance of 
committing a Type I error, it increases the chance of Type II error [449]. Perhaps with a 
larger sample size, these, or other factors would reach statistical significance after 
adjustment for multiple testing. 
The correlation detected between number of failed AEDs and KD response (the greater the 
number of AEDs, the less likely a favourable response to the diet) corresponds with two 
reports in the literature [105, 482], although other evidence is conflicting [55, 118, 121, 
123, 124, 127, 208, 360]. Patients are sometimes advised to wean off topiramate before 
initiating dietary treatment due to the increased risk of metabolic acidosis and renal stones, 
both from the drug [483] and the KD [484-486]. However, according to the literature, 
responder rates in patients taking topiramate and following the KD are similar to responder 
rates in patients taking other AEDs [211, 487]. Number of failed AEDs prior to diet onset is 
likely to be a surrogate for disease severity (individuals with more severe epilepsy will 
probably have tried, and failed, more AEDs than those with a less severe condition), and 
could be influenced by age, so may not be worth including as a covariate in the genetic 
analyses. Use of topiramate may also be inextricable from other factors, as this AED is often 
used for patients with Lennox-Gastaut syndrome [483], who are particularly refractory to 
treatment but may respond more favourably to the KD than patients with other epilepsy 
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syndromes [113, 359]. For this reason, together with the fact that these factors did not 
reach statistical significance when correcting for multiple testing, these factors will not be 
included as covariates in genetic analyses.  
Considering the conflicting evidence presented in Chapter 1, the lack of effect of other 
factors on KD response in this cohort is unsurprising. Some factors were not suitable for 
statistical analysis, such as epilepsy syndrome, as there were too few cases in each 
category, and intellectual status, as all but 18 cases had some degree of developmental 
delay. Particularly favourable response rates in patients with epilepsy with myoclonic 
atonic seizures are consistent with reports from the literature [338-340, 359]. SLC2A1 
mutations have been detected in approximately 5% of patients with this condition [348].   
No biochemical parameter had a significant relationship with KD response at all time points 
investigated. One may expect serum BHB, or even glucose, to relate to diet response, 
although evidence from the literature is conflicting. Due to their role in fatty acid transport, 
it is of interest that various carnitines were associated (p-value<0.05) with diet response at 
3-month follow-up, although (with the exception of octanoyl carnitine at 12-month follow-
up) these relationships were not maintained over time and, when adjusting for multiple 
testing, statistical significance was not reached. Blood is only taken (except in emergency 
situations) when patients attend KD clinic appointments and it must be considered that 
measures taken on one day may not be representative of the whole 3-month period. Urine, 
or sometimes blood ketones may be measured on a daily basis, particularly at the start of 
treatment. If these data were readily available from hospital records, it could be better 
determined whether levels correlate with seizure fluctuation over time. 
 Factors beyond seizure frequency 3.4.5
Although seizure frequency is the most common measure of response to the KD in the 
literature, other (potentially clinically useful) aspects of seizure control, such as seizure 
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severity and duration, or quality of life, must not be disregarded. Non-responders to the 
diet in terms of seizure reduction are not exempt from gaining other benefits on seizures, 
cognition or behaviour. The fact that a proportion of cases who fail to achieve ≥50% seizure 
reduction stay on the diet past the initial 3-month trial period demonstrates that other 
parameters are clinically relevant for some patients and their families and may outweigh 
any disadvantages that adherence to a dietary regime entails. A reduction in seizure 
severity and quicker recovery time have been shown to lead to improved quality of life in 
people with epilepsy [488-491]; thus, it is not surprising that individuals may remain on the 
KD if they obtain such benefits, even if they do not achieve ≥50% seizure reduction. 
Improved cognition may influence how long somebody remains on the KD more than 
seizure control [147]. Increased alertness is another commonly reported benefit from the 
diet [78, 143, 492, 493], as in this cohort, although the proportion of people who reap such 
benefits is not consistently reported in the literature and no reports were found 
demonstrating that this factor influences duration of the KD more than seizure frequency. 
The number of patients said to have successfully reduced AEDs in other studies are 
generally consistent with this cohort [358, 494], although proportions vary widely, 
depending on the population. For example, in a cohort of patients with Dravet syndrome, 
all those who did not achieve a dramatic reduction in seizures with the KD managed to 
reduce the number of AEDs taken to one or two [347]. Of course, it may be difficult to 
gauge how an individual reacts over a long period of time to a reduction in AEDs, due to the 
fluctuating nature of epilepsy.  
The approach used here – recording whether patients or his/her parent/guardian(s) 
reported any other effects of the diet aside from seizure frequency – is somewhat 
rudimentary and subjective. Although as many data sources as possible were used, this 
information was not systematically reported or recorded. In order to incorporate such 
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measures when classifying KD response and to allow replication of results by external 
groups, these parameters need to be quantified. Regarding effects on seizures other than 
frequency alone, quantifiable scales, such as the Chalfont [495], National Hospital [496] and 
Liverpool [497] seizure severity scales, would be possible tools. Use of a seizure frequency 
and severity scale, such as one based on the Veterans administration scale [498], would 
allow for consideration of more than one component of seizure control. Other benefits, 
such as alertness or happiness, may be more problematic, as different measures would be 
best assessed with different tools. Perhaps a quality of life questionnaire, such as the 
Cambridge London QoL questionnaire, currently being developed for use in KD clinics, 
would best encompass a range of such measures. With this range of tools, a more accurate 
and comprehensive classification of KD response can be made. This would be particularly 
important for cases who achieve approximately 50% seizure reduction (borderline cases) or 
when diet response fluctuates over time. 
 Conclusion 3.4.6
This cohort appears representative of the KD population as a whole, with response rates 
and cohort demographics consistent with the literature. Proportions of responders and 
non-responders, however, are highly dependent on definitions of diet effectiveness.  
Unlike many studies, where compliance to the diet is simply assumed or based solely on 
ketone levels, in this cohort (where data were available), serum BHB and questionnaires 
were used to demonstrate high compliance. However, serum BHB may have been 
influenced by other factors and so caution must be taken. An adjusted questionnaire with 
improved internal consistency is worth consideration for the future. 
When investigating putative correlations between diet response and patient demographics 
or clinical/biochemical data, response at all follow-up points available were considered. In 
this cohort, number of failed AEDs and use of topiramate showed strongest evidence 
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(although not statistically significant when adjusting for multiple testing) for association 
with diet response, but the extent to which this is influenced by other factors, such as 
disease severity, epilepsy syndrome and age, is unknown. The association between various 
carnitine fractions and diet response at various time points may be worth investigating in a 
larger cohort.  
Response may be classified at specific time points or as a summary of response over time. 
There is no single ‘correct’ phenotype; the criteria used to best classify response depends 
on what the data is being used for (for example, which genetic model is considered). Sole 
use of quantitative measures of response – namely seizure frequency – reduces ambiguity 
and facilitates replication of results, but it fails to account for other, potentially clinically-
relevant measures of response, such as seizure severity or increased alertness. In future 
studies, quantitative measurement (where possible) of such parameters would ideally be 
included. A uniform definition of KD response would be needed for replication of genetic 
analyses.  
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4 Candidate gene analysis 
 
4.1 Introduction 
 The candidate gene approach 4.1.1
When exploring the genetics behind a complex trait such as KD response, the candidate 
gene approach is a powerful and economical method of analysis [499]. Candidate gene 
studies are based on a priori knowledge about genes/variants and their effects on 
biological pathways or the trait in question. Whilst this reliance may, at first, appear 
limiting (as other biological pathways not previously associated with a phenotype may be 
of equal or more importance than those already identified), candidate gene studies have 
contributed much to our understanding of nutrigenetics [500]. One example is the effect of 
the homozygous APOE4/E4 genotype on response (in terms of reducing plasma cholesterol 
and cardiovascular disease risk) to changes in dietary intake of total fat, cholesterol and 
fatty acid composition [501]. Some results have even had clinical utility; for example, 
testing patients for KIF6 status prior to starting statin treatment was associated with 
improved treatment adherence at the 6-month point [502]. 
For genetic association studies (whether the analysis includes variants from specific genes 
or from across the whole genome), single nucleotide polymorphisms (SNPs - the 
substitution of a single nucleotide for another in a specific genetic location) are usually the 
marker of choice. They occur throughout the genome, more frequently in non-coding than 
in coding regions [503], and are considered to be a major genetic source of phenotypic 
variability within a given species [504]. The inclusion of all variants found from sequencing, 
rather than prior selection of polymorphisms, allows consideration of variants with lower 
MAF, although large sample sizes are needed to conduct association studies with rare 
variants. SNPs may be grouped into haplotype blocks, where variants are tightly linked with 
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each other, and these blocks used as markers for association studies. Haplotype markers 
are usually inferred, although blocks may differ, not only between loci but also between 
populations [505]; it is possible to directly infer haplotypes using molecular haplotyping 
methods [506], but these are rarely used in practice as they are expensive and time-
consuming. It has been said that haplotypes provide more power than single SNPs in the 
presence of multiple susceptibility alleles at a locus [507], and that haplotypes can capture 
epistastic interactions between SNPs [508], but evidence is conflicting and it seems that the 
putative advantages of haplotype analyses are dataset-dependent [509].  
Phenotypes may be quantitative, such as biochemical parameters, or binary, where one 
group of individuals (‘cases’) may be affected by the disease in question, or have responded 
in a particular way to some treatment, and the other (‘controls’) may be unaffected, 
randomly selected from the population, or have responded differently to treatment. An 
increased frequency of a particular SNP allele in cases compared to controls suggests an 
association of the allele with increased risk of disease or (un)favourable response to 
treatment. With quantitative phenotypes, a unit change in the measure in question may be 
associated with a SNP allele or a particular genotype. 
A major source of confounding in genetic association studies can be due to differences in 
allele frequencies between case and control groups arising from different populations, 
rather than the phenotypic trait in question. If population groups are not equally 
distributed between cases and controls, population-specific SNPs may appear to be 
associated with the phenotype simply because of differences in allele frequency in the 
various groups amongst cases and controls [510], or a lack of effect in one population 
compared to another [511]. In candidate gene studies, if genome-wide data are not 
available to calculate genetic distance/relatedness between participants, recruited 
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individuals should ideally be as ethnically-homogenous as possible, or self-reported 
ethnicity should be used as a covariate in analyses. 
Candidate gene analyses have a reduced multiple testing burden compared to its 
association study counterpart, the genome-wide association study (GWAS), and thus often 
boast higher statistical power to detect associations [512]. This is especially important with 
small sample sizes, although variant effect size and allele frequency will also affect the 
power a study has to detect an association [513].  
In this study, candidate gene variants were identified by Sanger sequencing. Although more 
time-consuming and costly compared to next-generation sequencing methods (which will 
be explored in more detail in subsequent chapters), Sanger sequencing is considered the 
‘gold standard’ [514] and remains in use predominantly for candidate gene analyses, small-
scale studies, or to verify variants identified from next-generation sequencing methods. 
The accuracy of base-calling is generally higher with Sanger sequencing than with next-
generation sequencing methods [515] and incomplete representation and coverage with 
next-generation sequencing may lead to mutations being missed [516, 517]. Sanger 
sequencing is based on a chain-termination method, whereby the DNA is denatured to give 
single strands, a specially-designed primer is added and binds to the DNA sequence of 
interest, and different dideoxynucleotides (which are the same as the nucleotides in DNA, 
except for the fact they contain a hydrogen group on the 3’ carbon instead of a hydroxyl 
group) are integrated into the sequence. When the enzyme DNA polymerase is added, the 
new strand of DNA is synthesised and when a dideoxynucleotide is incorporated into the 
chain instead of a normal nucleotide, the chain is terminated. This produces DNA sequence 
reads of varying lengths. The final products are run on a gel and separated by 
electrophoresis, which orders the DNA fragments by size; depending on whether the 
primer or nucleotides were radioactively or fluorescently labelled, the gel is exposed to 
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either ultraviolet light or x-ray in order to visualise the DNA bands. Alternatively, each 
dideoxynucleotide can be labelled with different colour dyes, which each fluoresce at a 
different wavelength, so when they are run on a gel, the identity of each band can be 
determined according to the wavelength at which it fluoresces.  
 Candidate genes: background information 4.1.2
Two genes have recently been suggested as attractive candidates putatively implicated in 
the antiepileptic mechanisms of the KD, Kcnj11 and Bad [226]:  
i) Kcnj11 (inwardly-rectifying potassium channel, subfamily J, member 11) 
encodes the Kir6.2 pore-forming subunit of KATP channels. 
KATP channels are best known for their role in glucose-stimulated insulin-secretion from 
pancreatic β cells: when glucose enters the β cell and is metabolised, the increase in 
intracellular ATP and decrease in magnesium-ADP inhibit the KATP channel and cause the 
channel to close. This leads to membrane depolarisation, which activates voltage-gated L-
type Ca2+ channels, causing insulin to be secreted from the cell by exocytosis [518, 519].  
Akin to their role in maintaining glucose homeostasis in pancreatic β cells, evidence 
suggests that Kir6.2-containing KATP channels are essential for glucose responsiveness in 
glucose-responsive neurons located in the ventromedial hypothalamus: approximately a 
quarter of Kir6.2+/+ neurons displayed increased spontaneous discharge rate in response to 
increased extracellular glucose concentrations; Kir6.2-/- neurons already showed a higher 
discharge rate at lower glucose levels compared to controls, but no further increase was 
observed  when the glucose concentration was increased [520].  
The Kir6.2 subunit of KATP channels has a suppressive effect on substantia nigra pars 
reticulata neuronal activity and determines seizure threshold during brief hypoxia: although 
the firing rate of Kir6.2-/- neurons did not differ significantly from wild-type neurons in the 
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normal state, in brief (90 seconds) hypoxia, the firing rate decreased in wild-type but 
increased in Kir6.2-/- neurons; wild-type mice showed no response to brief (150 seconds) 
hypoxia caused by oxygen deprivation, while all Kir6.2-/- mice responded with a myoclonic 
jerk, followed by a severe tonic-chronic convulsion and death [521].  
The E23K (p.Leu270Val) polymorphism in KCNJ11 has been associated with Type II diabetes, 
although evidence is inconsistent [522, 523]. Inactivating mutations in the gene lead to 
familial persistent hyperinsulinaemic hypoglycaemia of infancy (PHHI) [524] and 
heterozygous activating mutations are a common cause of permanent neonatal diabetes 
mellitus (PNDM), with a prevalence of 33-50% in large series of patients [519, 525]; some 
patients with such mutations also suffer from developmental delay, muscle weakness and 
epilepsy. KCNJ11 mutations have been identified in individuals with severe, intermediate 
and mild forms of DEND syndrome (developmental delay, epilepsy, and neonatal diabetes) 
[525-527]. 
Loss-of-function KCNJ11 mutations associated with PHHI, such as Y12X, are predicted to 
cause reduced sensitivity to magnesium-ADP or response to a fall in the intracellular 
ATP/ADP ratio, leaving the channel in a permanently closed/depolarised state and thus 
causing unregulated insulin secretion [528-530]. 
It has been postulated that mutations in KCNJ11 lead to decreased insulin secretion due to 
reduced sensitivity to ATP and thus gain of channel function [531]. Kir6.2[ΔN2-30]mice, 
which express pancreatic KATP channels with reduced ATP sensitivity, developed severe 
early-onset diabetes [529]. Phenotypic variations (neonatal diabetes +/- developmental 
delay, muscle weakness and epilepsy) are thought to be due to the severity of the reduction 
in ATP sensitivity [527]. The R201C mutation, identified in individuals with PNDM alone, 
produced smaller KATP currents and less change in ATP sensitivity than Q52R and V59G, 
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associated with ‘syndromic PNDM’ (PNDM + other features). R201C lies at the putative ATP-
binding site and is thought to impair ATP sensitivity directly, whereas Q52R and V59G are 
thought to impair sensitivity indirectly by increasing the open probability of the channel. 
Kir6.2 is also found in KATP channels in skeletal and cardiac muscle and the brain; these 
channels may only open in situations of metabolic stress, and so a greater reduction in ATP 
sensitivity may be required to increase the resting KATP current sufficiently to influence the 
function of these cells and cause a more severe phenotype [527]. 
ii) Bad (BCL2-associated agonist of cell death) encodes the minimal death domain 
BH3-only protein, a member of the B-cell lymphoma 2 protein family [532]. 
Heterodimerisation of BAD with the antiapoptotic proteins BCL-XL or BCL-2 at membrane 
sites prevents them from stopping apoptosis (shown in yeast) [533]. This allows BAX/BAK-
triggered apoptosis [534]. An example of this was seen in rats with kainic acid-induced 
seizures, where dissociation of BAD from its chaperone protein 14-3-3 was induced, 
allowing it to bind to BCL-XL and leaving BAX free to translocate to the mitochondria, 
causing release of cytochrome c from the mitochondria to the cytosol and activation of 
caspase-9 and caspase-3 [535]. An alternative theory is that BAX/BAK is bypassed, as BAD 
interacts with BCL-XL, displacing it from voltage-dependent anion channels, leading to the 
sensitisation of the mitochondrial permeability transition pore to Ca2+ [536]. Serine-
phosphorylated BAD (at serine residues Ser112, Ser136 or Ser155) is unable to bind BCL-XL 
or BCL-2 [537], leaving BCL-2 free to inhibit BAX-triggered apoptosis [538], promoting cell 
survival. Phosphorylation of BAD is regulated by various survival factors and death stimuli, 
such as protein kinase A (PKA), p21-activated protein kinase 1 (PAK1), protein Kinase B (PKB 
or AKT) and extracellular signal-regulated kinases 1 and 2 (ERK1/2) [539].  
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Due to its role in regulating apoptosis, potential neuroprotective properties have been 
assigned to BAD. The antiapoptotic properties of the cytokine tumor necrosis factor-like 
weak inducer of apoptosis are thought to be due to an induction in the expression of Bad 
phosphorylated at Ser112 in mouse cerebral cortical neurons, mediated by ERK 1/2 [540]. 
Phosphorylated BAD has also been implicated in the mechanisms of progesterone-mediated 
protection after ischaemic stroke: the decreased expression of phosphorylated Bad in rat 
cortical penumbra caused by permanent middle cerebral artery occlusion was attenuated 
by progesterone [541].  
BAD also plays a metabolic role through regulation of glucose homeostasis: Bad3SA/3SA (non-
phosphorylatable) and Bad-/- mice exhibited significant fasting hyperglycaemia and a 
‘marked’ defect in blood glucose clearance [542]. BAD has been found to associate with 
mitochondrial glucokinase in the liver [542, 543] and pancreatic β cells [544] and is essential 
for glucokinase activity [544]. This activation of glucokinase activity correlates with the 
ability of BAD to stimulate insulin secretion, a function which is independent from its 
apoptotic role: Bad3SA, whose binding to BCL-2 and BCL-XL cannot be inhibited, and Bad 
expressing the L151A mutant, which cannot bind to BCL-2 and BCL-XL, both displayed 
defective glucose-stimulated insulin secretion [544]. These dual functions of BAD, apoptotic 
and metabolic, are thought to be dependent on phosphorylation of BAD at Ser155: Ser155 
phosphorylation disrupts the interaction between BAD and BCL-XL [545] but is required for 
its control of glucose-stimulated insulin-secretion [544]. Furthermore, the fact that the 
modified BAD BH3 peptide, SAHBA(L,S,D→A), in which Leu151, Ser155 and Asp156 (required 
for the metabolic activity of BAD, measured by insulin release) are converted to alanine, 
was severely compromised in glucokinase binding, shows that the interaction of BAD with 
glucokinase enables regulation of glucose-stimulated insulin secretion [544].   
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It is of interest that islet Bad mRNA levels were significantly increased in mice fed a high-fat 
diet, compared to those on a control diet, and that several of the kinases that regulate BAD 
Ser155 phosphorylation are nutrient sensitive [544]: for example, AKT-p70S6 kinase in β 
cells is stimulated by glucose and glucagon-like peptide-1, a hormone released in response 
to feeding that stimulates glucose-associated insulin secretion [544, 546]. 
 Rationale for selection of candidate genes 4.1.3
BadS155A (non-phosphorylatable) and Bad-/- cortical neurons and astrocytes exhibited 
increased mitochondrial utilisation of BHB and decreased mitochondrial utilisation of 
glucose, measured by maximal respiration, compared with wild types [226]. These changes 
in energy substrate utilisation are reminiscent of the response to fasting or KD-/high-fat 
diet-feeding. The fact that similar changes were seen in BadS155A and Bad-/- cell types 
suggests that this alteration in fuel utilisation is linked to BAD’s metabolic, rather than 
apoptotic role, and may be regulated by its phosphorylation status (BadS155A and Bad-/- have 
opposite effects on BAD’s apoptotic function).  
BadS155A and Bad-/- mice were resistant to kainic acid- and pentylenetetrazole-induced 
seizures, compared to wild types. This resistance was diminished in Bad-/- , Kir6.2-/- mice, 
indicating that KATP channels mediate Bad’s effect on neuronal excitability and seizure 
resistance. Consistent with this, the open probability of single KATP channels was increased 
in Bad-deficient neurons, compared to wild types, and KATP conductance decreased, 
compared to wild types or neurons from Bad-/-, Kir6.2-/- animals. It was postulated that the 
increase in KATP channel activity was at least partly due to increased BHB, which links back to 
the earlier proposed ‘KATP-glycolysis hypothesis’ [295], whereby reduced glycolysis (and thus 
reduced glycolytic ATP production) brought about by low glucose/high ketone body 
concentrations triggers the opening of KATP channels (most importantly in the brain), 
depressing neuronal excitability. It must be noted that there was no significant difference in 
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total cellular ATP levels between wild type and Bad-/- brains [226], although it may be that 
the local reduction of ATP in the submembrane compartment is more relevant for KD 
response, rather than levels in system structures or whole organs. KATP channel activation by 
other metabolites, such as phosphatidylinositol-4,5-bisphosphate (PIP2), may also play a 
role [226, 547]. Whole brain BHB content was shown to be significantly higher in Bad-/- mice, 
compared to controls, indirectly supporting the link between ketone bodies, KATP channels 
and seizure protection. Serum BHB was similar in Bad-/- and wild type mice and liver-specific 
knockdown of Bad did not provide seizure protection, indicating that local, rather than 
systemic, changes in ketone body metabolism may be important. 
The apoptotic role of Bad has also been implicated in the antiepileptic mechanisms of the 
KD. Due to findings that, following a kainic acid-induced seizure, Bad dissociates from 14-3-3 
in rat hippocampus [535, 548], expression levels of components in this cell death/survival 
pathway were measured [549]: although there was no change in hippocampal Bad 
expression levels in KD-fed mice (with or without kainic acid-induced seizure), the KD 
significantly suppressed the kainic acid-induced reduction in Bad phosphorylated at Ser136 
(pBAD). The KD was also found to increase interaction between pBAD and 14-3-3, decrease 
binding of BAD to BCL-XL, and decrease activation of BAX and caspase-3 – confirmed by 
decreased levels of cleaved caspase-3, measured by Western blot analysis.  
Noh et al. (2006) suggest that, in their study, the Bad signalling pathway was modulated by 
Akt, as the KD attenuated the kainic acid-induced reduction in Akt phosphorylated at 
Ser473 (which is known to phosphorylate BAD at Ser136), and there were no changes in 
levels of Bad phosphorylated at Ser112 (which may be phosphorylated by ERK1/2 and PKA) 
between kainic acid-treated KD-fed mice and those fed a standard diet [550]. Consistent 
with this, the KD significantly reduced pAkt expression in rat hippocampus and liver [418]; 
the authors reported that this inhibition of Akt signalling was a marker of inhibition of the 
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mTOR pathway. This is supported by findings of increased AMP kinase (which inhibits mTOR 
via activation of the tuberous sclerosis complex) activity and phosphorylation in the liver 
and soleus muscle of KD-fed rats [192]. 
No evidence was found for direct KD-induced effects on the ERK1/2 and PKA pathways, 
although some related studies may be of interest: 
i) A high-fat diet was shown to have no effect on Erk-1 or -2 expression in 
mouse white adipose tissue, liver, and muscle, although Erk activity was 
more than three times higher in white adipose tissue from mice fed a high-
fat diet, compared to those fed a standard diet [551]; wild-type mice fed a 
high-fat diet became glucose intolerant, but Erk1−/− mice were protected 
from this.  
ii) Phosphorylation of Erk1/2 was observed in tumour cells of the adrenal 
medulla after exposure to butyrate [552]. 
iii) Fgfr1, whose expression is upregulated by KD-feeding [413], when bound to 
βKlotho and activated, phosphorylates Fgfr substrate 2, which leads to the 
downstream phosphorylation of Erk1/2 [553].   
Independent of the pathway involved, there is supporting evidence that the KD may provide 
a neuroprotective effect through regulation of the cell death cascade. The KD-induced 
reduction in rat hippocampal caspase-3 [549] coincides with findings that KD-feeding 
attenuates an obesity-induced increased in caspase-3 mRNA expression in rat whole brain 
[415]. The antiapoptotic properties of the KD may also be mediated by downregulation of 
hippocampal Pp2ca expression [290], which encodes an enzyme (PP2A) that may trigger 
apoptosis by inactivating BCL2 [422]. PP2A has also been shown to catalyse BAD 
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dephosphorylation (and thus its proapoptotic activity) [539] and has been implicated in the 
regulation of the phosphorylation status of Akt [554]. 
Collectively, these findings implicate KCNJ11 (encoding a subunit that is essential for 
activation of KATP channels in the presence of ketone bodies or reduced glycolysis) in the 
antiepileptic mechanisms of the KD, and introduce the possibility that variation in BAD may 
favourably affect response to the KD, an effect mediated through KCNJ11. It remains to be 
seen whether there is a place for the KATP/glycolysis hypothesis alongside the antiapoptosis 
theory, with BAD representing a point of convergence for various death/survival pathways. 
It may be that BAD plays a bifunctional (apoptotic vs metabolic [via KATP channels]) role in 
the antiepileptic effects of the KD. In this way, BAD variation may affect multiple pathways. 
The possibility also remains that different mechanisms of action come into play in distinct 
individuals, or in response to diverse situations.   
This is the first study to explore the putative association of KCNJ11 and BAD genetic 
variation with KD response in humans.  
4.2 Methods 
 Phenotypic data 4.2.1
KD response at 3-month follow-up was used as the main phenotype for the candidate gene 
analysis. As outlined in Chapter 3, using clinic letters and information from patient hospital 
records, individuals who achieved ≥50% seizure reduction were classified as ‘responders’ 
and those who reported <50% seizure reduction as non-responders’. 3-month KD response 
was chosen because: 
i) All cases received from Harvard Medical School had KD response classified at 
the 3-month point only.  
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ii) The maximum proportion of available data is used - the largest cohort consists 
of individuals with 3-month response data; this is the case whether Harvard 
data are used or not. 
iii) In clinical practice, response to the KD is first formally judged at 3-month 
follow-up.  
Another analysis was conducted with summary diet response (overall responders and non-
responders, taking into account long-term KD response), but data received from Harvard 
could not be used for this.  
Criteria for the summary diet response phenotype are outlined below:  
Responders: 
- Cases who achieved ≥50% seizure reduction at every time point recorded  
Non-responders: 
- Cases who achieved <50% seizure reduction at every time point recorded  
Excluded:  
- Cases who consistently reported approximately 50% seizure reduction over time, 
as responder/non-responder status is ambiguous 
- Cases with fluctuating diet response over time  
Extreme KD response was not included as a phenotype, as this association analysis is 
concerned with the effects of common variants in KCNJ11 and BAD, which are not expected 
to have a large phenotypic effect: purifying selection acts against deleterious variants [555] 
and, of all recently arisen variants, only the frequency of those with the most deleterious 
effect could have been affected by selection. 
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 Genetic data 4.2.2
DNA samples were diluted to 40μL at 50ng/μL by the researcher and sent to the Royal 
Devon & Exeter Hospital for sequencing of KCNJ11 and BAD, in two batches. Exon 1 of 
KCNJ11 was amplified in three fragments, and the three exons were amplified in BAD using 
M13 tailed PCR primers. Sequencing was performed using a Big Dye Terminator Cycler 
Sequencing Kit (Applied Biosystems, Warrington, UK) according to manufacturer’s 
instructions. Reactions were analysed on an ABI 3130 Capillary sequencer (Applied 
Biosystems, Warrington, UK) and sequences were compared to the published sequence 
(KCNJ11: NM_000525; BAD: NM_004322.3) using Mutation Surveyor v.4.0.6 (SoftGenetics, 
Pennsylvania, US). Identified variants were checked against known polymorphisms and 
mutations [556] and variant databases (dbSNP, the 1000 Genomes Project and Exome 
Variant Server). 
KCNJ11 sequencing results were also received from Harvard Medical School for a further 58 
cases. The full KCNJ11 gene had been sequenced bi-directionally using three 500-600bp 
amplicons with published primers [557]. Sequencing was performed using an ABI 377 
machine (PE Biosystems, NYSE:PEB) with Big Dye terminator chemistries (PE Biosystems, 
NYSE:PEB). Sequence traces were analysed using the GAP4 program of the Staden package 
(http://www.mrc-lmb.cam.ac.uk/pubseq).  
The total number of cases with candidate gene sequencing and diet response data is 
outlined in Figure 4.1.  
166 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Flow-chart of cases with diet response data and included in final candidate gene analyses 
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4.2.2.1 Quality control 
Relevant per-SNP and per-individual quality control measures, as outlined in [510], were 
conducted in PLINK (v1.07, http://pngu.mgh.harvard.edu/purcell/plink, [558]):  
SNPs with deviation from Hardy Weinberg equilibrium (HWE), p-value<1x10-6, were 
excluded (PLINK command: --hwe-all --hwe 0.000001). If not in HWE, variant allele 
frequencies are not expected to remain constant over time and the population is 
not behaving like a single randomly-mating unit without intense viability selection 
acting on the sampled loci [559]). 
Duplicate and related persons were excluded. Identity-by-descent (IBD) was 
calculated (PLINK command: --genome) between all pairs of individuals with 
genome-wide SNP data (see Chapter 5) and cases with Pi-hat [proportion of IBD] 
score >0.4 (duplicated cases and full sibling pairs) were excluded. All cases 
recruited by the researcher had genome-wide SNP data available, with the 
exception of three participants, for whom blood samples were received after the 
last batch was sent to AROS for genotyping with the array. Cases received from 
Harvard did not have genome-wide SNP data available.  
SNPs or individuals with >2% missing rates were excluded (PLINK command: --mind 
0.02 --geno 0.02); Harvard cases were analysed separately from other participants 
for this step, as they did not have BAD sequencing data. 
4.2.2.2 Association analysis 
For those SNPs with MAF>0.01 in this cohort, a Fisher’s allelic association exact test was 
performed in PLINK using the --fisher command, to determine whether allele frequency 
differed between responders and non-responders. This test is suited to small sample sizes 
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and avoids bias due to distributional approximation. The MAF cut-off point of 0.01 allowed 
SNPs of common and intermediate frequency in this cohort to be included in the 
association analysis. SNPs present in <1% of the cohort were not included in the analysis, as 
the variant would have to have a large effect size in order for the study to be appropriately 
powered to detect an association [560]; also, any association detected would have been 
driven by the genotypes of only a few individuals and would therefore be less robust [510].  
Allelic odds ratios were calculated (command: --ci 0.95), which compare the odds of 
favourable or unfavourable KD response in an individual carrying the minor allele to the 
odds in an individual carrying the major allele [561]. A 95% confidence interval (CI) was 
applied to indicate the reliability of the odds ratio estimate, as is widely used in 
biostatistics, indicating the probability that the values within the CI capture the true 
population parameter.  
P-values were obtained from 100,000 permutations, using the --mperm 100000 command. 
Permutation tests are considered the gold-standard when adjusting for multiple testing in 
genetic association studies [562]. Phenotypes are randomly shuffled with respect to 
genotypes among observed data, removing any genotypic-phenotypic association; each 
random shuffle of the data represents one possible sampling of individuals under the null 
hypothesis of no association, a process which is repeated a certain number of times [464, 
563]. The higher the number of permutations, the greater the precision of the generated p-
value, although this has been debated [564]. ≥10,000 permutations are needed to estimate 
a 0.01 threshold [565, 566]. In recent candidate gene studies, the number of permutations 
varies, ranging from 1,000 [567] to 100,000 [568] to 1,000,000 [569]. Here, 100,000 
permutations have been chosen, in order to obtain as precise p-values as possible whilst 
remaining realistic with regards to time needed for these computationally-intensive 
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permutation procedures (computation was not overly intensive in this case, due to the 
small number of SNPs to be tested). 
PLINK was used to conduct a haplotype analysis, including all previously known SNPs. No 
MAF threshold was applied because haplotype-based methods have higher power to 
detect an association between rare variants and a phenotypic trait, compared to single-SNP 
methods [570, 571]. Haplotype analyses may capture epistatic interactions between SNPs 
at a locus [508] and have higher power to detect an association than single SNP analyses in 
the presence of multiple susceptibility alleles, although this advantage may be lost when 
there is high linkage disequilibrium (LD) between SNPs [507]. The --hap-assoc command 
was used, which compares allele frequencies between cases and controls, along with the --
hap-window command, which specifies all haplotypes in sliding windows across the 
dataset. Permutation of p-values cannot be conducted with this test in PLINK and so a 
Bonferroni-adjusted threshold was set, which accounts for the number of independent 
SNPs included in the haplotype analysis (n=13), with an alpha value of 0.05 
(0.05/13=0.0038). 
4.2.2.3 Population structure  
The 1000 Genomes Project browser (http://browser.1000genomes.org) was used to 
investigate population genetics for variants included in the Fisher’s test. Variants that 
displayed statistically significant differences in population-specific allele frequencies 
(shown by chi-squared test conducted in Microsoft Excel 2010 (v. 14, Microsoft, 
Washington, USA) were analysed with a Cochran-Mantel-Haenszel test, using the --mh --
within command in PLINK. This is a single-SNP stratified association analysis, which tests for 
overall disease/gene association in case/control studies, conditional on strata/clusters (in 
this case, self-reported ethnicity), and is suitable both for a large number of small clusters 
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and a small number of large clusters. It has been found to adequately control for 
population stratification for variants of different MAFs, used as a reference to assess 
performances of other stratified association tests, as it adjusts exactly on the confounding 
factor introduced in the analysis [572]. This approach has been used in Wellcome Trust 
Case Control Consortium datasets to adjust for population substructure [573]. 
The self-reported ethnicity categories in this cohort were:  
1 - Caucasian (including Australian and American Caucasians), n=251 
2 – African, n=5 
3 - Middle Eastern, n=6 
4 - Central/South Asian, n=14 
5 - East Asian, n=2 
6 - Black and Caucasian mix, n=19 
7 - East Asian and Caucasian mix, n=3 
8 - South Asian and Caucasian, n=2  
9 - South American, n=1 
 
The Cochran-Mantel-Haenszel test cannot be used for haplotype analyses in PLINK. 
4.2.2.4 Information on variants found 
R2 values for all possible pairs of previously reported SNPs present in this cohort were 
calculated using PLINK, using the --r2 --ld-snp-list command. R2 values, which range 
between 0 and 1, represent a statistical measure of LD correlation between variants [464] - 
a higher r2 value indicates a greater degree of LD between two markers.  
Predictions of the functional impact of previously reported variants found in KCNJ11 and 
BAD in this cohort were obtained from various algorithms using wANNOVAR 
(http://wannovar.usc.edu, [574]): SIFT (Sorting Intolerant From Tolerant) [575], PolyPhen2 
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(Polymorphism Phenotyping v2) [576], LRT (likelihood ratio test) [577], Mutation Taster 
[578] and GERP++ (Genomic Evolutionary Rate Profiling) [579]. These scores were only 
available for non-synonymous variants. GERP++ scores for synonymous variants were 
obtained from National Heart, Lung, and Blood Institute (NHLBI) Exome Variant Server, 
NHLBI GO Exome Sequencing Project (ESP) (http://evs.gs.washington.edu/EVS). Variants 
were also looked up in Phenotype-Genotype Integrator 
(http://www.ncbi.nlm.nih.gov/gap/phegeni) to obtain information regarding human 
phenotypic-genotypic associations and function class of the variants, and in dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/index.html) to obtain MAF information.   
The predicted functional impact of previously unreported KCNJ11 and BAD variants, in 
terms of function class, SIFT score, nucleotide and amino acid conservation, and Mutation 
Taster score, was provided by Alamut (v2.2, Interactive Biosoftware LLC, Rouen, France). 
The aim of this was to aid interpretation of results, prioritising SNPs with a higher predicted 
impact on gene and protein function and, theoretically, the phenotypic trait in question 
[580].    
 Power calculations 4.2.3
Power calculations for the 3-month KD response cohort were conducted using PGA Power 
Calculator [581]. Curves depicting potential detectable relative risk and MAF in this cohort, 
with 80% power, were plotted. Power sample size curves using the MAF of the most 
significant SNP in the association analysis were also plotted. An alpha level according to the 
effective number of tests was used (0.05/7, as seven SNPs that were not in high LD were 
tested for in the association analyses).  
As there is no naturally-existing KD (or indeed sustained calorie restriction, at least in 
Europeans), disease prevalence (or prevalence of the trait) is hard to gauge. The disease 
prevalence of epilepsy (0.5%) was therefore used, as in other studies [582]. 
172 
 
The inheritance model is unknown and so power calculations were performed using co-
dominant (where the two alleles have an equal effect on the phenotype), dominant (where 
one allele masks the effect of the other allele on the phenotype) and recessive (where the 
phenotype is only seen if the individual is homozygous for the risk allele) penetrance 
models. 
4.3 Results 
 Quality control 4.3.1
No SNPs were removed due to deviation from HWE or missingness rates. Two cases were 
removed due to relatedness (both had no missing genotypes - in the case of different 
missingness rates, the subject with the lower rate would have been excluded). One subject 
was removed due to presence of SLC2A1 mutation (identified from whole exome 
sequencing, after recruitment and candidate gene sequencing). KCNJ11 and BAD 
sequencing failed in two subjects. 
 Common variation in KCNJ11 and BAD 4.3.2
4.3.2.1 Overview 
In this cohort, nine previously-reported SNPs were found in KCNJ11 and five in BAD. These 
are given in Table 4.1, along with their predicted functional impact. 
Variants were also looked up in The Human Gene Mutation Database 
(http://www.hgmd.cf.ac.uk, [583]) and NCBI (National Center for Biotechnology 
Information) Variation Viewer (www.ncbi.nlm.nih.gov/sites/varvu). rs5219, rs5215 and 
rs5218 were all reported to be associated with Type II diabetes in The Human Gene 
Mutation Database. rs5219 was classified as a ‘drug-response’ variant in NCBI Variation 
Viewer, rs5215 had no clinical interpretation (although 21 publications were linked to the 
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variant, which analysed its association with Type II diabetes) and rs5218 was not present in 
NCBI Variation Viewer.   
Despite being classified as disease-causing by MutationTaster, rs1800467 was not present 
in either database, and rs41282930 was classified as ‘probable non-pathogenic’ in NCBI 
Variation Viewer and was not present in The Human Gene Mutation Database.  
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Table 4.1: Previously reported SNPs found in KCNJ11 and BAD in Ketogenic diet cohort 
Gene 
SNP rs 
number 
Location  
(build 
37/hg19) 
Variant 
nomenclature 
(cDNA level and 
protein level)* 
Function 
class 
Minor Allele 
Frequency 
(1000 
Genomes 
Project) 
dbNSFP SIFT 
score and 
class 
Polyphen2 
score and  
class 
LRT score 
and class 
Conservation 
score GERP++ 
Mutation 
Taster score 
and class 
KCNJ11 
rs5219 
11: 
17,409,572 
NM_000525.3:c.6
7A>G 
p.Glu23Lys  
missense 0.274 
0.75 
Tolerated 
0 
Benign 
0.927728 
Neutral 
3.65 
0  
Polymorphism 
rs5218 
11: 
17,409,069 
NM_000525.3:c.5
70C>T 
p.Ala190Ala 
synonymous 0.275 n/a n/a n/a -0.1 n/a 
rs5216 
11: 
17,408,838 
NM_000525.3:c.8
01C>G 
p.Leu267Leu 
synonymous 0.017 n/a n/a n/a 2.21 n/a 
rs1800467 
11: 
17,408,831 
NM_000525.3:c.8
08C>G 
p.Leu270Val 
missense 0.022 
0.98 
Deleterious 
0 
Benign 
0.999656 
Deleterious 
4.79 
0.687162 
Disease-
causing 
rs5215 
11: 
17,408,630 
NM_000525.3:c.1
009G>A 
p.Val337Ile  
missense 0.280 
0.76 
Tolerated 
0.002 
Benign 
0.947433 
Neutral 
-2 
1.00x10-5 
Polymorphism
-automatic 
rs8175351 
11: 
17,408,496 
NM_000525.3:c.1
143G>A 
p.Lys381Lys 
synonymous 0.006 n/a n/a n/a 4.26 n/a 
rs4128293
0 
11: 
17,408,485 
NM_000525.3:c.1
154C>G 
p.Ser385Cys 
missense 0.0114 
1 
Deleterious 
0.27 
Benign 
0.696141  
Neutral 
4.52 
0.630056 
Disease-
causing  
rs5214 
11: 
17,408,550 
NM_000525.3:c.1
089A>G 
p.Ser363Ser 
synonymous 0.003 n/a n/a n/a -10.4 n/a 
rs1120704
96 
11: 
17,409,531 
NM_000525.3:c.1
08G>A  
p.Val36Val 
synonymous 0.002 n/a n/a n/a 3.66 n/a 
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*according to Human Genome Variation Society recommendations for the description of DNA sequence variants - v2.0 http://www.hgvs.org/mutnomen/recs-
DNA.html  
SIFT Pathogenicity score from dbNSFP: tolerated < 0.95, deleterious > 0.95 
PolyPhen2 Pathogenicity score from dbNSFP: probably damaging > 0.85, possibly damaging 0.85-0.15, benign < 0.15 
GERP++ Nucleotide conservation score from dbNSFP GERP: higher number is more conserved, > 0 is generally conserved 
LRT Pathogenicity probability score from dbNSFP: closer to 1 is more likely to be damaging. Deleterious fulfils the following criteria: (i) from a codon defined by 
LRT as significantly constrained (original LRT score <0.001 and <1), (ii) the AA position has more than 10 eutherian mammal alignments. Neutral:  the alternative 
AA is presented in at least one of the eutherian mammals, or the codon is not defined by LRT as significantly constrained; otherwise unknown. 
MutationTaster Pathogenicity probability score from dbNSFP: closer to 1 is more likely to be damaging 
BAD 
rs3488200
6 
11: 
64,051,823 
NM_004322.3:c.1
8G>A 
p. = (p.Glu6Glu) 
synonymous 0.0133 n/a n/a n/a 4.79 n/a 
rs7505260
0 
11: 
64,051,853 
NM_004322.3:c.-
13C>T 
p.? 
5’ UTR 0.0137 not found not found not found 0.8 not found 
rs2286615 
11: 
64,039,175 
NM_004322.3:c.2
88C>A 
p.= (p.Arg96Arg) 
synonymous 0.0934 n/a n/a n/a 3.87 n/a 
rs2286616 
11: 
64,039,136 
NM_004322.3:c.3
27C>A 
p.= (p.Arg109Arg) 
synonymous 0.006 n/a n/a n/a -2.44 n/a 
rs5928362
9 
11: 
64,037,679 
NM_004322.3:c.*
2C>T 
p.? 
3’ UTR 0.0201 not found not found not found not found not found 
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Due to its function class, SIFT, PolyPhen2, LRT and Mutation Taster classifications, and 
location in a conserved region, rs1800467 in KCNJ11 is considered most likely to have a 
deleterious effect on gene function, although it is not present in The Human Gene 
Mutation Database. rs41282930 in KCNJ11 is of interest, although two out of the five 
functionality prediction algorithms used have classified this variant as ‘benign’ or ‘neutral’. 
Due to their association with Type II diabetes, rs5219, rs5215 and rs5218 are also of 
interest. 
The details displayed in Table 4.1 will aid interpretation of association results; if an 
association is reported, the potential effect of the variant on the gene or its expression may 
be judged. No variants will be excluded from the association analysis based on function 
class, predicted deleterious, or presence in mutation databases.  
As shown in Table 4.2, only rs5219 and rs5215 are in high LD in this cohort. One of these 
SNPs could be removed from the association analysis, as knowing the alleles present at one 
SNP provides knowledge of those at the other SNP.  
As most SNPs are not in high LD with each other, this indicates that the predictive power of 
haplotypes, as well as single SNP tests, may be exploited. 
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Table 4.2: R
2
 values between pairs of previously reported KCNJ11 and BAD SNPs found in Ketogenic diet cohort 
KCNJ11 SNPs BAD SNPs 
KCNJ11 
SNPs 
 rs112070496 rs41282930 rs8175351 rs1800467 rs5219 rs5218 rs5216 rs5215 rs5214 rs75052600 rs59283629 rs34882006 rs2286616 rs2286615 
rs112070496 1 0.0001 0.0002 0.0003 0.0031 0.0024 0.0002 0.0030 1 0.0000 0.0000 0.0003 0.0000 0.0015 
rs41282930 - 1 0.0224 0.0086 0.0012 0.0006 0.0276 0.0012 0.0001 0.0000 0.0001 0.0007 0.0001 0.0169 
rs8175351 - - 1 0.0000 0.0082 0.0093 0.0027 0.0083 0.0002 0.0001 0.0177 0.0027 0.0002 0.0006 
rs1800467 - - - 1 0.0519 0.0112 0.0000 0.0507 0.0003 0.0003 0.0009 0.0019 0.0006 0.0028 
rs5219 - - - - 1 0.1657 0.0259 0.9933 0.0031 0.0036 0.0000 0.0006 0.0019 0.0083 
rs5218 - - - - - 1 0.0018 0.1613 0.0024 0.0020 0.0004 0.0111 0.0062 0.0031 
rs5216 - - - - - - 1 0.0260 0.0002 0.0002 0.0006 0.0001 0.0004 0.0044 
rs5215 - - - - - - - 1 0.0030 0.0036 0.0000 0.0005 0.0019 0.0076 
rs5214 - - - - - - - - 1 0.0000 0.0000 0.0003 0.0000 0.0015 
BAD 
SNPs 
rs75052600 - - - - - - - - - 1 0.0000 0.0003 0.0000 0.0015 
rs59283629 - - - - - - - - - - 1 0.0010 0.0001 0.0045 
rs34882006 - - - - - - - - - - - 1 0.0007 0.0013 
rs2286616 - - - - - - - - - - - - 1 0.0030 
rs2286615 - - - - - - - - - - - - - 1 
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4.3.2.2 Population genetics 
Population genetics data from the 1000 Genomes Project were available for all variants 
used in the association analysis, with the exception of rs5219 (although population genetics 
information for this SNP may be inferred from rs5215). As shown in Table 4.3, all SNPs have 
significant population-specific differences (according to the 1000 Genomes Project) in allele 
frequencies. 
Table 4.3: Observed and expected population genetics data for KCNJ11 and BAD SNPs (from the 
1000 Genomes Project) and results from Chi-square test of independence 
Gene 
SNP rs 
number 
Population 
Observed 
counts 
for allele 
1 
Observed 
counts 
for allele 
2 
Expected 
counts 
for allele 
1* 
Expected 
counts 
for allele 
2** 
P-value 
from Chi-
squared 
distribution 
KCNJ11 
rs5218 
African 32 952 271 713 
6.9x10-120 
Asian 532 612 315 829 
American 132 592 199 525 
European 506 1010 417 1099 
rs5216 
African 4 980 17 967 
1.66 x10-12 
Asian 20 704 12 712 
American 0 1144 19 1125 
European 50 1466 26 1490 
rs1800467 
African 2 982 22 962 
1.52 x10-18 
Asian 0 1144 25 1119 
American 28 696 16 708 
European 66 1450 33 1483 
rs5215 
African 54 930 275 709 
2.36 x10
-71
 
Asian 434 710 320 824 
American 224 500 203 521 
European 510 1006 424 1092 
rs817351 
African 978 6 978 6 
0.0027 
Asian 1144 0 1137 7 
American 714 10 719 5 
European 1504 12 1506 10 
Asian 0 1144 13 1131 
American 12 712 8 716 
European 6 1510 17 1499 
BAD 
rs34882006 
African 492 0 485 7 
6.78 x10-7 
Asian 572 0 564 8 
American 356 6 357 5 
European 735 23 748 10 
rs2286615 
African 11 482 46 447 
1.22 x10-15 
Asian 40 532 53 519 
179 
 
American 32 330 34 328 
  European 121 637 71 687  
*expected counts for allele 1 were calculated by the sum of observed counts of alleles 1 and 2 in the 
specific population, multiplied by the total count for allele 1 (in all populations), all divided by the 
total observed counts of alleles 1 and 2 (in all populations) 
**expected counts for allele 2 were calculated by the sum of observed counts of alleles 1 and 2 in 
the specific population, multiplied by the total count for allele 2 (in all populations), all divided by 
the total observed counts of alleles 1 and 2 (in all populations) 
 
 
As shown in Table 4.4, the number of responders/non-responders observed in each 
population in this cohort is not significantly different (p-value>0.5) to expected numbers, 
although there were only small numbers of individuals in most groups. When comparing 
observed and expected numbers of responders/non-responders in all population groups 
simultaneously, p-value=0.66, demonstrating that there is no significant difference in 
responder/non-responder rates among different populations in this cohort. 
However, due to potential population-specific allele frequencies, stratified association 
analyses were also conducted with self-reported ethnicity as strata.  
Table 4.4: Breakdown of Ketogenic diet responders and non-responders by ethnicity, n=303 
Ethnicity 
Observed 
number of 
responders 
Observed 
number of 
non-
responders 
Expected 
number of 
responders* 
Expected 
number of 
non-
responders** 
P-value from 
Chi-squared 
distribution 
Caucasian 148 103 146 105 0.78 
Black African 2 3 3 2 0.41 
Middle 
Eastern 
3 3 3 3 0.69 
Central/South 
Asian 
7 7 8 6 0.54 
East Asian 2 0 1 1 0.23 
Black African 
and 
Caucasian mix 
10 9 11 8 0.63 
East Asian 
and 
Caucasian mix 
2 1 2 1 0.76 
South Asian 
and 
Caucasian mix 
2 0 1 1 0.23 
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South 
American 
0 1 1 0 0.24 
*expected number of responders were calculated by the sum of observed number of responders 
and non-responders in the specific ethnic group, multiplied by total number of responders (in all 
ethnic groups), all divided by the total number of responders and non-responders (in all ethnic 
groups) 
**expected number of non-responders were calculated by the sum of observed number of 
responders and non-responders in the specific ethnic group, multiplied by total number of non-
responders (in all ethnic groups), all divided by the total number of responders and non-responders 
(in all ethnic groups). 
 
 Association analysis  4.3.3
Results of the association analysis, including SNPs with MAF>0.01, are given in Table 4.5. 
The lowest p-value was for rs5216: the G allele was more frequently present in KD non-
responders than responders. 16 individuals were heterozygous for the minor allele (0 were 
homozygous), 2 of which were non-responders and 14 were responders. The unadjusted p-
value was <0.05, but the p-value obtained from 100,000 permutations was not statistically 
significant. 
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Table 4.5: Results of association analysis: common and intermediate variation in KCNJ11 and BAD in Ketogenic diet responders and non-responders (n=303 for 
KCNJ11 and n=246 for BAD) 
Gene SNP rs number 
Location 
(build 37/hg19) 
Minor allele (in 
Ketogenic diet 
cohort) 
Frequency of 
minor allele in 
non-responders 
Frequency of 
minor allele in 
responders 
Unadjusted 
p-value 
Odds ratio [95%CI] 
P-value 
(100,000 
permutations) 
KCNJ11 
rs8175351 11: 17,408,496 A 0.02756 0.02557 1 1.08 [0.3969-2.939] 1 
rs1800467 11: 17,408,831 G 0.07087 0.04261 0.1481 
1.714 [0.8466-
3.468] 
0.6355 
rs5219  
(same as for rs5215) 
11: 17,409,572 A 0.3268 0.3381 0.7938 
0.9504 [0.6745-
1.339] 
0.9997 
rs5218 11: 17,409,069 T 0.248 0.304 0.1429 
0.7552 [0.5247-
1.087] 
0.6122 
rs5216 11: 17,408,838 G 0.007874 0.03977 0.01872 
0.1916 [0.04316-
0.8507] 
0.132 
BAD 
rs34882006 11: 64,051,823 A 0.05 0.03175 0.3645 
1.605 [0.6445-
3.998] 
0.9406 
rs2286615 11: 64,039,175 T 0.1125 0.1706 0.07133 
0.6161 [0.3671-
1.034] 
0.362 
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All SNPs were analysed including ethnicity as a covariate. As shown in Table 4.6, p-values 
were similar to those obtained when ethnicity was not considered. 
Table 4.6: Results of association analysis: common and intermediate variation in KCNJ11 and BAD 
in Ketogenic diet responders and non-responders, including ethnicity as a covariate (n=303 for 
KCNJ11 and n=246 for BAD) 
Gene SNP rs number 
Unadjusted p-
value 
Odds ratio [95%CI] 
P-value (100,000 
permutations) 
KCNJ11 
rs8175351 0.9842 1.01 [0.369-2.766] 1 
rs1800467 0.1668 1.656 [0.8072-3.396] 0.7343 
rs5219 and rs5215 0.9602 1.009 [0.7099-1.434] 1 
rs5218 0.1712 0.7728 [0.5342-1.118] 0.7514 
rs5216 0.01847 0.1975 [0.0444-0.8784] 0.1318 
BAD 
rs34882006 0.3133 1.598 [0.6387-3.997] 0.9329 
rs2286615 0.07559 0.6219 [0.3682-1.05] 0.4272 
 
No SNPs were significantly associated with summary KD response, as shown in Table 4.9 
and Table 4.10 in Appendix 4.1 and 4.2. rs8175351 had the lowest p-value. 
 Previously unreported variants or SNPs with minor allele frequency <0.01 4.3.4
KD response in cases with previously unreported variants or those with MAF<0.01 in this 
cohort, along with the predicted functional impact of these variants, is given in Table 4.7.  
NM_00525.3:c.[451G>A];[=], p.Val151Met is of most interest, as it encodes a highly-
conserved amino acid (the amino acid is conserved up to Tetraodon), has a deleterious SIFT 
classification and is classified as disease-causing by Mutation Taster. This variant was found 
in one non-responder. The missense variant, rs41282930, is also of interest due to its 
predicted high functional impact, and was present in individuals with a range of responses 
to the KD. 
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Independent of predicted functional impact, there does not seem to be a consistent effect 
of these novel/rare variants on KD response singly, although the cohort size is too small to 
assess significance.   
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Table 4.7: KD response in cases with previously unreported variants or variants with MAF<0.01 (in this cohort) in KCNJ11 and BAD 
Gene 
Variant nomenclature 
(cDNA level and protein level)* 
or rs number (dbSNP) 
Location build 
Predicted 
function class 
SIFT 
pathogenicity 
score 
Conserved?** 
Mutation 
Taster 
classification 
Number of cases 
with variant 
(genotype) 
Description of diet response 
KCNJ11 
NM_00525.3:c.[1116C>T];[=] 
p.= (p.Ser372Ser) 
11:17408523 synonymous - - - 
1 
(CT) 
Case 1: No change in seizures. Weaned 
off diet after 6 months 
NM_00525.3:c.[912C>T];[=] 
p.= (p.Tyr304Tyr) 
11:17408727 synonymous - - - 
1 
(CT) 
Case 2: No change in seizures. Weaned 
off diet after 3 months 
NM_00525.3:c.[451G>A];[=] 
p.Val151Met 
11:17409188 
 
missense 
Deleterious 
(score 0.00) 
Weakly 
conserved 
nucleotide; 
highly 
conserved 
amino acid 
Disease-causing 
(p-value 0.991) 
1 
(GA) 
Case 3: No change in seizures. Weaned 
off diet after 3 months 
rs5214 
11:17408550 
 
synonymous - - - 
1 
(GA) 
Case 4: Partial responder in first 3 
months, then improved response in 
second 3 months (>75% seizure 
reduction). Currently 6 months on diet. 
NM_00525.3:c.[291C>T];[=] 
p.= (p.His97His) 
11:17409348 
 
synonymous n/a n/a n/a 
1 
(CT) 
Case 5: Around 40% reduction in 
seizures, and much more alert and 
interactive. Currently on diet for 3 
months 
rs112070496 
11:17409531 
 
synonymous - - - 
1 
(AG) 
Case 6: Partial responder in first 3 
months, then improved response in 
second 3 months (>75% seizure 
reduction). Currently 6 months on diet. 
(same case as with rs5214) 
NM_00525.3:c.[817A>G];[=] 
p.Ser273Gly 
11:17408822 
 
missense 
Deleterious 
(score 0.03) 
Not conserved 
nucleotide; 
Highly 
conserved 
amino acid 
Polymorphism 
(p-value 1.0) 
1 
(AG) 
Case 7: Partial responder at the start, 
and more alert, interactive and vocal. 
Slight reduction in seizures did not last, 
so weaned off diet after 6 months 
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rs41282930 11:17408485 missense 
Deleterious 
(score 0.00) 
GERP++ score 
4.52 
 
Disease-causing 
6 
(all GC) 
Case 8: According to seizure diary, 
seizures increased by 386% in first 3 
months, compared to baseline. 
Parents describe that the diet had had 
no effect on seizure frequency, but the 
patient had increased awareness 
Case 9: >50% seizure reduction in first 
3 months. Seizure frequency increased 
during following 3 months and the 
patient was weaned off diet. Seizure 
frequency and severity further 
increased. Patient went back on diet 
but no improvement. 
Case 10: Achieved >50% seizure 
reduction with KD (summary of 
response over time) 
Case 11: Achieved >90% seizure 
reduction with KD (summary of 
response over time) 
Case 12: Achieved >50% seizure 
reduction with KD (summary of 
response over time) 
Case 13: Achieved >50% seizure 
reduction with KD (summary of 
response over time) 
BAD 
NM_004322.3:c.[142G>A];[=] 
p.Ala48Thr 
11:64051699 
 
missense 
Tolerated 
(score 0.68, 
median 4.32) 
Not conserved 
nucleotide; 
moderately 
conserved 
amino acid 
Polymorphism 
(p-value 0.997) 
1 
(GA) 
Case 14: No change in seizures 
(possible increase). Weaned off diet 
after 3 months 
rs75052600 
11:64051853 
 
5’ UTR unknown unknown unknown 
1 
(CT) 
Case 15: No change in seizures, tired 
and irritable. Weaned off diet before 
3-month point 
NM_004322.3:c.-41G>A;[=] 
p.? 
11:64051881 
 
5'UTR unknown unknown unknown 
1 
(GA) 
Case 16: Responder (50-75% seizure 
reduction). Weaned off diet after 6 
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months due to abdominal pain but 
went back on diet – initial good 
response 
rs2286616 
11:64039136 
 
synonymous - - - 
2 
(Both CT) 
Case 17: Extreme responder – almost 
seizure-free. Seizure frequency 
variable after 3 years on diet 
Case 18: Slight improvement in 
seizures but weaned off diet after 3 
months due to compliance difficulties 
NM_004322.3:c.[456G>A];[=] 
p.= (p.Gln152Gln) 
11:64037732 
synonymous 
 
- - - 
1 
(GA) 
Case 19: Responder (50-75% seizure 
reduction). Remains on diet long-term. 
rs59283629 
11:64037679 
 
3’ UTR unknown unknown unknown 
3 
(All CT) 
Case 20: Responder (>75% seizure 
reduction). One year on diet 
Case 21: No change in seizures. 
Currently at the 3-month point and 
weaning off diet 
Case 22: No change in seizures, but 
much more alert. Currently on diet for 
6 months 
NM_004322.3:c. [226T>A];[=] 
p.Tyr76Asn 
11:64039237 
 
missense 
Deleterious 
(score 0.00, 
median 4.32) 
Weakly 
conserved 
nucleotide; 
highly 
conserved 
amino acid 
Polymorphism 
(p-value 0.537) 
2 
(Both TA) 
Case 23: Seizure-free. Currently 6 
months on diet 
Case 24: No change in seizures. Off 
diet after 3 months 
*according to Human Genome Variation Society recommendations for the description of DNA sequence variants - v2.0 http://www.hgvs.org/mutnomen/recs-
DNA.html  
** Predictions of conservation are provided by Alamut for novel variants, based on PhyloP score (nucleotide conservation) and cross-species alignment (amino acid 
conservation) 
SIFT Pathogenicity score from wANNOVAR: the closer the number is to 0, the more damaging the variant 
PolyPhen2 Pathogenicity score from wANNOVAR: probably damaging >0.85, possibly damaging 0.85-0.15, benign <0.15 
GERP++ Nucleotide conservation score from wANNOVAR: higher number is more conserved, >0 is generally conserved 
Mutation Taster p-value is an indication of the probability of the prediction. A value close to 1 indicates a high 'security' of the prediction 
http://www.mutationtaster.org/info/documentation.html. P-values not provided in wANNOVAR.  
 
187 
 
 Haplotype analyses 4.3.5
Haplotype tests yielded similar p-values to the single SNP tests, none of which were below 
the Bonferroni-adjusted threshold of 0.0038. The haplotypes with the 10 lowest p-values, 
as shown in Table 4.8, all contained rs5216, and the haplotype with the lowest p-value was 
rs5216|rs5215|rs5214 (GAA). Apart from the single SNP haplotype (only containing 
rs5216), all haplotypes also contained rs5215.    
Table 4.8: Top 10 most significant results for haplotype association analysis: variation in KCNJ11 
and BAD in Ketogenic diet responders and non-responders (n=303 for KCNJ11 and n=248 for BAD) 
 
In the summary KD response haplotype analysis, no significant results were obtained (see 
Table 4.11 in Appendix 4.3).   
 Power calculations 4.3.6
As shown by Figure 4.2, with a sample size of 303 (as used in the 3-month KD response-
KCNJ11 analysis), variants with a MAF of 0.075 and a relative risk of approximately 2.5 
could be detected with 80% power; assuming a dominant penetrance model, variants with 
SNPs in haplotype Haplotype 
Frequency in 
non-responders 
Frequency in 
responders 
Unadjusted 
p-value 
rs5216|rs5215|rs5214 GAA 0.007874 0.03989 0.01544 
rs5216 G 0.007874 0.03977 0.01566 
rs5216|rs5215 GA 0.007874 0.03977 0.01566 
rs5216|rs5215|rs5214|rs75052600 GAAC 0.007905 0.03989 0.01575 
rs5216|rs5215|rs5214|rs75052600|
rs59283629 
GAACC 0.007969 0.04004 0.01608 
rs5218|rs5216|rs5215|rs5214|rs750
52600|rs59283629 
CCAACC 0.4216 0.3312 0.02384 
rs5219|rs5218|rs5216|rs5215|rs521
4|rs75052600|rs59283629 
GCCAACC 0.4217 0.3315 0.02416 
rs5218|rs5216|rs5215|rs5214|rs750
52600 
CCAAC 0.419 0.3305 0.0265 
rs5219|rs5218|rs5216|rs5215|rs521
4|rs75052600 
GCCAAC 0.419 0.3305 0.0265 
rs41282930|rs8175351|rs1800467|r
s5219|rs5218|rs5216|rs5215|rs521
4|rs75052600|rs59283629 
CGCGCCAACC 0.3852 0.2989 0.02864 
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a MAF of approximately 0.1 with a relative risk of approximately 2.5 could be detected; 
assuming a recessive penetrance model, the MAF of the variant would have to be at least 
0.34-0.4 if the variant had the same relative risk.  
 
Figure 4.2: Detectable relative risk and disease allele frequency curves for 3-month KD response 
cohort, with 80% power, assuming a disease prevalence of 0.5%, an alpha of 0.007, 126 cases and 
control:case ratio of 1.4. Black line=recessive model; purple line=dominant model; orange line=co-
dominant model 
Taking the MAF of the variant with the lowest p-value in the 3-month KD response 
association analysis (MAF=0.017), approximately 800 individuals would be needed to 
achieve 80% power if the variant had a relative risk of 2.0, as shown in Figure 4.3. Over 
3000 individuals would be needed if the variant had a relative risk of 1.5, and 4500 if the 
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variant had a relative risk of 1.4. This is assuming a co-dominant model; larger sample sizes 
would be required if a recessive model was assumed.   
Figure 4.3: Power and sample size curves, using a co-dominant model, disease and marker allele 
frequencies of 0.017, assuming a disease prevalence of 0.5%, control:case ratio of 1.4 and alpha of 
0.007. Black line=relative risk of 2.0; orange line=relative risk of 1.5; purple line=relative risk of 
1.4.  
 
4.4 Discussion 
Key findings: 
 The G allele of KCNJ11 rs5216 (p.Leu267Leu) had the lowest p-value in the 3-month 
diet response association analysis, but it was not statistically significant when 
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adjusting for multiple testing (p-value obtained by permutation). This variant also 
had the lowest p-value when including self-reported ethnicity as a covariate, but 
the association was not statistically significant. The same variant did not have the 
lowest p-value in the summary KD response association analyses.    
 No conclusions can be drawn from previously unreported variants in KCNJ11 and 
BAD or those SNPs with MAF<0.01 in this cohort, due to the small sample size. 
 Haplotype analyses (including all previously-reported variants in KCNJ11 and BAD) 
yielded similar p-values to single SNP analyses. The haplotype with the lowest p-
value in the 3-month response analysis contained rs5216 (p.Leu267Leu), rs5215 
(p.Val337Ile) and rs5214 (p.Ser363Ser). The haplotypes with the 10 lowest p-values 
all contained rs5216 and rs5215.   
 Replication is needed with a larger cohort. 
The lack of statistically significant results in the candidate gene analysis is likely due to low 
power - the probability of successfully detecting a genotypic-phenotypic association. Power 
depends on the effect size of the variant, allele frequency, sample size, level of statistical 
significance set [584] and the type of assumed association (dominant, recessive or co-
dominant), which is unknown. Due to the nature of dietary interventions such as the KD, 
the sample size in this study is necessarily small, at least in terms of genetic analyses. 
Approximately 250 patients were following the KD for epilepsy in the UK in 2011-2012 and 
264 started the KD in 2012-2013 (personal communication with Katherine Lord, Head of 
Nutrition and Dietetics, Southmead Hospital, and Chair of Ketogenic Diet Professional 
Advisory Group, UK). Further international collaboration would be needed to obtain a 
larger cohort size. If this were achieved, there would be more power to detect associations 
from variants with smaller MAF and lower effect sizes.  
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Appropriate measures were taken to account for multiple testing (although the multiple 
testing burden in these analyses was not great due to the small number of variants) and 
population structure. The variants with the lowest p-values in the association analyses still 
had the lowest p-values when including ethnicity as a covariate, which suggests that the 
results in the original association analyses were not confounded by population 
stratification. Standard methods of dealing with potential population stratification would 
have been preferable, but were problematic in this cohort: matching cases and controls in 
terms of ethnic group would have been practically difficult and self-reported ethnicity is 
not always accurate, as individuals may not be aware of their own ethnic admixture; 
inclusion of family-member controls was not possible as a family-based study design was 
not used; use of a panel of polymorphic markers that were unlinked to the candidate gene 
to test for stratification, was not possible as genome-wide SNP data were not available for 
all cases [585].  
No SNPs were excluded from analyses based on predictions of functional consequence, due 
to the lack of certainty associated with classifying variants as functional or non-functional. 
In genetic association analyses, variants in coding regions tend to be prioritised, as they 
have been more consistently associated with Mendelian traits than have variants in 
intronic and regulatory regions, and are the least common types of polymorphisms [586]. 
However, synonymous or non-exonic variants can also affect gene function, although, 
when looked at singly, they are generally less likely to be associated with disease [586, 
587]. The extent to which non-coding variants or variants not predicted to be of high 
functional importance (for example, those located in unconserved regions) contribute to 
complex diseases or traits is unknown. Variants predicted to be functional (or non-
functional) by a single prediction algorithm are likely to have high false-positive rates [588], 
which is why scores from multiple algorithms were used in this study. Sole reliance on 
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functional prediction algorithms to include/exclude variants for analysis was not considered 
wise; for example, just because a variant is classified as a polymorphism, or it is present in 
dbSNP, that does not guarantee lack of association with a disease or phenotypic trait, as is 
the case with rs5219, rs5215 and rs5218. In this study, known information about variants is 
used to aid interpretation of results, for example, to determine whether top associated 
variants have a biologically plausible function with regards KD response. 
 Potential consequences of SNPs with lowest p-values 4.4.1
p.Leu267Leu merits further examination, due to the fact that it had the lowest p-value 
(even if not statistically significant) in the single-SNP association analysis and was present in 
the haplotypes most closely associated with 3-month diet response. The potential 
significance of p.Val337Ile and p.Ser363Ser (particularly when present together with 
p.Leu267Val), which also occurred in the haplotypes with the lowest p-values, is also of 
interest, as well as rs8175351 (p.Lys381Lys), which had the lowest p-value in the summary 
KD association analysis.    
In pancreatic β cells, the binding of adenine nucleotides to Kir6.2 pore closes the channel; 
thus, variants affecting this subunit could influence the open-channel probability and alter 
cell excitability [589]. KCNJ11 is expressed in many other human tissues aside from 
pancreatic β cells, including smooth and skeletal muscle, the brain, cerebellum, thyroid, 
adipocytes and the heart (www.genecards.org). If any of the variants of interest were to 
alter KATP open-channel probability in the brain, this may have implications for KD response. 
Considering the ‘KATP-glycolysis hypothesis’ [295], a mutant Kir6.2 subunit may affect the 
activation or opening of KATP channels in the presence of ketone bodies and/or reduction of 
ATP in the submembrane compartment, resulting in a failure to depress neuronal 
excitability.  
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The functional consequences of p.Leu267Leu and p.Lys381Lys on KATP channel activity are 
unknown. These variants are located in a conserved region and are rare in the general 
population, indicating that they influence gene/protein function and may be damaging: 
purifying selection acts against deleterious variants [555]. Synonymous variants may 
influence mRNA splicing (by creating new ‘cryptic’ splice sites or, indirectly, by affecting 
exonic splicing enhancers or silencers), leading to protein isoforms with different functions, 
mRNA stability or secondary structure (which affects splicing and processing of pre-mRNA), 
with downstream effects on protein expression and phenotypic traits [590-592]. 
Synonymous variants may also affect the tertiary structure of a protein or its function, 
which are not solely determined by the amino acid sequence of a protein, but also by 
translation rate; rare codons may cause pauses in ribosomal translation and common 
codons may speed up translation [593], and so changes in codon usage may influence 
protein folding and cause change in protein conformation and activity [591, 592]. No 
functional studies were found examining the effects of p.Leu267Leu or p.Lys381Lys.  
Some studies indicate that a particular haplotype may have more functional significance 
than a single SNP. For example, the presence of both homozygous p.Glu23Lys, p.Val337Ile 
and heterozygous p.Leu270Val has been associated with higher insulin sensitivity index, 
compared with the combined wild-type genotypes in humans [594]. p.Leu270Val (alone, or 
in combination with other polymorphisms) had no effect on insulin secretion after 
intravenous glucose load or on ‘glucose effectiveness’ (undefined in the publication), 
although individuals who were heterozygous for p.Leu270Val and compound homozygous 
for  p.Val337Ile and p.Glu23Lys had on average 62% higher insulin sensitivity index, 
compared to wild type carriers [594]. In theory, haplotype analysis could help determine 
whether the suggestive association between p.Leu267Leu and KD response is truly driven 
by this SNP alone and/or localise a region that contains other influential variants. Indeed, 
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results suggest that p.Leu267Leu in combination with p.Val337Ile and p.Ser363Ser is more 
closely correlated with 3-month KD response (due to the slightly lower p-value) than 
p.Leu267Leu alone. 
The effects of p.Ser363Ser, a rare synonymous variant located in a non-conserved region, 
are unknown. The missense variant p.Val337Ile is not predicted to be of functional 
consequence according to SIFT, PolyPhen2, LRT and MutationTaster classification. This 
variant alone has not been associated with Type II diabetes [595] and it does not influence 
the properties of reconstituted human SUR1/KIR6.2 channels (including expression rate, 
single channel conductance, spontaneous open probability, and nucleotide and drug 
sensitivities [596, 597]. However, p.Val337Ile was tightly linked with rs5219 (p.Glu23Lys) in 
this cohort, as has been reported in other cohorts [594, 598, 599]. The high concordance 
between these two variants suggests that they may have originated in a common ancestor 
[595]. p.Glu23Lys has been associated with Type II diabetes in Caucasian [522, 599, 600], 
Indian [601] and Chinese/East Asian [602-605] subjects, although results are conflicting 
[606-608]. A meta-analysis of case/control studies investigating the relationship between 
KCNJ11 polymorphisms and Type II diabetes found a significant result for p.Glu23Lys (odds 
ratio of 1.13); when stratifying results by ethnicity, a significant association was found in 
East Asians and Caucasians, but not among South Asians and other populations [609]. 
p.Glu23Lys is thought to have a diabetogenic effect by enhancing the open probability and 
reducing the sensitivity to ATP of the KATP channel, leading to the inhibition of insulin 
secretion [596, 610]. p.Glu23Lys has been shown to impair glucose-induced insulin release 
in humans [611] and individuals with EE (encoding two copies of glutamate) were found to 
have a higher disposition index (a marker of insulin sensitivity) than those with EK (one 
copy of lysine and one of glutamate) or KK (two copies of lysine) [612]. Others have not 
found differences in glucose-stimulated insulin secretion between carriers and non-carriers 
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of p.Glu23Lys [557, 613]. In one study, p.Glu23Lys was not associated with β-cell 
dysfunction or insulin resistance, but it was associated with diminished suppression of 
glucagon secretion in response to hyperglycaemia [614].  
In addition to the putative effects of the variants of interest on ATP sensitivity or open 
probability of KATP channels in the brain, it is feasible that greater insulin sensitivity, leading 
to increased insulin-mediated glucose disposal (for example, into muscle [via GLUT4] or 
adipose tissue) may adversely affect KD response. For example, increased uptake of 
glucose into the liver (indirectly affected by insulin) would inhibit ketone body production 
[615]. It would be of interest to see if fasting plasma glucose, indices of insulin sensitivity 
(such as glycated hemoglobin - a measure of average plasma glucose concentration over 
prolonged periods of time) or β-cell function differ between carriers and non-carriers of 
certain KCNJ11 variants in this cohort, or between all KD responders and non-responders.  
If the same variants had generated the lowest p-values (or had the greatest difference 
between MAF in responders and non-responders) in association analyses conducted with 
3-month and summary KD response, more credence would have been assigned to its 
putative effect on KD response. This was not the case, although the proportion of people 
classified as responders or non-responders in the 3-month and/or summary response 
categories was different; for example, somebody who was classified as a responder at the 
3-month point may have subsequently had an increase in seizures and so would not be 
included in the summary KD group. In the 3-month analysis, any variant harboured by this 
individual would be associated with a favourable response but would not be associated 
with any sort of response in the summary analysis. Alternatively, it may be that certain 
variants only play a role in influencing KD response in the early stages of treatment, as 
blood glucose levels reduce and fatty acids are released by adipose tissue in order to allow 
effective conversion of fatty acids into ketone bodies by the liver. Gene-environment 
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interactions may also play a part; individuals who are overweight or obese may be more 
susceptible to impairment of glucose homeostasis due to KCNJ11 variation (p.Leu27Leu or 
other variants) [595]. Variation in carbohydrate consumption may also affect to what 
extent such variation influences seizure control.  
 Rare and novel variation in KCNJ11 and BAD 4.4.2
No conclusions can be drawn from the previously unreported variants or those SNPs with 
MAF<0.01 in this cohort. Based on its location in a highly conserved amino acid and 
predicted disease-causing or deleterious effect on gene function, 
NM_00525.3:c.[451G>A];[=], p.Val151Met is most likely to be of consequence. It was 
present in one non-responder, but more individuals with this variant are required to see 
whether it has a consistent effect on the phenotype. 
Deep resequencing (Sanger sequencing of PCR-amplified DNA, where each nucleotide is 
read an increasing number of times during the sequencing process and reads are 
assembled against a reference genome) may be needed to detect rare, recent variants, not 
previously reported, for example, in dbSNP [616]. When the region of interest is limited (as 
in a candidate gene study), Sanger sequencing remains the gold standard, although deep 
resequencing with application of stringent genotype call probabilities may be the only way 
to identify the full extent of rare genetic variation in an individual [616].  
 Conclusions and future work 4.4.3
In conclusion, the candidate gene association study suggests that p.Leu267Leu in KCNJ11, 
possibly in combination with p.Val337Ile and/or p.Ser363Ser, may influence KD response at 
the 3-month point, and p.Leu267Leu with overall KD response, although results were not 
statistically significant when adjusting for multiple testing. It is possible that KD response is 
affected by KATP channel open probability and sensitivity to ATP, which influences insulin 
sensitivity (this is particularly plausible due to the linkage between p.Val337Ile and 
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p.Glu23Lys), but it unknown whether the variants of interest, either alone or in 
combination, have this effect on KCNJ11 gene expression or protein function, in the brain 
or elsewhere. Even if they were to have this consequence, the effect sizes of the 
variants/haplotypes were not shown to be large, at least in this cohort. If a 
variant/haplotype was found, for example, in no non-responders and a high proportion of 
responders (no matter what time point response was measured at, or whether summary 
KD response was used), this would be of greater clinical value. Replication is needed in a 
larger, ideally ethnically-homogenous cohort, or at least one in which genome-wide SNP 
data were available for all participants. 
The possibility cannot be discarded that other variants in KCNJ11 or BAD, not found in this 
cohort, may play a role in KD response. Rare variants, which are predicted to have a larger 
phenotypic effect than common variants, are of particular interest.  
GWAS results may aid selection of further candidate genes and potentially allow the 
candidate gene approach to be used on a genome-wide scale, as more SNPs (some located 
within or near candidate genes, or associated with them through LD) are identified 
throughout the genome [617]. 
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5 Common genetic variation and response to the 
Ketogenic diet: a Genome-wide Association Study 
 
5.1 Introduction 
 The genome-wide association study approach 5.1.1
For cohorts of unrelated individuals, GWAS are a widely-used method for identifying the 
genetic contribution to disease and treatment response. In contrast to candidate gene 
analyses, they may be conducted with no a priori assumptions, meaning that biological 
pathways not previously associated with a phenotype may be identified [500]. 
GWAS are based on the common disease/common variant hypothesis [618, 619], which 
states that common diseases are often due to combinations of alleles that occur frequently 
within the population [620]. Common diseases or traits tend to have multiple susceptibility 
alleles, each with a low effect size compared to those for rare disorders.  
SNPs are used as genetic markers, exploiting the concept of LD - ‘the degree to which an 
allele of one SNP is inherited or correlated with an allele of another SNP within a 
population’ [464]. It is thought that a panel of 500,000-1,000,000 SNPs can capture >80% of 
common SNPs in European populations [621]. Phenotypic associations may thus be direct, 
where a genotyped SNP is shown to be statistically associated with the phenotype and this 
association is thought to be biologically plausible, or indirect, where a ‘tag’ SNP, which is in 
high LD with the potential SNP of interest, is shown to be statistically associated with the 
phenotype [464]. This concept is illustrated in Figure 5.1. The notion of indirect association 
may represent an advantage or disadvantage compared to candidate gene analyses; 
indirect association is an efficient way of obtaining genome-wide coverage with a subset of 
SNPs [622], but if the selected candidates are the primary functional genes with regards to 
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the trait in question, a GWAS may only be advantageous if the influential variant is actually 
genotyped [512]. Follow-up studies may be performed to investigate all variants in 
complete or near-complete LD with the tag SNP to identify causal variants [623]. 
 
Figure 5.1: Illustration of the concept of direct or indirect association in GWAS 
 Quality control 5.1.2
In order to avoid bias (potentially leading to Type I or Type II error) arising from poor-
quality SNPs and samples, a range of quality control criteria is customarily applied prior to 
GWAS analyses, on a per-SNP and a per-individual basis [510].  
Commonly-used per-SNP quality control criteria include the following: 
- SNPs with a certain proportion of missing genotypes, including those with significantly 
different missing genotype rates between cases and controls, are excluded in order to 
ensure accurate genotyping calls and to eliminate those with poor genotype probe 
performance [624, 625]. Different rates of missingness in case/control groups can lead to 
false associations.  
- Deviation from HWE is principally used to identify gross genotyping error [626]. It is 
important to check deviation from HWE, as differences in allele frequencies in the two 
populations may be due to selection acting in different ways at a particular locus, rather 
than as a result of reproductive isolation of the populations. A fair comparison could not be 
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made between two populations if there were other factors involved, such as natural 
selection or non-random mating, that caused deviation from HWE in one population.  
- When heterozygosity rates are higher than expected under HWE, this may indicate 
sample contamination, potentially due to interfering SNPs during hybridisation [573, 624, 
627].  
- Due to the need for very large sample sizes to detect associations from variants with low 
MAF, a threshold is usually set (such as 1, 2 or 5%, depending on the cohort size). 
Furthermore, there tends to be more error with lower MAF SNPs in cluster-based calling 
algorithms, as it is more difficult to define a cluster with fewer observations [624, 625].  
Commonly-used per-individual quality control criteria include the following: 
- Exclusion of individuals with high or low proportions of heterozygous SNPs. Excess 
heterozygosity may indicate DNA contamination and low heterozygosity may indicate 
hybridization problems or inbreeding for that individual [573, 628]. 
- Gender mismatch between the phenotypic information collected and that imputed from 
genotyping data.  
- Removal of duplicate and related persons; if the genotypes within a family are 
overrepresented, the cohort may no longer accurately reflect allele frequencies in the 
general population [510].  
- Removal of persons with high proportions of missing data, which imply hybridisation 
problems, possibly caused by faulty arrays or poor DNA quality [573, 624, 625]. 
Quality control measures should not differ between different processing batches; if some 
aspect of the experiment is not randomised with respect to the phenotypic trait, this may 
lead to spurious associations.  
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Even after filtration of sub-optimal SNPs and individuals, manual inspection of cluster plots 
(particularly of top-associated SNPs) is still considered the best way to ensure genotype 
calls are robust [510]. 
 Population stratification 5.1.3
There are various approaches for dealing with potential population stratification in GWAS. 
One is genomic control λ (λGC) [629, 630], defined as the ‘median χ
2 (1 degree of freedom) 
association statistic across SNPs divided by its theoretical median under the null 
distribution’ [631]. This approach corrects for population stratification, where necessary, by 
dividing the association-test statistic at each SNP by a common factor: the inflation factor 
[632]. 
Individuals may also be stratified according to genetic distance/relatedness with other 
participants. A common way of determining pairwise genetic distance/relatedness is by 
measuring identity-by-state (IBS). Pairwise differences in IBS (the genome-wide average 
proportion of shared alleles [558]) can be attributed to relatedness or to population-
specific allele frequencies, according to geographic or ethnic groups [633]. IBS accounts for 
relationships up to 2Nc (where Nc is the effective population size) generations ago, as 
opposed to IBD, which depends on markers inherited from a recent common ancestor 
without recombination, and which only takes into account a limited number of generations 
within a known pedigree [634]. IBS can be used to demonstrate the pairwise genetic 
correlation between subjects and create a similarity matrix for principal component 
analysis (PCA) or the related multidimensional scaling (MDS). It is assumed that each 
population is defined by a characteristic set of allele frequencies, that each population is in 
HWE equilibrium, and that there is complete LD between loci within each population [635]. 
With PCA and MDS, each subject is placed in a point/vector in an X-dimensional space and 
the distance between each point reflects the relationships within the similarity matrix. The 
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genetic background of each subject is then represented by a vector of coordinates that 
reflects the genetic correlation relationships between subjects as closely as possible [631, 
632]. The first vector represents the axis that accounts for the largest genetic variation; the 
second vector represents that which accounts for the second largest genetic variation, and 
so on [632]. A common way of accounting for population stratification in GWAS is to use 
these vectors as covariates, a technique employed by The Wellcome Trust Case Control 
Consortium [573]. Scree plots, where each vector is plotted against the proportion of 
phenotypic variation that it explains, are commonly used to decide how many vectors to 
include as covariates [636-638], as well as the plateauing of λGC [639]. Regions of long-range 
LD should be removed prior to computation of these vectors, as this could give an axis of 
variation which corresponds to genetic variation at that particular locus, rather than to 
genome-wide ancestry [631]. 
 The multiple testing burden 5.1.4
Due to the fact that many markers are used in GWAS, the number of associations that 
could arise due to Type I error is large. The classic Bonferroni-corrected threshold of 5×10-8 
or 1×10-8, for an α of 0.05 and 0.01 respectively is often cited [640]. However, this wrongly 
assumes all markers are independent, and is thus overly conservative. Permutation is now 
considered the gold standard when adjusting for multiple testing in genetic association 
studies [562]. Phenotypes are randomly shuffled with respect to genotypes among 
observed data, removing any genotypic-phenotypic association; each random shuffle of the 
data represents one possible sampling of individuals under the null hypothesis of no 
association, a process which is repeated a certain number of times [464, 563].  
A quicker and less computationally-intensive method is the calculation of the effective 
number of tests and then adjustment of the alpha threshold based on this number. There 
are various methods that have been proposed to calculate the effective number of tests, 
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such as the Cheverud-Nyholt method [641, 642] and Keff (by Moskvina and Schmidt) [643]. 
The Cheverud-Nyholt method is based on the premise that, given a pairwise correlation LD 
matrix with eigenvalues, there are two extreme scenarios: all SNPs are perfectly correlated, 
or all SNPs are uncorrelated. The variance of the eigenvalues is used as a correlation 
measure for the effective number of SNPs. Moskvina and Schmidt’s method tests, at every 
genetic locus, the null hypothesis that the distribution of the risk allele in the entire target 
population is equal to the distribution of the risk allele in cases, dependent on pairwise 
marker correlation coefficients, as well as on the significance level chosen for the individual 
tests.  
Finally, false discovery rate has been proposed as a way to measure and control Type I 
error [644, 645]. Each marker is assigned a corresponding q-value instead of a p-value, 
which is a measure of significance in terms of the false discovery rate rather than the false 
positive rate (represented by p-values), that account for multiple testing. In this way, the 
researcher can control the expected proportion of false positives: for example, a threshold 
of 0.05 would mean that 5% of the observed results may be false positives [646]. However, 
q-values are determined from the overall distribution of p-values observed in the data and 
they are based on the assumption that the p-values are uniformly distributed under the 
null hypothesis of no association, which may not always be the case [643]. Moreover, false 
discovery rate is considered conservative for GWAS [647] and the original procedure 
proposed by Benjamini and Hochberg [645] is only valid when the tests are independent 
[648].  
 Interpreting results 5.1.5
One major difficulty with GWAS lies in the interpretation of results. Only 7% of SNPs 
previously found to be associated with a disease or trait in GWAS are located in protein-
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coding regions [649, 650], and significant associations do not guarantee a causal effect. In 
this way, GWAS are more observational than experimental studies.  
The first GWAS success identified a polymorphism in the Complement Factor H gene to be 
a major risk factor for age-related macular degeneration [651]. Since then, many 
associations have been reported, of which those within the context of pharmacotherapy 
and nutrition are of particular interest; for example, rs8014194, located within the CLMN 
gene, has been associated with variability in response to statins in terms of reduced total 
cholesterol [652]. Such genetic results have not commonly been assimilated into clinical 
practice, possibly due to small cohort sizes and/or the small effect size of identified 
variants, but they have certainly furthered understanding of the biology behind differential 
response to certain treatments and may help generate new hypotheses for further 
research. 
 Alternative approaches to the single-SNP method 5.1.6
The single-SNP analysis is a suitable approach when conducting the first GWAS for a 
particular phenotypic trait but, if one considers that a SNP is only a very small part of a 
larger biological web, the limitations of the single-SNP analysis approach when analysing 
complex diseases becomes clear. The effect of a variant on the phenotype may depend on 
the presence of other variants [653] or interactions with other interdependent components 
of the biological pathways within which the variant/gene plays a role [654]; it may be a 
combination of many factors that contributes to the phenotype. Alternative methods of 
processing SNP data may increase power to detect phenotypic-genotypic associations. 
There are three main approaches that are adopted when using preliminary GWAS findings 
for subsequent analysis: 
i) pooling information from multiple GWAS in a meta-analysis. 
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This increases the chances of separating true positives from false positives and is said to 
increase power [655-657].  
ii) modelling of epistatic interactions – association tests conditional on 
interactions, accounting for the effects that alleles of one SNP have on the 
effects of alleles of another SNP on the phenotypic trait. 
This approach is based on the premise that stronger associations are revealed when genes 
interact. GWAS that account for SNP-SNP interactions may be more powerful than single-
SNP GWAS in certain circumstances, and power is strongly affected by allele frequency of 
the susceptibility variants and by the extent of LD between tagged and typed variants 
[658]. However, interaction effects are even more difficult to detect than main effects and 
so if a GWAS is underpowered to detect associations from main effects, there is very little 
chance of detecting interaction effects if all possible pairwise interactions are considered 
[655]. It is common to consider only those pairwise interactions with a significant result, 
although this may mean that variants with modest effect sizes and large interactions may 
be missed [658].  
iii) pooled-variant approaches: most commonly pathway-based analyses, where 
single SNP GWAS results are grouped together in a known biological pathway 
to test whether the pathway is associated with the phenotypic trait [655], as 
well as gene-based analyses where SNPs are grouped into genes.   
Pathway analyses are based on the premise that a SNP with too small an effect size to be 
associated with the phenotype by itself may have a greater effect when aggregated (in 
combination with other variants within the same unit) into a gene or pathway. This is 
particularly appropriate for complex traits, which may result from accumulated effects of 
genetic variants within genes or pathways. Variant-pooling approaches, particularly 
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pathway-based analyses, account for genetic heterogeneity: although affected individuals 
may share the same disrupted pathways, the mutated genes or variants within those 
pathways may differ amongst individuals. This approach also accounts for the fact that 
genes, particularly those present in a particular pathway, interact with other components 
[659]. Variant-pooling analyses may provide greater power to detect an association, if 
several of the SNPs within genes, or several of the genes within a pathway influence the 
phenotype; if only one SNP or gene has an effect, including others in the test will reduce 
power to detect an association [660].  
Gene- or pathway-based analyses were first used to identify common themes amongst 
differentially expressed genes in gene expression datasets. There are several difficulties 
with using GWAS data for these analyses. Firstly, with gene expression data, each gene is 
represented by one value (the extent of over- or under-expression), but with GWAS, each 
gene is represented by a variable number of SNPs [661]. Secondly, standard genotyping 
platforms select SNPs based on LD patterns to provide maximum coverage of the genome, 
rather than coverage of all genes. Therefore, genes or pathways with more variants typed 
are more likely to be detected in association studies. Furthermore, aside from SNPs that 
are present in coding or regulatory regions, assigning SNPs to genes is difficult as SNPs may 
be in LD with multiple genes. There are several programmes that facilitate the transition of 
SNP lists to gene or pathway lists, which take into account LD (genes that are in high LD 
with a group of variants with low p-values, or with genes already known to be associated 
with the phenotypic trait, are more likely to be represented in the list of ‘most associated’ 
genes), such as ProxyGeneLD [662], INRICH [663] or Prioritizer [664]. However, there are no 
standard rules for assigning non-coding SNPs or those not in regulatory regions to genes 
and no single method has been shown to outperform others in analyses of different GWAS 
datasets [655]. There is less ambiguity when assigning variants to genes when using exome 
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chip genotyping arrays (or combination arrays, as used in this study) and so gene/pathway 
analysis may be a powerful approach. These are different to standard arrays, as they only 
include coverage of exonic regions; they aim to type putative functional variants – mostly 
non-synonymous variants but also other variants, such as those located in splice sites, 
promoter regions and extended major histocompatibility complex regions. In many cases, 
the functional interpretation will be easier, although this may not necessarily be the case 
for variants in regulatory regions.  
Pathway-based analyses fall into two categories: those that test the competitive 
hypothesis, which assumes that genes with a particular function or involved in a particular 
pathway appear at the same frequency as in the reference genome, and those that test the 
self-contained hypothesis, which assumes that there is no association between the target 
gene set and the phenotypic trait [666].  
One of the most popular methods that tests the competitive hypothesis is the GSEA 
algorithm [667], originally developed for gene expression data. Variants are assigned to 
genes (SNPs that are 500Kb away from any gene are discarded), and each gene is given a 
statistical value, which is equal to that of the variant assigned to the gene with the 
maximum X2 value or the lowest p-value. Enrichment scores are calculated based on the 
extent to which the target gene set falls within certain pathways and normalised to account 
for gene size bias. The significance of the enrichment score for each pathway is estimated 
through permutation. Gene-wide p-values may also be obtained from programmes such as 
ProxyGeneLD [662], which assigns unadjusted p-values to each gene in the same way as 
GSEA (the SNP with the lowest p-value assigned to that gene becomes the gene-wide p-
value) and then adjustment is made by multiplying that p-value by the number of SNPs 
assigned to the gene [668]. Another option is GSEA-SNP [669], in which variants are ranked 
according to results from single variant association tests and a group of variants, for 
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example within a certain pathway, is taken as a set. A variant-level enrichment score is 
calculated, which reflects the degree to which the variant set is over-represented at the top 
of the list of ranked variants. Whichever method is adopted, once a list of nominally-
significant genes associated with the phenotype has been created (for example, those with 
p-value<0.05), instead of considering genes one by one, one can determine whether a 
particular biological function is represented in this list more than what would be expected 
by chance. Programmes such as Database for Annotation, Visualization and Integrated 
Discovery (DAVID) [670], Protein ANalysis THrough Evolutionary Relationships (PANTHER) 
[671], and Ingenuity Pathways Analysis (IPA, from QIAGEN), facilitate enrichment analysis. 
After creating a list of nominally significant genes, this list can be uploaded into such 
programmes, some of which are available online, and enrichment scores calculated. 
Competitive analyses may not necessarily increase power in association studies, but serve 
to determine whether there is any biological function in common among all nominally-
significant genes associated with the phenotype.  
Another approach is to group variants into genes and conduct an association study testing 
the null hypothesis that no particular gene is associated with the phenotypic trait. An 
immediate generalisation of gene-based tests can then be conducted by grouping these 
genes into pathways. Examples of methods that test this self-contained hypothesis are the 
SNP Ratio Test [672] and the set-based test implemented in PLINK [558]. The SNP Ratio 
Test builds on the ratio of significant SNPs (as defined by a threshold, for example, 0.05) in 
a pathway and estimates the significance of the ratio via permutation. With the PLINK set-
based test, the user must specify sets, which may genes or pathways, including which SNPs 
are included in which set. A group of independent SNPs within each set are identified, 
based on LD, and the statistic for each set is calculated as the mean of these single SNP 
statistics. Empirical p-values are then calculated, which correct for the number of 
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independent SNPs within a set. The advantage of the self-contained approach, compared to 
the competitive approach, is that there is no danger of underestimating the importance of 
a pathway because variants/genes that contribute to the effect of a particular phenotype 
on a pathway but that, individually, have less of an effect size than other variants/genes, 
are not included (as may occur if only the most significant SNPs were considered) [661].   
Gene-or pathway-based analyses have identified significant genotypic-phenotypic 
associations, even when no individual SNP passed genome-wide significance thresholds 
[661]. A multiple-component approach has been recommended when analysing GWAS data 
[673].    
A GWAS will be the first step in attempting to identify whether common genetic variation 
(in genes aside from KCNJ11 and BAD) influences KD response. A single-SNP, gene-based 
and pathway-based approach will be adopted. This may help elucidate the mechanisms 
behind the antiepileptic effects of dietary treatment.   
5.2 Methods 
 Phenotypic data 5.2.1
Two approaches were adopted: 
i) Using KD response at 3-month follow-up. 
A binary phenotype was adopted, using seizure reduction thresholds that are considered 
clinically relevant to the population in question: ≥50% seizure reduction=responder; ≤50% 
seizure reduction=non-responder. 3 months after diet onset is the first time point at which 
KD response is formally assessed in the KD clinic and the greatest number of individuals in 
this study has KD response data available at this point.  
ii) Using a summary of KD response over time. 
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KD response is not always consistent over time, as shown in Chapter 3, and a summary of 
longitudinal response attempts to account for this variability, rather than taking response 
at one specific point in time. Individuals who achieved ≥50% seizure reduction at every 
time point recorded were classified as responders, and those who achieved <50% seizure 
reduction at every time point recorded were classified as non-responders. Thus, this 
category serves as a measure of long-term (consistent) response. Cases who consistently 
reported approximately 50% seizure reduction over time, or those with very fluctuating 
diet response over time were excluded from the summary diet response classification, as 
responder/non-responder status was ambiguous. 
This GWAS is primarily concerned with common genetic variants, which are predicted to 
have a small effect size, and so extreme KD response (defined as ≥75% seizure reduction) 
was not used as a phenotype.   
 Genetic data 5.2.2
DNA sample concentration was measured with NanoDrop ND-1000 Spectrophotometer 
(Thermo Fisher Scientific Inc., USA) and then diluted to 6μl at 50ng/μl. Samples were sent 
to AROS Applied Biotechnology A/S, Denmark to be genotyped with the Infinium 
HumanOmniExpressExome Beadchip (Illumina Inc, San Diego, USA) in two batches. See 
Figure 5.2 for numbers of individuals recruited and included in the final GWAS. 
The Illumina chip has 730,525 common variants at >5% MAF and >240,000 functional 
exonic markers, selected from >12,000 exome and genome sequences. Through LD (r2>0.8), 
it provides coverage for 73% MAF>5% and 58% MAF>1% outside coding regions from the 
1kGP European cohort (Human OmniExpress BeadChip Data Sheet, www.illumina.com) and 
10% MAF>5%, 9.6% MAF>2.5% and 8.8% MAF>1% (r2>0.8) within exonic regions 
(HumanExome BeadChips Data Sheet, www.illumina.com). 
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Raw genotyping data was analysed by Dr Costin Leu, using Illumina GenomeStudio software 
(v2011.1, Illumina Inc, San Diego, USA) with the Genotyping module (v1.0, Illumina Inc, San 
Diego, USA). PLINK (v1.07, http://pngu.mgh.harvard.edu/purcell/plink, [558]) was used for 
quality control and to conduct the GWAS. 
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Figure 5.2: Flowchart of cases recruited and included in final GWAS 
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 Quality control 5.2.3
All DNA samples were prepared to 6μl at 50ng/μl to ensure consistently high DNA 
quality/concentration. 
All markers and individuals had to pass several tests to be included in the GWAS, with the 
aim of excluding poor-quality SNPs and samples without removing genuine phenotype-
genotype associations. Guidelines on such quality control criteria have been outlined 
elsewhere [510] and implemented in previous epilepsy GWAS [582]. 
5.2.3.1 Per-individual quality control exclusion criteria 
i) Individuals with an excessive (>0.33) or reduced (<0.25) proportion of 
heterozygote genotypes. 
The observed number of homozygous genotypes and total number of non-missing 
genotypes were calculated in PLINK (command: --het). The proportion of heterozygous 
SNPs for each individual, stratified by self-reported ethnicity, was plotted in Microsoft Excel 
2010 (v. 14, Microsoft, Washington, USA), as shown in Figure 5.3. These ethnic groups 
reflect the range of ethnicities in this cohort, bearing in mind that allele frequency 
differences between different continents are much greater than those within continental 
subgroups [639] and that population admixture also affects allele frequency due to influx of 
alleles from other subpopulations [674]. Visual inspection of this plot enabled the 
researcher to eliminate outliers in each ethnic group (outliers are marked within circles in 
Figure 5.3).  
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Figure 5.3: Mean heterozygosity rates per individual, separated by ethnicity 
ii) Mismatch between gender reported in the phenotype file and gender imputed 
from PLINK (command: --check-sex).  
Homozygosity estimates were calculated across all X-chromosome SNPs for each individual; 
a male call was made when homozygosity estimate>0.8 and a female call was made when 
homozygosity estimate<0.2.   
iii) Duplicate and related persons. 
IBD was calculated between all pairs of individuals (Pi-hat [proportion of IBD] >0.4; 
command: --genome). Full siblings share an average of 0.498 genome-wide IBD, with a 
range of 0.374–0.617 [675]. A pi-hat threshold of 0.4 is therefore thought to remove 
duplicated cases and full sibling pairs. Where related individuals were found, the case with 
the lower call rate was removed.  
iv) Individuals with >2% missing SNP data (command: --mind 0.02).  
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5.2.3.2 Per-SNP quality control exclusion criteria 
i) Genotyping rate <0.02 (command: --geno 0.02), following manual re-clustering 
of SNPs with >1% ‘no calls’ in GenomeStudio (clustering within Batch 1 did not 
appear to differ from Batch 2).  
‘No calls’ refers to the number of genotypes in each sample with a GenCall score (a quality 
score indicative of the reliability of each genotype call) below 0.15 - genotypes with a 
GenCall score<0.15 are not assigned genotypes as they are considered to be too far from 
the centre of the cluster to which the data point is associated to make reliable genotype 
calls (TECHNICAL NOTE: ILLUMINA® DNA ANALYSIS. Infinium® Genotyping Data Analysis: A 
guide for analyzing Infinium genotyping data using the Illumina GenomeStudio® 
Genotyping Module, www.illumina.com).  
ii) Cluster separation values <0.3 and Het-excess values between 0.1 and -1 and 
between 0.1 and 1, given in GenomeStudio.  
These exclusion criteria avoid SNP calling errors from the re-clustering steps. Higher cluster 
separation values (a measure of how close the raw colour signal data corresponds to each 
allele when assigning genotypes; a value close to one indicates homozygosity for one allele, 
a value close to 0 indicates homozygosity for the other allele and 0.5 indicates a 
heterozygous genotype) and Het-excess values (a measure of excess heterozygote calls 
relative to the expectation under HWE; Het-excess=-1 when no heterozygotes are called 
and =1 when all genotypes are called heterozygotes) closer to 0 indicate more reliable 
genotype calls.  
iii) MAF <0.05 (command: --maf 0.05).  
Some previous GWAS have set the MAF threshold at 0.01 (including common SNPs and 
those of intermediate frequency) [582, 676, 677] but, as outlined in Section 5.3.5, this 
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study is already underpowered and so it would not be worth including variants with much 
smaller MAF.  
iv) Deviation from HWE, p-value<1x10-6, obtained from an exact test [678] 
(command: --hwe-all --hwe 0.000001), a threshold that has been used in many 
previous GWAS [625, 679-682].  
This threshold was principally set to identify gross genotyping error, for which extreme 
deviation from HWE is typically used [626]; it should not be used for identifying minor 
genotyping error, as deviation from HWE has low sensitivity for testing for genotyping error 
[683-685]. The exact test method was used for testing deviation from HWE because it 
controls Type I error rates within large and small cohorts and is accurate for rare and 
common allele frequencies [678]. In contrast, deviation from HWE calculated using the chi-
squared test may be inaccurate for small sample sizes or rare alleles; there may not be 
enough individuals in the sample to adequately represent all genotypes, and so the 
asymptotic assumption of the chi-squared distribution (the sum of k independent random 
variables with finite mean and variance, which converges to a normal distribution when k is 
of a sufficiently large size) no longer holds. 
 Covariates and population structure 5.2.4
As outlined in Chapter 3, the effect of a range of demographic and clinical factors on KD 
response was assessed by logistic regression. 
IBS distance was calculated between all pairs of individuals in PLINK, using the commands --
genome, and --read-genome --cluster. Known regions of high LD (see Table 5.2 in Appendix 
5.1) were excluded and the dataset was thinned to create a set of independent SNPs, using 
the command --indep-pairwise 1500 150 0.2. With this command, all SNPs were pruned in a 
sliding window of size 1500 and were required to have r2<0.2. It is recommended to 
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exclude long-range LD regions and perform LD pruning [686], as some regions of the 
genome may be over-represented due to high LD and these regions may bias clustering: 
vectors that capture population differentiation (such as those used in PCA and MDS) may 
only reflect genetic variation at those specific loci [631, 687].   
Self-reported ethnicity or country of origin could have been used to account for ethnicity 
(for example, with a stratified Cochran-Mantel Haenzel test), but using IBS to determine 
genotypic differences between participants has the advantage that genotyping data may 
distinguish between people who reported themselves to be from a specifically-defined 
population, or reveal population admixture. Pairwise IBS distance was visualised by 
performing MDS analysis on the matrix (PLINK command --mds-plot) and plotting the value 
of the position on the first vector against the value of the position on the second vector for 
each individual in Microsoft Excel 2010 (v. 14, Microsoft, Washington, USA). This produced 
a scatter plot where each point represents one individual, giving a two-dimensional 
reduced representation of the data. As shown in Figure 5.4, self-reported ethnicity did not 
always correlate with genotypic similarity. 
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Figure 5.4: For all individuals with Ketogenic diet response data: plot of values of the first and 
second vectors obtained by multidimensional scaling of pairwise identity-by-state values, with 
ethnicity highlighted 
The MDS vectors were also plotted with responders and non-responders highlighted in 
order to determine whether there were any systematic differences in the data – this would 
be shown by any clustering of responders/non-responders. These differences may not only 
be due population structure, but also other factors that may confound association analyses 
such as cryptic relatedness or batch effect.  Response status at the 3-month point was 
taken, as most individuals had response data for this time point. 
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Figure 5.5: For all individuals with Ketogenic diet response data: plot of values of the first and 
second vectors obtained by multidimensional scaling of pairwise identity-by-state values, with 3-
month response highlighted 
As shown by Figure 5.5, responders and non-responders overlap and are virtually 
indistinguishable from each other, indicating that the phenotypes are appropriately 
randomised.   
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In order to determine the extent to which these vectors account for phenotypic variability 
in this cohort, a scree plot (see Figure 5.6) was plotted in R: A Language and Environment 
for Statistical Computing (v. 3.0.0, R Foundation for Statistical Computing, Vienna, Austria). 
Using the ‘ibs()’ and ‘cmdscale()’ functions, pairwise IBS values were calculated and MDS 
analysis performed on the distance metrix, just as in PLINK. Eigenvalues (scalar multipliers 
of the vectors) were then calculated for each vector and a scree plot completed using the 
‘plot(cps.full$eig[1:10]/sum(cps.full$eig)’ function (‘cps.full’ is the name given to the 
distance matrix). 
Figure 5.6: Scree plot for the first 10 eigenvalues of the Multidimensional scaling matrix 
From this plot, one can see that the first vector only explains 5% of the total phenotypic 
variance; the second vector explains close to 0% of the variance, and the remaining vectors 
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explain even less. Based on these results, it may be considered reasonable to include the 
first component in association analyses but, as it accounts for so little phenotypic 
variability, the question is also raised of whether vectors need to be included in analyses at 
all. If more components are included in analyses than are necessary, noise is introduced 
into analyses [688]. As explained in the following section, analyses were completed with no 
adjustment for population stratification, and also including the first vector as a covariate. 
λGC [629, 630], was calculated in PLINK with the command --adjust, and used as a measure 
of bias due to population stratification in association analyses. 
 GWAS 5.2.5
An association analysis was performed using a Fisher’s allelic association exact test (which 
compares frequencies of alleles in cases versus controls) in PLINK, with the commands --
fisher --adjust --ci 0.95. This test is suited to small sample sizes and avoids bias due to 
distributional approximation. 
A logistic regression additive model was also performed in PLINK (commands --logistic --
covar), including the first MDS vector values as covariates.  
To facilitate the creation of quantile-quantile plots, the command --qq-plot was added. 
Quantile-quantile plots are a commonly used tool to represent GWAS data and assess 
whether more significant results have been generated than expected by chance. If results 
deviate from the expected values across the whole distribution, this may be due to 
undetected population stratification, cryptic relatedness or batch effects [689]; variants 
with the lowest p-values that deviate from expected values correspond to those with the 
greatest effect on the phenotype.  
 Correction for multiple testing 5.2.6
PLINK was used to obtain p-values by permutation, with the commands --mperm 1000. 
≥1,000 permutations are needed to estimate a 0.05 threshold [565, 566]. 1000 
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permutations were chosen in order to obtain precise p-values whilst remaining realistic 
with regards to time needed for these computationally-intensive permutation procedures. 
The significance threshold was set at 0.05, as is widely adopted [690]. 
An alternative (and less computationally-intensive) method of correcting for multiple 
testing was also used: the effective number of independent tests was calculated, according 
to Moskvina’s method [643], by Dr Jon White. This method accounts for the pairwise LD of 
the typed SNPs and the significance level used in the individual tests. Moskvina’s method is 
preferable to many other methods, as the tests remain independent even for markers that 
are moderately or highly correlated [643]. For example, both the Cheverud-Nyholt method 
and simple M overestimate the effective number of tests if large groups of markers are 
highly correlated [568, 691]. With simple M, if each chromosome is not broken down into 
smaller regions, analysis requires a great deal of computational memory and time; the 
accuracy of the threshold applied may depend on variations in region size [640].  
Taking the significance threshold for a single test to be 0.05, the threshold adjusted for 
multiple testing (based on the effective number of tests) was calculated using the SIDAK 
method [692], by Dr Jon White: (1 − (1 − α)1/number of tests) [561]. 
A suggestive significance threshold was set by dividing 1 by the number of tests, a strategy 
used in previous publications [693, 694].  
 Visualisation of GWAS results 5.2.7
Haploview (v4.2, http://www.broadinstitute.org/haploview, [695]) was used to generate 
Manhattan plots and to visualise the LD pattern around the SNPs of most interest. Regional 
plots for the most significant SNPs were created using LocusZoom 
(http://csg.sph.umich.edu/locuszoom, [696]), with genome build/LD population hg19/1000 
Genomes March 2012 EUR. LD was displayed as D’/LOD (D’, the normalised covariance for 
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a given marker pair, indicating to what degree two alleles have or have not been separated 
by recombination; LOD, logarithm of the odds, is a statistical estimate of whether two loci 
are likely to be located near to each other on a chromosome and are therefore likely to be 
inherited together). The LD Display Spacing in Haploview was adjusted so as to ensure the 
position of the SNPs lined up as closely as possible to the Locuszoom display. This does 
make the display of D’/LOD a little less clear, as the space between each coloured triangle 
is increased, but it facilitates visualisation of which gene(s) the SNPs are in LD with.    
Quantile-quantile plots were created using R: A Language and Environment for Statistical 
Computing (v. 3.0.0, R Foundation for Statistical Computing, Vienna, Austria) and the 
commands plot(-log(data$QQ, 10), -log(data$UNADJ,10) and abline(a = 0, b = 1).  
Genes located within the LD blocks of the top SNPs were looked-up in Genedistiller (v2, 
www.genedistiller.org, [697]) to obtain information regarding protein families (ENSEMBL), 
pathways (KEGG), Mouse Genome Database phenotypes and GeneOntology terms, with 
data based on NCBI genome build #37. Human phenotypic-genotypic associations were 
investigated using Online Mendelian Inheritance in Man (http://omim.org), The Database 
of Genotypes and Phenotypes (http://www.ncbi.nlm.nih.gov/gap), Genetic Association 
Database (http://geneticassociationdb.nih.gov, [698]) and Phenotype-Genotype Integrator 
(http://www.ncbi.nlm.nih.gov/gap/phegeni, [699]). These sites were used to determine 
whether the genes had been associated with a neurological or metabolic phenotype.  
The top associated SNP was looked up in UCSC Genome Browser (http://genome.ucsc.edu) 
and HapMap Genome Browser release #28 (http://hapmap.ncbi.nlm.nih.gov) to search for 
physically close genes (including transcripts), SNPs and gene regulatory elements. 
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 Power calculations 5.2.8
All power calculations were performed using PGA Power Calculator [581], taking the 
sample size/case:control ratio from the 3-month diet response phenotype model, as this 
was the largest cohort. 
Curves depicting potential detectable relative risk and MAF in this cohort, with varying 
power, were plotted, as were power and sample size curves. An r2 value of 0.9 between a 
genotyped marker and causal variant was assumed, and an alpha level according to the 
effective number of tests was used.  
As there is no naturally-existing KD, or indeed calorie restriction, at least in Europeans, 
disease prevalence (or prevalence of the trait) is hard to gauge. The disease prevalence of 
epilepsy (0.5%) was therefore used, as in other studies [582]. 
The inheritance model is unknown and so power calculations were performed using co-
dominant, dominant and recessive penetrance models. 
 Gene- and pathway-based analyses 5.2.9
Each variant present in the association analyses was assigned to a gene in wANNOVAR 
[574]. Variants in exonic regions, those that overlapped 5’ UTRs (untranslated regions), 
3’UTRs or introns, those within 2bp of splicing junctions, or within 1kb of a transcript start 
site were assigned to the corresponding gene (as per default setting for wANNOVAR 
annotation). Intergenic variants were discarded, as it is often difficult to determine with 
which gene in their LD region (if any) they interact and thus their functional consequence is 
hard to interpret.  
A set file was created for use in PLINK, with a list of genes and the SNPs included in those 
genes. The PLINK set-based test [558], which has been found to be more powerful 
(although also slower) than other gene-based algorithms [700], was used to test whether 
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any particular gene(s) are associated with KD response (command --set-test --set Genes.txt 
--mperm 1000 [where Genes.txt is the list of genes and SNPs included in those genes]). This 
self-contained approach, rather than a competitive approach was adopted in order to 
account for possible interactions from variants with less of an effect size. Furthermore, due 
to the low power of the study, a limited number of genes would be classed as nominally 
significant. As the gene list is determined by single variant tests, if these are underpowered, 
the power of enrichment tests will also be low as the number of nominally significant genes 
is low – the higher the number of genes in the list, the more likely they are to generate a 
low p-value [701]. 
The PLINK set-based test first determines a set of independent SNPs within each set, based 
on their LD relationship. It then conducts a single SNP analysis (in this case, a Fisher’s exact 
test with the same quality control filtering as adopted as in the single variant GWAS) and 
selects independent SNPs within each set with a p-value below a pre-defined threshold. 
The statistic for each set is calculated as the mean of the p-values of each of these SNPs. 
Empirical p-values are created by permutation, which accounts for the number of multiple 
SNPs within a set but not for the number of sets 
(http://pngu.mgh.harvard.edu/~purcell/plink). The reason for creating a set of independent 
SNPs is that p-values of SNPs within the same gene are often not independent, as SNPs may 
be in LD. P-values for a gene or pathway will therefore be inflated if there are large 
correlations among SNPs in the gene. The reason for setting a maximum number of SNPs 
within each set is that genes or pathways with more variants typed are more likely to show 
association by chance alone [702]. In this study, SNP independence was defined as r2<0.5 
(as per default settings), the maximum number of independent SNPs within a set was 
defined as 5 (as per default settings) and all SNPs with a p-value of <1 were included.  
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A PLINK set-based test was also used to conduct a self-contained pathway-based analysis, 
as opposed to taking a proportion of genes from the gene-based test and conducting a 
competitive analysis, in order to account for possible interactions from variants/genes with 
less of an effect size. A list of genes and their associated pathways was downloaded from 
the Broad Institute website (www.broadinstitute.org/gsea). This list included KEGG, 
PANTHER, REACTOME, BIOCARTA and PID (Pathway Interaction Database) pathways. This 
avoids potential bias from limiting oneself to one set of pathways. Analyses were not 
conducted with GO (Gene Ontology) terms due to the general nature of many of these 
categories, which makes interpretation difficult. Another set file was created for use in 
PLINK with a list of pathways and a list of SNPs included in these pathways.   
A Bonferroni-adjusted significance threshold was set by dividing 0.05 by the number of 
genes or pathways included in the analysis.   
5.3 Results 
 Quality control  5.3.1
A breakdown of average SNP call rates by batch and plate is given below: 
Batch 1, Plate 1 (11/06/12): average call rate=0.997. No samples had a call rate<0.990 
Batch 1, Plate 2 (11/06/12): average call rate=0.995. Two samples had a call rate<0.990 
(these were the two samples that failed) 
Batch 1, Plate 3 (15/08/12): average call rate=0.993. Eight samples had a call rate<0.990  
Batch 1, Plate 4 (15/08/12): average call rate=0.996. No samples had a call rate<0.990 
Average call rate within Batch 1=0.995 
Batch 2, Plate 1 (29/01/13): average call rate=0.993. Four samples had a call rate<0.990  
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These average call rates (all >0.990) are consistently high across all plates/batches. 
Genotype concordance rate was not checked, as no samples were genotyped twice (with 
the exception of two samples that failed in Batch 1).  
One subject was removed because of imputed relatedness to another study participant (a 
pair of siblings were recruited and the subject with the lowest call rate was removed). 
Seven subjects were removed due to low genotyping rates. Two subjects were removed 
due to excess/reduced heterozygosity rates. One subject was removed due to presence of 
SLC2A1 mutation (identified from whole exome sequencing, after recruitment and 
genotyping). 
 Covariates and population structure 5.3.2
There was no strong evidence to suggest that KD response was affected by any clinical or 
demographic factors (see Chapter 3) and so none were included as covariates in the GWAS.  
λGC was 1.00 in the Fisher’s exact test, both with the 3-month response phenotype, and 
with the summary response phenotype. In the logistic regression including the first MDS 
vector values as covariates, λGC was 1.008 in the 3-month KD response GWAS and λGC was 
1.0002 in the summary KD response GWAS. This indicates absence of importance of 
population stratification, and that noise is introduced when including MDS vectors as 
covariates. 
Quantile-quantile plots were also examined to determine whether results deviated from 
the expected values across the whole distribution (this may be due to undetected 
population stratification or cryptic relatedness) to a lesser extent in the Fisher’s exact test, 
compared to the logistic regression. 
Quantile-quantile plots of the genome-wide distribution of results for all GWAS (see Figure 
5.7 and Figure 5.8) indicate deviation from the null hypothesis of no association only in the 
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upper tails, corresponding to the SNPs with strongest evidence for association. Consistent 
with the previous findings, slightly less bias is seen when using the Fisher’s exact test – the 
line of black dots (each representing a p-value) is closer to the line representing the 
expected p-values. 
 
Figure 5.7: Quantile-quantile plots of GWAS results from Fisher’s exact test, using unadjusted p-
values. A) 3-month diet response, λ=1.00; B) Summary diet response, λ=1.00 
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Figure 5.8: Quantile-quantile plots of GWAS results from logistic regression, using unadjusted p-
values. A) 3-month diet response, λ=1.008; B) Summary diet response, λ=1.0002 
Based on the above findings, the Fisher’s exact test was used for association tests. 
 Correction for multiple testing 5.3.3
The threshold for genome-wide significant association was set at 0.05 for p-values obtained 
from 1000 permutations.  
The alternative significance threshold was 1.01x10-7 (α=0.05) and the suggestive 
significance threshold was 2.12x10-6 (α=1.00), after SIDAK correction for testing 471,955 
effectively independent SNPs.  
 GWAS results 5.3.4
Following quality-control filtering and exclusion of ethnic outliers, 614902 SNPs remained 
in each GWAS. 
116 non-responders and 122 responders were included in the 3-month diet response 
GWAS; 100 non-responders and 110 responders were included in the summary diet 
response GWAS. 
λGC=1.0 
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rs12204701 reached significance in the 3-month KD response GWAS (unadjusted p-
value=7.34x10-8; p-value obtained from 1000 permutations=0.039): the minor allele, A, was 
more frequent in non-responders than responders. rs12402021 (unadjusted p-
value=4.28x10-7; p-value obtained from 1000 permutations=0.17) and rs4696766 
(unadjusted p-value=1.29x10-6; p-value obtained from 1000 permutations=0.40) reached 
suggestive significance.  
No SNPs reached significance in the summary KD response GWAS. rs4674639 reached 
suggestive significance (unadjusted p-value=1.31x10-6; p-value obtained from 1000 
permutations=0.40).  
Regional association plot and LD maps for intergenic SNPs of significance or suggestive 
significance are given below. 
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Figure 5.9: Regional association plot and linkage disequilibrium (LD) map for rs12204701+/-500Kb. 
In the association plot, the left y-axis represents -log10 (P-values) for association with 3-month KD 
response; the right y-axis represents the recombination rate; the x-axis represents base-pair 
positions along the chromosome (human genome build 37). The top variant, rs12204701, is shown 
in purple, the rest of the variants are coloured according to their linkage disequilibrium r2 value 
with rs12402021. In the LD map, LD is indicated as D’/LOD. The colour white = LOD < 2, D' < 1; blue 
= LOD < 2, D' = 1; shades of pink/red = LOD ≥ 2, D' < 1; bright red = LOD ≥ 2, D' = 1. LD pattern is 
based on genotype data obtained for this study. Confidence interval minima for strong LD: lower: 
0.7, upper 0.98; Upper confidence interval maximum for strong recombination: 0.9; Fraction of 
strong LD in informative comparisons is at least 0.95; markers with <0.05 MAF are excluded. 
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Figure 5.10: Regional association plot and linkage disequilibrium (LD) map for rs12402021+/-
500Kb. In the association plot, the left y-axis represents -log10 (P-values) for association with 3-
month KD response; the right y-axis represents the recombination rate; the x-axis represents 
base-pair positions along the chromosome (human genome build 37). The top variant, 
rs12402021, is shown in purple, the rest of the variants are coloured according to their linkage 
disequilibrium r2 value with rs12402021. In the LD map, LD is indicated as D’/LOD. The colour 
white = LOD < 2, D' < 1; blue = LOD < 2, D' = 1; shades of pink/red = LOD ≥ 2, D' < 1; bright red = 
LOD ≥ 2, D' = 1. LD pattern is based on genotype data obtained for this study. Confidence interval 
minima for strong LD: lower: 0.7, upper 0.98; Upper confidence interval maximum for strong 
recombination: 0.9; Fraction of strong LD in informative comparisons is at least 0.95; markers with 
<0.05 MAF are excluded. 
 
As shown in Figure 5.9, rs12204701 is in an LD block next to, but not within, the CDYL gene. 
It is located in a region rich with recombination hot spots (by comparison, the mean sex-
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averaged recombination rate in humans is 1.13cM/Mb [59]) and the LD structure is broken 
down because of this. Due to its ubiquitous expression in humans, CDYL is thought to be a 
potential housekeeping gene. Of the 22 proteins found to interact with CDYL, most play a 
role in transcriptional repression [703]. rs12204701 is also located  508770 bases from 
ECI2, which encodes a mitochondrial enzyme involved in the beta-oxidation of unsaturated 
fatty acids. 
As shown in Figure 5.10, rs12402021 is located within an LD block with PARP1 and C1orf95. 
PARP1 encodes an enzyme that modifies various nuclear proteins by polyADP-ribosylation. 
It is involved in the repair of single-stranded DNA breaks and apoptosis and is thought to 
participate in the pathophysiology of Type I diabetes [704, 705]. C1orf95 is 
uncharacterised.  
rs4696766 is located in the intronic region of ABLIM2. This gene has not been extensively 
studied but it is associated with the GO annotations ‘actin binding’ and ‘zinc ion binding’ 
and it is assumed that the ABLIM2 protein is necessary for the normal functioning of 
neurons [706]. 
rs4674639 is located in the intronic region of PAX3, a gene which encodes a transcription 
factor that is thought to regulate cell proliferation, migration and apoptosis. It is expressed 
early on in progenitors of the dorsal spinal cord and is thus thought to be involved in neural 
development [707]. 
As shown in Figure 5.11, rs12204701 is located adjacent to (but not quite overlapping) the 
transcript KU-MEL-3. Such long non-coding transcripts have been found to play a role in 
various cellular processes, including regulation of transcription and gene expression [708], 
and so variants located inside or adjacent to transcribed regions may be of interest. 
Although this gene did not appear on the Locuszoom plot (presumably because it is an RNA 
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gene – the sequence of DNA from which a non-coding RNA is transcribed), its position at 
6:4610846-4612153 indicates that rs12204701 is in high LD with it. 
 
Figure 5.11: HapMap figure of rs12204701 +/-500Kb, including nearby Entrez genes and dbSNP 
SNPs 
 Power calculations 5.3.5
As shown by Figure 5.12, with the sample size used in the 3-month diet response GWAS 
(238 subjects), only common variants (marker allele frequency approximately 0.1 to 0.2) 
with a relative risk of approximately 3-4 could be detected with 80% power, assuming a co-
dominant penetrance model; on the other end of the spectrum, assuming a recessive 
penetrance model, the marker allele frequency would have to be at least 0.45 to detect a 
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variant with a relative risk of around 6. 
 
Figure 5.12: Detectable relative risk and disease allele frequency curves for 3-month KD response 
cohort, with 80% power, assuming r2  of 0.9 between genotyped marker and causal variant, a 
disease prevalence of 0.5%, alpha=1.00x10-7, 116 cases and control:case ratio of 1.01. Black 
line=recessive model, orange line=dominant model, purple line=co-dominant model 
 
As shown in Figure 5.13, assuming a co-dominant or dominant genetic model, a sample size 
of approximately 2000 would have 80% power to detect variants with allele frequency 0.2 
and relative risk of 1.4; a much larger sample size of approximately 14000 would be needed 
to detect variants with the same allele frequency and relative risk, assuming a recessive 
genetic model. Larger sample sizes would be needed to detect variants of lower allele 
frequency or lower relative risk. 
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Figure 5.13: Power and sample size curves, using a recessive model (black line), dominant model 
(orange line) and co-dominant model (purple line), assuming r2=0.9 between genotyped marker 
and causal variant, a disease prevalence of 0.5%, disease and marker allele frequencies of 0.2 and 
relative risk of 1.4, alpha=1.00x10-7 and a control to case ratio of 1.4  
 
 Gene- and pathway- based analyses 5.3.6
A significance threshold of 2.59x10-6 (0.05/19291) and a suggestive significance threshold 
of 5.18x10-5 (1/19291) was set for the gene-based tests. A significance threshold of 
3.79x10-5 (0.05/1320) and a suggestive significance threshold of 0.00076 (1/1320) was set 
for the pathway-based tests. 
No gene or pathway reached significance or suggestive significance either in the 3-month 
or summary KD response analyses.   
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Nine genes had the lowest p-value (p=0.000999) in the 3-month KD response analysis and 
12 genes in the summary KD response analysis (p=0.000999). These genes are given in 
Table 5.1, along with their associated GO terms and pathways, as identified from the online 
DAVID database and Gene Cards (www.genecards.org).  
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Table 5.1: Genes with lowest p-values in 3-month and summary KD response gene-set analysis 
Gene 
abbreviation 
Gene name GO Biological Process GO Molecular Function 
Associated 
Pathways 
Genes with lowest p-value in 3-month KD response analysis 
ARRB2 
arrestin, beta 
2 
endocytosis, receptor-mediated endocytosis, cell surface receptor linked signal 
transduction, enzyme linked receptor protein signalling pathway, transmembrane 
receptor protein serine/threonine kinase signalling pathway, transforming growth 
factor beta receptor signalling pathway, sensory perception, membrane 
invagination, membrane organization, vesicle-mediated transport, receptor 
internalization, receptor metabolic process, neurological system process, cognition 
KEGG pathways: MAPK 
signalling pathway, 
Chemokine signalling 
pathway, Endocytosis, 
Olfactory transduction, 
PANTHER pathways: 
Heterotrimeric G-protein 
signalling pathway-Gi alpha 
and Gs alpha mediated 
pathway, Inflammation 
mediated by chemokine and 
cytokine signalling pathway, 
Wnt signalling pathway, 
Angiotensin II-stimulated 
signalling through G 
proteins and beta-arrestin 
- 
C10orf68 
chromosome 
10 open 
reading frame 
68 
Not found 
Associated with Alzheimer's disease (http://www.genecards.org) 
C19orf35 
clathrin, 
heavy chain-
like 1 
Not found 
Uncharacterised protein 
CLTCL1  
intracellular protein transport, endocytosis, receptor-mediated endocytosis, protein 
localization, membrane invagination, protein transport, membrane organization, 
vesicle-mediated transport, cellular protein localization, establishment of protein 
localization, intracellular transport, cellular macromolecule localization 
structural molecule activity 
KEGG pathways: 
Lysosome, 
Endocytosis, 
Huntington's 
disease.  
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PANTHER 
pathways: 
Heterotrimeric G-
protein signaling 
pathway-Gi alpha 
and Gs alpha 
mediated 
pathway, 
Heterotrimeric G-
protein signaling 
pathway-Gq alpha 
and Go alpha 
mediated 
pathway. 
REACTOME 
pathways: Gap 
junction 
trafficking and 
regulation, 
FCN1 
ficolin 
(collagen/fibri
nogen domain 
containing) 1 
immune effector process, ion transport, phosphate transport, anion transport, 
endocytosis, phagocytosis, immune response, opsonization, membrane 
invagination, inorganic anion transport, membrane organization, vesicle-mediated 
transport 
antigen binding, calcium ion 
binding, sugar binding, 
carbohydrate binding, ion 
binding, cation binding, 
metal ion binding 
- 
MPO 
myeloperoxid
ase 
response to reactive oxygen species, oxygen and reactive oxygen species metabolic 
process, antiapoptosis, defense response, response to oxidative stress, response to 
inorganic substance, regulation of cell death, cellular response to stress, 
macromolecular complex remodeling, protein-lipid complex remodeling, plasma 
lipoprotein particle remodeling, low-density lipoprotein particle remodeling, cellular 
response to oxidative stress, cellular response to reactive oxygen species, response 
to hydrogen peroxide, hydrogen peroxide metabolic process, hydrogen peroxide 
catabolic process, regulation of apoptosis, negative regulation of apoptosis, 
regulation of programmed cell death, negative regulation of programmed cell death, 
macromolecular complex subunit organization, oxidation reduction, negative 
regulation of cell death, cellular response to hydrogen peroxide 
chromatin binding, 
peroxidase activity, iron ion 
binding, calcium ion binding, 
antioxidant activity, 
oxidoreductase activity, 
acting on peroxide as 
acceptor, heme binding, ion 
binding, cation binding, 
metal ion binding, 
tetrapyrrole binding, 
transition metal ion binding 
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RAB20 
RAB20, 
member RAS 
oncogene 
family 
intracellular signalling cascade, small GTPase mediated signal transduction, protein 
localization, protein transport, establishment of protein localization 
nucleotide binding, GTP 
binding, purine nucleotide 
binding, guanyl nucleotide 
binding, ribonucleotide 
binding, purine 
ribonucleotide binding, 
guanyl ribonucleotide 
binding 
- 
SLC12A8 
solute carrier 
family 12 
(potassium/ch
loride 
transporters), 
member 8 
ion transport, cation transport, potassium ion transport, monovalent inorganic 
cation transport, metal ion transport, transmembrane transport 
symporter activity, 
potassium ion binding, 
chloride ion binding, alkali 
metal ion binding, ion 
binding, anion binding, 
cation binding, metal ion 
binding 
- 
XPO1 exportin 1 
protein import into nucleus, docking, RNA localization, protein complex assembly, 
protein targeting, protein import into nucleus, protein export from nucleus, 
intracellular protein transport, nucleocytoplasmic transport, protein localization, 
response to virus, regulation of catabolic process, regulation of cell cycle process, 
regulation of centrosome duplication, protein transport, nucleobase, nucleoside, 
nucleotide and nucleic acid transport, protein import, regulation of microtubule-
based process, regulation of organelle organization, protein localization in organelle, 
protein localization in nucleus, cellular protein localization, cellular macromolecular 
complex subunit organization, cellular macromolecular complex assembly, 
regulation of protein catabolic process, cellular protein complex assembly, 
macromolecular complex subunit organization, establishment of protein 
localization, regulation of centrosome cycle, intracellular transport, nucleic acid 
transport, RNA transport, mRNA transport, nuclear export, nuclear transport, 
nuclear import, establishment of RNA localization, regulation of cytoskeleton 
organization, regulation of cell cycle, macromolecular complex assembly, protein 
complex biogenesis, regulation of microtubule cytoskeleton organization, cellular 
macromolecule localization 
RNA binding, protein 
transporter activity 
REACTOME 
pathways: Cell 
Cycle, Mitotic, 
Influenza 
Infection, HIV 
Infection 
Genes with lowest p-value in summary KD response analysis 
C10orf68 
chromosome 
10 open 
Not found 
Associated with Alzheimer's disease (http://www.genecards.org) 
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reading frame 
68 
CAMTA2 
calmodulin 
binding 
transcription 
activator 2 
muscle system process, transcription, regulation of transcription, DNA-dependent, 
regulation of transcription from RNA polymerase II promoter, positive regulation of 
biosynthetic process, positive regulation of macromolecule biosynthetic process, 
positive regulation of macromolecule metabolic process, positive regulation of gene 
expression, cardiac muscle adaptation, striated muscle adaptation, muscle 
hypertrophy, striated muscle hypertrophy, cardiac muscle hypertrophy, positive 
regulation of cellular biosynthetic process, muscle adaptation, regulation of 
transcription, positive regulation of transcription, DNA-dependent, positive 
regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process, 
positive regulation of transcription, positive regulation of transcription from RNA 
polymerase II promoter, positive regulation of nitrogen compound metabolic 
process, regulation of RNA metabolic process, positive regulation of RNA metabolic 
process 
chromatin binding, 
calmodulin binding, 
transcription factor binding, 
enzyme binding, 
transcription regulator 
activity, histone deacetylase 
binding 
- 
CHRNG 
cholinergic 
receptor, 
nicotinic, 
gamma 
muscle system process, ion transport, cellular ion homeostasis, muscle contraction, 
cellular homeostasis, regulation of membrane potential, homeostatic process, 
chemical homeostasis, ion homeostasis, cellular chemical homeostasis 
ion channel activity, 
extracellular ligand-gated 
ion channel activity, cation 
channel activity, channel 
activity, ligand-gated ion 
channel activity, 
acetylcholine receptor 
activity, passive 
transmembrane transporter 
activity, ligand-gated 
channel activity, gated 
channel activity, substrate 
specific channel activity, 
neurotransmitter receptor 
activity, neurotransmitter 
binding, acetylcholine 
binding, amine binding, 
metal ion transmembrane 
transporter activity 
PANTHER 
pathway: Nicotinic 
acetylcholine 
receptor signaling 
pathway 
ENO3 enolase 3 monosaccharide metabolic process, glucose metabolic process, glucose catabolic magnesium ion binding, KEGG pathways: 
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(beta, muscle) process, generation of precursor metabolites and energy, glycolysis, aging, response 
to wounding, carbohydrate catabolic process, hexose metabolic process, hexose 
catabolic process, regeneration, growth, wound healing, tissue regeneration, 
response to drug, skeletal muscle regeneration, cellular carbohydrate catabolic 
process, alcohol catabolic process, monosaccharide catabolic process, 
developmental growth 
phosphopyruvate hydratase 
activity, hydro-lyase activity, 
identical protein binding, 
protein homodimerization 
activity, ion binding, cation 
binding, metal ion binding, 
protein heterodimerization 
activity, protein 
dimerization activity 
Glycolysis / 
Gluconeogenesis, 
RNA degradation. 
PANTHER 
pathways 
:Glycolysis, 
REACTOME 
pathways: 
Integration of 
energy 
pathways, 
Metabolism of 
carbohydrates, 
Diabetes 
pathways 
HHLA2 
HERV-H LTR-
associating 2 
No associated Biological Process or Molecular Function 
Encodes a protein that is thought to regulate 
cell-mediated immunity by binding to a receptor on T lymphocytes and inhibiting 
the proliferation of these cells (http://www.genecards.org) 
-  
INCA1 
inhibitor of 
CDK, cyclin A1 
interacting 
protein 1 
negative regulation of cell proliferation, negative regulation of cyclin-dependent 
protein serine/threonine kinase activity, positive regulation of apoptotic process 
cyclin-dependent protein 
serine/threonine kinase 
inhibitor activity, cyclin 
binding, protein binding 
- 
LOC10065284
6 
uncharacteris
ed 
LOC10065284
6 
Not found 
OR10J5 
olfactory 
receptor, 
family 10, 
subfamily J, 
member 5 
cell surface receptor linked signal transduction, G-protein coupled receptor protein 
signaling pathway, sensory perception, sensory perception of chemical stimulus, 
sensory perception of smell, neurological system process, cognition 
olfactory receptor activity 
REACTOME 
pathways: 
Signalling by 
GPCR. 
KEGG pathways: 
Olfactory 
transduction 
PFN1 profilin 1 embryonic epithelial tube formation, neural tube formation, neural tube closure, actin binding, cytoskeletal KEGG pathways: 
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morphogenesis of an epithelium, regulation of transcription, DNA-dependent, 
regulation of transcription from RNA polymerase II promoter, cytoskeleton 
organization, embryonic development ending in birth or egg hatching, primary 
neural tube formation, morphogenesis of embryonic epithelium, neural tube 
development, actin filament-based process, actin cytoskeleton organization, tube 
lumen formation, tube morphogenesis, tube development, chordate embryonic 
development, regulation of transcription, embryonic morphogenesis, tissue 
morphogenesis, regulation of RNA metabolic process, epithelium development, 
epithelial tube morphogenesis, tube closure 
protein binding, Ras GTPase 
binding, Rho GTPase 
binding, enzyme binding, 
small GTPase binding, 
GTPase binding, proline-rich 
region binding 
Regulation of 
actin 
cytoskeleton, 
PANTHER 
pathways: 
Cytoskeletal 
regulation by Rho 
GTPase, 
REACTOME 
pathways: 
Hemostasis 
REPS2 
RALBP1 
associated Eps 
domain 
containing 2 
protein complex assembly, cell surface receptor linked signal transduction, enzyme 
linked receptor protein signalling pathway, transmembrane receptor protein 
tyrosine kinase signalling pathway, epidermal growth factor receptor signalling 
pathway, macromolecular complex subunit organization, macromolecular complex 
assembly, protein complex biogenesis 
calcium ion binding, ion 
binding, cation binding, 
metal ion binding 
- 
SHFM1 
split 
hand/foot 
malformation 
(ectrodactyly) 
type 1 
double-strand break repair via homologous recombination, recombinational repair, 
DNA metabolic process, DNA repair, double-strand break repair, DNA 
recombination, proteolysis, response to DNA damage stimulus, cellular response to 
stress 
peptidase activity 
KEGG pathways: 
Proteasome, 
Homologous 
recombination 
ZNF273 
zinc finger 
protein 273 
transcription, regulation of transcription, DNA-dependent, regulation of 
transcription, regulation of RNA metabolic process 
DNA binding, zinc ion 
binding, ion binding, cation 
binding, metal ion binding, 
transition metal ion binding 
- 
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The PID ‘PRL (protein of regenerating liver) Signalling events’ pathway generated the 
lowest p-value in the 3-month KD response analysis (p=0.0019) and the summary KD 
response analysis (p=0.00099).   
The PID PRL Signalling events pathway is within the pathway category ‘Tyrosine-specific 
phosphatase mediated signalling pathways’. It contains the following genes: AGT, ATF5, 
BCAR1, CCNA2, CCNE1, CDK2, CDKN1A, EGR1, ITGA1, ITGB1, MAPK1, MAPK3, PTP4A1, 
PTP4A2, PTP4A3, RABGGTA, RABGGTB, RAC1, RHOA, RHOC, ROCK1, SRC and TUBA1B. A 
snapshot of the pathway (the whole pathway is very large) is given in Figure 5.14. 
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Figure 5.14: A Snapshot of the Protein Interaction Database PRL Signalling events pathway, taken 
from http://pid.nci.nih.gov. 
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5.4 Discussion 
Key findings: 
 The A allele in rs12204701 was significantly associated with unfavourable KD 
response in the 3-month diet response Fisher’s exact test. This result is difficult to 
interpret.  
 No significant results were obtained from the summary KD response single-SNP 
GWAS. This was most likely due to a lack of power to detect genotypic-phenotypic 
associations, even from common variants, due to the small sample size. 
 SNPs of suggestive significance were within or in LD with genes that have a 
biologically plausible function with regards KD response. 
 Gene and pathway-based analyses have highlighted some areas of interest, in 
particular regulation of cell survival/apoptosis.  
 Different genes may affect KD response in the short- and long-term, although these 
genes may play similar roles and participate in the same pathways.  
 Replication is needed with a larger sample size. 
 Significant results  5.4.1
The difficulty with interpreting the importance of the association of rs12204701 with 3-
month KD response is that this SNP is located in a non-coding region and has no obvious 
function. Only 7% of SNPs previously found to be associated with a disease or trait in GWAS 
are located in protein-coding regions [649, 650]. Non-coding SNPs may alter expression of 
genes, rather than altering the protein-coding sequence or protein structure, presumably 
via transcription factor binding (variants that affect the ability of a transcription factor to 
bind to DNA) or by influencing gene splicing [709]. It is of interest that rs12204701 is 
located in the vicinity of, and is in strong LD with the lincRNA KU-MEL-3 - a non-coding 
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transcript of >200 nucleotides length, which has been found to regulate gene expression 
[710, 711]. An association analysis of rs12204701 with (potentially tissue-specific) 
expression levels of KU-MEL-3 would confirm any effect of these SNPs on the gene, as has 
been recently done with a range of lincRNAs [710]. 
rs12204701 is located close to CDYL in a region rich with recombination hot spots, where 
the LD structure is broken down.  Furthermore, as a potential housekeeping gene that 
interacts with many different proteins, it is difficult to determine exactly how CDYL may 
influence KD response. It is of interest that CDYL is involved in the repression of 
transcription of genes, such as the proto-oncogene TrkC, which is important for 
suppression of cellular transformation [703]. Also, nearby SNPs, located between KU-MEL-3 
and CDYL, have been associated with phenotypic traits relevant to metabolism of high-fat, 
low-carbohydrate diet: cholesterol levels [712] and susceptibility to Type II diabetes [713]. 
rs12204701 may tag other SNPs or even copy number variants that may influence KD 
response. It may, of course, be the case that rs12204701 does not regulate its most nearby 
gene; for example, expression of genes, such as GLI3 and PAX6, are at least partly regulated 
by cis elements distant from the gene itself [717]. 
The lack of significant results in the summary KD response GWAS is likely because of the 
lack of power – the sample size was even smaller than in the 3-month response GWAS. 
Most associations discovered from GWAS have effect sizes of 1.1–1.4 [714] and large 
sample sizes are required to detect associations with an odds ratio of 1.5–2 [715]. It may 
also be the case that causal/influential variants or genes are not in high LD with, or 
adjacent to genotyped variants, which further reduces the power to detect an association 
[716].  
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Another alternative is that causal/influential variants, despite being in LD with genotyped 
variants, have such small effect sizes that they do not reach statistical significance. These 
are most likely to be intermediate/rare variants [716], which will be explored in Chapter 6. 
Variants with small effect sizes may not have immediate implications for clinical practice, 
but may further understanding of the mechanisms behind the antiepileptic effects of the 
KD.  
Other elements of GWAS methodology, such as the fact that SNPs are tested in isolation 
and that individuals have different environmental pressures acting on them, mean that 
associations may be missed if they are dependent on gene-gene or gene-environment 
interactions. Grouping SNPs together into sets may be a powerful way of detecting 
associations that would not otherwise be detected; by itself, an individual SNP may have a 
small effect on the phenotype but, in combination with other SNPs (which may all be in LD 
with the causal/influential variant), it may have a larger effect [718]. In this study, gene- 
and pathway-based approaches were also underpowered, as they were based on single 
SNP results. In combination with the single SNP approach, however, they did highlight 
some biologically plausible themes of interest.  
The fact that different SNPs had the lowest p-values in the two GWAS (for example, 
rs12204701 did not even reach suggestive significance in the summary KD response GWAS) 
indicates that different variants/genes may play a greater role in influencing short-time KD 
response, whereas others come into play with more long-term response. Specific gene 
expression changes may materialise after different time periods following the onset of 
dietary treatment. It is not necessarily the case that taking KD response at a particular point 
in time is more or less accurate than the summary diet response phenotype (although, of 
course, an individual who achieves seizure reduction during the first three months on the 
KD may not maintain this seizure control during the subsequent three months) – they are 
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different models, both of which may help with understanding different aspects of the 
relationship (if any) between genetics and KD response. If a sufficiently large cohort was 
recruited (>2000 participants, according to power analyses), with long-term follow-up for 
as many patients as possible, appropriately-powered GWAS could be conducted using KD 
response at 3-, 6-, 12-, 18- and 24-month+ follow-up, in addition to a summary diet 
response model.  This would allow investigators to better determine whether different 
variants/genes are relevant for KD response in the short- and long-term and, if so, at which 
point specific variants/genes cease to be relevant. 
 Potential sources of error 5.4.2
5.4.2.1 Phenotypic  
As outlined in Chapter 3, the classification of individuals into responders and non-
responders is somewhat arbitrary. Ideally, there would be standardised phenotypic criteria 
for defining KD response, such as the McDonald criteria for multiple sclerosis [719], but in 
this study, a seizure frequency threshold that is viewed as meaningful in clinical practice 
was used. Individuals or their parent/guardian(s) may have different definitions of what is 
clinically-significant for them, but ‘personalised’ definitions of response would make inter-
individual comparisons very difficult. Furthermore, unless prospective data are specifically 
collected for research purposes, one is limited by the data available: for example, the only 
quantitative measure of response recorded in the study sites was seizure frequency and, in 
most cases, even this measure was not recorded on a daily basis. The measurement error, 
potentially introduced when relying on clinic letters for information, could have been 
reduced by more widespread use of seizure diaries, perhaps enabling use of a quantitative 
phenotype. This would have increased power to detect associations [720], and may have 
had a more interpretable outcome.  
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As there is no consistent evidence for an effect of any clinical or demographic factors on KD 
response, either in the literature or in our cohort (as outlined in Chapter 3), none were 
included as covariates. The inclusion of known covariates in GWAS may reduce power for 
detecting associations, depending on the prevalence of the trait being studied [722]. It is, of 
course, possible that other unknown, non-genetic covariates have led to Type I or Type II 
error. 
5.4.2.2 Genotypic  
The Illumina chip provides high coverage across the genome and powerful tag SNPs. With 
the exception of replicate genotyping of the same subjects, standard measures were taken 
to avoid genotyping errors and systematic bias, which decrease the power for detecting 
associations. For example, exclusion of SNPs with significant deviation from HWE, as well as 
low quality genotype calls, aims to reduce Type I error [723]. Due to the lack of precise 
guidelines for cut-off values for quality control variables in GWAS, these could be 
considered somewhat arbitrary and they do vary between studies. Bearing in mind 
thresholds used in other epilepsy GWAS, as well as the small sample size in this study, the 
effects of each variable was considered with the aim of striking a balance between 
maintaining only high-quality data without removing genuine phenotype-genotype 
associations. Potential bias due to batch effects was also considered. Changes in the 
number of samples in each batch (sample size affects the error involved in genotype calling 
for SNPs, particularly those of low MAF) and batch composition (in terms of proportions of 
cases and controls, and samples from different ethnic groups) may affect genotype calls 
[724]; discordant results may arise from varying probe synthesis efficiency between 
batches [725]. DNA concentrations may also differ between batches, or depending on the 
technique used for DNA extraction (two techniques are used at GOSH - Autogen and 
FujiFilm - and another is used in Melbourne, which is based on the same technology as 
Autogen [FlexiGene]), but preparation of all DNA samples to a specific concentration should 
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have ensured homogeneity. Although not comparing FlexiGene and filtration technologies 
specifically, various DNA extraction techniques have been found to perform similarly in 
terms of quantity and quality of the final DNA product [726]. Another potential contributor 
to batch effects - different DNA sources - was not applicable in this study, as all DNA was 
extracted from capillary blood. MDS plots showed that, even if there were differences in 
the data (for example, due to recruitment site or processing batch), these effects were 
random with respect to responder/non-responders status. 
It is well-cited that population stratification may lead to cofounding in GWAS. In the 
context of the KD, controlling for population stratification may be particularly important, as 
there may be a selection advantage against starvation in particular ethnic groups – 
responsiveness of the pancreas to exogenous glucose load, minimising postprandial 
excretion of glucose into the urine and favouring the storage of calories as fat, due to 
repeated exposure to periods of food shortage throughout history [727]. This ‘thrifty gene’ 
hypothesis has been suggested as an explanation why aboriginal populations, such as 
Native Americans, now have increased levels of obesity and increased risk of Type II 
diabetes and atherosclerosis [728, 729]; the genetic propensity to store excess calories as 
fat may be advantageous in situations of feast or famine, but not in the face of increased 
food availability and a more sedentary lifestyle. This genetic propensity may be beneficial in 
the context of KD diet-feeding. 
The fact that λGC was 1.00 in both GWAS models suggests absence of importance of 
population stratification in this cohort. The notion of GC inflation assumes that the loci 
have roughly equal mutation rates and equal deviation from HWE and that existing 
population structure has a uniform influence throughout the entire genome. This 
disregards the fact that the genetic architecture of an individual is often an admixture of 
various genetic backgrounds [624], as well as SNP-specific differences [639]. λGC is thought 
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to adequately correct for population structure if enough loci (≥500 markers) are used to 
estimate the correction factor [730]. The number of markers used in this study was well 
above 500. The quantile-quantile plots also showed almost no deviation from the null 
across the entire distribution, which indicates lack of undetected population stratification 
or any other systematic differences in the data that may confound association studies, such 
as batch effect.  
Ideally, non-Caucasians would have been excluded from recruitment in the first place to aid 
the creation of a homogenous sample set. However, this would have been practically 
difficult and self-reported ethnicity may not always be accurate – individuals may not be 
aware of their own ethnic admixture.  
Appropriate statistical correction for multiple testing was undertaken in this study to avoid 
Type I error: the gold-standard, permutation, as well as Moskvina’s effective number of 
tests method.  
The effects of environmental factors may be an issue, although only extreme circumstances 
would result in changes in allele frequency in either cases or controls [639]. The population 
groups in this study were not selected based on specific demographic factors (aside from 
adherence to KD treatment), which may skew allele frequencies due to other factors. Take, 
for example, the selection of smokers as cases in a study - where allele frequencies may be 
affected by selection for nicotine addiction [639]. 
 SNPs of suggestive significance 5.4.3
The SNPs of suggestive significance are within genes or in the same LD block as genes with 
roles that could be relevant to KD response. 
For example, it is biologically plausible that variants that affect PARP1 function could 
influence KD response. PARP1 has been implicated in the pathogenesis of diabetes mellitus 
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[731-733]; PARP1 activation (percentage of PARP-positive endothelial nuclei) was higher in 
individuals with Type II diabetes and in those with a family history of diabetes compared 
with controls [734]. The protein has been associated with diabetes-related complications, 
including endothelial dysfunction [735] and neuropathy [736, 737]. Variants in PARP1 have 
also been associated with melanoma [738], Alzheimer’s disease susceptibility [739] and 
protection against Parkinson’s disease [740] (although there is conflicting evidence for the 
latter [741]). Inhibition of PARP1 has been shown to be neuroprotective in models of 
cerebral ischaemia [742-744], in vivo Parkinson's disease model [745] and soman-induced 
seizure-related brain damage [746]. Potential neuroprotective mechanisms include 
improved neuronal conductance, reduction of cell death and reduction of ATP depletion 
[747]. The PARP1 protein regulates the production of inflammatory mediators, such as 
inducible nitric oxide synthase, potentially through interaction with NFᴋB; PARP1 is thought 
to be a coactivator of transcription factors that regulate such immune and inflammatory 
response genes. It is also a substrate of caspases, mediating apoptotic and necrotic cell 
death [748]. The role of PARP1 in mediating the death of pancreatic β-cells may be the 
reason for its association with diabetes [749]. Both antiinflammatory effects and 
prevention of neuronal cell death are postulated mechanisms of action for the antiepileptic 
effects of the KD, as outlined in Chapter 1. It is feasible that variants affecting any of these 
PARP1 functions may affect response to the KD. The fact that rs12402021 is supported by 
nearby SNPs in high LD provides further reassurance that this result is not an artifact. This 
is, however, debatable: if one SNP is associated with a trait by chance, then another SNP in 
LD with the first SNP may also be associated by chance. 
Interpretation of the importance of ABLIM2 with regards KD response is difficult, as little is 
known about its function. Highest expression of ABLIM2 has been observed in the brain 
and eyes [706]; others have found it to be most highly expressed in skeletal muscle, with 
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slightly lower levels in the brain (mostly in the caudate/putamen and hippocampus) [750]. 
ABLIM2 binds strongly to F-actin and interacts with striated muscle activator of Rho 
signalling (STARS) in order to enhance STARS-dependent activation of serum response 
factor. It has been suggested that (in muscle), ABLIM2 is involved in cellular adaptation to 
biomechanical stress and (in the brain), it is involved in delivering signals toward the actin 
cytoskeleton. The C. elegans homologue of ABLIM proteins, Unc115, has been shown to 
participate in neuron guidance [751-753]; due to its tissue-specificity, it has been 
speculated that the protein plays the same role in humans [750].  
PAX3 is required for normal development of the embryo and mutations in the gene are 
associated with Waardenburg syndrome, characterised by craniofacial and limb 
abnormalities, deafness and pigmentation of the skin, hair and iris [754, 755]. The gene 
encodes a transcription factor that plays a role in the development of the neural tube and 
peripheral nervous system, leading to cell proliferation in the brain and differentiation of 
specific cell types [707, 756, 757]. Bone morphogenetic protein [758], Wnt [759] and Sonic 
hedgehog signalling [760] have been shown to be involved in controlling PAX3 expression; 
different factors may be involved as development progresses [707]. PAX3 is located within 
a region that has been linked with juvenile myoclonic epilepsy [761] and expression of the 
gene is upregulated in high-grade glioma tissues compared to low-grade and normal brain 
tissues, and expression increases as the grade of the tumour increases and patient survival 
rate decreases [762]. It is unknown exactly how mutations in PAX3 may influence KD 
response, but the fact that this gene is involved in brain development and implicated in 
brain abnormalities suggests that it is a biologically plausible candidate.    
 Gene- and pathway-based analyses 5.4.4
No statistically significant results were obtained from gene or pathway analyses and many 
genes generated the lowest p-value in both 3-month and summary KD response analyses. A 
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higher number of permutations could have been undertaken to obtain p-values that were 
accurate to a greater number of decimal places, but the computational cost of this would 
be large. Furthermore, it is likely that more than one gene is responsible for variability in 
KD response, and that some have greater effects on KD response, compared to other 
genes. Some common themes were present amongst the functions of the genes with the 
lowest p-values: cell cycling, neurological processes, immune/stress response, glucose 
metabolism, ion and cation binding/transport and GTP or GTPase binding/regulation. Most 
genes were different in the 3-month and summary KD response lists, although the same 
themes pervaded. The only gene that did overlap was C10orf68, which is of unknown 
function, but is located within a region that has been associated with late-onset Alzheimer 
disease [763].  
The fact that many genes generated equally low p-values in the set-based tests, together 
with the fact that several common themes can be identified amongst their functions, 
indicates that investigation of pathways may be more fruitful than investigation of single 
genes. This section will therefore concentrate on the pathway with the lowest p-value in 
the 3-month and summary KD response analyses (PRL signalling events).  
PRL proteins, which consist of PRL1, PRL2 and PRL3, are a protein tyrosine phosphatase 
subfamily, which are ROS effector proteins (they are reversibly oxidized by ROS) [764]. PRLs 
are thought to play a role in cell growth, proliferation, migration and invasion [765, 766], 
potentially by increasing expression of cyclins that are critical for cell cycle transitions [767]. 
PRL1 was found to be mainly localised in the brain and muscle, with increased expression in 
the cerebral cortex following ischaemia [768], PRL2 was found mainly in skeletal muscle, 
and PRL3 in cardiac and skeletal muscle [769]. PRLs are thought to promote tumorigenesis 
and metastasis, and overexpression of PRLs, in particular PRL3 and PRL1, has been 
frequently found in tumour tissues and metastatic human cancers [764]. When PRLs are in 
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their reduced state (not oxidised), their phosphatase activity is active and they may 
promote cancer metastasis; when oxidised by ROS, their phosphatase activity is inhibited 
and so metastasis is not promoted. It is unknown exactly how PRLs regulate metastasis, 
and they may exert their effects via various pathways [770]. PRL activation has been found 
to stimulate the PI3K/AKT pathway, which has an antiapoptotic effect [771], as well as 
stimulating phosphorylation of mTOR, which is mediated by PI3K/AKT (PI3K activates 
serine/threonine protein kinase AKT, which then activates mTOR), and regulates the start 
of translation and entry into the cell cycle [772]. PRL can activate the ERK1/2 pathway, 
which is involved in cell survival and proliferation [773], by interacting with integrin β1. 
Others have reported that PRL3 exerts its effects via regulation of the Rho family GTPase 
[774, 775], activation of Src [776] or janus tyrosine kinases (JAKs) [777].   
This pathway could feasibly contribute to the antiseizure effects of the KD and thus genetic 
variation that affects this pathway could account for variability in KD response. The 
biological functions highlighted in the PRL pathway (integrins/cell cycling/regulation of 
survival and apoptosis) have many implications. Through binding of integrins to signalling 
intermediaries such as SRC and PI3K, which in turn increases tyrosine phosphorylation and 
signalling through RAS, RAF, MEK, and small GTPases (such as Rho and Rac), a wide variety 
of basic cellular functions are influenced, including cell cycling, gene expression and cell 
survival [778]. There are a plethora of brain-specific functions that could be relevant in this 
cohort of people with drug-resistant epilepsy: for example, integrins are thought to be 
involved in stabilising long-term potentiation and synaptic function [778]; the MAPK 
pathway is known to play a role in survival of neurons [779, 780]; dysregulation of SRC 
family kinases has been said to contribute to epileptogenesis by regulating ion channel 
activity and synaptic transmission [781, 782]; cell cycle regulators have been found to be 
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necessary for neuronal cell death in response to injury and disregulation of the cell cycle in 
neurons has also been associated with epilepsy [783].  
Furthermore, these pathways have been shown to regulate insulin sensitivity and thus 
contribute to glucose homeostasis: the PI3K/AKT has been said to regulate cell 
survival/death via its effects on glucose uptake (promoting the translocation of glucose 
transporters to the cell membrane) and metabolism (stimulating activity of hexokinase, the 
first enzyme in the glycolytic pathway) [784, 785]; the MAPK family member ERK is needed 
for increased glucose uptake and glycolysis during T cell activation (this is for the survival, 
proliferation and cytokine production of activated T cells) [786]; SRC inhibition has been 
shown to decrease insulin-induced glucose uptake [787]; the Rho family GTPase RAC1 has 
been implicated in the regulation of insulin-dependent glucose uptake and shown to 
influence insulin-dependent translocation of GLUT4 to the cell membrane in skeletal 
muscle cells [788-790]. These results suggest that genetics may play a role in KD response, 
but they do not point to a single mechanism of action that is responsible for variability of 
KD response in this cohort. 
Aside from the general nature of these categories, the results of the pathway analyses do 
not give any information on the direction of the effect on KD response. P-values are 
derived from the single-SNP analyses, which simply reflect a difference in frequency of 
variants between responders and non-responders. It may be that some genes in the PRL 
signalling events pathway have a favourable effect on KD response, whilst others have a 
detrimental effect.   
Another point to consider when interpreting the results of gene- and pathway-based 
analyses is that, when using technology such as the Illumina chip, one is limited by the 
content of the array. Arrays aim to provide genome-wide coverage, but not coverage 
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within every gene. In these analyses, variants were only assigned to a gene if they fell 
within the gene or its transcript. The benefit of this is that one can be confident that these 
variants are associated with the ‘correct’ gene (if variants are present in an LD region in 
which there are many genes, this complicates assignment to a gene) and their functional 
consequence is easier to interpret. The disadvantage is that many potentially useful 
intergenic variants are excluded. One may use certain programmes to assign GWAS SNPs to 
genes, but these assignments are not certain and are often based on pre-existing 
knowledge about genes/variants associated with the phenotypic trait. Furthermore, 
interpretation of the functional consequences of such (predominantly non-coding) variants 
is often problematic. Use of sequencing data, in which (subject to error) every variant 
present is captured, eliminates this bias. Sequencing data could also be used for gene-
based tests that assume a uni-directional effect of variants. This would help to determine 
the direction of effect of certain genes, which may lie within a certain pathway.      
Different definitions and classifications of pathways may generate different results. For 
example, in a previous study, one over-represented pathway was the PANTHER pathway 
‘inflammation’, which included 315 genes [702]. When using other pathway definitions, 
these 315 genes were divided up into smaller pathways that were related to inflammation. 
To avoid such bias, it is important to use a range of pathway definitions and to explore the 
top associated pathways to determine whether they can be linked together. Results also 
depend on the algorithm used, for example, whether the SNP with the lowest p-value is 
used as the set-wide p-value or an average of all SNP p-values in the set. In order to avoid 
potentially biased application of any one algorithm, one may use a variety of approaches 
and compare those genes or pathways that overlap [665]. The number of algorithms one 
uses is obviously time-dependent and could easily be adopted as a topic of focus by itself.  
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 Conclusions and future work 5.4.5
rs12204701 was significantly associated with KD response at the 3-month point, but no 
significant results were obtained from the summary KD response single-SNP GWAS. These 
GWAS were underpowered to detect phenotypic-genotypic associations, even for variants 
of MAF>0.05 and large effect sizes, and so it cannot be confirmed that other common 
variants do not influence KD response. Some variants with the lowest p-values are of 
interest due to their proximity (and LD patterns) to genes associated with metabolic and/or 
neurological processes. The fact that different results were obtained in the various GWAS 
suggests that different variants and genes may be relevant to KD response in the short-
term and long-term. Cell cycling, regulation of cell death/survival and glucose metabolism 
may be relevant to both short- and long-term KD response, although different genes may 
play more of a role in different individuals or at different time points.  
The logical next step would be a higher-powered study, achieved with a larger, ethnically-
homogenous cohort. Although this would greatly increase the duration and cost of data 
collection, in this case, a lack of statistically significant associations could not be blamed on 
a lack of power. GWAS could be conducted with KD response classified at specific time 
points (if long-term follow-up data were available for a large enough cohort) or as a 
summary of response over time. If statistically significant associations were then observed, 
the most significant variants should be tested in an independent replication cohort, ideally 
using an independent genotyping platform [654]. 
‘Missing’ SNP genotypes (those not present on the genotyping array) may be extrapolated 
by imputation using LD patterns, for example, from HapMap. The benefits of imputation 
are that it is a cost-effective way of increasing coverage, and it increases power and allows 
pooling of data from various GWAS in meta-analyses [791]. Imputation provides a higher-
resolution view of the region of interest, facilitating identification of casual SNPs [792]. 
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Other sources of structural variation can also be imputed from genotyped SNP, such as 
CNVs [792] and common small insertions and deletions (indels) [793]. Imputed missing data 
has been shown not to significantly impact on the statistical properties of the data [794], 
although it must be considered that the ability to impute a genotype for a given SNP 
depends on the accuracy of the genotyped SNPs in the region and their correlation to the 
‘missing’ SNP [791]. Particular care should be taken with rare variants, as the asymptotic 
theory may not hold and the effects of population structure may lead to false positives 
[792]. 
If a variant or gene were to be securely implicated with differential KD response (from 
GWAS with bigger sample sizes and replication of results in other cohorts), fine-mapping of 
trait-associated loci or animal models assessing the impact of knocking-down or deleting 
the region or genes in question, may aid demonstration of causality [795]. At the very least, 
evidence should be provided that the variants in question show a consistent association 
with factors that are highly correlated with KD response, such as regulation of expression of 
a gene associated with a metabolic or neurological phenotype.  
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6 Rare genetic variation and response to the 
Ketogenic diet: Illumina exome chip 
 
6.1 Introduction 
 The common disease/rare variant hypothesis 6.1.1
An alternative to the common disease/common variant hypothesis, upon which most 
GWAS are based, is that, despite the fact that most genetic variation is common, most 
disease-causing variants are rare [716]. Based on evolutionary theory, if these variants have 
a deleterious effect on fitness, there will be a negative purifying selection pressure acting 
against them. Recent studies have reported that non-synonymous single nucleotide 
variants (SNVs) with lower MAF are more likely to be non-neutral (disease-related) than 
those with higher MAF [555, 588, 796]. This is not surprising, as rare variants are most 
often present in protein-coding regions [797, 798].  
In support of the rare variant hypothesis is the fact that, even in the most successful GWAS, 
variants associated with complex diseases only tend to account for a small proportion of 
heritability [715]. This ‘missing heritability’ may be at least partly accounted for by low MAF 
or rare variants. These rare variants may not be tagged by common SNPs in GWAS as, due 
to their low MAF, they often are not in LD with common (or indeed other rare) SNPs [799]. 
Alternatively, it may be the case that other variants have not yet been found to be 
associated with disease because their effect sizes are too small to reach statistical 
significance, especially with single-SNP analyses and limited sample sizes [800]. There is 
increasing evidence that rare variants play a role in complex diseases: for example, five rare 
variants in NOD2, which act independently of one another, were found to be associated 
with Crohn’s disease risk [801-803]; rare variants that impair melatonin receptor 1B 
function were found to collectively contribute to Type II diabetes risk [804]; a rare missense 
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variant in MYH6 was found to be associated with an approximately 12-fold increase risk of 
sick sinus syndrome [805].  
An immediate difficulty that comes to mind when considering how to detect rare variant 
genotypic-phenotypic associations is the issue of sample size. The statistical power to 
detect an association is lower for rare variants than for common variants with a similar 
effect size, due to the small number of observations per variant and the higher likelihood of 
genotyping errors [796, 806]; one may thus assume that large sample sizes (larger than for 
common variants) are needed when looking at the effects of rare variants, particularly if 
the effect sizes of these variants are small [714]. It is expected, however, that rare variants 
have larger effect sizes than common variants, which may be detectable with smaller 
cohorts. As common variants tend to be older than rare variants, common variants (in 
order to remain common) must have survived purifying negative selection pressures over 
time; this is less likely to be the case if they have large deleterious functional effects, unless 
the variant is still in the process of being depleted from the population [807]. Many rare 
Mendelian and complex diseases are due to rare variants with large effect sizes [808], such 
as variants within CFTR for cystic fibrosis [809] and BRCA1 and BRCA2 for breast cancer 
[810].  
In addition to variant-pooling approaches (discussed in Chapter 5), there are various 
approaches to increasing power in rare variant association studies. These are discussed 
below.  
 Variant prioritisation: variant class 6.1.2
A common approach for increasing power in genetic association studies is to incorporate 
information from functional prediction algorithms by selecting only functional variants – 
those that are more likely to be causal – for analysis [806, 807]. This further reduces the 
multiple-testing burden. If only putatively functional variants are included in analyses, one 
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has more confidence that they have a functional effect [807]. However, distinguishing 
between variants with and without functional consequence is not an easy task, as there is 
no standard classification system used to categorise variants by predicted functionality. For 
example, non-synonymous variants may disrupt biochemical function but not necessarily 
lead to disease or influence the phenotypic trait in question; it may depend on interactions 
with other variants or genes. It must also be considered that not all protein functions are 
known and so a variant may erroneously be classified as non-susceptible.  
When trying to predict functionality of variants, a common first step is to divide them into 
variant classes according to their likelihood of altering the protein sequence or gene 
expression. Non-synonymous coding variants are primarily of interest in association 
studies: they lead to a substitution in the encoded amino acid and thus may alter the 
protein product, which may affect a phenotypic trait, and they have a lower MAF and occur 
less frequently in most protein-coding genes compared to synonymous variants [811], 
which indicates that they are under strong purifying selection [812]. Over half of the 
disease-associated variants in the Human Gene Mutation Database are non-synonymous 
[813]. 25–50% of rare (MAF<0.5%) non-synonymous variants are estimated to be 
deleterious [814]. Non-synonymous variants may be classified as missense (a variant that 
changes the encoded amino acid to another amino acid), stop-gain (a variant that changes 
a codon to a stop-codon), stop-loss (a variant that changes at least one base in a stop-
codon), indels (insertion or deletion of a number of bases; can be in multiples of three [in 
frame or non-frameshift], or not in multiples of three [frameshift]), or splice-site (a variant 
located within the region of a splice site).  
Loss-of-function variants, which have been defined as stop-gains, frameshift indels in 
coding sequences and disruptions to essential splice sites, have a high probability of being 
deleterious [815]. Stop-gains and frameshift indels that indirectly lead to a premature stop 
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codon may cause degradation of the entire transcript via nonsense-mediated decay – a 
quality control mechanism that targets and eliminates mRNAs that contain premature stop 
codons in order to reduce errors in gene expression and deleterious gain-of-function or 
dominant-negative protein products, where the gain-of-function is different from that of 
the original protein [816]. Both in highly-conserved coding regions and non-conserved 
regions, most stop-gain variants and, to a lesser extent, disruptions to splice sites, are rare 
(MAF<0.5%), indicating that these mutations can be highly deleterious, whatever the level 
of sequence conservation [814]. Coding variants that affect splicing, both within the splice 
junctions that define exon boundaries or those located near to these junctions, can lead to 
the creation of unstable mRNA and defective protein structure, or cause deleterious effects 
by altering the balance of expression of different protein isoforms produced from 
alternative splicing [817]. Variants may affect exonic splicing enhancers, which assist in 
splice-site recognition of exons and promote exon inclusion (gain of sequences), or exonic 
splicing silencers, which inhibit exon inclusion (loss of sequences). Annotation software can 
be useful for prioritising loss-of-function variants, as known stop-gain variants can be 
identified, both in exonic and exonic splicing regions. However, information may not be 
given about the effects of variants in non-coding regions, such as 3’ and 5’ UTRs, despite 
the fact that they may cause loss-of-function.  For example, functional analyses revealed 
that the c.-21C>T mutation in the 5´ UTR of CDKN2A, found in melanoma patients but not 
in controls, lead to a ‘severe’ negative impact on luciferase reporter activity, compared 
with the wild-type 5’ UTR sequence, indicating that it predisposes individuals to melanoma 
[818]. 
Furthermore, loss-of-function variants are not all deleterious: they can also have small 
phenotypic effects, for example, if they disrupt the function of a non-essential gene or a 
pseudogene [819]. The fact that a typical ‘healthy’ person bears approximately 100 loss-of-
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function variants in their genome, most of them in the heterozygote state [815], suggests 
that loss-of-function variants are often benign – stop-gain variants may lead to a truncated 
but still functional protein and functional transcripts can still be generated from alternative 
splicing; they may even be beneficial, as is the case with caspase-12 where a loss-of-
function SNP increases sepsis resistance and decreases mortality risk in hospital 
surroundings [820]. Even alternative splicing variants that affect a large proportion of the 
transcript, potentially leading to exon skipping (a type of alternative splicing, where an 
exon [a ‘cassette’ exon] is spliced out of the transcript along with its flanking introns [821]), 
may in fact partially rescue the biological function of the gene. This has been shown with 
the dystrophin gene, where exon skipping can restore the open reading frame so a 
shortened but still functional dystrophin protein is produced, leading to the milder Becker 
muscular dystrophy instead of Duchenne muscular dystrophy [822]. The deleterious effect 
of frameshift indels can be limited by nearby compensatory indels that restore the reading 
frame, or those that occur near the 3′-end of genes that have no effect on gene sequence 
or length [823]. 
The functional consequences of other non-synonymous variants are also difficult to predict. 
Approximately 20% of rare missense mutations in humans result in a loss of function, 53% 
are subject to purifying selection, and around 27% are effectively neutral [824]. In-frame 
indels are often predicted to be of neutral impact, as the reading frame is maintained. They 
can, however, be strongly deleterious when located in exons, or when the indel does not 
coincide with codon boundaries [825]; selection against exonic in-frame indels is similar to 
that against missense variants [826]. Stop-loss variants, which result in an elongated 
transcript, may be harmless or render the protein non-functional.  
Synonymous variants, which require different transfer RNAs to decode the single base pair 
changes but do not lead to a change in the encoded amino acid, tend to be considered 
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functionally neutral. However, as has been demonstrated, for example, with variants within 
ADAMTS13 [591], synonymous variants can affect protein function and expression and are 
subject to evolutionary constraint and/or conservation [590].  
Non-coding variants may also contribute to disease risk. About 10% of the non-coding 
genome is selectively constrained [579], suggesting that it is of some functional importance 
[590]. Non-coding variants may impact the genome through modulation of gene 
expression. This has been shown with a 20kb deletion, which is in high LD (r2 of 1.0) with a 
SNP that is strongly associated with Crohn’s disease (rs13361189), and which overlaps the 
promoter for the gene encoding immunity-related GTPase family M protein (IRGM), 
altering its expression [827]; the authors suggest that the association of Crohn’s disease 
and IRGM arises from changes in IRGM gene regulation, which affects the efficacy of 
autophagy. 
Intronic variants, including those within 5’ and 3’ UTRs, can act as intronic splicing 
enhancers and silencers - variants in upstream 3’ splice sites tend to inhibit splicing and 
those in downstream 5’ sites tend to enhance splicing [828]. Variants within these splicing 
regulatory elements (just like exonic splicing enhancers and silencers) can interfere with 
the recognition of splice sites, which is crucial for the correct excision of introns, and may 
cause exon skipping, which can affect the 3D structure of proteins or its interactions with 
other elements [829]. For example, a mutation within intron 7 of SMN1 (survival motor 
neuron 1) was found in patients with spinal muscular atrophy [830]; this variant is 
predicted to disrupt the consensus exon 7 splice donor motif and it results in increased 
production of the alternatively spliced transcript SMNΔ7 and low levels of full-length form 
SMN.  
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Variants affecting any of the following aspects of 5’ UTRs can lead to impaired protein 
synthesis through altered regulation of translation: the length or secondary structure of 5’ 
UTRs, the upstream open reading frames, internal ribosome entry site or iron-responsive 
elements present in 5’ UTRs [831]. The length of the 5’ UTR determines how much energy a 
ribosome needs to reach the AUG start codon, thus influencing translation efficiency. 
Variants that reduce the length of upstream open reading frames, that cause a frameshift 
in them, eliminate them or induce creation of novel upstream open reading frames, can 
also affect translation, either by destabilising the mRNA or by causing the ribosome to 
dissociate at a premature stop codon and potentially start re-scanning at a downstream 
open reading frame. Variants that affect internal ribosome entry sites can also influence 
regulation of translation and have been associated with various diseases, such as Charcot-
Marie-Tooth disease and fragile X syndrome. Variants that affect the stability or structure 
of iron-responsive elements (regions of secondary structure within the 5’ UTR to which 
mRNA-binding proteins bind in order to repress or promote translation) have also been 
associated with disease, such as hereditary hyperferritinaemia/cataract syndrome [831, 
832].  
Evidence regarding the functionality of 3’ UTRs is not as strong as it is for 5’ UTRs, but this 
region of mRNA has been shown to influence the translation, localisation and stability of 
mRNA [831]. Variants that influence the stop codon, either increasing or decreasing the 
length of 3’ UTRs, can lead to premature termination of translation and formation of 
truncated polypeptides, or to elongated mutant proteins that may interfere with the 
functions of the normal protein or those proteins with which it associates. Variants in the 
polyadenylation signal – a highly-conserved sequence motif recognised by RNA-binding 
factors – although rare, can lead to premature termination of transcription and decrease 
the efficacy of cleavage and polyadenylation of pre-RNA [833]. Variants that affect the 
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secondary structure of 3’ UTRs (such as sequence alterations in the 3' UTR of GATA4, 
predicted to alter RNA folding and contribute to cardiac malformations and coronary heart 
disease risk [834]) alter its interaction with associated proteins and may affect translation 
efficacy of the mRNA transcript and transport to its site of function [835].  
This demonstrates that, although non-synonymous variants and those within regulatory 
regions are more likely to affect gene expression and protein function compared to 
synonymous and non-coding variants, relying on variant class alone does not guarantee 
accurate prediction of functionality/neutrality. Additional information is needed to 
prioritise putative disease-associated variants.  
 Variant prioritisation: bioinformatics tools 6.1.3
Bioinformatics software, which is particularly useful when a large number of variants needs 
to be categorised, can also provide a variety of prediction tools based on molecular 
evolutionary patterns, protein sequence and/or structure. For example, the ‘sorting 
tolerant from intolerant’ (SIFT) algorithm is based on the premise that highly-conserved 
amino acids tend not to tolerate substitutions, whereas those with a lesser degree of 
conservation tolerate most substitutions [836]. The probability is calculated that an amino 
acid at a certain position is tolerated, conditional on the most frequent amino acid being 
tolerated. The ‘Polymorphism Phenotyping 2’ (PolyPhen 2) algorithm is, along with SIFT, 
the most widely used algorithm [837] and both have been found to be among the top most 
accurate methods for predicting functionality [838]. PolyPhen2 calculates the probability 
that a given mutation will be damaging, based on various sequence- and structure-based 
predictive features, as outlined in the algorithm release publication [576]. Other algorithms 
include: the ‘likelihood ratio test’ (LRT), which compares the null model - that each codon is 
evolving neutrally, with no difference in the rate of non-synonymous to synonymous 
substitution - to the alternative model - that the codon has evolved under negative 
269 
 
selection with a free parameter for the ratio of non-synonymous to synonymous 
substitution rates of the codon [577]; MutationTaster, which integrates information from 
various databases, such as dbSNP, the splice site prediction programme NNSplice, and 
SwissProt, and evaluates results with a naïve Bayes classifier [578]; ‘Genomic Evolutionary 
Rate Profiling++’ (GERP++), which identifies constrained elements by computing position-
specific expected rates of evolution with use of a maximum likelihood estimation; and 
PhastCons [839], which is based on a phylogenetic hidden Markov model, a statistical 
model of sequence evolution. 
The reliability of bioinformatics tools has been called into question, particularly considering 
that classifications from different methods may not always overlap [577, 588, 806]. The 
criteria generally used to evaluate these methods are false positive rate (the percentage of 
substitutions predicted to be damaging on substitutions known to be functionally neutral), 
false negative rate (the percentage of substitutions predicted to be functionally neutral on 
a set of substitutions that are known to affect protein function), and accuracy (the number 
of true positives plus negatives divided by the number of total positives plus negatives). 
Evaluation measures reported in various studies for some of the aforementioned 
algorithms are given below:   
SIFT: 20% false positive rate and 31% false negative rate [812]; 74% accuracy [840]. 
PolyPhen2: 72% accuracy [578, 840]; 75% false positive rate when looking at ultra-
conserved sites [841]. 
LRT: 28% false-negative rate and 6.7% false-positive rate [577]. 
MutationTaster: 85.7% accuracy [578]; 90.2% accuracy reported on the software’s 
website (http://www.mutationtaster.org/info/statistics.html). 
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GERP++: when plotting specificity against sensitivity, GERP++ had an area under the 
curve of 0.8921 for introns, 0.5976 for promoters and 0.8453 for coding regions 
[842].  
It must be noted that measures of evaluation vary between studies, as they depend on 
which dataset the algorithm was compared to, the type of variants considered and the 
level of site conservation. 
Variants predicted to be functional or non-functional by a single method are likely to have 
high false-positive rates and thus concordance of classifications from multiple algorithms is 
often considered more reliable and allows the user to harness the strengths of each 
method [588, 837, 843-845]. Databases such as ANNOVAR [846] and dbNSFP [847], which 
provide functional prediction scores for non-synonymous SNPs from various popular 
algorithms, facilitate comparison between methods. Even if concordance between multiple 
algorithms is relied on, however, it must not be forgotten that most algorithms focus on 
protein changes caused directly by a change in the DNA sequence, without considering the 
impact it may have on gene expression, for example through alternative splicing of mRNA 
[848, 849]. Furthermore, concordance between multiple algorithms may simply reflect the 
similarities in the methods upon which the predictions are made. For example, both SIFT 
and PolyPhen2 base their ‘position-specific independent count’ scores (a measure of the 
probability that a substituted amino acid will be tolerated) on multiple sequence 
alignments of the protein in question and related proteins; when scores differ, this may be 
dependent on technical details, such as which sequence alignments were used, rather than 
a fundamental difference in methods [850]. When relying on concordance between 
multiple algorithms, it is important to use algorithms that adopt a range of methods upon 
which to base their predictions. If all methods used the same criteria upon which to base 
their classifications, there would (or should) be no disparity between results and thus no 
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need to use more than one algorithm. As some scores are more correlated than others, one 
may have more confidence in a consensus between two scores that are less correlated 
than that between two highly correlated scores. 
Consensus classifier algorithms have also been developed, which use scores from various 
pre-existing algorithms to obtain a consensus score, for example by taking a weighted 
average of the normalised scores of individual methods or by using a support vector 
machine approach. Although consensus classifier algorithms such as CONDEL, [851] CoVEC 
[852] and CAROL [840], have been shown to outperform individual methods when 
predicting the deleteriousness of variants, this is not always the case: for example, use of 
MutationTaster scores alone was shown to outperform CONDEL, in terms of true and false 
positive rates, when classifying pathogenic variants from the ExoVar dataset [853]. With 
the HumVar dataset, CONDEL outperformed all individual algorithms, but the area under 
the curve (0.88) was similar to that of PolyPhen2 (0.87) and MutationTaster (0.863). Even 
algorithms that use the same original scores to deduce a consensus score (albeit via 
different methods), such as CAROL and CONDEL, which both use original SIFT and 
Polyphen2 scores, can give conflicting results and may yield results that contradict the 
predictions from which they are derived [837].  
There is no gold standard against which the performance of such algorithms, either 
consensus-based or concordance approaches, can be validated. There are many different 
databases of known disease-causing mutations, but they are often specific to a certain 
disease, such as the Amyotrophic Lateral Sclerosis Online Genetics Database 
(http://alsod.iop.kcl.ac.uk/Index.aspx) or Alzheimer Disease & Frontotemporal Dementia 
Mutation Database (http://www.molgen.ua.ac.be/ADMutations). Efforts have been made 
to collate findings from locus-specific databases, such as the Human Gene Mutation 
Database (http://www.hgmd.org), Human Genome Variation Database 
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(http://gwas.biosciencedbc.jp) and European Bioinformatics Institute Sequence Variation 
Database (http://srs.ebi.ac.uk). There is no consensus over which database should be used 
for validation; indeed, some may be more appropriate than others, depending on the 
phenotypic trait or variant in question. Validation results for a particular algorithm depend 
on the database to which it is compared [576]. It must also not be forgotten that such 
databases may not contain data on unpublished mutations. 
 Extreme phenotypes 6.1.4
Another way to increase power when investigating rare variant genotypic-phenotypic 
associations is to identify individuals who are most likely to have highly-penetrant rare 
mutations, for example, those with more severe disease types or more extreme responses 
to treatment. This method, known as selective genotyping or extreme trait phenotyping, is 
based on the assumption that rare variants have a stronger effect size than common 
variants (few common variants reported in the literature have an odds ratio of >2 [mostly 
between 1.1-1.4], whereas most rare variants have an odds ratio >2, with a mean odds 
ratio of 3.74 [854]) and that the frequency of disease/trait-associated alleles are enriched 
in one or both groups with extreme phenotypes and so these individuals are genetically 
more informative [855, 856]. The extreme trait phenotyping approach has been used to 
identify an excess of rare variants in the ABCA1 gene in individuals with low levels of high-
density lipoprotein (HDL) cholesterol [857]. With quantitative traits, one can define 
extreme phenotypes by using cases whose phenotypes deviate from the population mean 
by a certain amount (those with unusually high or low trait values) [858]. Cases with trait 
values above or below the set thresholds can be treated as cases and controls [859], 
although this has been described as ‘inefficient’ as not all available data are used [858]. 
When using only cases with extreme phenotypes, a much larger source population size and 
recruitment cohort are needed to obtain the same numbers as used with standard case 
273 
 
control studies. However, given that sampling the extremes leads to higher power to detect 
associations, compared to random sampling, both for single-variant-based analyses [860, 
861] burden analyses [861] and in family-based designs [862], this allows a smaller size to 
be used without compromising power. Accurate phenotyping is vital – as the sample size is 
reduced, even a small proportion of misclassified individuals could affect the analysis [863].  
Considering the potential power gain when using extreme trait phenotyping, variant-
pooling methods, and prioritising variants based on their likelihood of influencing disease 
risk or a phenotypic trait, predicted either by variant class or by prediction algorithms (the 
more variants are tested, the lower the p-value has to be to be declared statistically 
significant), it seems prudent to combine these methods. Theoretically, this would allow a 
causal variant/gene/pathway to be detected with an even lower number of cases.   
Following on from the exploration of common variation and KD response with the 
candidate gene analysis and GWAS, an investigation of whether rare genetic variation 
across the genome influences KD response will be conducted. Various methods, including 
extreme trait phenotyping, variant prioritisation and gene- and pathway-based analyses, 
will be employed with the objective of maximising power.  
6.2 Methods  
 Phenotypic data 6.2.1
The extreme trait phenotyping strategy was adopted in order to putatively identify those 
individuals most likely to have highly penetrant rare mutations that affect KD response. 
Extreme responders and non-responders were included – a two-tailed selective genotyping 
approach. Two-tail selective genotyping has been shown to be more powerful than one-tail 
selective genotyping (when only one phenotypic extreme is selected for, and otherwise 
random sampling is used) [864], although a one-tailed approach is more appropriate when 
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the distribution of phenotypes is not normally-distributed, which suggests that cases in the 
dominant distribution arm are likely to be more genetically informative [865]. As shown in 
Figure 6.1, the distribution of responder status of the 108 (106 of which were genotyped 
with the Illumina chip) cases classified as extreme responders or non-responders 
(equivalent to the extreme summary response category, as outlined in Chapter 3), is not 
heavily skewed.  
The criteria for classification as an extreme responder or non-responder is stringent (details 
are outlined in Chapter 3): extreme responders are those who achieved the most extreme 
reduction in seizure frequency and who maintained this seizure reduction over time and 
extreme non-responders are those who followed the diet for the shortest length of time 
with no beneficial effects, or with adverse effects on seizures; individuals included in this 
category are thus suitable for the extreme trait phenotyping strategy. Error in response 
classification is also reduced: if an individual reports a reduction in seizure frequency over a 
longer period of time (as opposed to a measure taken at just one time point) whilst 
following the KD, this is less likely to be due to chance. 
 
Figure 6.1: Extreme responders and non-responders, n=106 (out of 250 individuals with diet 
response data and genotyped with the Illumina chip) 
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 Genetic data 6.2.2
Participants were genotyped with the Infinium HumanOmniExpressExome Beadchip 
(Illumina Inc, San Diego, USA). Such chips are a ‘halfway house’ between a standard 
genotyping array and exome sequencing and represent a powerful and cost-effective 
method of identifying rare variation in individuals and assessing association with 
phenotypic traits, as has been recently demonstrated [866].  
 Quality control and variant filtering 6.2.3
All markers present on the chip were subject to the same quality control procedures as 
employed in Chapter 5. 
Per-individual quality control exclusion criteria: 
Individuals with proportion of heterozygous SNPs <0.25 or >0.33 (command: --het). 
Mismatch between gender reported in the phenotype file and gender imputed 
from PLINK (command: --check-sex).   
Duplicate and related persons, by calculating IBD between all pairs of individuals 
(Pi-hat [proportion of IBD] >0.4; command: --genome). 
Individuals with >2% missing SNP data (command: --mind 0.02).  
Per-variant quality control exclusion criteria: 
Cluster separation values <0.3 and Het-excess values between 0.1 and -1 and 
between 0.1 and 1, given in GenomeStudio. 
Genotyping rate <0.02 (command: --geno 0.02) 
Deviation from HWE in the whole cohort: p-value<1x10-6 (command: --hwe-all --
hwe 0.000001) 
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All quality control-filtered variants were annotated using wANNOVAR 
(http://wannovar.usc.edu, [574]) and the hg19 reference genome. wANNOVAR is a web 
interface to the ANNOVAR software: a widely-used functional annotation tool that can help 
select variants most likely to be associated with disease or phenotypic traits. wANNOVAR 
has the advantage that it does not need ANNOVAR software or databases to be installed 
(which is very time-consuming), and it is easy to use.  
The following information (representing all possible options available from wANNOVAR) 
was obtained for each variant:  
Variant class (exonic, intronic, intergenic, UTR and so on) 
Gene Name (using RefSeq gene definition) 
Exonic variant function (non-synonymous, synonymous and so on) 
Amino acid changes  
Region-level phastCons LOD scores 
Sequence identity score for the segmental duplication region in which the variant is 
located 
Alternative allele frequency in all subjects in the NHLBI-ESP project with 6500 
exomes  
Alternative allele frequency data in 1000 Genomes Project (Feb 2012 release) 
dbSNP ID (taken from dbSNP135)   
Whole-exome SIFT scores for non-synonymous variants (based on Ensembl55 
database) 
Whole-exome PhyloP scores*  
Whole-exome LJBSIFT (1-SIFT) scores* 
Whole-exome PolyPhen version 2 scores*  
Whole-exome LRT scores* 
Whole-exome MutationTaster scores*  
Whole-exome GERP++ scores* 
 
* wANNOVAR/ANNOVAR obtains these scores from dbNSFP [847] 
Based on the premise that rare variants are more likely than common variants to 
contribute to disease risk, variants were filtered by MAF according to 1000 Genomes 
Project Feb 2012 release and Exome Sequencing Project dataset (ESP6500). Variants with 
missing MAF information in ANNOVAR were excluded from analyses. Analyses were first 
conducted including all variants with MAF<5%. This threshold has been adopted in 
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publications to define uncommon or rare variants [867-869] and it complements the GWAS 
(see Chapter 5), which was designed to detect variants of MAF>5%. Further analyses were 
conducted with a more stringent definition of rare variation (MAF <0.5%), on the basis that 
the rarer the variant the more likely it is to be damaging. This definition of rare variation 
(MAF <0.5%) has been adopted in recent papers testing rare variant genotypic-phenotypic 
associations [797, 799, 866, 870-872].  
Variants were not filtered according to MAF in this cohort. Variants, although rare in the 
general population (according to public databases), may not be rare in this cohort if one 
responder group is appropriately enriched for that variant, compared to the other group.  
These variants (all rare variants, independent of variant class or prediction algorithm 
scores) will be referred to as group 0. These analyses account for the fact that synonymous 
SNPs or other non-coding variants may still affect gene behaviour – non-exonic splicing 
variants, for example, can lead to loss-of-function phenotypes [873]. When considered 
alone, these effects may be subtle but when considered alongside other variants, they may 
be critical [592]. It has been shown that filtering variants solely according to MAF or 
presence in public databases can be sufficient to detect a causal gene [874]. Furthermore, 
with SNP arrays, associations may be direct or indirect; it may be that a susceptibility 
variant (which may be synonymous, non-synonymous, coding or non-coding) is in LD with 
the susceptibility variant. Most common disease-associated variants found in GWAS are 
located in non-coding regions and are thought to affect regulatory elements; the same may 
be true for rare variants and so it is important not to discard them immediately from 
analyses. 
Group 0 variants (both with MAF <5% and MAF<0.5%) were further filtered to include only 
exonic (including exonic and exonic splicing) non-synonymous, stop-gain, stop-loss and 
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splicing variants. These variants are referred to as group 1. This is based on the premise 
that non-synonymous variants alter the protein coding sequence and are likely to be 
deleterious, thus increasing power to detect an association. If the associations were 
indirect, filtering variants in this way may not be of assistance – a non-synonymous variant 
may not necessarily be in high LD solely with other non-synonymous variants, but with 
variants of any class. However, the Illumina exome chip was designed to include functional 
exonic variants: it contains markers for variants associated with complex traits (such as 
diabetes, blood lipids and psychiatric traits) in previous GWAS, ancestry-informative 
markers (markers that showed strong differentiation between samples of African and 
European ancestry, and those of native American and European ancestry), markers for IBD 
estimation (markers that showed little differentiation between samples of African, 
European and Asian ancestry), a small set of ‘functionally interesting variants’, random 
synonymous variants, tags for human leukocyte antigen genes, coding variants in the 
mitochondria, a set of SNPs currently used as fingerprint SNPs at the University of 
Washington and Broad Institute, and a set of Y chromosome SNPs. With these variants, it is 
therefore more likely that a direct genotypic-phenotypic association is detected. Extracting 
coding variants that are more likely to be of functional consequence (non-synonymous 
variants) may increase power to detect an association and would facilitate interpretation of 
any association signals detected.  
An additional analysis, solely with stop-gain and splice site variants, was considered a 
possibility. This analysis was not conducted as, akin to other non-synonymous variants, 
there is no guarantee that they result in loss-of-function or whether they are in LD with a 
variant that causes loss-of-function. Moreover, due to the small number of such variants 
present on the Illumina chip, power would be greatly reduced to detect a genotypic-
phenotypic association.    
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Due to the uncertainty and variability associated with predictions from bioinformatics 
algorithms, which may lead to inclusion of neutral variants or exclusion of disease-
associated variants, these will not be used to filter variants prior to analysis. They may, 
however, be used as a guide to estimate the effects of the most interesting variants (those 
that have the most differential distribution between responders and non-responders) on 
gene/protein function, although it should not be forgotten that variants on the Illumina 
chip (even if they were chosen to be on the exome chip, although this is less likely) may act 
as tag SNPs, rather than being the causal variants themselves.   
 Covariates and population structure 6.2.4
As outlined in Chapter 3, the effect of a range of demographic and clinical factors on KD 
response was assessed by logistic regression. 
Association studies with rare variants are more susceptible to the effects of population 
stratification, leading to an increased risk of false-positive associations, compared to 
analyses with common variants. Rare variants are typically the result of recent mutations 
and so they are expected to be geographically clustered, or potentially only present in 
specific geographic populations (private alleles) [875]. This geographic clustering has been 
shown for variants with MAF <0.5%, both within European populations (Finnish populations 
had lower levels of allele sharing with other European populations than predicted by 
geographic distance) and, to a greater extent, across difference continents [798]. Pairwise 
IBS distance was calculated between all individuals and MDS performed, as outlined in 
Chapter 5.  
 Association analyses 6.2.5
Binary files of quality control-filtered variants (group 0 and group 1), including phenotypes 
for all extreme responders and non-responders (excluding genetic outliers) were created in 
PLINK (v1.07, http://pngu.mgh.harvard.edu/purcell/plink, [558]).  
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Single variant association analyses were conducted in PLINK (command: --fisher), as 
outlined in Chapter 5. In all analyses, λGC was 1.00, indicative of absence of importance of 
population structure. Therefore, as in the common variant GWAS, MDS vector values were 
not included as covariates. 
Analyses were first conducted including only quality control-filtered variants with MAF<5% 
(both with no filtering for variant class, and then just for non-synonymous and splicing 
variants) and then for variants with MAF<0.5% (with no filtering and then with filtering for 
variant class). P-values were obtained from 1000 permutations to adjust for multiple 
testing.  
It has been shown that, even with a cohort consisting of approximately 7,000 cases and 
17,000 controls, there is limited power to detect association signals using single variant 
tests for variants of MAF<0.5% with a modest effect size (odds ratio of 3) [797]. Because of 
the small sample size in this study, allele counts in responders and non-responders were 
examined, as well as p-values from the association tests. dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP) and Locuszoom 
(http://csg.sph.umich.edu/locuszoom, [696]), were used to determine whether the variants 
of interest were located within or were in LD with biologically plausible genes. 
 Gene- and pathway-based analyses 6.2.6
As in Chapter 5, variants were assigned to genes using wANNOVAR [574] and PLINK was 
used to conduct a gene-based set test and a self-contained pathway-based test. A 
Bonferroni-adjusted significance threshold was set by dividing 0.05 by the number of genes 
or pathways included in the analysis.   
Variants with MAF<5% with no filtering for variant class were used as, although 
synonymous variants or variants of unknown function are often hard to interpret when 
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examined individually, they may play important roles in specific networks or pathways; 
using the less stringent MAF filtering also avoids exclusion of potentially interesting 
variants/genes.  
6.3 Results 
 Quality control and variant filtering 6.3.1
In total, there were 950976 makers on the Illumina chip, 81965 of which had a MAF<5% in 
1000 Genomes Project Feb 2012 release or Exome Sequencing Project dataset (ESP6500). 
48117 variants had a MAF<0.5%. The function and, where applicable, exonic function of 
these variants (information taken from wANNOVAR output file) is given in Table 6.1. 
Table 6.1: Function of variants included in the Group 0 MAF<5% and MAF<0.5% analyses (prior to 
per-SNP quality control filtering) 
Variant function Exonic function 
Number of variants 
present on chip minor 
allele frequency<5% 
Number of variants 
present on chip minor 
allele frequency<0.5% 
Downstream n/a 360 36 
Exonic Non-synonymous 53847* 43919* 
 Stop-gain 213* 197* 
 Stop-loss 149* 131* 
 Synonymous 1976 1326 
 Unknown 379 282 
Exonic splicing Non-synonymous 475* 432* 
 Stop-gain 2* 2* 
 Synonymous 248 202 
 Unknown 3 2 
Intergenic n/a 11716 317 
Intronic n/a 10062 509 
Exonic non-coding RNA n/a 81 19 
Intronic non-coding RNA n/a 591 4 
Splicing non-coding RNA n/a 0 0 
UTR3 non-coding RNA n/a 16 2 
UTR5 non-coding RNA n/a 1 0 
Splicing n/a 591* 535* 
Upstream n/a 302 26 
Upstream; downstream n/a 15 3 
UTR3 n/a 836 148 
UTR5 n/a 102 25 
Total 81965 48117 
*variants included in Group 1 analyses (missense, nonsense and splicing variants) 
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After per-SNP quality-control filtering, 79169 SNPs remained in Group 0 MAF<5%. 31 
markers failed the HWE test (p-value<1x10-6). 2773 SNPs failed the missingness test (geno > 
0.02). 
After per-SNP quality-control filtering, 46517 SNPs remained in Group 0 MAF<0.5%. 4 
markers failed the HWE test (p-value<1x10-6). 1597 SNPs failed the missingness test (geno > 
0.02). 
After per-SNP quality-control filtering, 53409 SNPs remained in Group 1 MAF<5%. 12 
markers failed the HWE test (p-value<1x10-6). 1861 SNPs failed the missingness test (geno > 
0.02). 
After per-SNP quality-control filtering, 43720 SNPs remained in Group 1 MAF<0.5%. 4 
markers failed the HWE test (p-value<1x10-6) and 1493 SNPs failed the missingness test 
(geno > 0.02). 
Following quality-control filtering, 66 non-responders and 38 responders remained in 
association analyses.  
There was no strong evidence to suggest that KD response was affected by any clinical or 
demographic factors (see Chapter 3) and so none were included as covariates.  
 Association analyses 6.3.2
6.3.2.1 Single variant approach 
Group 0: 
No statistically significant results were obtained from the single variant association test 
MAF<5%. rs12565493 and rs12192673 had the lowest p-value (unadjusted p-value=0.0019, 
p-value obtained from 1000 permutations=0.96). 
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rs7969998 had the largest differences in minor allele count between responders and non-
responders, with a frequency of 0.1705 in non-responders and 0.01923 in responders. 
The variants with the highest case- or control-unique minor allele counts were rs12565493 
and rs12192673, with a frequency of 0 in non-responders and 0.1154 in responders, and 
rs752318, rs10038594, rs2039979, rs11788407, rs17593299 and rs11076243, with a 
frequency of 0.1222 in non-responders and 0 in responders. 
rs12565493 is located in the intronic region of FAF1. 
rs12192673 is located in the 3’UTR of GNL1 . 
rs7969998 is not located within any gene. It is in an LD region with THAP2, TMEM19, 
RAB21, TBC1D15, MRS2P2, TPH2 and ZFC3H1.  
rs17395014 is located in the intronic region of CACHD1. 
rs752318 is located in the intronic region of PLXDC2. 
rs10038594 is in an LD block with PLK2, GAPT and RAB3C. 
rs2039979 and rs11788407 are in an LD block with ANXA1. 
rs17593299 is not in an LD block with any gene. 
rs11076243 is located in the intronic region of NDRG4. 
Many of these genes play a role that could feasibly influence KD response. For example, 
interaction of FAF1 with the FAS antigen (TNFRSF6) mediates apoptosis. THAP2 (THAP 
domain containing, apoptosis associated protein 2), by its name, is also associated with 
apoptosis.  
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RAB21 encodes a GTPase that plays a role in trafficking of integrins and so regulates cell 
adhesion and migration. TBC1D15 encodes a brain GTPase activating protein that is 
thought to regulate intracellular trafficking. Both GNL1 and RAB3C have the GO term ‘GTP 
binding’. Variants in RAB3C and variants located between RAB3C and GAPT have been 
associated with insulin resistance [713].     
TPH2 is predominantly expressed in the brain stem and encodes a protein that catalyses 
the first step in serotonin synthesis. Mutations in this gene have been associated with 
autism [876], attention-deficit/hyperactivity disorder [877], obsessive compulsive disorder 
[878], major depression [879, 880] and susceptibility to suicide [881, 882].  
CACHD1 encodes a protein that is thought to regulate voltage-dependent calcium channels. 
Annexin I, encoded by ANXA, may have antiinflammatory activity as it inhibits 
phospholipase A2. 
NDRG4 encodes a protein that contributes to the homeostasis of intracerebral BDNF levels. 
The MAF<0.5% analysis generated higher p-values than the MAF<5% analysis, and the 
variant with the lowest p-value in the MAF<0.5% analysis had exactly the same p-value in 
the MAF<5% analysis. This indicates that no power was gained from excluding variants with 
MAF 0.5-5%.  
exm237818, exm544941 and exm648484 had the lowest p-value (unadjusted p-
value=0.047; p-value obtained from 1000 permutations=0.95) and the highest case- or 
control-unique minor allele counts, with a frequency of 0 in non-responders and 0.058 in 
responders. These variants are located in SCN2A, DAAM2 and ATXN7L1 respectively.  
The variants with the greatest difference in minor allele counts between responders and 
non-responders were rs923296 and exm1581807, both with a frequency of 0.044 in non-
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responders and 0.019 in responders. rs923296 is located in an LD block with many genes 
(HHIPL2, TAF1A, MIA3, AIDA, BROX, FAM177B, DISP1, TLR5, SUSD4 and C1orf65) and it is 
difficult to know which gene is relevant; exm1581807 is located in PCNT. 
SCN2A (sodium channel, voltage-gated, type II, alpha subunit) may be biologically relevant 
with regards to influencing KD response. Mutations in SCN2A, a sodium channel gene which 
is expressed in the brain, have been associated with several seizure disorders, including 
benign familial neonatal infantile seizures, febrile seizures plus, and intractable epilepsy of 
infancy [883-885]. rs2228980 was found in three responders, all with the genotype A/G. 
Two of the responders were thought to have epilepsy with myoclonic atonic seizures (one 
at the ‘severe end of the spectrum’ and one with ‘probable myoclonic astatic epilepsy’) and 
one had an unspecified epilepsy syndrome (according to clinic letters). This is a missense 
variant, which has a GERP++ score of 5.14 and is classified as damaging by LRT, but is 
classified as tolerated by SIFT, benign by PolyPhen2 and as a polymorphism by 
MutationTaster. rs2228980 may be relevant to the cause of epilepsy in these individuals 
and this type of epilepsy may respond well to the KD. 
DAAM2 has the GO term ‘Rho GTPase binding’ and ATXN7L1 has been associated with 
Alzheimer’s disease [886]. 
Group 1: 
When including all non-synonymous or splicing variants with MAF<5% in the single variant 
association test, no statistically significant results were obtained. exm255464 and 
exm799515 had the lowest p-value (unadjusted p-value=0.0058; p-value obtained from 
1000 permutations=0.91). 
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Aside from these variants, the variants with the largest difference in minor allele counts 
between responders and non-responders were exm887741 and exm1204532, which had a 
frequency of 0.11 in non-responders and 0.019 in responders.  
The variants with the highest case- or control-unique minor allele counts were 
exm1188563, with a frequency of 0 in responders and 0.11 in non-responders, and 
exm255464 and exm799515, both with a frequency of 0 in non-responders and 0.009 in 
responders. 
exm255464 is located in RFTN2. 
exm799515 is located in TMEM141. 
exm887741 is located in OLFML1.  
exm1204532 is located in GFER. 
exm1188563 is located in WDR93. 
None of these genes have an obviously relevant biological function with regards KD 
response. 
In the Group 1 MAF<0.5% analysis, exm237818, exm544941, exm648484 had the lowest p-
value (unadjusted p-value=0.04731; p-value obtained from 1000 permutations=0.93), the 
same variants with the lowest p-values in the Group 0 analysis. Variants with the largest 
difference in minor allele count between responders and non-responders (rs923296 and 
exm1581807) and the highest case- or control-unique minor allele counts (exm237818, 
exm544941, exm648484) were noted in Group 0 analyses, as above. 
6.3.2.2 Gene and pathway-based approaches 
A significance threshold of 3.21x10-6 (0.05/15589) and a suggestive significance threshold 
of 6.41.x10-5 (1/15589) were set for the gene-based tests. A significance threshold of 
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3.79x10-5 (0.05/1320) and a suggestive significance threshold of 0.00076 (1/1320) were set 
for the pathway-based tests. 
No gene or pathway reached significance or suggestive significance. The gene with the 
lowest p-value (p=0.0019) was MCMBP and the pathway with the lowest p-value 
(p=0.0019) was the PID ‘S1P4’ (Sphingosine 1-phosphate type 4) pathway.  
The following GO Biological Processes are associated with MCMBP: DNA-dependent DNA 
replication, mitosis, mitosis S phase and sister chromatid cohesion. The following GO 
Molecular Processes are associated with MCMBP: chromatic binding and protein binding.  
The S1P4 pathway contains CDC42, GNA12, GNA13, GNAI1, GNAI2, GNAI3, GNAO1, GNAZ, 
MAPK1, MAPK3, PLCG1, RHOA, S1PR4 and S1PR5. This pathway is shown in Figure 6.2.  
  
 
Figure 6.2: The Pathway Interaction Database S1P4 pathway, taken from http://pid.nci.nih.gov 
6.4 Discussion  
Key findings: 
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 No significant results were obtained from single variant, gene-based or pathway-
based association analyses, although some common themes pervade that could 
feasibly account for variability in KD response.  
 Filtering for rare, non-synonymous and splicing variants did not improve power in 
association tests.  
 The lack of significant results may be due to a number of reasons: lack of power to 
detect an association, using an array to detect rare variants, or simply because rare 
variation does not influence response to the KD. 
 Certain genes with variant(s) that have the greatest difference in minor allele count 
in responders and non-responders could feasibly influence KD response. 
Interpretation is difficult as only a few individuals harbour variants in these genes.  
 Power: study design and variant prioritisation 6.4.1
The principal reason why this study was underpowered to detect a rare variant genotypic-
phenotypic association was due to the sample size, which was even further reduced by only 
including participants with an extreme response to the KD. The rationale for this was to 
increase power by selecting those individuals thought to be most genetically enriched for 
variants associated with the phenotype.   
Use of a quantitative, rather than a dichotomous, phenotypic trait would have increased 
power and enabled determination of a quantitative relationship between any gene/variant 
found to be associated with the phenotype [887]. The difficulties of achieving this when 
clinic letters are the predominant data source, has been discussed in previous chapters.  
The aim of narrowing down the number of variants to exclude those that were more likely 
to be phenotypically neutral was to increase power. Most analyses focus on protein-
altering variants, as these are the most amenable to functional interpretation. As outlined 
in the Introduction of this chapter, when prioritising non-synonymous variants (or loss-of-
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function or whatever criteria are chosen), it is not guaranteed that one ends up with a 
functionally-enriched subset of the genome and one risks losing any causal synonymous or 
non-coding variants. In this study, group 1 analyses generated higher p-values than group 0 
analyses, which is most likely to be due to the reduced number of variants. Using 
bioinformatics tools to filter variants is also fraught with uncertainty: they may not always 
reflect up-to-date versions of their source resources, such as public SNP databases [850] 
and, at least when using software that provide multiple sources of information, such as 
wANNOVAR and dbNSFP, no reliability measures are provided for each prediction. There is 
a need to continue developing methods to robustly identify functionally important 
variation. 
Due to the ambiguity that filtering variants entails, in this study, analyses were also 
conducted with variants purely filtered based on MAF (Group 0). Two definitions of rare 
variation were adopted, one less stringent than the other. A definition of MAF<0.5% as a 
hard filter could be considered too stringent to adopt and it may have excluded some 
potential variants of interest. A risk allele that affects a certain trait in its homozygous form 
may exist at a relatively high frequency in a heterozygous form in the general population. 
Also, there may not be a strong negative selection pressure for variants that influence KD 
response, as they may not affect fitness in the general population. For example, survival in 
the face of starvation may not be relevant for certain populations and variants that 
adversely affect KD response may be important for another phenotypic trait. Finally, a 
relaxation in natural selection in recent generations may favour the accumulation of 
deleterious rare alleles in the population [888, 889]. Analyses were also conducted 
excluding variants with MAF>0.5% as, if the common disease/rare variant hypothesis is true 
in the case of KD response, it could be assumed that very rare variants are more likely to 
have a large phenotypic effect. Several variants examined from the MAF<0.5% analyses 
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were of interest, and variants such as those in SCN2A, which are highly relevant to this 
population, would have been missed if only the top results from the MAF<5% analyses 
were examined (no significant results were obtained in any analysis and so only those 
variants with the lowest p-values or the greatest difference between responder/non-
responder minor allele counts were examined). It is a vicious cycle: the less filtering used in 
the first place, the higher the multiple testing burden, which reduces the likelihood of 
obtaining statistically significant results. No significant results were obtained in any analysis 
(each with a different grade of variant filtering) and so it seems unlikely that ‘suboptimal’ 
filtering was the cause of the lack of significant findings.  
There are various alternative ways either to prioritise variants prior to analysis or to aid 
interpretation of results. One example of this is consideration of gene expression profiles in 
tissues thought to be relevant to the phenotype. The most likely candidates for this with 
regards KD response would be the brain, liver and pancreas, considering the role of these 
organs in fatty acid and glucose metabolism and seizure onset. This is not to say that genes 
expressed elsewhere may not be of importance. For example, the kidneys, due to their role 
in glucose and ketone excretion, may influence KD response, as may ubiquitously-
expressed fatty acid/carnitine/glucose transporters. Indeed, the main known genetic 
influence on KD response, SLC2A1, is expressed in the endothelial cells of normal brain, but 
also ubiquitously expressed in most cells; it is the most widely expressed of the hexose 
transporters [890]. Based purely on expression levels, one may expect SLC2A3 (encoding 
GLUT3) to be more relevant to KD response, due to its specific expression in neurons [891]. 
Considering this is the first genetic analysis to be conducted with regards KD response, it 
seems prudent to use such strategies to aid interpretation of results, rather than to exclude 
genes/variants in the first place.  
291 
 
Another option would be to prioritise candidate mutations by quantifying gene intolerance 
to functional mutation, using a residual variation intolerance score [892], which can be 
used by itself or in combination with a variant-level prediction of functionality, such as 
those adopted in this chapter (GERP++, SIFT, PolyPhen2 and so on). This score is based on 
the premise that genes intolerant to mutation are less likely to harbour damaging 
mutations, unless they are contributing to disease, which was shown to be true for genes 
that cause Mendelian disorders – they are more likely to have a lower residual variation 
intolerance score, reflective of lower tolerance to mutation. However, whether genes are 
more likely to influence a phenotype if they do not tend to harbour functional variants in 
the general population or whether they commonly harbour functional variation, seemingly 
with no clinical association, depends on the phenotypic trait in question. This was shown, 
for example, with genes linked to developmental disorders, which were more likely to be 
caused by genes that were intolerant to functional variation, and immunological disorders, 
which were more likely to be caused by genes with an excess of common functional 
variation, compared to the genome-wide average number of common functional variants 
found in genes with a similar burden of mutations. It is unknown whether it would be best 
to prioritise genes with low or high intolerance scores and so it would not make sense to 
filter variants/genes prior to analysis, based on this strategy. Furthermore, one cannot 
prioritise variants using a large number of strategies until the desired results are obtained, 
as this increases the multiple testing burden and could be considered as manipulation of 
results. Until a gold standard is set for prioritising or filtering variants/genes, one must 
decide on a particular strategy, or at least limit the number of strategies adopted. By virtue 
of the lack of statistically significant results in any analysis, none of the aforementioned 
strategies were adopted to interpret results. 
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The fact that λGC was equal to 1.00 in all single variant analyses indicates that results were 
not biased by population stratification.  
 Results of interest 6.4.2
Independent of statistical significance, some interesting results were obtained when 
looking at single variant, gene-based and pathway-based analyses. Some variants with the 
greatest difference in responder/non-responder minor allele counts or with case- or 
control-unique variants were located in genes that could feasibly be linked with KD 
response. Several genes play a role in apoptosis, a process which has been proposed as a 
mechanism of action of the KD. FAF1, for example, is a member of the cell death-inducing 
signalling complex mediated by FAS (it binds directly to FAS and caspase-8) [893], and it 
suppresses NF-κB activity, which has a downstream effect on expression levels of genes 
involved in the immune response, inflammatory processes and apoptosis [894]. It has been 
postulated that FAF1 is related to the pathogenesis of neurodegenerative diseases: gene 
expression was reported to be increased in the brains of people with Parkinson’s disease 
and Alzheimer’s disease [895] and FAF1 deficiency blocked biochemical events that are 
linked with these disorders, including caspase and JNK activation, ROS generation and cell 
death [896].  
Other genes of interest in these analyses are involved in neurological processes, such as 
serotonin synthesis and regulation of BDNF levels. Both may be relevant to KD response: 
serotonin may influence seizure susceptibility [304] and concentrations were shown to be 
reduced in the CSF of children following the KD, compared to pre-diet levels, although 
concentrations did not differ between responders and non-responders [378]; as BDNF-
mediated activation of TrkB pathways have been shown to promote hyperexcitability and 
kindling [897, 898], if reduced glucose levels from KD-feeding inhibit expression of BDNF 
(this has been shown in animal models where glycolysis was interrupted with 
293 
 
administration of 2DG [237]), this would be a plausible mechanism for reducing seizures 
[233].  
Another predominant theme was genes encoding GTPases, or GTPase-activating or -binding 
proteins. Some genes, such as TBC1D15, may be relevant to KD response: TBC1D15 Is a 
Rab7-selective GTPase-activating protein (it inactivates Rab7) and its expression leads to 
lysosome fragmentation and decreases cellular sensitivity to growth factor withdrawal-
induced apoptosis [899, 900]. Dysregulation of specific Rab (including Rab7) has been 
postulated as a marker for neuronal dysfunction, due to the association of upregulation of 
these genes with Alzheimer’s disease mild cognitive impairment. 
Variation in SCN2A may be relevant to the cause of epilepsy in certain individuals. A 
missense transcript variant (K908R) at chr2:166201225 was found in three responders (in 
addition to many other synonymous or non-coding variants, which were present in 
individuals in both response groups). No publications were identified that reported an 
association between variation at this locus and seizures, but it has been patented for a 
genetic assay for determining predisposition to epilepsy, following discovery of the 
mutation in an individual with idiopathic generalised epilepsy [901] (patent publication 
number US7485449 B2). The mutation is thought to be important as it is located in an 
extracellular domain between two transmembrane domains that form the wall of the 
transmembrane pore, which allows the sodium to enter the cell. The phenotypes of two 
out of the three individuals in which this variant was found fit into the spectrum of epilepsy 
with myoclonic atonic seizures or generalized epilepsy with febrile seizures plus, which 
have been associated with SCN2A mutations [902-904]. The other individual was described 
as having an ‘unspecified epilepsy syndrome’ with two types of seizures: one (the 
predominant seizure type) where  the patient becomes stiff and suddenly jerks all over, 
lasting for 2-3 minutes, and another where the left arm raises and the eyes deviate to left, 
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which occur in clusters. These results highlight the potential to unearth genotypic 
relationships with phenotypes other than that which is principally being investigated, such 
as cause of epilepsy. They may not be clinically useful when predicting likelihood of KD 
response in patients but, if the mutation is confirmed with sequencing and found to be of 
functional importance, it may still be of interest to patients and their families with regards 
the cause of their epilepsy, regardless of whether it changes clinical management or not. It 
is possible that more discoveries of this nature could have been made if personalised 
markers (for example, variants associated with known epilepsy-candidate genes) had been 
added to the chip.  
MCMBP, the gene with the lowest p-value in the gene-based analysis, encodes a protein 
that regulates initiation of DNA replication and elongation. For DNA to replicate, so-called 
‘pre-replicative complexes’ are assembled during the G1 (Gap 1 – the first stage of 
interphase) phase of the cell cycle; these pre-replicative complexes are activated at the S 
phase of the cell cycle [905]. The minichromosome maintenance (MCM) complex is an 
essential component of pre-replicative complexes. The MCMBP protein can bind to any of 
the subunits within the MCM complex, interacting most strongly with MCM4 and MCM7 
[905]. Phosphorylation of MCM4 by cyclin A/Cdk2 regulates the activity of the MCM 
complex [906], as does protein interaction with MCM7 [907]. Deletion of the MCMBP 
ortholog gene in yeast leads to cell cycle arrest and overexpression of the gene inhibits 
DNA replication and causes DNA damage [908]. MCM proteins have also been found to 
regulate hypoxia-inducible factor 1 (HIF1) activity (a gene that mediates changes in gene 
expression in response to hypoxia, including [among many others] regulation of GLUT1): 
MCM proteins were shown to directly interact with HIF1α and negatively regulate HIF1 
activity, which prevents the induction of cell cycle arrest that is normally induced by HIF1 
when oxygen is in low supply [909]. When oxygen is not in low supply, MCM proteins 
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promote cell cycle progression by inhibiting HIF1 but, in situations of hypoxia, MCM 
expression is downregulated and the activity of HIF1 works to inhibit cell cycle progression 
(otherwise, this would exacerbate the difference between oxygen supply and demand). It is 
feasible that variation in MCMBP affects cell cycle progression and other functions of the 
MCM complex, such as the response to hypoxia. MCMBP may influence KD response via 
regulation of cell cycle progression and cell survival/death in neurons.  
The most closely associated pathway with KD response was the S1P4 pathway. S1P4, one of 
the S1P (Sphingosine-1-phosphate) receptors, is predominantly expressed in cells and 
tissues of the lymphoid system and is thought to play a role in immune response [910]. It 
has been shown to activate Gα12/13 and the small GTPase Rho; overexpression or ectopic 
expression of S1P4 lead to increased cell motility and rearrangements in the cytoskeleton 
[911]. Binding of S1P4 to S1P activates the MAPK ERK [912] and phospholipase C (PLC) 
downstream pathways [913, 914], both of which are involved in many processes, including 
cell proliferation [915, 916], apoptosis [917, 918] synaptic plasticity/the BDNF cascade [919, 
920], and insulin sensitivity/glucose transport [921-924]. Binding of S1P4 to S1P has also 
been found to induce cell migration via activation of CDC42 [925], a member of the Rho 
family of small GTPases that regulates cell cycle progression, induces apoptosis in response 
to stress in neurons [926, 927] and is essential for insulin secretion [928, 929].  
As outlined in Chapter 5, the MAPK and other pathways related to cell cycling could 
potentially play a role in seizure control due to effects on neuronal survival/death. The 
effects on glucose-stimulated insulin secretion represent an alternative way through which 
the KD may exert its antiseizure effects, although the two mechanisms of action are not 
necessarily mutually exclusive.  
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These observations suggest that certain genes may influence KD response in particular 
individuals. It may be the case, for example, that individuals with certain types of epilepsy 
(with specific genetic causes) respond in a particular way to the KD. Variation in the S1P4 
pathway may impair or enhance the effects induced by the KD that lead to seizure 
reduction. Depending on how many individuals the variant(s) were present in, this would 
not necessarily be picked up with an association analysis, nor when examining those 
variants or genes with the largest difference in responder/non-responder minor allele 
counts. For example, one non-responder may harbour a variant that adversely affected 
his/her response to the KD but, as it was only present in one individual, it would not 
generate a low p-value in association analyses; examination of all genes in which one 
responder or non-responder harbour a variant would not be feasible and there would be 
no way of determining whether these variants/genes actually influenced KD response or 
not. Genes with related functions may overcome, or at least partially overcome, the 
impaired function of certain genes. Larger sample sizes are needed in order to identify 
more individuals with rare variants, but interpretation will still be complicated by the many 
complex mechanisms underlying the antiseizure effects of the KD.  
 Rare variant detection with arrays versus sequencing 6.4.3
The Illumina chip used for these analyses, which is a combination of a SNP array and an 
exome chip, allows a higher frequency of rare, putatively functional variants across the 
genome to be typed, compared to standard SNP arrays, which typically provide information 
(through LD correlation) for 80-90% of common variation (MAF>5%), far less for variants of 
intermediate frequency (MAF 0.01-5%) and virtually none for rare variants [500]. Such 
chips still rely on LD mapping – any association signal found may be the true causal variant 
or may just be in LD with it. With rare variants, indirection association mapping is not ideal, 
as LD tends to be weak between common tag SNPs and rare variants [862, 930]. 
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Considering that there are more low MAF variants typed on this Illumina chip compared to 
standard SNP arrays, it is more likely that a higher number of rare variants (with similar 
MAFs to the typed variants) will be highly correlated, but even rare variants may not be in 
strong LD with rare SNPs [799]. Although putative functional exonic variants were included 
on the chip, there is no guarantee that these variants affect KD response, whether they lie 
within genes that affect KD response, or whether they are in LD with variants that affect KD 
response.  
Sequencing is the preferred method for detection of rare variants, as it only relies on direct 
association mapping and coverage is obviously more complete, allowing for analysis of very 
rare or private variants. Extremely rare variants will either not have been seen before or 
have such low allele frequencies that they have not been included in commercially 
available genotyping chips [714]; with the exome chip, non-synonymous variants had to be 
observed at least three times in two or more studies, and splicing and stop-altering variants 
had to be observed at least twice in two or more studies 
(http://genome.sph.umich.edu/wiki/Exome_Chip_Design). A further advantage of 
sequencing is that it provides more information on structural genetic variation, as opposed 
to the exome chip, which contains only 181 indels and is unable to address frameshift 
mutations. 
Despite these drawbacks of exome array genotyping, genotypic-phenotypic associations 
have been reported using this technology. In a study including over eight thousand 
participants, two variants in genes at known loci and three new genes were shown to be 
associated with either fasting proinsulin concentrations or insulinogenic index (the ratio of 
the increase in insulin concentration to the increase in plasma glucose after a glucose load) 
[866]. In another study, including almost 3,000 breast cancer cases and over 7,000 controls, 
rs145889899 showed a statistically significant association with breast cancer and was 
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almost exclusively seen in African Americans. No statistically significant results were 
obtained for prostate cancer [714]. These studies serve as a proof-of-concept for rare 
variant genotypic-phenotypic detection using array-based technology, but they also 
highlight the need for large sample sizes. This is easier to achieve with arrays, compared to 
whole exome or genome sequencing, due to lower prices. 
 Rare variant/common disease hypothesis 6.4.4
Considering the results from these analyses, it is difficult to conclude whether rare genetic 
variation influences KD response, due to the small cohort size. In order for rare variants to 
play an important role in explaining the missing genetic contribution to disease/a 
phenotypic trait and be detectable in association studies, they must have larger effect sizes 
than those observed for common variants. If one concentrates on coding variants, the 
effect sizes have to be even higher, as variants are selected from a very small proportion of 
the genome [714]. It may be that genetic variation (whether it be common or rare) 
contributes to KD response but the effect sizes of each variant are too small for 
associations to be detected. This is particularly likely to be the case in studies such as this, 
with a small cohort. Effect sizes are likely to be higher when variants are grouped together, 
for example, by GO term or pathway, but results from this approach were hard to interpret 
in this study.  
Structural variants, such as indels, larger CNVs, translocations and inversions, which are 
incompletely captured by genotyping arrays, as well as undetected gene-gene or gene-
environment interactions may also play a role in the genetic contribution to disease (for 
example, the expression of one gene may be altered by another loci or by the environment, 
which may results in a different effect on the phenotype) [931, 932], or, in this case, KD 
response. Sequencing can help with the matter of structural variation, and aggregate 
analyses that consider groups of genes in a pathway or gene-gene interactions may help 
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elucidate the complex and as-of-yet undiscovered genetic contribution to KD response. 
Incorporating the effects of environmental interactions into genetic models is problematic, 
principally because it is unknown what exactly the relevant environments are. One may 
stratify association studies by environment, but this would likely only reveal the largest 
interaction effects [932].  
 Conclusions and future work 6.4.5
Using single variant, gene-based and pathway-based association tests, no significant 
associations of rare genetic variation with KD response were found. When examining 
responder/non-responder minor allele counts, some biologically plausible genes were 
identified that may at least partly explain KD response or even the cause of epilepsy in 
certain individuals. Some genes of interest share common functions; taken together with 
results from the pathway analysis, it seems that rare variation affecting cell cycle 
progression, cell survival/apoptosis, neurological processes and insulin sensitivity 
contribute to KD response. Due to the fact that no single gene can be pinpointed as the 
reason for extreme KD response (whether favourable or unfavourable) in this cohort, this 
makes clinical translation of results difficult.  
The lack of significant results may be explained by a number of reasons, including small 
sample size, small effect size of rare variants, the number of variants in a gene and their 
frequency, and the indirect association mapping approach of the genotyping array; even 
though the Illumina chip contains a higher number of rare, putative functional variants than 
standard SNP arrays, discovery of any potential genotypic-phenotypic associations is 
limited by the content of the array.  
If there is no prior knowledge regarding the type of variant (for example, whether it is 
present in a conserved region or not) or properties of genes that are likely to affect the 
phenotypic trait in question, as is the case with KD response, it may be best to adopt less 
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stringent filters, or indeed no filters at all, and then use information such as variant class 
and predicted deleteriousness to aid interpretation of results post-analysis. Even with the 
knowledge that functional variants are more skewed towards the lower end of the MAF 
spectrum [933], it is unknown whether variants that affect KD response also tend to be 
rare, or whether they are subject to purifying selection at all (especially when we are 
dealing with response to treatment, rather than a disease state per se). 
Ideally, sequencing, where the matter of incomplete LD between tag and causal variants is 
not an issue, would be used to investigate the effects of rare variants on KD response. This 
is the focus of the next chapter. 
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7 Exonic variation and response to the Ketogenic diet: 
whole exome sequencing  
 
7.1 Introduction 
Unbiased sequencing approaches – whole genome or whole exome sequencing (targeted 
sequencing of all coding regions of the genome) – have become increasingly available, both 
for family-based studies and for groups of unrelated individuals, since the commercial 
release of a next-generation sequencing instrument in 2005, at increased speeds and 
reduced costs compared to traditional Sanger sequencing [934, 935]. Technologies such as 
Illumina Genome Analyzer or HiSeq, Life Technologies SOLiD, or Roche 454 Genome 
Sequencer [936], generate sequence data (generally short reads of 35-450 base pairs [937]) 
from hundreds of millions of spatially segregated, amplified DNA templates in parallel [938, 
939].  
The often prohibitive cost of whole genome sequencing means that use of whole exome 
sequencing has thus far been more widespread. With exome sequencing, the DNA sample 
is reduced or enriched, leading to a sample where the content is made up of the protein 
coding regions of the genome, along with adjacent intronic content such as UTRs and 
miRNA binding sites. This is most commonly achieved by PCR, which takes a single-stranded 
piece of DNA as a primer, obtained by denaturing the DNA with heat, and amplifies specific 
DNA sequences through use of enzymes and probes attached to targeted regions, using the 
original strands as templates. Capture will never be 100% complete, as some regions of 
interest resist the enrichment strategy. This is followed by high-throughput next-generation 
sequencing of the exon-enriched sample. 
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Currently, most exome sequencing success stories have been for Mendelian disorders, such 
as congenital chloride diarrhoea (SLC26A3) [940], Miller syndrome (DHODH) [941] and non-
syndromic hearing loss (GPSM2) [942]. Such mutation identification is important for those 
who desire a diagnosis, even if it does not necessarily lead to a change in disease treatment 
and management. There is now hope that exome sequencing will be of use in unearthing 
the genetic basis of complex traits, for which genetic variation may influence disease risk or 
a phenotypic trait, rather than cause it [943-945]. Most commonly, individuals at the 
extreme ends of the phenotypic spectrum are studied; this approach will most probably 
remain common until it is routine to sequence many thousands of samples in one study. 
The first example of this approach was in 2010, when sequencing the exomes of patients 
with combined hypolipidaemia (individuals with very low triglyceride, LDL and HDL 
cholesterol levels) identified two nonsense mutations in ANGPTL3 that, when both 
nonsense alleles are present, lead to combined hypolipidaemia [946].  
Exome sequencing allows investigation of both common and rare coding variation, with a 
relative excess of rare variation [944]. This rare variation can partly be attributed to recent 
population expansion [616, 947, 948] and also because rare variants in protein-coding 
regions are under purifying selection and are thus more likely to be deleterious [948, 949]. 
In comparison to genotyping arrays, where rare variant investigation is made problematic 
by the fact that, due to their low MAF, rare causal variants are less likely to be in high LD 
with (and therefore tagged by) nearby markers, the direct association mapping provided by 
sequencing allows discovery of rare, potentially private variation and the opportunity to 
explore their phenotypic effects. Not limited just to single point mutations, sequencing also 
permits discovery and exploration of indels and larger structural variants, such as copy 
number variants (CNVs - defined as DNA segments of ≥1 kb in size present at variable copy 
number in comparison with a reference genome [950]), which are known to be prevalent 
303 
 
and can be of functional consequence in humans [951]. Indels are the most abundant form 
of genetic variation in humans after SNPs [825] and both frameshift and in-frame indels 
have been linked with various diseases, such as cystic fibrosis [952]. Structural variants 
affect a higher proportion of the genome than do SNPs [953, 954] and they have been 
associated with various diseases, such as autism [955, 956], schizophrenia [957, 958] and 
Crohn’s disease [827, 959].  
Considering that many Mendelian genetic disorders are caused by mutations in protein-
coding sequences [874, 961], whole exome sequencing is a powerful approach for 
exploring rare genotypic-phenotypic associations as, theoretically, the sample is enriched 
for variants of functional consequence. Due to its lower cost compared to whole genome 
sequencing, more samples can be sequenced at higher depths, leading to higher accuracy 
in rare variant calls [962]. Potentially important regulatory variation present in non-coding 
regions will, however, be missed [963]. This may be of consequence for complex traits, 
where non-coding genetic variation is believed to play a larger role than in Mendelian 
disorders [944]. Characterisation of such non-coding variation may be difficult as their 
effects are often unknown, making it harder to pinpoint causative genes [964]. 
Furthermore, considering that the effect sizes of non-coding variants are thought to be 
smaller than those of coding variants, studies may be underpowered to detect phenotypic 
associations [944].  
 Accurate variant detection 7.1.1
One of the main challenges with next-generation sequencing data is accurate variant 
detection. A mismatch when aligning the sequence reads against the reference genome 
could represent a true SNV, but could also be the result of an error in the reference 
genome sequence, an error generated in the library, misalignment or base-calling error. 
Steps can be taken at every stage in the variant detection process to avoid such errors: 
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7.1.1.1 Avoiding errors generated in the library 
The PCR amplification step in library preparation can result in incorrect DNA fragments in 
the final library, which show up as mismatches in the alignment, falsely indicating genetic 
variation in the sample. Duplicate DNA fragments may falsely manifest as high read 
depth/coverage. PCR-free protocols do exist (such as Illumina’s TruSeq DNA PCR-Free 
Sample Preparation Kits), but they require large amounts of input DNA, are very sensitive 
to variations in DNA quality and purity, and do not necessarily guarantee unbiased 
sequencing data; mean coverage, for example, was shown to be equal when using PCR-
amplified and PCR-free protocols [965]. With PCR-amplified libraries, PCR duplicates are 
commonly removed after alignment, using programmes such as Picard (SourceForge, Dice 
Holdings, Inc., http://picard.sourceforge.net) [966].  
7.1.1.2 Avoiding base-calling error 
After sequencing is complete, the quality of raw reads must be evaluated. With many base-
calling algorithms, uncertainty can be quantified, as each nucleotide base call is 
accompanied by a statistical measure of uncertainty or Phred quality score – a Phred score 
of 20 corresponds to a 1% error rate in base-calling [967]. The researcher may filter out 
bases to include only those of high confidence. Poor-quality tails of reads (bases at the 3’ or 
5’ end of a sequencing read) may be trimmed off, although the importance of this filter is 
debatable: it has been shown to reduce expected error rates (the average error probability 
of each base assigned as quality scores) from 7.09% to 0.16% and from 16.43% to 0.23% 
[968], but others found that trimming led to more alignment artifacts and thus caused 
more false-positive variant discovery than when using raw reads [969]. The authors stated 
that ends of reads may be helpful for read mapping. Reads may also be filtered according 
to other parameters, such as reads with at least one uncalled base (N content) or GC bias 
[966, 968]. It has been reported that, with Illumina data, erroneous base calls are 
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frequently preceded by base G [970] and A-C base conversions are the most frequent [970, 
971]. 
7.1.1.3 Avoiding alignment (or mapping) error 
When aligning reads to a reference genome, either hash-based alignment algorithms, such 
as MAQ [972], Novoalign (http://www.novocraft.com/main/index.php) and Stampy [973], 
or Burrows-Wheeler transform-based algorithms, such as Bowtie [974], SOAP2 [975] and 
BWA [440], are used. Hash-based alignment algorithms are based on a hash table – a 
common data structure that may be created using either the reference genome or the set 
of sequencing reads [976]. Either the reference genome is used to scan the hash table of 
sequencing reads, or the sequencing reads are used to scan the hash table of the reference 
genome. The reads are then associated with the region of the genome where they are most 
likely to align. With Burrows-Wheeler transform-based algorithms, an index of the 
reference genome assembly is first created by modifying the sequence order of the 
reference genome so that sequences that exist multiple times now appear next to each 
other and then the final index is created. This facilitates rapid read placement along the 
genome. Hash-based alignment algorithms, although slower, are more accurate than 
Burrows-Wheeler transform-based aligners and the former are recommended, especially 
for short reads [967, 976].  
Alignment is more difficult for regions with higher levels of diversity between the reference 
genome and the sequenced genome, as more mismatches between the sequencing reads 
and reference genome must be allowed, and also for shorter reads (which, from next-
generation sequencing, are already shorter than reads from Sanger sequencing), as there 
may be several places in the reference genome from which they could have been read. This 
difficulty can at least partly be overcome by using longer reads and paired-end reads, 
where long fragments are taken from the donor genome and a number of bases are 
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sequenced from both ends of the fragment, rather than from only one end (single-end 
reads) [973, 977]. As the distance between each paired read is known, alignment 
algorithms can use this information to map the reads more precisely, which is particularly 
important for repetitive regions of the genome [978]. 
7.1.1.4 Calling variants  
Once high-confidence base calls are aligned to position, variant calling is conducted. This is 
often separated into two steps: genotype assignment and variant identification [979]. It is 
determined at which positions at least one of the bases differs from the reference 
sequence and then, for positions in which a variant has already been called, the genotype 
can be determined. GATK [980] and SAMTools [981] are two popular tools used for variant 
identification.  
Genotype-assignment is conducted using probabilistic methods, where the probability of a 
particular genotype at a particular site is calculated, assuming independence among reads, 
and the genotype with the highest probability is generally chosen. A measure of statistical 
uncertainty for the genotype call is also provided. The prior probability for each genotype, 
which must be estimated in order to produce posterior probabilities for the genotypes, 
may assign equal probability to all genotypes, or external information (for example, from 
the reference sequence, SNP databases or an available population sample) may cause more 
weight to be given to a particular genotype over others. It has been recommended that 
prior probabilities are calculated by analysing multiple individuals at the same time (multi-
sample variant/genotyping calling), as allele frequencies (either from the dataset in 
question or from population databases) can be used to estimate how likely the presence of 
a particular genotype is for an individual [967]. The probability that all genotypes are 
homozygous for the reference type can be estimated, giving both an SNV call and an 
associated measure of confidence. LD patterns at nearby sites can also be used to improve 
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genotype-calling accuracy [967], although this may not be of much use for rare variants 
that are not present in reference databases. 
Most variant-calling software focuses on detecting SNVs, but indels can also be detected 
from sequencing data, either by gaps in the read mapper alignments, de novo assembly of 
short reads and comparison of contiguous, overlapping sequence reads (contigs) to a 
reference sequence, or from lists of indels available in databases, such as dbSNP [987]. 
Detection of indels can be difficult, as they occur at a lower rate than SNVs, the position of 
an indel with respect to the reference genome is often ambiguous (they may not be 
uniquely positioned onto the reference, especially if they are located in repetitive regions 
of the genome) and there is much variation in fluorescence signal intensity for a specific 
homopolymer length [988], often resulting in high error rates in indel calls. Error rates are 
affected by indel frequency (extremely high indel frequencies may decrease sensitivity of 
indel-calling algorithms), read length (increased read length is associated with improved 
performance of indel-calling algorithms), indel size (longer indel length is associated with 
lower positive predictive value in some softwares), and read depth (increased coverage is 
associated with increased indel-calling sensitivity) [989, 990]. It is common to realign reads 
around indels, as misalignment of reads where the first or last few bases overlap an indel 
may lead to false SNV calls – ungapped alignments (those that do not allow gaps in 
alignment) optimise local alignment by minimising the number of mismatched bases  [986, 
990-992]. Use of tools that allow gaps in alignments can reduce error rates in SNV 
detection [990]. It has been recommended to call SNVs after realignment of reads by the 
indel-calling algorithm [987]. 
Detection of larger structural variant detection from exome sequencing data is a challenge, 
as it is sparser than genome sequencing data and there is more variation in read depth. 
Variants >15bp have rarely been reported in exome studies [996]. Some methods have 
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been developed to detect CNVs from exome sequencing data, such as CoNIFER [997], 
which has an estimated sensitivity of approximately 76% for rare CNVs containing three or 
more exons. The authors acknowledge that some exonic CNVs are likely to be missed and 
state that ‘owing to the significantly lower probe density and the targeted nature of 
exome-capture platforms, our algorithm cannot fully replace currently available high-
density array-comparative genome hybridisation or SNP microarray platforms if genome-
wide detection of CNVs is the goal.’ Another algorithm, Splitread [996], uses a split-read 
approach whereby clusters of paired-end reads with one end that maps to the reference 
genome but not at the other end (because it crosses a breakpoint) are searched for. The 
unmapped ends are broken down into sequences either of equal length (balanced splits) or 
unequal length (unbalanced splits) and clusters of split reads are searched for, using the 
balanced splits as seeds. The authors claim that Splitread can detect insertions and 
deletions of any size, whilst acknowledging that accurate characterisation of insertions is 
influenced by read length and that some genetic variation was still missed. Concordance 
between multiple algorithms was recommended, as not all calls predicted by Splitread 
were also predicted by other methods, and a substantial fraction of calls were unique to a 
particular method.  
One can increase the accuracy of SNV/indel/CNV calling by increasing depth of coverage – 
the number of times a nucleotide is read during the sequencing process. With low- 
coverage sequencing (an average of <5× per site per individual), there is high probability 
that only one of the two chromosomes of a diploid individual has been sampled at a 
specified site [967]. As sequence coverage increases, genotype likelihoods should peak 
around the true genotype, as more sets of reads contain a particular allele [998]. When 
coverage is low and there may be no reads covering a site, LD patterns in nearby sites may 
be taken advantage of to infer genotypes [998]. With indel-calling, some algorithms have 
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been shown to reach a plateau of true indel calls when coverage is >30, whereas others 
showed an increase in true indel calls as average coverage increased [989]. Higher coverage 
provides higher resolution of CNV break point detection, giving higher accuracy [999, 
1000]. Of course, reducing uncertainty by increasing coverage (to either medium coverage 
[5-20x] or deep sequencing [>20x]) is often prohibited by financial constraints and, even 
with average higher coverage, there is still variation in coverage across regions [1001]. 
Researchers may rely upon the proportion of targeted base-pairs that are covered at (or 
greater than) a particular depth (for example, 20×). Some target regions may have a lower 
coverage due to, for example, an increased proportion of G and C bases in a region [1002], 
or higher coverage due to, for example, similarity between intergenic and exonic regions, 
causing non-specific binding during the capture process [1003]. It has been shown that, in 
association studies, a greater increase in power is gained by sequencing more individuals at 
a lower depth than by sequencing fewer individuals at high depth [1004].  
Even if parameters such as coverage are consistent, variant detection still depends on the 
algorithm used. Discrepancies have been observed between different algorithms both for 
SNV [1005-1007] and indel [990, 1005, 1006, 1008] detection, which suggests high false 
negative and false positive rates of these algorithms. Concordance between indel-calling 
algorithms (26.8%) has been shown to be lower than with SNV-calling algorithms (57.4%) 
[1005]. Indels of low frequency may be less likely to be called by multiple algorithms [990]. 
Just as for larger structural variations, concordance between multiple algorithms is 
recommended. This approach is supported by findings that indel events called by two or 
more methods had the highest concordance with dbSNP and 1000 Genomes Project calls 
[996].  
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7.1.1.5 Variant filtering 
Post-calling, variants can be further filtered according to various parameters in order to 
obtain a set of high-confidence calls. Such parameters include read depth, genotype quality 
score, differences in quality scores for reference and alternative alleles, allelic balance 
ratio, base quality score, mapping quality score, deviations from HWE, and proximity to 
indels [967, 986, 1003]. Filtering can be undertaken with variant alignment software, such 
as GATK and SAMTools, or a programme designed for manipulation of variant calling files 
(vcf), Vcftools (SourceForge, Dice Holdings, Inc., http://vcftools.sourceforge.net). As for the 
filtering steps that can be conducted prior to variant-detection, there is no gold standard as 
to which thresholds to adopt. The most common algorithms have default settings and 
variants can also be filtered according to other parameters at the researcher’s discretion. 
In the output vcf files, a QUAL score is given for each variant - a measure of how confident 
the algorithm is that the SNV is true. Researchers may filter variants based on this QUAL 
score, as well as on other scores such as read depth, although recommendations vary. 
GATK does not recommend applying a hard filter for read depth with exome sequencing 
data as, with capture data, the relationship between misalignments and depth is not clear. 
It has been reported that a QUAL score of approximately 20 and a read depth ≥5 can 
generally be applied to give a high validation rate when using variants called by 
SAMtools:mpileup [1011]; these thresholds were determined by comparing accuracy 
versus recall with different combinations of score cut-offs, although the authors 
acknowledge that thresholds may be dataset-specific. The authors recommended checking 
allele/strand bias but applied no filtering rules based on allele/strand balance (reads 
supporting reference allele forward, reference allele reverse, alternate allele forward, and 
alternative allele reverse) in their dataset, as neither accuracy nor recall improved 
substantially. Others have excluded SNVs with read depth<10 and those located outside of 
exome-capture regions [1005], or SNVs with a quality score <20 and indels <50 [1011].  
311 
 
The quality of SNV calls can be evaluated by checking performance metrics, such as 
transition to transversion (Ti/Tv) ratio and genotype quality score. Filtering criteria can then 
be adjusted to an optimum level, whereby both high genotype consistency rates and Ti/Tv 
ratios close to expected values are achieved: Ti/Tv ratios of approximately 3.0 (3.5 for 
known variants and 3.0 for novel variants) are expected for whole exome datasets and 
approximately 2.0 for whole genome datasets (2.10 for known variants and 2.07 for novel 
variants) [980, 1012, 1013], although the ratio for synonymous variants is higher than for 
non-synonymous variants [945, 1014]. In one study, the two most effective thresholds 
affecting sequencing data genotype quality were found to be genotype quality score≥ 20 
and depth≥ 5 – these filters resulted in both high genotype consistency rates and Ti/Tv 
ratios close to expected values [1003]. Accuracy of an algorithm can also be estimated by 
comparison of results with calls from SNP genotyping platforms, array-comparative 
genome hybridisation data or Sanger sequencing verification. The proportion of calls 
reported in dbSNP provides a rough measure of accuracy [980], as do heterozygosity rates, 
as sequencing can easily be mistaken for heterozygous sites, especially where coverage is 
low [1015]. A visual examination of reads – checking coverage and quality of local 
alignment around the site of variation – has also been recommended for the identification 
of false positives [1011]. 
 Strategies for identifying susceptibility variants or genes in exome sequencing 7.1.2
data  
Another challenge with next-generation sequencing data is how to identify variants or 
genes that are associated with the phenotypic trait amongst a plethora of non-pathogenic 
variants/genes (assuming, of course, that sequencing error has been eliminated as much as 
possible). 
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One approach is to prioritise variants based on novelty, or rather lack of presence in public 
databases, such as dbSNP or 1000 Genomes Project, based on the premise that common 
variants are less likely to be disease-causing. This does exclude a high proportion of 
variants, leaving only around 2% of SNVs identified by exome sequencing [935], but it also 
assumes that such databases contain no pathogenic variants, which is not the case. In 
family studies, de novo mutations may be prioritised, although these are more likely to be 
relevant in severe early-onset disorders where transmission to subsequent generations is 
often prevented – they are under strong negative selection [943].  
Variants can be filtered solely by MAF, based on the premise that deleterious variants are 
subject to purifying selection and tend to show high sequence conservation. The MAF 
threshold for ‘rare’ variants, however, is arbitrary – normally defined as either 1% or 0.5% 
in publications, but variants with MAFs as high as 5% have been described as ‘rare’ [868, 
869], rather than ‘low frequency’. Excluding variants with a very low MAF in the general 
population may erroneously exclude causal variants. For example, if a disorder is recessive, 
the alternative allele may be present at a higher frequency in the general population, as its 
deleterious effects would be masked in the heterozygous form, compared to a dominant 
disorder. This is the case with the CFTR gene for cystic fibrosis.  
As outlined in Chapter 6, filtering variants based on class – those that are most likely to be 
deleterious, such as non-synonymous or loss-of function variants – is a common approach, 
but does not account for variants that indirectly alter protein-coding sequences. Moreover, 
high levels of functional genetic variation are present in the exomes of healthy individuals, 
and around 100 variants are thought to be loss-of-function [798, 815, 935, 947, 992, 1016]. 
Predicting deleteriousness based on bioinformatic tools is an alternative method, although 
there is often discrepancy between results from different algorithms and most are 
restricted to non-synonymous variants. PhastCons, PhyloP and GERP++ do give scores for 
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synonymous variants, but if one is looking for concordance with other algorithms that 
account for other factors besides evolutionary conservation, all variants apart from non-
synonymous SNVs will be most probably be filtered out. Filtering according to algorithms 
may lead to erroneous exclusion of susceptibility variants. For example, even if most SNPs 
associated with Mendelian disease are located in highly conserved regions, this may not 
necessarily be the case for those associated with complex traits [1017] and so filtering 
variants according to PhastCons, PhyloP and GERP++ scores, for example, would not be 
appropriate. Rather than using these algorithms to filter variants in the first place, it may 
be best to use them post-analysis, to strengthen existing evidence of 
pathogenicity/association. 
As well as prioritising variants based on putative functional consequence, variants can also 
be pooled into genes. This may be particularly important when searching for the genetic 
contribution to complex traits, where power to detect an association is often limited by low 
penetrance, small effect size, locus heterogeneity, variable expressivity and pleiotropy 
[1018]. It does not have to be the same variant that is over-represented in one 
responder/disease group, as long as the variants all affect the same gene and are likely to 
be of functional consequence [863]. As exonic variants can typically be clearly assigned to a 
gene, unlike with GWAS, where variants are often intergenic, gene-based tests are 
commonly used with sequencing data. 
Association tests may be more suitable than discrete filtering for complex traits, where 
variants that influence disease risk or a phenotypic trait may not be fully penetrant, 
mutations in different genes may lead to the same phenotype, or more complex 
phenotypes may be explained by the presence of multiple variants [943]. Gene-based 
association tests are commonly performed with whole genome or exome sequencing data 
to increase power to detect genotypic-phenotypic associations [806, 1019]; these data are 
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particularly suitable for such analyses as one is not limited by the content of an array – 
theoretically, every variant is captured. Unless rare variants have a large effect on the 
phenotype, there is limited power to detect an association with a single rare variant, even 
with large sample sizes – it is expected that over 10,000 exomes will be required to achieve 
sufficient statistical power to robustly detect associations of rare variation with complex 
traits [944]. In gene-based association tests, group frequency or distribution, as opposed to 
single variant frequency or distribution, is compared between cases and controls. In the 
absence of pedigrees, individuals at extreme ends of the phenotypic spectrum are often 
selected, based on the premise that these individuals are genetically more informative and 
that the frequency of disease/trait-associated alleles are enriched in one or both ‘extreme’ 
groups [855, 856]. 
There is a caveat with gene-based tests: not all variants within a gene may affect its 
function and those that do affect gene function may affect it in different directions [963]. 
Examples of genes where different variants have opposite effects on the phenotype include 
PCSK9, in which loss-of-function variants are associated with reduction in mean LDL 
cholesterol and gain-of-function variants are associated with decreased LDL receptors and 
hypercholesterolaemia [1020], and APOB, in which rare missense mutations can result in 
hypercholesterolaemia and hypocholesterolaemia [1021]. Certain gene-based tests, such as 
the c-alpha test [660] (a test of dispersion), account for the fact that some variants may be 
protective and others deleterious with regards to the phenotype in question. Other tests 
assume that the effects of all variants within a gene are in the same direction: damaging 
with regards the phenotypic trait.  
Variant prioritisation, for example by variant class, may also be performed so that only 
putative functional variants are included in gene-based analyses, although recent studies 
have highlighted the importance of not restricting analyses solely to variants in coding 
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regions. For example, Harismendy et al. sequenced individuals with extreme BMIs and used 
a collapsed marker test to identify rare variants associated with extreme obesity [1026]. 
Most of the associated variants were located in regulatory elements, either close to the 
gene promoter or in transcriptional enhancers. Furthermore, none of the associated 
variants in the aforementioned study were present in evolutionarily conserved sequences, 
as determined by PhyloP score, which highlights the dangers of missing true genotypic-
phenotypic interactions when filtering variants based on prediction algorithms. 
The aforementioned methods, or a combination of them, have been used to increase 
power in association studies and pinpoint candidate genes. The ‘novelty’ approach was 
adopted in the first publication to show, as proof-of-concept, that exome sequencing can 
identify the cause of Mendelian disorders [874]. The authors searched for genes with non-
synonymous, splice acceptor and donor site variants and short coding indels, not present in 
public databases, present in all cases (individuals with Freeman-Sheldon syndrome) but no 
controls (individuals from the HapMap and Human Genome Structural Variation projects); 
one variant had to be present in the case of a dominant disorder, or two (in the same gene) 
in the case of a recessive disorder. After such filtering, the only gene remaining was MYH3. 
Filtering variants by those predicted to be damaging according to PolyPhen also served as 
an effective filter, again narrowing down the candidate gene to MYH3, although the 
previous filters (only including genes containing at least one rare coding indel, non-
synonymous or splice-site variant, and excluding variants present in dbSNP [common 
variants]and in any controls) were sufficient. Others have prioritised genes in which all 
affected individuals had novel variants at different genomic positions (making it more likely 
that the variants are causative and not simply unidentified SNPs) [1027], or genes with at 
least one previously unobserved heterozygous non-synonymous or splice site substitution 
or a coding indel in all affected individuals [1028]. This approach assumes not only that the 
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variant is rare and likely to be previously unidentified, but also that the variants are fully 
penetrant. A similar strategy has been previously adopted that allows variants to be 
present in a proportion of cases, not necessarily all cases, which allows for a degree of 
genetic heterogeneity and/or missing data [1029].  
Many family-based exome studies have targeted de novo mutations, in particular those 
thought to be deleterious, based either on variant class or functional prediction algorithms. 
O’Roak et al. found there to be a higher rate of non-synonymous de novo variants in trios 
with autism spectrum disorder than expected [961, 1030]. Variants were classed as severe 
if they were truncating, missense with Grantham score ≥50 and GERP score ≥3 or only 
Grantham score ≥85, or deleted a highly conserved amino acid [1030]. Sander et al. 
narrowed down candidate genes by looking for ≥2 ‘disruptive’ de novo mutations in the 
same brain-expressed gene in unrelated individuals, as this was unlikely to occur by chance, 
due to the very low rates for de novo nonsense and splice-site mutations [1031]. The 
authors found that functional prediction algorithms did not provide any more information 
with regard to disease risk, compared to classifying variants based on class (non-
synonymous  versus synonymous), and then further filtered to nonsense and splice site 
mutations. In such studies, it must be considered that the probability that a gene contains 
multiple gene-disrupting de novo mutations by chance increases with sample size, and that 
there is a higher probability of observing multiple missense variants, compared to gene-
disrupting variants, as the mutation rate generating missense is approximately 20 times 
higher than that generating gene-disrupting variants [1032].  
Which strategies to adopt depends on practical considerations – whether one has samples 
from a pedigree or unrelated probands, how many samples can be sequenced with the 
available budget, and various assumptions: whether the phenotypic trait is thought to be 
due to de novo or inherited variants (for family-based studies) and the assumed mode of 
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inheritance of a trait, the extent of locus heterogeneity for a trait (whether or not the trait 
is caused by variants in genes at different chromosomal loci), whether only rare variants or 
both rare and common variants are expected to contribute to the phenotypic trait, or 
whether protective and risk variants are expected [935, 1033]. 
 Pathway analysis 7.1.3
As with array data, grouping variants based on their role(s) in a biological pathway, such as 
those defined by PANTHER ([671], http://www.pantherdb.org/pathway) or KEGG ([1034], 
http://www.genome.jp/kegg/pathway.html), can increase power if a trait is affected by 
multiple causal genes in a pathway. One may apply the same principles as with GWAS, for 
example, by assigning SNPs to a gene, taking the SNP with the lowest p-value to be the p-
value for that particular gene, and determining whether a particular pathway or biological 
function is over-represented in a set of genes with p-values below a specified threshold, 
compared to what would be expected by chance. One may also use results from gene-
based tests, although results will be affected by the assumptions of the original analyses 
(for example, gene-based tests that assume all variants have a uni-directional effect will 
generate different p-values to tests that allow for bi-directional effects). The limitations of 
this competitive approach are the same as with genotyping data in that not all SNPs/genes 
are represented in the list of nominally significant genes. Furthermore, a major difference 
between array genotyping and sequencing is that only one or a few variants per gene are 
represented on arrays, whereas with exome sequencing, all exonic variants in a gene are 
included. If several variants within a gene are of moderate effect size, taking the SNP with 
the lowest p-value may result in a loss of information [666]. A self-contained analysis, 
where one extends gene-based analyses by assigning variants to a pathway or a particular 
GO term, instead of just to a gene, to test the null hypothesis that no pathway is associated 
with the phenotypic trait, avoids this loss of information. 
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 Population stratification 7.1.4
Whichever strategy is adopted, for studies involving unrelated individuals, population 
structure requires consideration, as rare variants, which are typically the result of recent 
mutations, are likely to segregate in a population-specific manner [875, 945]. For example, 
a deficiency of rare alleles has been observed in Europeans and East Asians compared with 
expectations for a constant-sized population [1035]; West Africans had fewer rare alleles 
than expected. The former was attributed to the ‘out-of-Africa bottleneck’ or decline in 
population size and consequential reduction in genetic variation as people migrated from 
Africa, and the latter was attributed to an expansion in African population. East Asians 
were found to have even fewer rare alleles than Europeans as East Asians had greater 
genetic drift (varying frequency of a gene variant in a population over time due to chance) 
throughout history. Controlling for potential population substructure is particularly 
important for exome sequencing studies, where discovering rare variation is often the goal. 
In an association study, if a higher proportion of cases had African ancestry compared to 
controls, one would expect to observe an excess of rare variants in cases, not due to any 
influence the variants have on the phenotypic trait, but because Africans harbour more 
rare variants than non-Africans [944].  
In contrast to GWAS, methods for achieving this with sequencing data are not fully 
established and it is unknown whether the methods traditionally used for detecting and 
controlling for population stratification in studies with common variants are suitable for 
studies that also contain rare variants [1036]. Ideally, as with GWAS, cases and controls 
would be matched for population proportions and disease risks in subpopulations. 
However, this is not always feasible, particularly when matching is based on indices such as 
geographical proximity or self-reported ethnicity and thus subpopulations may remain 
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unidentified; for example, participants may not know about their genetic admixture. A 
variety of alternative approaches have been used thus far. 
Principal component analysis: In an analysis of rare variants from an exome data set, 
principal component analysis (using three vectors, obtained from common [MAF>0.05] 
non-synonymous SNPs) reduced Type I error due to population stratification, but it did 
not improve the power to detect causal variants [1037]. Ten principal components were 
incorporated in logistic regression based analyses of exome sequencing data, which 
mitigated spurious association rates due to population stratification, although power was 
reduced in every case [1038]. In another study, which used exon pilot data from the 1000 
Genomes Project, with subjects from seven populations, the inclusion of principal 
components as covariates in rare variant aggregation tests tended to (but not consistently) 
reduce Type I error rates [1039]. The top ten principal components, based on rare and 
common variants, were used as covariates to control for population stratification in a 
sequencing dataset [1040]. This was effective with a small number of sub-populations, 
although the authors note that this approach may not be sufficient in other scenarios. 
Although inclusion of a large number of principal components will remove virtually all 
stratification, it is unknown how many are required and the more components included, 
the lower the power to detect true associations [1041].  
Permutation: Kiezun and coauthors claimed to effectively control Type I error in association 
tests conducted on exome sequencing data by ‘modifying the permutation scheme to 
account for subpopulations’: case-control status was permuted within each population, 
assuming known population labels [944].  
Genomic control λ: using simulated genome-wide genotype data, it has been shown that, 
with gene-based tests such as the burden and c-alpha test, the inflation caused by 
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population stratification varies across genes, depending on their size and on the MAFs of its 
variants [1036]. Therefore, λGC, which inflates the association-test statistic by a common 
factor, is not suitable for gene-based association tests. It was showed that, when there are 
two sub-populations, using the top few vectors from principal component analysis, 
constructed from either common or rare variants, controlled for population stratification, 
but this was not achieved when ten sub-populations were present.  
 Interpretation and utility of results 7.1.5
The final challenge regarding sequencing data is the interpretation and subsequent 
usefulness of obtained results. Assuming that mapping and variant-calling errors are 
controlled for, finding variants is not necessarily the greatest problem, but rather how to 
identify the particular mutation relevant to the disease or phenotypic trait and how exactly 
it exerts an influence. Excluding all non-loss-of-function variants may not necessarily be the 
answer, as a typical exome harbours approximately 100 loss-of-function variants [815]. 
Multiple observations, either of the same variant (which is unlikely in the case of complex 
disorders) or of independent variants in the same gene either in cases or controls, increase 
confidence when classifying particular alleles or genes as risk-conferring, even if association 
test results do not reach statistical significance, for example due to a small sample size. 
Once one or a small group of candidate genes have been identified, targeted sequencing of 
these genes, for example by Sanger sequencing, can help verify the association of specific 
variants with the trait in question [1033]. Just as with genetic association analyses based on 
genotyping arrays, functional studies can help interpret association signals, providing 
insight into the mechanisms behind disease/trait risk [945]. 
As for the clinical utility of sequencing data, it is clear that, at least with Mendelian 
disorders, it can facilitate diagnosis, in particular when clinical presentation or biochemical 
parameters may not be indicative of the disorder. This may or may not alter clinical 
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management. The clinical application of genome/exome sequencing for complex diseases is 
not yet fully established [935], although it is likely to provide insight into the allelic and/or 
locus heterogeneity of such diseases and how this relates to phenotypic variation.  
It is hoped that whole exome sequencing will identify one or more genes/pathways that 
influence KD, or help elucidate some of the mechanisms of action of dietary treatment for 
epilepsy.  
7.2 Methods  
 Phenotypic data 7.2.1
As in Chapter 6, the extreme trait phenotyping strategy was adopted in order to identify 
those individuals most likely to have highly penetrant rare mutations that affect KD 
response. Funds were available for sequencing of 45 samples. 
18 extreme responders and 27 extreme non-responders who had enough DNA available for 
whole exome sequencing were selected. The 18 responders had diet response data for at 
least 12 months and had maintained ≥75% seizure reduction at all follow-up points. The 27 
non-responders reported an increase or no change in seizure frequency and weaned off the 
diet either prior to the 3-month point or approximately at the 3-month point due to a lack 
of response or adverse response.  
The following cases were not considered for inclusion in the extreme non-responder 
category for exome sequencing: 
- individuals who weaned off the diet due to lack of tolerability or compliance. 
- individuals who experienced a dramatic reduction in seizure frequency soon after starting 
the diet but whose seizure frequency subsequently increased so that, by the time they 
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reached the 3-month clinic appointment, seizure frequency was no different to prior to 
starting the diet. 
- individuals who had no change in seizure frequency but did experience other seizure-
related benefits. 
- individuals who reported any non-seizure-related benefits and who continued following 
the diet due to these benefits.  
A brief outline of the chosen 45 individuals’ experience with the KD is given in Table 7.1. 
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Table 7.1: Description of Ketogenic diet response in 45 samples who had whole exome sequencing 
Extreme responders Response to KD 
Case 1  >75% reduction in seizure frequency for 2 years. Seizure control was then variable and the patient was weaned off the diet 5 years 
after commencing the KD as further manipulations had not led to improved seizure control. There was no deterioration in seizure 
control.  
Case 2 >75% reduction in seizure frequency for the 2.5 years that the patient followed the diet. The patient then ‘weaned’ onto a low 
glycaemic-index regime (not supervised by a dietitian) and seizure control has remained variable but not as poor as prior to starting 
the KD. 
Case 3 
 
>75% reduction in seizure frequency for the two years that the patient followed the diet. During the last few months on the diet, 
the patient showed signs of abdominal pain, which resolved when cow’s milk was eliminated, although episodes of seemingly 
generalised pain later returned. No change in seizure control when weaned off the diet and episodes of pain gradually disappeared.  
Case 4 ‘Dramatic’ >75% reduction in seizure frequency for the 18 months that the patient followed the diet. After weaning off the diet, the 
patient initially experienced more frequent clusters of epileptic spasms/tonic seizures but seizure control subsequently improved. 
Case 5 >75% reduction in seizure frequency for the 18 months that the patient followed the diet. The diet was then weaned due to 
behavioural problems – obsessions with food – although the patient remained on a gluten-free diet. There was no deterioration in 
seizure control.  
Case 6 Consistently >90% reduction in seizure frequency over the 4 years when the patient followed the diet. Diet was weaned due a loss 
of efficacy. 
Case 7  Consistently >90% reduction in seizure frequency over the 8 years the patient has followed the diet. The patient is essentially 
seizure-free except during attempted weaning of diet when seizures returned. 
Case 8 
 
>75% reduction in seizure frequency during first three months on the diet. Subsequently became seizure-free with recurrence of 
seizures just before the 24-month point. Seizure-control improved (not quite seizure-free). The patient was weaned off the diet 3.5 
years after starting, with no deterioration in seizure control.    
Case 9 Became seizure-free during the first three months after starting the diet. Remained almost seizure-free for two years. When 
attempting to wean the diet, seizures recurred. The patient went back on the diet, with some improvements, and is still following 
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 the diet.  
Case 10 
 
A ‘dramatic’ improvement in seizure control, noted 3-4 days after starting the diet. This improvement (almost seizure-free) was 
maintained for 2.5 years, when seizure frequency increased. The patient was weaned from the diet but further deteriorated. The 
patient was not put back on the diet (as of Oct 2013) due to problems with digestive system/bowel habits. 
Case 11 Almost seizure-free when following the diet for three years. Seizure control then became variable but still better than prior to 
starting the diet. 
Died 4.5 years after starting the diet 
Case 12 
 
Became seizure-free during the first month after starting the diet. The patient had been following the diet for 2 years 3 months and 
remained seizure-free, with the exception of one isolated incidence of seizure exacerbation, which subsequently came under 
control, and one seizure in Feb 2013 associated with febrile illness. The patient was weaned off the diet to improve oral intake and 
reinitiated the diet (and AEDs were increased) in September 2013 due to a hospital admission with infection and breakthrough 
seizures, which lead to an improvement. The patient is currently weaning off the diet again.  
Case 13 >75% reduction in seizure frequency in first three months on the diet. This further improved to >90% reduction, which is still the 
case 10 years later (still on diet). The patient has periods of seizure-freedom. 
Case 14 Has been following the diet for over two years and still has a 90% reduction in seizure frequency (achieved in first three months on 
diet). 
Case 15 Became seizure-free three weeks after starting the diet. The patient remains seizure-free 24-months later (still on diet). 
Subsequently diagnosed with GLUT-1 deficiency. 
Case 16 
 
70-80% reduction in seizures during first three months on the diet. The patient has now been following the diet for 18 months and 
approximately 80% reduction in seizure frequency has been consistently achieved over this time, with the exception of periods of 
illness when frequency increases. 
Case 17 Consistently >90% reduction in seizure frequency over the 3 years the patient has followed the diet. 
Case 18 Became seizure-free during the first three months on the diet and the patient currently remains seizure-free 2.5 years later (still on 
diet).  
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Extreme non-responders Response to KD 
Case 1  No change in seizures. Weaned off diet before the 3 month-point 
Case 2 No change in seizure frequency. The patient experienced longer events. 
Case 3 Eyelid myoclonia increased in frequency and severity/more prolonged; no change in vacant spells  
Case 4 No change in seizures. Weaned off diet before the 3 month-point 
Case 5 No change in seizures. 
Case 6 
No change in seizures. Weaned off diet before the 3 month-point. 
Increased brightness, awareness and interaction, but thought to be due to reduction in clobazam dose. 
Case 7 No change in seizures  
Case 8 No change in seizures. The only reported benefit was an improvement in bowel habits 
Case 9 No change in seizures 
Case 10 No change in seizures. Weaned off diet before the 3 month-point. Died a few months later. 
Case 11 No benefit from diet - possible seizure increase 
Case 12 No change in seizures. Weaned off diet before the 3 month-point  
Case 13 No benefit from diet - possible seizure increase. Weaned off diet before the 3 month-point 
Case 14 No benefit from diet - possible seizure increase. 
Case 15 No change in seizures. 
Case 16 
No change in seizures for almost 3 months. The patient then had an episode of status epilepticus, the first such episode for five 
years. The patient was weaned off the diet. 
326 
 
Case 17 Clinic letters indicate no change in seizures. Seizure diary indicates an increase in seizure frequency.  
Case 18 Increase in frequency of absence seizures at 3-month point. 
Case 19 No benefit from diet - possible seizure increase. 
Case 20 
Increase in seizure frequency. Weaned off diet before the 3 month-point. 
Parents stated that seizures are ‘currently the worst ever and have been escalating since the patient started the diet’. 
Case 21 Increase in seizure frequency.  
Case 22 
Patient stated that there were no improvements in seizure frequency or pattern. Seizure diary showed an increase in seizure 
frequency 
Case 23 
Sudden increase in seizure frequency. As soon as the patient went into ketosis, the patient deteriorated rapidly. Seizure clusters 
could not be stopped and the patient was admitted to hospital.  
Case 24 Increase in seizure frequency but seizures slightly shorter. 
Case 25 
 
Increase in seizure frequency. The patient started having seizures from wakefulness during the day, which hadn’t happened in a 
very long time. These evolved into a nocturnal cluster requiring emergency medication. 
Weaned off diet before the 3 month-point. 
Case 26 Increase in seizure frequency. Weaned off diet before the 3 month-point. 
Case 27 ‘Dramatic’ increase in seizure frequency. Weaned off diet before the 3 month-point. 
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 Genotypic data 7.2.2
DNA for the 45 extreme responders and non-responders were measured with NanoDrop 
ND-1000 Spectrophotometer (Thermo Fisher Scientific Inc., USA) and diluted to 60μL at 
30ng/μL by the researcher. Samples were given to Miss Deborah Hughes at UCL Institute of 
Neurology Neurogenetics Unit in a random order (so that all responders were not 
sequenced before non-responders, or vice versa) for whole exome sequencing. Samples 
were sequenced in two batches, although data from several runs were combined for six 
samples.  
The sample library was optimised using the Nextera DNA Sample Preparation Kit (Illumina, 
Inc., San Diego, USA) and targeted regions were captured with the Nextera Exome 
Enrichment Kit. Illumina HiSeq® 2500 was used as the platform for sequencing. 8GB per 
sample was sequenced. 
The following steps were completed by Dr Alan Pittman at UCL Institute of Neurology 
Neurogenetics Unit: 
i) Alignment of sequencing reads to the reference genome sequence Genome 
Reference Consortium Human Build 37 with Novoalign (Novocraft Technologies 
Sdn Bhd, Malaysia, http://www.novocraft.com/main/index.php). Novoalign is a 
hash-based alignment algorithm, which, although slower, is more accurate 
than Burrows-Wheeler transform-based aligners [967, 976]. Novoalign allows 
gapped alignments and is thus more sensitive to indel detection: in one study, 
approximately 90% of indels of a particular size were correctly detected in 
reads aligned by Novoalign [990]; <50% were detected in BWA alignments. 
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ii) Removal of PCR duplicates with Picard (SourceForge, Dice Holdings, Inc., 
http://picard.sourceforge.net), to leave only unique reads. 
 
iii) Calling of variants and creation of .vcf files from BAM alignment files using 
SAMTools (SourceForge, Dice Holdings, Inc., http://samtools.sourceforge.net, 
[981]).  
The following commands were used to call quality-controlled filtered variants: 
mpileup -q 20 -L 400 -d 400 
-q 20 = skip alignments with read mapping quality smaller than 20 
-L 400 = skip indel calling if the average per-sample depth is above 400 
-d 400 = at a position, read maximally 400 reads per input BAM 
Variants were then further filtered using SAMTools default settings. Variants with a 
QUAL score of <18 were also removed.  
SAMTools sets the prior probability for a heterozygous SNV at 0.001 for novel 
variants, and 0.2 for known SNVs [1005] and has a mean sensitivity of 94.47 and 
mean specificity of 99.59. SNV calling by SAMTools has been called conservative, as 
a larger number of false negatives were observed, compared to the programmes 
‘Variant Caller with Multinomial probabilistic Model’ and GATK [1006]. Indels are 
called from the pileup of reads at every position along the reference sequence. 
SAMTools has been shown to identify a larger number of indels compared to the 
other programmes and was found to have a high false positive rate; SAMTools also 
identified a higher number of common indels compared to the other two methods, 
indicating a lower false negative rate [1006].  
329 
 
iv) Annotation of variants with ANNOVAR 
(http://www.openbioinformatics.org/annovar [846]). 
7.2.2.1 Quality control 
7.2.2.2 Per-variant quality control 
In addition to the criteria applied when calling SNVs and indels, performance metrics were 
calculated to see if the quality of the data could be improved by applying further 
thresholds. Vcf files were manipulated and merged by the researcher, using Vcftools 
(v0.1_11, SourceForge, Dice Holdings, Inc., http://vcftools.sourceforge.net), to create one 
file including all exonic variants for all individuals (used for performance metrics) and one 
including all exonic and splicing variants for all individuals (used for association analyses). 
These merged vcf files were imported into PLINK/SEQ 
(https://atgu.mgh.harvard.edu/plinkseq).  
The Ti/Tv ratio, proportion of variants present in public databases (such as dbSNP, 1000 
Genomes Project [April 2012 release], or NHLBI [data release ESP6500]), number of 
singletons, and mean genotype quality score were calculated for each individual 
(PLINK/SEQ command: i-stats), firstly when no additional quality control thresholds were 
applied, and then when adjusting certain thresholds (for example, excluding genotypes 
with a quality score [GQ - Phred-scaled probability that the called genotype is wrong] <10 
or <20). Such statistics are useful as broad indicators of the quality of the data set [944]. 
The Ti/Tv ratio is a useful diagnostic metric because transitions (A<-> G and C <-> T) 
naturally occur more often than transversions (A <-> C, A <-> T, G <-> C or G <-> T); for 
exons present in the Consensus Coding Sequence Project database, the average Ti/Tv ratio 
should be close to 3:1 [1042]. The percentage of variants found in public databases is used 
to obtain an approximate false-positive rate of variant calling. There is no standard 
definition of the proportion of variants that should be present in public databases 
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(previously-reported proportions vary widely: in one study, 85-88% of identified variants 
were found to be present in dbSNP [1043], depending on the platform used for sequencing; 
in another, an average of 92% of variants were already annotated in dbSNP (v129) [874]), 
but individuals with a lower proportion compared to others in the dataset may indicate an 
increased false positive discovery rate. It should be noted that the proportion of novel 
variants varies between regions with different ancestries; individuals of Native American 
ancestry have a higher proportion of novel variants compared with those of European 
ancestry, and individuals of African ancestry have the highest rates of novelty [814]. 
Random errors in sequencing are likely to be limited to a single sequence within the 
population sample and so an elevated number of singletons could indicate that errors are 
present [1044]; it has been stated that the proportion of singletons should be below 10% 
[1012, 1042], although the ‘normal’ number of singletons will depend on individual genetic 
diversity.  
Additional quality control filtering made little difference to the performance metrics. 
7.2.2.3 Per-individual quality control 
All samples were screened to see if they had any non-synonymous variants in SLC2A1 (this 
was in addition to the Custom Amplicon sequencing of SLC2A1).  
Individuals with <20,000 exonic variants detected were removed (this would be <24,000 for 
Africans but no individuals with full African heritage were exome sequenced). With this 
criterion, most of the exome should be covered; from whole exome sequencing data, 
approximately 10,000-12,500 synonymous variants, 9,500-12,000 non-synonymous 
variants and 100–200 stop or splice altering variants are expected per individual, giving a 
total of approximately 24,000 SNVs in African American samples and 20,000 in European 
American samples [935, 945]. 
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Individuals were not excluded based on mean coverage depth, a metric commonly used 
with whole genome sequencing data. This metric has almost no value in capture 
experiments, because the distribution of reads is uneven as a result of the capture [1045]. 
One threshold that has been previously adopted is ≥80% bases with ≥20x coverage [945, 
1046], although, due to the variation in efficiency of exome enrichment, each exome must 
be sequenced to an average depth of 60-80× in order to obtain this level of coverage [945]. 
Instead, the percentage coverage of exonic bases at 2x/10x/20x/30x was inspected for 
each individual to detect outliers (by visual inspection of scatter plots created in Microsoft 
Excel 2010 (v. 14, Microsoft, Washington, USA)): see Figure 7.1, Figure 7.2, Figure 7.3 and 
Figure 7.4. Outliers are highlighted in circles; these individuals were removed from 
association analyses. 
 
Figure 7.1: Proportion of exonic bases achieving ≥2X coverage 
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Figure 7.2: Proportion of exonic bases achieving ≥10X coverage 
 
Figure 7.3: Proportion of exonic bases achieving ≥20X coverage 
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Figure 7.4: Proportion of exonic bases achieving ≥30X coverage 
The mean Ti/Tv ratio, mean genotype quality score, the number of singletons and the 
proportion of heterozygous genotypes per individual were also plotted in a scatter graph to 
identify outliers due to potential sequencing errors (see Figure 7.5, Figure 7.6, Figure 7.7 
and Figure 7.8).  
 
Figure 7.5: Ti/Tv ratio of all exonic variants per individual 
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Figure 7.6: Mean genotype quality score per individual  
 
Figure 7.7: Proportion of singletons per individual 
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Figure 7.8: Proportion of heterozygous genotypes per individual 
 
In order to exclude individuals with a greater degree of relatedness compared to others, for 
each pair of individuals who passed quality-control criteria, the number of genotypes for 
which both individuals carry an alternative allele was calculated in PLINK/SEQ (command: 
ibs-matrix --long-format --two-counts). The number of genotypes where both members of 
the pair carry an alternative allele divided by the total number of non-missing genotypes 
for the pair was plotted in a scatter graph. Outliers were determined by visual inspection of 
the plot (see Figure 7.9) and the individual from the pair with the lowest coverage was 
removed from association analyses.  
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Figure 7.9: Identity-by-state matrix: genotypic similarity between all pairs of individuals 
 Population structure 7.2.3
In order not to bias association study results, differences in population structure must be 
balanced between responders and non-responders. There are several measures that can be 
used to check ancestry mismatching. Non-synonymous variants show greater levels of 
population differentiation than synonymous variants [1047] and the ratio of non-
synonymous to synonymous variation varies between regions with different ancestries 
[814]. The proportion of heterozygous genotypes and novel variants also varies between 
populations: individuals of African ancestry show the highest rates of heterozygosity and 
novelty, compared to those of Native American and European ancestry [814]. The 
proportion of non-synonymous, non-synonymous:synonymous, novel and heterozygous 
variation may thus be used as a rough indication of ancestry. An unpaired t-test of unequal 
variance was used to determine whether the mean proportions were different between 
responders and non-responders. As outlined in Table 7.2, these metrics are not significantly 
different.  
0
0.1
0.2
0.3
0.4
0.5
0.6
0 200 400 600 800
R
at
io
 o
f 
th
e
 n
u
m
b
e
r 
o
f 
ge
n
o
ty
p
e
s 
w
h
e
re
 
b
o
th
 m
em
b
er
s 
o
f 
th
e 
p
ai
r 
ca
rr
y 
an
 
al
te
rn
at
iv
e
 a
lle
le
 t
o
 t
h
e
 t
o
ta
l n
u
m
b
e
r 
o
f 
n
o
n
-m
is
si
n
g 
ge
n
o
ty
p
e
s 
fo
r 
th
e
 p
ai
r 
Pairs of individuals 
Identity-by-state matrix: genotypic similarity 
between all pairs of individuals 
337 
 
Table 7.2: Mean performance metrics for responders and non-responders as measures of ancestry 
matching 
 Responders 
Non-
responders 
P-value from 
t-test* 
Proportion of novel exonic variants** 2.50 2.51 0.46 
Proportion of non-synonymous variants 47.11 46.92 0.08 
Ratio of non-synonymous:synonymous 
variants 
1.05 1.06 0.10 
Proportion of heterozygous genotypes 0.59 0.59 0.17 
*unpaired Student’s t-test with a two-tailed distribution calculated in Microsoft Excel 
**not reported in dbSNP137, 1000 Genomes Project (April 2012 release), or NHLBI (data release 
ESP6500, with 6,503 individuals), according to ANNOVAR annotation 
 
 Association analyses 7.2.4
7.2.4.1 Single variant approach 
A Fisher’s exact test, excluding variants with deviation from HWE (p=1x10-6) was conducted 
in PLINK/SEQ (command: v-assoc --mask hwe=0:1e-6). In view of the small sample size, 
reference/alternative allele counts in responders and non-responders were examined, and 
p-values obtained from the association test.  
λGC cannot be calculated in PLINK/SEQ. The vcf file was thus converted to PLINK format 
using Vcftools and the Fisher’s exact test run in PLINK with the command --fisher --adjust.  
7.2.4.2 Gene-based approach 
As a complex trait, it may be that multiple variants in a gene (present in different people) 
influence KD response. A gene-based test is therefore appropriate, and it should give 
higher power to detect association signals from variants (especially those of low MAF or 
with small effect sizes), compared to single-variant tests [797] and there is evidence to 
suggest that rare variants often act collectively to influence disease risk [857, 1048, 1049]. 
Binary files were imported into PLINK/SEQ (v0.08, 
http://atgu.mgh.harvard.edu/plinkseq/index.shtml), where gene-based association tests 
were conducted (command: assoc --mask loc.group=refGene --mac=1-9999).  
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refGene refers to a reference gene region file that was uploaded to the locus database. This 
file, based on the RefSeq file provided by PLINK/SEQ (NCBI Reference Sequence Database), 
using hg19 coordinates, was checked and amended by Dr Costin Leu. --mac=1-9999 
specifies that only variants with between 1 and 9999 (any high number could be used in 
this case) copies of the alternative allele are included. P-values were obtained by adaptive 
permutation (permutation in PLINK/SEQ gives empirical p-values and does not account for 
multiple testing). 
The c-alpha test [660] was first conducted (command: assoc --tests calpha), as it accounts 
for the possibility that a gene may contain both protective and deleterious (with relation to 
the phenotypic trait being analysed) variants and thus has higher power than one-
directional tests when the association effects of variants in a gene are not uni-directional 
[660, 1036, 1050]. In this study, controls are not representative of the general population 
(the phenotypic trait is not a disease, it is response to a treatment) and so it cannot be 
assumed that susceptibility variants will be damaging. Mutations in SLC2A1, for example, 
are protective with regards KD response. Instead of using a burden-based summary statistic 
over a gene region, the c-alpha test compares the observed and expected distribution of 
minor alleles in cases and controls at each locus, assuming independence of each variant, 
to determine whether there is evidence of an ‘unusual distribution’. Evidence from multiple 
loci is combined to form the test statistic. Singleton variants are pooled into a single 
binomial count per phenotype, akin to a burden test.  
A gene burden and count of case-unique alleles test were also performed in PLINK/SEQ, as 
c-alpha was found to have low power in certain circumstances. These tests assume that all 
variants within a gene act in the same direction and that a higher burden of variants is 
damaging, rather than protective with regards the phenotypic trait. In the gene burden 
test, the number of non-reference alleles in a gene present in cases is compared to those in 
339 
 
controls; in the unique test, the number of case-unique non-reference alleles is compared. 
These tests were conducted once with non-responders as cases and once with responders 
as cases in order to identify genes that are associated with unfavourable and favourable KD 
response. 
As well as examining p-values from gene-based tests, the ‘DESC’ columns in the output files 
were also examined to identify genes with the greatest differential distribution of 
alternative alleles between the responder and non-responder groups. In the c-alpha test, 
for example, this column gives a frequency breakdown of the number of variants with 
alternative alleles in cases and controls. The rationale for this is that, even if the differential 
distribution of alternative alleles in one gene amongst cases and controls does not 
generate a low p-value (for example, due to the small sample size), if all or many 
responders harbour the alternative alleles of variants in a particular gene but no or very 
few non-responders do, this suggests that the gene (or the variants within that gene) have 
a strong effect on the phenotype. The greater the number of samples in one response 
group with variants in that particular gene, the stronger the effect size these variants 
should have on the phenotype. For example, a gene with variants in all responders (or all 
but one/two/three responders and so on) but no (or very few) non-responders would 
certainly be of interest. If variants in a particular gene that influenced KD response were 
fully penetrant, they would be expected to be present in all members of one response 
group, compared to no members of the other response group. This may not be the case 
with KD response, but it is a prudent first step in the rare variant analysis process. The 
genes with the greatest differential distribution of variants in responders/non-responders 
or those with the lowest p-values in the gene-based tests were looked up in online 
databases (http://www.ncbi.nlm.nih.gov/gene and http://www.genecards.org) to 
determine whether they are known to be associated with neurological/metabolic function.  
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One set of association analyses (referred to as group 0) was conducted with all exonic and 
splicing variants, with no filtering based on MAF or predicted functional consequence. This 
accounts for the fact that variants that affect KD response may not be subject to negative 
selection pressure in the general population – response to starvation or metabolic 
therapies that mimic starvation may not affect fitness, particularly in populations with less 
exposure to periods of famine throughout history. The group 0 analyses also account for 
the fact that synonymous variants may also be of importance, although they have been less 
frequently associated with disease compared to non-synonymous variants.   
Further analyses were then conducted with various filtering criteria, to include variants that 
are most likely to be functional: 
i) group 1: only including all common and rare functional exonic variants (non-
synonymous [SNVs or indels in multiples of three], stop-gain, stop-loss, 
frameshift indels and splice site variants). 
ii) group 2: only including loss-of-function and splicing variants (stop-gain SNVs, 
frameshift indels and splice site variants). Loss-of-function SNVs are enriched 
for low-frequency alleles compared to synonymous and missense SNVs [815] 
and so this filtering approximates a rare variant analysis. 
Variants were not filtered according to predictions of functional consequence by algorithms 
because of the uncertainty associated with such algorithms. They may be used as a guide to 
estimate the effects of the most interesting variants. 
The novelty approach (where only previously-unidentified variants are included, a 
technique commonly used for Mendelian disease gene identification) was not used, as it 
assumes that the susceptibility variant is rare and likely to be previously unidentified. 
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7.2.4.3 Correction for multiple testing 
Adjustment for multiple testing was made with a Bonferroni correction for the number of 
genes considered in each test: 0.05 divided by the number of genes that could generate a 
p-value<1 (i-value [an estimate of the minimal achievable p-value for a gene given in 
PlinkSeq] <1). This approach has been used in recent studies to set significance thresholds 
for gene-burden tests when assessing rare variant genotype-phenotype associations [714, 
797, 944]. 
A suggestive significance threshold was set by dividing 1 by the number of tests, a strategy 
used in previous publications [693, 694].  
7.2.4.4 Pathway-based analysis 
As a complex trait, response to the KD may be influenced by many different genes, rather 
than just one single gene. A self-contained pathway analysis was conducted, testing the 
null hypothesis that no particular pathway is associated with KD response. A list of genes 
and their associated pathways was downloaded from the Broad Institute website 
(www.broadinstitute.org/gsea). This list included KEGG, PANTHER, REACTOME, BIOCARTA 
and PID pathways. This avoids potential bias from limiting oneself to one set of pathways. 
Analyses were not conducted with GO terms due to the general nature of many of these 
categories, which makes interpretation difficult.  
The list of genes and associated pathways was uploaded into the locus database in 
PLINK/SEQ. Association analyses were performed with the same method used for gene-
based association tests, but subsequently specifying the pathway with which the gene is 
associated (command:  assoc --mask locset.group=refGene,allPathways --mac=1-9999 ). In 
this way, variants are grouped into genes (identified in the refGene file) and these genes 
are then grouped into pathways (located in the allPathways file). The gene burden and 
case-unique tests were conducted as the primary analyses (once with non-responders as 
342 
 
cases and once with responders as cases). The c-alpha test was not used in order to 
distinguish between those pathways that adversely affect KD response and those that 
favourably affect KD response.   
7.3 Results 
 Quality control and population structure 7.3.1
One extreme responder was excluded due to presence of a non-synonymous variant in 
SLC2A1. This was subsequently confirmed in a clinical lab at Birmingham Children’s 
Hospital. 
Three individuals were excluded as <20,000 exonic variants were discovered and the 
proportion of variants with 2x/10x/20x/30x coverage was lower than in other samples. 
Another individual was excluded due to low coverage.  
One pair of individuals were identified as outliers in terms of genotypic similarity. The 
individual with the lower coverage (2x, 10x, 20x and 30x) was removed.  
Three individuals were excluded due to high proportions of heterozygous variants and 
number of singletons. 
No individuals were excluded on the basis of Ti/Tv ratio or genotype quality. 
No individuals were excluded based on proportions of novel exonic variants as, for all 
individuals, ≥96% of all called exonic variants were previously reported in public databases. 
14 responders and 22 non-responders were included in the analyses. 
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Table 7.3: Function of variants included in the exome sequencing analyses 
Variant function Exonic function Number of variants 
Downstream n/a 60 
Exonic Frameshift substitutions 256 
 Non-frameshift substitutions 509 
 Non-synonymous 39017 
 Stop-gain 539 
 Stop-loss 37 
 Synonymous 35301 
 Unknown 698 
Exonic splicing Frameshift substitutions 7 
 Non-frameshift substitutions 4 
 Non-synonymous 280 
 Stop-gain 5 
 Synonymous 211 
 Unknown 9 
Intergenic n/a 2491 
Intronic n/a 1988 
Exonic non-coding RNA n/a 727 
Intronic non-coding RNA n/a 119 
Splicing non-coding RNA n/a 8 
UTR3 non-coding RNA n/a 7 
UTR5 non-coding RNA n/a 2 
Splicing n/a 318 
Upstream n/a 76 
Upstream; downstream n/a 4 
UTR3 n/a 495 
UTR5 n/a 253 
Total 83421 
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Table 7.4: Performance metrics for all exonic variants for all samples included in analyses, n=36 
Sample 
Number of called 
exonic variants 
Percentage of novel 
exonic variants* 
Percentage of non-
synonymous variants 
Mean Ti/Tv 
ratio 
Percentage of 
heterozygous 
genotypes 
Percentage 
of 
singletons 
Mean quality score 
1 20717 4.04 46.99 2.92 58.55 8.72 149.53 
2 22207 2.34 47.24 2.90 60.91 5.72 147.33 
3 20852 2.56 46.81 2.87 59.40 5.44 150.83 
4 20290 2.24 46.66 2.97 58.46 6.03 151.57 
5 21563 2.62 46.61 2.81 60.54 6.29 145.78 
6 21267 2.09 46.80 2.94 59.58 5.62 146.89 
7 21134 3.73 46.98 2.82 56.39 9.90 144.18 
8 21534 3.66 46.95 2.81 59.67 5.76 144.85 
9 21235 2.20 46.80 2.93 58.91 5.77 146.58 
10 20159 2.52 47.18 2.87 58.52 6.09 149.94 
11 21184 2.26 47.23 3.02 59.49 5.48 145.24 
12 20489 2.39 47.37 2.93 58.25 3.44 148.96 
13 20292 2.41 46.71 2.92 57.18 5.66 150.19 
14 22713 2.48 47.08 2.84 60.87 6.77 147.09 
15 21686 3.02 47.57 2.89 59.66 6.80 148.65 
16 20413 2.38 46.74 2.91 58.35 5.76 151.23 
17 20410 1.97 46.94 2.94 58.65 5.52 146.59 
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*not reported in dbSNP137, 1000 Genomes Project (April 2012 release), or NHLBI (data release ESP6500, with 6,503 individuals), according to ANNOVAR 
annotation
18 22748 2.44 47.58 2.75 59.69 6.30 145.91 
19 21560 3.61 47.27 2.87 55.71 7.06 145.77 
20 20659 2.80 46.76 2.95 59.17 7.21 151.27 
21 22779 2.48 46.89 2.89 61.19 6.50 147.37 
22 22758 2.50 48.02 2.81 61.44 7.21 142.28 
23 21649 2.38 46.80 2.95 59.71 5.82 149.56 
24 22113 2.35 47.20 2.89 60.51 5.81 145.93 
25 20531 2.25 47.00 2.94 58.24 5.75 150.84 
26 20151 2.00 47.04 2.94 57.95 5.39 150.91 
27 20547 2.56 46.52 2.89 56.69 5.54 151.05 
28 20472 2.12 46.93 2.88 57.85 5.57 149.37 
29 20802 2.45 46.71 2.83 58.53 5.85 149.74 
30 21031 2.17 46.91 2.89 59.59 5.45 148.40 
31 22019 2.39 47.09 2.89 60.33 5.80 144.10 
32 20171 2.43 46.38 2.84 59.54 5.51 151.90 
33 21656 2.36 47.33 2.85 61.06 5.78 148.21 
34 20601 2.33 46.56 2.89 58.70 5.69 149.44 
35 21018 2.47 47.21 2.97 60.19 5.91 148.79 
36 21951 2.29 46.92 2.91 59.81 5.97 146.46 
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 Association studies 7.3.2
7.3.2.1 Single variant approach 
λGC was 1.00, indicative of lack of importance of population structure.  
A significance threshold of 6.42x10-7 was set, based on testing for 84905 variants. No 
statistically significant results were obtained, nor were any p-values below the suggestive 
significance threshold of 1.177x10-5 (1/number of variants or tests). The lowest p-value was 
0.00019998, from rs3986599, a non-synonymous SNV in TRPM5, which was present in 
17/22(77%) non-responders and 1/14 responders, all with genotype A/G. 
Other variants with the largest differences in alternative allele count between responders 
and non-responders were:  
rs5005869, a non-synonymous SNV in ANKRD36C, present in 17/22(77%) non-responders 
and 1/14(7%) responders, all with genotype C/T.  
rs79074863, a non-synonymous SNV in XPO1, present in 13/22(59%) non-responders and 0 
responders. 
rs2490085, a SNV in the 5’UTR of CCNYL2, present in 12/22(%) non-responders and 0 
responders, all with genotype A/T. 
rs77242743, a synonymous SNV in BMP1, present in 12/22(%) non-responders and 0 
responders, all with genotype A/C. 
NIPA2, L2HGDH, ADM5, NBPF8 and CDH23 each had a variant present in 11/22(50%) non-
responders and 0 responders. Only those variants present in L2HGDH (c.T593G:p.V198G at 
chr14:50750699; all individuals had genotype A/C) and ADM5 (c.G344C:p.R115P at 
chr19:50193632, all individuals had genotype C/G) were exonic.  
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rs79074863 and c.T593G:p.V198G are likely to affect gene function. They are predicted to 
be damaging by all functional algorithms in ANNOVAR (SIFT score=0, PolyPhen2 score=1, 
LRT score=1, MutationTaster score=1) and are located in conserved regions (GERP++ 
scores=5.43 and 5.22 and PhyloP scores=0.999). The effects of the other variants on gene 
function are unknown: rs3986599 is not predicted to be damaging by any of the algorithms 
in ANNOVAR and it is not highly conserved (GERP++ score=1.57); rs5005869 has a SIFT 
score of 0.35 (the closer the score is to 0, the more damaging the variant) but no other 
ANNOVAR annotation; no annotation was available for rs2490085 or c.G344C:p.R115P. 
None of these variants have been associated with any disease/traits, according to 
Phenotype Genotype Integrator. 
Of the genes including coding variants, L2HGDH, TRPM5 and XPO1 have a role that could 
feasibly influence KD response. 
L2HGDH encodes L-2-hydroxyglutarate dehydrogenase, an enzyme that oxidizes L-2-
hydroxyglutarate to alpha-ketoglutarate, which is an intermediate in the Krebs cycle. 
Mutations in L2HGDH cause the neurometabolic disorder L-2-hydroxyglutaric aciduria.  
TRPM5 encodes a calcium-activated cation channel (transient receptor potential cation 
channel subfamily M member 5), which plays a role in the signal transduction for bitter and 
sweet taste in sensory neurons [1051] and has been shown to regulate glucose-stimulated 
insulin secretion: Trpm5-/- mice had prolonged elevation of blood glucose levels compared 
to wild-type mice after a glucose load [1052]. 
XPO1 encodes exportin 1, which mediates nuclear export signal-dependent protein 
transport. This protein has been shown to mediate cellular response to stress and may 
influence glucose homeostasis.  
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Little is known about the role of ANKRD36C. ADM5 is thought to encode a non-functional 
remnant of adrenomedullin-5, which is a short chain of amino acids associated with 
tumours of the medulla of the adrenal glands.  
7.3.2.2 Gene-based approach 
C-alpha analyses:  
i) Group 0: all exonic and splicing variants, no filtering. 
ii) Group 1: missense exonic and splicing variants - non-synonymous (SNV or 
indels in multiples of 3), stop-gain, stop-loss, frameshift indels and splice site 
variants. 
iii) Group 2: exonic loss-of-function and splicing variants. 
Group 0: 16314 genes with i-value <1 = significance threshold of 3.06x10-6 and a suggestive 
significance threshold of 6.13x10-5. ANKRD36C reached statistical significance (p=2.00x10-6) 
and five genes reached suggestive significance.  
Group 1: 13167 genes with i-value <1 = significance threshold of 3.79x10-6 and a suggestive 
significance threshold of 7.59x10-5. Seven genes reached suggestive significance.  
Group 2: 1662 genes with i-value <1 = significance threshold of 3.008x10-5 and a suggestive 
significance threshold of 0.000601. No genes reached significance or suggestive 
significance.  
Genes that reached significance or suggestive significance in c-alpha Group 0 and 1 
analyses are given in Table 7.5. 
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Table 7.5: Genes that reached significance or suggestive significance in c-alpha analyses: Groups 0 and 1 
Group 0 
Gene 
Number of 
variants in 
gene 
P-value I-value 
Frequency breakdown: non-responder/responder alternative allele counts for particular variants  
(variant class and rs number or position given from ANNOVAR annotation) 
ANKRD36C 48 2.00x10-6 1.00x10-6 
8 variants present in 0 non-responders and 1 responder: synonymous SNV (rs201755982), non-synonymous 
SNV at chr2:96521262,  non-synonymous SNV (rs74328999),  synonymous SNV (rs10211258),  non-
synonymous SNV (rs78780931), synonymous SNV at chr2:96591119, frameshift insertion at chr2:96610401, 
non-synonymous SNV at chr2:96557418 
3 variants present in 0 non-responders and 2 responders: stop-gain SNV (rs74941794), synonymous SNV 
(rs183934154), splicing variant (rs202102082) 
1 variant present in 0 non-responders and 5 responders: non-synonymous SNV rs80350011 
9 variants present in 1 non-responder and 0 responders: non-synonymous SNV (rs200478637), non-
synonymous SNV (rs5005871), non-synonymous SNV (rs2951081), non-synonymous SNV (rs112858216), 
frameshift deletion at chr2:96525668..96525672, synonymous SNV (rs189877528) 
non-synonymous SNV (rs199969223), synonymous SNV at chr2:96601236), synonymous SNV (rs115480888) 
1 variant present in 1 non-responder and 1 responder: non-synonymous SNV (rs78585559) 
1 variant present in 1 non-responder and 2 responders:  synonymous SNV (rs75657861) 
1 variant present in 10 non-responders and 2 responders: non-synonymous SNV (rs78473403) 
1 variant present in 12 non-responders and 2 responders: splicing variant (rs1819101) 
1 variant present in 14 non-responders and 13 responders: non-synonymous SNV (rs62154594) 
1 variant present in 16 non-responders and 9 responders: non-synonymous SNV (rs74946480) 
1 variant present in 17 non-responders and 1 responder: rs5005869 non-synonymous SNV)* 
1 variant present in 17 non-responders and 13 responders: non-synonymous SNV (rs78739183) 
1 variant present in 17 non-responders and 14 responders: non-synonymous SNV (rs77710257) 
1 variant present in 17 non-responders and 9 responders: synonymous SNV (rs1636081) 
1 variant present in 18 non-responders and 12 responders: non-synonymous SNV (rs62154562) 
3 variants present in 19 non-responders and 14 responders: synonymous SNV (rs62154593), non-synonymous 
SNV (rs62154561), non-synonymous SNV (rs62154618) 
1 variant present in 2 non-responders and 2 responders: synonymous SNV (rs202113195) 
1 variant present in 2 non-responders and 4 responders: non-synonymous SNV (rs35461149) 
1 variant present in 20 non-responders and 12 responders: non-synonymous SNV (rs1636083) 
1 variant present in 21 non-responders and 13 responders: non-synonymous SNV (rs199988716) 
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1 variant present in 21 non-responders and 8 responders: synonymous SNV (rs5005870) 
1 variant present in 22 non-responders and 14 responders: synonymous SNV (rs148485539) 
1 variant present in 3 non-responders and 2 responders: synonymous SNV (rs4907220) 
1 variant present in 3 non-responders and 5 responders: non-synonymous SNV (rs79908880) 
1 variant present in 4 non-responders and 7 responders: synonymous SNV (rs10211258) 
1 variant present in 5 non-responders and 0 responders: synonymous SNV (rs62156871) 
1 variant present in 6 non-responders and 0 responders: non-synonymous SNV (rs5005868) 
1 variant present in 8 non-responders and 7 responders: synonymous SNV (rs10211258) 
1 variant present in 9 non-responders and 6 responders: non-synonymous SNV (rs11695514) 
CCDC104 3 2.70x10
-5
 3.85x10
-6
 
1 variant present in 1 non-responder and 10 responders: non-synonymous SNV (rs3762513) 
1 variant present in 3 non-responders and 1 responder: non-synonymous SNV (rs1045920) 
1 variant present in 3 non-responders and 2 responders: non-synonymous SNV (rs1045910) 
TBC1D3 6 3.14x10
-5
 2.24x10
-6
 
3 variants present in 0 non-responders and 1 responder: non-synonymous SNV (rs11550750), non-
synonymous (rs199547231), synonymous SNV (rs4606788) 
1 variant present in 0 non-responders and 5 responders: non-synonymous SNV (rs4795237) 
1 variant present in 5 non-responders and 12 responders: non-synonymous SNV (rs306818) 
1 variant present in 6 non-responders and 0 responders synonymous SNV (rs306820) 
TRPM5 11 3.22x10-5 2.30x10-6 
1 variant present in 0 non-responders and 1 responder: frameshift insertion at chr11:2434061 
1 variant present in 1 non-responder and 0 responders: synonymous SNV (rs141187622) 
1 variant present in 1 non-responder and 2 responders: non-synonymous SNV (rs34364959) 
1 variant present in 10 non-responders and 0 responders: synonymous SNV (rs4929981)  
1 variant present in 10 non-responders and 3 responders: non-synonymous SNV (rs4929982) 
1 variant present in 12 non-responders and 9 responders: synonymous SNV (rs2074234) 
1 variant present in 17 non-responders and 1 responder: non-synonymous SNV (rs3986599) 
1 variant present in 2 non-responders and 0 responders: non-synonymous SNV (rs34551253) 
1 variant present in 2 non-responders and 2 responders: non-synonymous SNV (rs34350821 
1 variant present in 4 non-responders and 5 responders: synonymous SNV (rs800342) 
1 variant present in 9 non-responders and 9 responders: non-synonymous SNV (rs886277) 
HMGXB4 2 3.33x10-5 2.38x10-6 
1 variant present in 1 non-responder and 0 responders: frameshift insertion at chr22:35661553 
1 variant present in 2 non-responders and 11 responders: non-synonymous SNV (rs1053593) 
C1orf105 10 4.20x10-5 3.00x10-6 
1 variant present in 0 non-responders and 1 responder: non-synonymous SNV at chr1:172411009* 
3 variants present in 1 non-responder and 0 responders: non-synonymous SNV at chr1:172410881*, non-
synonymous SNV (rs139238043)*, synonymous SNV (rs2285175)* 
1 variant present in 1 non-responder and 1 responder: non-synonymous SNV (rs34001453)* 
2 variants present in 1 non-responder and 4 responders: splicing variant (rs41310899), non-synonymous SNV 
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(rs16844498) 
1 variant present in 1 non-responder and 9 responders: non-synonymous SNV (rs1129942) 
1 variant present in 7 non-responders and 12 responders: non-synonymous SNV (rs1063412)* 
1 variant present in 7 non-responders and 7 responders: synonymous SNV (rs2230471)* 
 
Group 1 
Gene 
Number of 
variants in 
gene 
P-value I-value 
Frequency breakdown: non-responder/responder alternative allele counts for particular variants 
(variant class and rs number or position given from ANNOVAR annotation) 
ANKRD36C 33 1.20x10-5 1.00x10-6 
5 variants present in 0 non-responders and 1 responder: non-synonymous SNV at chr2:96521262,  non-
synonymous SNV (rs74328999),  non-synonymous SNV (rs78780931), frameshift insertion at chr2:96610401, 
non-synonymous SNV at chr2:96557418 
2 variants present in 0 non-responders and 2 responders: stop-gain SNV (rs74941794), splicing variant 
(rs202102082) 
1 variant present in 0 non-responders and 5 responders: non-synonymous SNV rs80350011 
9 variants present in 1 non-responder and 0 responders: non-synonymous SNV (rs200478637), non-
synonymous SNV (rs5005871), non-synonymous SNV (rs2951081), non-synonymous SNV (rs112858216), 
frameshift deletion at chr2:96525668..96525672, non-synonymous SNV (rs199969223) 
1 variant present in 1 non-responder and 1 responder: non-synonymous SNV (rs78585559) 
1 variant present in 10 non-responders and 2 responders: non-synonymous SNV (rs78473403) 
1 variant present in 12 non-responders and 2 responders: splicing variant (rs1819101) 
1 variant present in 14 non-responders and 13 responders: non-synonymous SNV (rs62154594) 
1 variant present in 16 non-responders and 9 responders: non-synonymous SNV (rs74946480) 
1 variant present in 17 non-responders and 1 responder: non-synonymous SNV (rs5005869) 
1 variant present in 17 non-responders and 13 responders: non-synonymous SNV (rs78739183) 
1 variant present in 17 non-responders and 14 responders: non-synonymous SNV (rs77710257) 
1 variant present in 18 non-responders and 12 responders: non-synonymous SNV (rs62154562) 
2 variants present in 19 non-responders and 14 responders: non-synonymous SNV (rs62154561), non-
synonymous SNV (rs62154618) 
1 variant present in 2 non-responders and 4 responders: non-synonymous SNV (rs35461149) 
1 variant present in 20 non-responders and 12 responders: non-synonymous SNV (rs1636083) 
1 variant present in 21 non-responders and 13 responders: non-synonymous SNV (rs199988716)3/5(1) 
1 variant present in 6 non-responders and 0 responders: non-synonymous SNV (rs5005868) 
1 variant present in 8 non-responders and 7 responders: synonymous SNV (rs10211258) 
1 variant present in 9 non-responders and 6 responders: non-synonymous SNV (rs11695514) 
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HMGXB4 2 1.56x10
-5
 2.22x10
-6
 
1 variant present in 1 non-responder and 0 responders: frameshift insertion at chr22:35661553 
1 variant present in 2 non-responders and 11 responders: non-synonymous SNV (rs1053593) 
C1orf105 8 1.56x10
-5
 1.11x10
-6
 
1 variant present in 0 non-responders and 1 responder: non-synonymous SNV at chr1:172411009* 
2 variants present in 1 non-responder and 0 responders: non-synonymous SNV at chr1:172410881*, 
synonymous SNV (rs2285175)* 
1 variant present in 1 non-responder and 1 responder: non-synonymous SNV (rs34001453)* 
2 variants present in 1 non-responder and 4 responders: splicing variant (rs41310899), non-synonymous SNV 
(rs16844498) 
1 variant present in 1 non-responder and 9 responders: non-synonymous SNV (rs1129942) 
1 variant present in 7 non-responders and 12 responders: non-synonymous SNV (rs1063412)* 
CCDC104 3 3.33x10
-5
 2.38x10
-6
 
1 variant present in 1 non-responder and 10 responders: non-synonymous SNV (rs3762513) 
1 variant present in 3 non-responders and 1 responder: non-synonymous SNV (rs1045920) 
1 variant present in 3 non-responders and 2 responders: non-synonymous SNV (rs1045910) 
TBC1D3 4 3.35x10
-5
 4.78x10
-6
 
2 variants present in 0 non-responders and 1 responder: non-synonymous SNV (rs11550750), non-
synonymous (rs199547231) 
1 variant present in 0 non-responders and 5 responders: non-synonymous SNV (rs4795237) 
1 variant present in 5 non-responders and 12 responders: non-synonymous SNV (rs306818) 
IFI27L1 3 4.49x10-5 9.94x10-5 
1 variant present in 0 non-responders and 5 responders: non-synonymous SNV at chr14:94568370 
1 variant present in 0 non-responders and 2 responders: non-synonymous SNV (rs117094493) 
1 variant present in 0 non-responders and 5 responders: stop-gain SNV (rs79237142) 
TRPM5 7 4.54x10
-5
 3.24x10
-6
 
1 variant present in 0 non-responders and 1 responder: frameshift insertion at chr11:2434061 
1 variant present in 1 non-responder and 2 responders: non-synonymous SNV (rs34364959) 
1 variant present in 10 non-responders and 3 responders: non-synonymous SNV (rs4929982) 
1 variant present in 12 non-responders and 9 responders: synonymous SNV (rs2074234) 
1 variant present in 2 non-responders and 0 responders: non-synonymous SNV (rs34551253) 
1 variant present in 2 non-responders and 2 responders: non-synonymous SNV (rs34350821 
1 variant present in 9 non-responders and 9 responders: non-synonymous SNV (rs886277) 
*variants also overlap with PIGC gene 
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In this dataset, the c-alpha test was found to have low power to detect associations with 
genes containing variants that are all detrimental with regards KD response. With such 
genes, lower p-values are generated with tests that only allow for damaging variants. For 
example, when conducting the gene burden and count of case-unique alleles tests, which 
assume a uni-directional effect of variants, XPO1 generated the lowest p-value: 
Group 0 
Burden test p=3.59x10-5 
Count of case-unique alleles test p=3.73x10-5 
compared to c-alpha test p=9.30x10-5 (just below suggestive significance) 
XPO1 reached suggestive significance in the burden and count of case-unique alleles test 
tests. rs143005485, a synonymous SNV, was present in two non-responders and 0 
responders) and rs79074863, a non-synonymous SNV, was present in 13 non-responders 
and 0 responders (as identified from the single variant approach). 
Group 1 
XPO1 also generated the lowest p-value in the Group 1 burden and count of case-unique 
alleles tests, although it did not reach suggestive significance.  
Group 2  
No individual in this cohort harboured loss-of-function or splicing variants in XPO1. CDC27 
generated the lowest p-value in the burden test. OR52J3 generated the lowest p-value in 
the count of case-unique alleles test. No genes reached significance or suggestive 
significance in any test. 
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Testing for protective variants (this assumes that harbouring the alternative allele is 
beneficial for KD response): 
Group 0 
POTEB (p=3.59x10-5) and SGOL2 (p=5.63.x10-5) reached suggestive significance in the 
burden test; OR5M10 (p=1.43x10-5) and IFI27L1 (p=5.70x10-5) reached suggestive 
significance in the case-unique alleles test. 
Group 1 
TBC1D3 (p=2.08x10-5) and C1orf105 (p=2.98x10-5) reached suggestive significance in the 
burden test; OR5M10 (p=1.78x10-5) and IFI27L1 (p=3.35x10-5) reached suggestive 
significance in the case-unique alleles test. 
Group 2 
No genes reached significance or suggestive significance in any test. PAPPA had the lowest 
p-value in the burden test. IFI27L1 had lowest p-value in the in the case-unique alleles test. 
Examining alternative allele counts in responders/non-responders, XPO1 is the gene in 
which the highest number of non-responders (and no responders) harbours variants. 
12/22(55%) non-responders and no responders harbour variants in ADM5. 
Other genes (not with case or control-unique variants) that may be of interest are GBF1 
and APBA2, in which 12/22(55%) non-responders and one responder harbour variants. 
Information (taken from www.genecards.org, http://www.ncbi.nlm.nih.gov and literature 
searches) regarding the roles of genes that reached significance or suggestive significance 
or those genes with the greatest difference in the number of responders/non-responders 
harbouring alternative alleles is given in Table 7.6.  
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Table 7.6: Genes of most interest from exome sequencing analyses 
Gene Name Role GO terms Pathways 
XPO1 
exportin 1 (CRM1 
homolog, yeast) 
Encodes exportin 1, which mediates leucine-rich nuclear export 
signal-dependent protein transport. 
The protein may influence glucose homeostasis via 
translocation of hepatic glucokinase [1053, 1054] and lead to 
drug-resistance in cancer [1055, 1056]. 
Receptor activity, 
intracellular protein transport, 
nucleobase, nucleoside, nucleotide and 
nucleic acid transport, 
transcription from RNA, polymerase II 
promoter, 
mRNA transcription, 
protein metabolic process 
REACTOME 
pathways: cell 
cycle, mitotic; 
influenza reaction, 
HIV infection,  
ANKRD36C 
ankyrin repeat 
domain 36C 
Unknown. 
Associated diseases are osteomalacia and uremia. 
Protein binding, 
ion channel inhibitor activity 
- 
TRPM5 
transient receptor 
potential cation 
channel subfamily 
M member 5 
Encodes a member of the transient receptor potential protein 
family that an important role in taste transduction, 
and has characteristics of a calcium-activated, non-selective 
cation channel. It carries Na+, K+, and Cs+ ions equally well, but 
not Ca(2+) ions. 
TRPM5 has been shown to affect blood glucose levels [1052]. 
receptor activity 
ion channel activity 
KEGG pathways: 
Taste transduction 
CCDC104 
coiled-coil domain 
containing 104 
May act as an effector for ADP-ribosylation factor-like 3 (ARL3) 
[1057]. It has been shown to increase susceptibility to 
Citrobacter infection [1058].  
Protein binding - 
TBC1D3 
TBC1 domain 
family, member 3 
Encodes an oncogene that is over-represented in many 
different types of cancer, and controls cell proliferation [1059]. 
Acts as a GTPase activating protein for RAB5. 
It delays IRS1 degradation and increases insulin/IGF1-induced 
signal transduction [1060]. 
hydrolase activity, 
protein binding, 
small GTPase regulator activity, 
intracellular protein transport, 
exocytosis, 
cellular component morphogenesis 
- 
HMGXB4 
HMG box domain 
containing 4 
Encodes a nonhistone chromosomal protein that is thought to 
negatively regulate Wnt/beta-catenin signalling during 
development 
transcription factor activity, 
chromatin binding, 
receptor binding, 
intracellular signalling cascade, 
regulation of transcription from RNA 
PANTHER 
pathways: p53 
pathway-High 
mobility group 
protein 1 
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polymerase II promoter, 
establishment or maintenance of 
chromatin architecture 
C1orf105 
chromosome 1 
open reading frame 
105 
Uncharacterised - - 
CCNYL2 cyclin Y-like 2 A pseudogene. 
Protein kinase binding, 
regulation of cyclin-dependent protein 
serine/threonine kinase activity 
- 
ADM5 
adrenomedullin 5 
(putative) 
Probable non-functional remnant of adrenomedullin-5 
cysteine-type peptidase activity, 
ubiquitin-protein ligase activity, 
RNA splicing factor activity, 
transesterification mechanism 
mRNA binding 
gamete generation, 
nuclear mRNA splicing via spliceosome, 
proteolysis 
- 
GBF1 
brefeldin A 
resistant guanine 
nucleotide 
exchange factor 1 
Encodes a guanine nucleotide exchange factor, localised to the 
Golgi apparatus, that plays a role in vesicular trafficking by 
activating ADP ribosylation factor 1 (ARF5). ARF5 interacts with 
GLUT-4.  
Diseases associated with this gene include hepatitis c and 
Alzheimer's disease. Among its related super-pathways are 
‘Golgi Associated Vesicle Biogenesis and Cholesterol and 
Sphingolipids transport’ and ‘Transport from Golgi and ER to 
the apical membrane’. 
protein binding, 
small GTPase regulator activity, 
guanyl-nucleotide exchange factor 
activity, 
amino acid transport, 
intracellular protein transport, 
exocytosis, 
cellular amino acid catabolic process 
REACTOME 
pathways: 
Membrane 
trafficking 
APBA2 
beta (A4) precursor 
protein-binding, 
family A, member 2 
Encodes a neuronal adapter protein that stabilises amyloid 
precursor protein (APP) and inhibits production of proteolytic 
APP fragments, including the A beta peptide that is deposited 
in the brains of Alzheimer's disease patients. The protein is also 
thought to be play a role in vesicular trafficking protein in the 
brain by binding to STXBP1. 
 
protein binding and beta-amyloid 
binding, 
intracellular protein transport 
PANTHER 
pathways: 
Alzheimer disease-
amyloid secretase 
pathway-Amyloid 
beta A4 precursor 
protein-binding 
family A;  
Alzheimer disease-
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amyloid secretase 
pathway-HIV-1 Tat 
interactive protein, 
60kDa 
POTEB 
POTE ankyrin 
domain family, 
member B 
Associated with prostatitis and prostate cancer. 
plasma membrane, extrinsic to 
membrane 
- 
SGOL2 
shugoshin-like 2 (S. 
pombe) 
Involved in chromosome segregation during mitosis and 
meiosis 
M phase, cell cycle, chromosome 
segregation, sister chromatid cohesion, 
meiosis, protein localization, cell cycle 
process, cell cycle phase, meiotic 
chromosome segregation, meiotic sister 
chromatid cohesion, chromosome 
organization, cell division, meiotic cell 
cycle, M phase of meiotic cell cycle, 
meiotic sister chromatid cohesion, 
centromeric 
REACTOME 
pathways: cell 
cycle, mitotic 
OR5M10 
olfactory receptor, 
family 5, subfamily 
M, member 10 
Encodes an olfactory receptor.  
cell surface receptor linked signal 
transduction, G-protein coupled 
receptor protein signaling pathway, 
sensory perception, sensory perception 
of chemical stimulus, sensory perception 
of smell, neurological system process, 
cognition, olfactory receptor activity   
KEGG pathways: 
Olfactory 
transduction 
Reactome pathway: 
Signalling by GPCR 
IFI27L1 
interferon, alpha-
inducible protein 
27-like 1 
Associated with hepatitis. Integral component of membrane  
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There are several predominant functions/themes amongst the genes in Table 7.6: 
i) Protein binding/transport (TBC1D3, XPO1, ANKRD36C, TRPM5, CCDC104, 
CCNYL2, GBF1 and APBA2). 
ii) GTP-ase regulation (CCDC104, GBF1 and TBC1D3) 
iii) Cell cycling (SGOL2, CCNYL2 and XPO1) 
iv) Glucose transport/homeostasis and insulin signalling (XPO1, TRPM5, GBF1 
[activates ARF5, which interacts with GLUT-4], and TBC1D3).  
v) Neurological processes (APBA2, GBF1 and OR5M10).  
It is unknown what effects the variants in any of the genes of interest have on gene 
function. Only four variants were predicted to be damaging and conserved by all prediction 
algorithms given in ANNOVAR: rs79074863 in XPO1, c.T593G:p.V198G in L2HGDH (both as 
previously noted), rs1063412 and the non-synonymous SNV at chr1:172410881, both in 
C1orf105 (intronic region) and PIGC (exonic region). 
7.3.2.3 Pathway analyses 
With a significance threshold of 0.05/1320=3.79x10-5, no pathway was significantly 
associated with either favourable or unfavourable KD response with the burden test. 
When testing for association with unfavourable KD response, the PID ‘ERBB1 
Internalisation’ pathway reached significance (p=2.64x10-5) in the count of case-unique 
alleles test. The BIOCARTA ‘PTC1’ pathway generated the second lowest p-value, which 
reached suggestive significance (threshold=1/1320=0.00076, with a p-value of 4.67x10-5).  
When testing for association with favourable KD response, the REACTOME pathway 
‘Triglyceride biosynthesis’ reached suggestive significance in the burden test.  
The PID ‘ERBB1 Internalisation’ pathway is very large (a figure displaying the pathway can 
be found at http://pid.nci.nih.gov). This pathway includes 41 genes: AMPH, ARHGEF7, CBL, 
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CBLB, CDC42, CHMP3, DNM1, EGF, EGFR, EPN1, EPS15, GRB2, HGS, HRAS, ITSN1, KRAS, 
LRIG1, NRAS, PIK3CA, PIK3CB, PIK3CD, PIK3R1, PIK3R2, PIK3R3, PTK2, RAB5A, RAF1, 
SH3GL2, SH3KBP1, SHC1, SOS1, SPRY2, SRC, STAMBP, SYNJ1, TSG101, UBE2D1, UBE2D2, 
UBE2D3, USP8, and ZFYVE28. 
The PTC1 pathway is outlined in Figure 7.10. 
 
Figure 7.10: BIOCARTA PTC1 Pathway, taken from http://www.biocarta.com/pathfiles    
The genes included in this pathway are: 
CDK7 cyclin-dependent kinase 7  
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CDK1 cyclin-dependent kinase 1    
MNAT1 menage a trois homolog 1, cyclin H assembly factor 1 
PTCH1 patched homolog 1  
SHH sonic hedgehog homolog  
XPO1 exportin 1  
CCNB1 cyclin B1  
CCNH cyclin H  
CDC25A cell division cycle 25A  
CDC25B cell division cycle 25B  
CDC25C cell division cycle  
 
42 genes are involved in the REACTOME ‘Triglyceride biosynthesis’ pathway: ACLY, ACSL1, 
ACSL3, ACSL4, ACSL5, ACSL6, AGPAT1, AGPAT2, AGPAT3, AGPAT4, AGPAT5, AGPAT6, 
AGPAT9, ACACA, DGAT1, DGAT2, ELOVL1, ELOVL2, ELOVL3, ELOVL4, ELOVL5, ELOVL6, 
ELOVL7, GK, GK2, GK3P, GPAM, GPAT2, GPD1, GPD1L, HSD17B12, HSD17B3, LCLAT1, 
LPCAT1, LPCAT4, LPIN1, LPIN2, LPIN3, FASN, SLC25A1, TECR and TECRL. 
 
7.4 Discussion 
Key findings: 
 ANKRD36C was significantly associated with unfavourable KD response in the c-
alpha gene-based test. XPO1 reached suggestive significance in uni-directional 
gene-based tests. Common themes identified amongst genes of interest include 
protein transport, cell cycling, glucose transport and neurological processes.  
 Group 0, 1 and 2 analysis results indicated that non-synonymous variants were 
mostly driving the association signals and that potential results of interest may be 
lost when stringent filtering is used. 
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 The ERBB1 Internalisation pathway reached significance when using the count of 
case-unique alleles test; other pathways most closely associated with favourable or 
unfavourable KD response are biologically plausible. 
 An overview of strategies adopted to increase power 7.4.1
With such a small sample size, association studies are problematic because a variant (or 
group of variants in a gene) would have to be present in a sufficiently large number of 
individuals in one response group in order to generate a significant p-value. For this reason, 
a range of strategies were adopted to increase power. 
In addition to selecting individuals with the most extreme (and consistent) KD response, 
power to detect rare risk variation was increased in this study by combining variants within 
genes. This approach is particularly important for complex disorders or phenotypic traits, 
such as the KD, for which the effect of a particular gene, let alone a particular variant, on 
the phenotype is thought to be modest. The sole effect of such a variant would not be 
detected, especially when comparing variation across the whole genome [660]. Gene-
based tests, however, can still be underpowered to detect an association; power depends 
on the sample size, the number of variants per gene, variant frequencies, effect sizes and 
the direction of their effect [963]. Of course, in order to have sufficient power, variants 
must firstly be present in the same gene [944]. For a specific gene, one will have more 
power to detect an association if a higher proportion of variants in that gene are causal, if 
these variants have higher MAFs and larger effect sizes, and (for gene burden tests) if the 
effects of the variants are in the same direction [1050]. Using the sum of rare variants gene 
burden analysis, it has been reported that, in a study with 1,000 cases and 2,000 controls, 
there is 80% power to detect a minor allele with an odds ratio of 3.1 in a gene with 10 
variants, each of frequency 0.001 [714]; for genes with 100 variants of the same frequency, 
there is 80% power to detect minor alleles with an odds ratio of >1.6. 
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Power also depends on the test used and, for this reason, various gene-based association 
tests were conducted. The c-alpha test was the first choice, primarily based on the fact that 
it allows for the effects of variants to be bi-directional. Power was found to be low in the c-
alpha test when all variants in a gene were detrimental with regards KD response – in such 
cases, tests that assume a uni-directional effect of variants generate lower p-values. 
Furthermore, if results from the c-alpha test were to be used for pathway analysis, it would 
be difficult to gauge whether genes in that particular pathway affected KD response in a 
favourable or unfavourable way, or indeed whether they all had the same direction of 
effect. For these reasons, tests that assume a uni-directional effect of variants were also 
conducted. The genes of most interest tended to be identified from more than one 
approach (the single-variant test or one/several of the gene-based tests).    
In addition to analyses with no filtering, association tests were conducted with various 
grades of filtering to exclude variants that were less likely to be of functional consequence. 
This is based on the premise that, even if a gene harbours phenotypically relevant 
variation, it may still harbour many other variants that are phenotypically neutral, which 
would create noise in a gene-based test and mute any association signal. Furthermore, it is 
difficult to interpret how synonymous variants or those of unknown consequence affect 
the gene in question. One may conduct a literature search, but this will only help if previous 
functional studies have been conducted. On the other hand, if these variants are influential 
then potential true genotypic-phenotypic associations will be lost by excluding them from 
analyses.  
In the gene-based analyses, very similar results were obtained in group 0 and group 1 
analyses. This does not necessarily mean that synonymous variants or those of unknown 
consequence are phenotypically neutral, but it indicates that non-synonymous variants are 
driving the association signals. Group 2 analyses contained too few variants to generate 
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low p-values. Even more stringent filters could have been adopted, for example, using 
previously defined methods to identify high-confidence loss-of-function variants (proposed 
criteria include destruction of all known protein-coding transcripts of the gene, removal of 
more than 5% of the remaining protein, and so on) [797, 815] but power would have been 
even further reduced due to the low number of variants. The results obtained highlight the 
dangers of missing potentially useful results when adopting stringent filtering criteria, 
without first considering the potential effects of other variants. For example, one gene of 
interest, XPO1, would not have been identified if only loss-of-function variants had been 
included in analyses. For this reason, a graded filtering approach was adopted and 
bioinformatics tools were used post-analysis to predict functional consequence. Adopting 
stringent criteria to identify truly damaging variants is better suited to Mendelian disorders, 
where candidate genes tend to be identified by narrowing down variants. 
With a complex trait such as KD response, it may not only be different variants within a 
gene that influence the trait, but also different genes. Variation in a particular gene that 
influences KD response may be present in only one or a few individuals. Even with a large 
sample size, the effects of these genes may be difficult to pick up, depending on how many 
individuals they were present in. For this reason, a self-contained pathway analysis was 
performed, where variants are pooled into genes and then pooled into pathways. If several 
genes within a pathway influence the phenotype, this approach should be more powerful 
than single variant or gene-based approaches. Power depends on the proportion of genes 
in the pathway that have more variants in one response group. Presumably due to the 
small sample size, the pathway analysis did not generate significant results, but those 
pathways with the lowest p-values are certainly of interest. 
Even with variant-pooling approaches, the cohort size was too small to generate significant 
associations from genes or pathways with such (small) effect sizes. One may argue that, in 
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set-based analyses, adjusting for multiple testing based on the number of sets (whether 
this be genes or pathways) is overly conservative because many sets do not have sufficient 
variation to achieve the ‘asymptotic properties for the test statistic’ [944]; that is to say, if 
too few variants within a gene/pathway are present in the entire cohort, independent of 
KD response status, a low or statistically significant p-value could not be generated, unless 
the cohort size was very large. It has been suggested to adjust for the number of 
genes/pathways with an i-value below a certain threshold (such as 1x10-3), based on the 
premise that those with an i-value above the threshold have no power to detect an 
association. How to determine this threshold, however, is unclear, and this practice has not 
been readily adopted in publications.  
 Potential sources of error 7.4.2
As outlined in the Introduction, there are opportunities for error in several steps in the 
exome sequencing analysis process; false variants in a gene can be called because of errors 
in alignment or mismapped reads and, if these errors occur at a different rate in cases and 
controls, this would bias association tests. Some aspects in the sequencing and variant-
calling process are out of the researcher’s control if these are undertaken elsewhere, 
whereas other aspects (predominantly post variant-calling) can be manipulated with 
quality control procedures. In this study, the alignment tool used is considered the most 
accurate (although also the most time-consuming) of all available and the quality-control 
criteria used to call variants rendered high-quality performance metrics, indicating that a 
high proportion of the variants called are true variants. The quality control parameters 
used by ION Neurogenetics Unit have been developed by UCL genetics workers and 
optimised over years of study with many different datasets. Of course, there will always be 
some uncertainty regarding optimal pipeline parameterisations for specific experiments, 
but the fact that performance metrics were not greatly improved by more stringent quality 
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control criteria was a good sign; further increasing stringency filters would increase the rate 
of false negatives. 
Two aspects that could potentially be improved would be a) use of multi-sample variant 
calling instead of single-sample variant calling, and b) use of multiple variant-calling 
pipelines, instead of just one pipeline.  
a) The advantage of calling variants simultaneously in a group of people is that the 
genotype at a particular locus for an individual is informed by that of other people: 
a variant is less likely to be false if it is present in more than one individual. This is 
particularly beneficial with low-coverage sequencing data. For example, in single-
sample calling, one may have little confidence in an SNV with only two supporting 
reads, but if it is present in many samples, one has the equivalent of more reads. 
The disadvantage is that more true variants, in particular rare and private variants, 
will be lost using multi-sample variant calling. Some algorithms may be better 
suited to multi-sample calling than others: the sensitivity of GATK and glfMultiples 
were found to be increased with multi-sample calling, whereas SAMtools missed 
many variants using this approach [979]. 
b) Capture varies between bioinformatics algorithms; when using ‘near-default’ 
settings, not all variants called from the same raw sequencing data using various 
algorithms are concordant and 'unique-to-pipeline' variants exist, even in regions 
of high coverage [1005, 1062]. Concordance between pipelines was found to be 
lower for indel-calling, compared to SNV-calling. These discrepancies are likely due 
to the underlying models utilised by the variant-calling algorithms, such as how the 
prior probabilities are set [1005]. By only using those variants that are called by 
different pipelines, regardless of parameterisation, the false-positive rate can be 
minimised, although some unique-to-pipeline true variants may be missed. This 
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complex approach would require access to various pipelines (not all are freely 
available) and knowledge of how to use all necessary programmes; it would also be 
very time-consuming. Samples could be sequenced by various platforms that use 
different technologies, if the budget allowed for this. Some algorithms can also 
account for potential batch effects when calling variants [997].  
Measures were taken to account for other potential sources of bias in association analyses 
that were within the researcher’s control. For example, several indicators of relatedness 
due to population specificity or ancestry were used to create a cohort that was as 
homogeneous as possible: proportion of non-synonymous variation, heterozygosity and 
pairwise IBS. Visualisation of these parameters allows for exclusion of clear ethnic outliers. 
One may also use standard deviation from the mean to exclude outliers, but there does not 
seem to be a consensus regarding what is considered as ‘too far’ from the mean. For 
example, outliers have been defined as individuals whose ancestry was at least 2 [1063], 3 
[1064] and 6 [1065] standard deviations from the mean.  
Other strategies include permutation and inclusion of PCA covariates in association 
analyses, but even these have not consistently been shown to effectively control for 
population stratification in rare variant analyses [962]. This is the disadvantage when 
working with whole exome (or genome) sequencing data: as it is relatively new, 
approaches to deal with such potential problems as population stratification and software 
to implement these approaches are not as well-developed as they are for common variant 
GWAS with array data. Exploration of complex traits with whole exome sequencing data 
has only recently begun; this approach is more well-established with Mendelian disorders, 
in which case, instead of association studies, candidate genes tend to be narrowed down 
by process of elimination according to, for example, novelty and likelihood of functional 
consequence of variants. With this approach, potential sources of bias such as population 
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stratification are less of an issue. In any case, it is commonly cited that it is ideal to have a 
homogenous population before conducting association analyses, whether this be by 
selective recruitment and/or identification of genetic outliers. Various indicators of 
ancestral homogeneity have been used in this chapter – all indicate a balance between 
responders and non-responders and so bias due to population stratification should not be 
an issue. This was supported by the fact that λGC was equal to 1.00 in the single variant test.  
Another potential source of bias in association studies with sequencing data is variability in 
coverage and variant discovery between cases and controls. This can result in bias similar 
to that from population stratification if such errors are not balanced between cases and 
controls [660]. Identification and exclusion of outliers with a lower total number of called 
exonic variants than what is commonly expected from whole exome sequencing, or with 
excess or reduced proportions of singleton variants, exonic bases with X-fold coverage, 
mean Ti/Tv ratio and genotype quality scores, compared to all other individuals, ensured a 
homogenous cohort. Such approaches further limit the sample size and thus the power to 
detect an association, but they are a necessary step in reducing bias and ensuring 
confidence in the results obtained. Even though coverage in this cohort was not as high as 
in other published cohorts (for example, with the 1000Genome Project, all exome samples 
had 70% of their targets covered at least 20x 
[http://www.1000genomes.org/category/sample]), it was uniform and so should not have 
biased association studies. In the future, funds should be directed towards sequencing 
more samples, even if this is at the expense of coverage, rather than sequencing fewer 
samples at higher coverage, in order to increase power. Alignment of reads has the 
greatest effect on proportions of true/false variants and, even if samples are sequenced to 
a greater depth, this does not necessarily lead to detection of more variants (personal 
communication with Dr Alan Pittman).   
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The homogeneity of the cohort in terms of performance metrics is also an indication of a 
lack of batch effect. This would not necessarily identify variability in specific subsets of 
genes, which may be differently affected by batch effects [1066] but it shows that, in 
general, the data is of high quality, independent of batch or other factors, such as 
case/control status. Furthermore, all individuals were sequenced on the same machine and 
samples were handed over to the ION Neurogenetics Unit with responders and non-
responders randomly ordered.  
The possibility cannot be discounted that non-coding variation causes variability in KD 
response, either separately or in conjunction with coding variation. Whole genome 
sequencing would allow for investigation of this, although interpretation of non-coding 
variants, particularly intergenic variants that cannot be easily assigned to a gene, is 
problematic. Relevant large indels or structural variants may have been missed by 
sequencing [516] and, if one wanted to concentrate on such variation, perhaps a 
combination of sequencing- and array-based methods would be appropriate [994].  
 Results of interest  7.4.3
7.4.3.1 Single variant and gene-based approach 
The only statistically significant result was for ANKRD36C from the c-alpha test. This result 
seems to be driven by rs5005869 and other variants that have a large difference between 
minor allele counts in responders and non-responders; there are many other variants 
within ANKRD36C with less of a difference between responder/non-responder alternative 
allele counts and so this gene was not among those with the lowest p-value in the tests 
that assume a uni-directional effect of variants. The difficulty lies in a) interpreting the 
functional consequences of the variants of most interest on the gene, and b) interpreting 
how this may influence KD response. There is little information available on the function of 
ANKRD36C. It has the GO term ‘ion channel inhibitor activity’ – identified from 
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haemangioma cells from an individual with oncogenic osteomalacia and 
hypophosphataemia, it was found to inhibit renal epithelial phosphate transport [1067]. 
Mutations in other ankyrin repeat proteins have been associated with cancer and bare 
lymphocyte syndrome, which causes immunodeficiency [1068]. According to public 
databases, ANKRD36C is most highly expressed in the brain (http://embl-ebi.org) and it 
interacts with PRKACB and UBC proteins (http://thebiogrid.org). PRKACB encodes a subunit 
of cAMP-dependent protein kinase, through which cAMP exerts its effects, for example, 
inhibiting gluconeogenesis, stimulating lipid oxidation and regulating apoptosis [1069, 
1070]; UBC encodes ubiquitin C, which is involved in many processes, including cell cycle 
progression and apoptosis [1071].  
Other genes with the lowest p-values in gene-based tests, or with the largest difference 
between responder/non-responder alternative allele counts, are easier to interpret. For 
example, mutations in L2HGDH have been associated with L-2-hydroxyglutaric aciduria, 
characterised by mild to moderate psychomotor retardation, cerebellar ataxia, variable 
macrocephaly, and epilepsy [1072]. This is a recessive disorder and so, considering that the 
genotype of the individuals with the putatively damaging variant in L2HGDH was A/C, this 
would not lead to a diagnosis of a neurometabolic disorder; rather, this indicates that the 
function of the L-2-hydroxyglutarate dehydrogenase enzyme may be partially affected – 
not necessarily enough to result in a neurometabolic phenotype but enough to influence 
KD response. Alpha-ketoglutarate is the keto acid produced by the breakdown of the 
excitatory neurotransmitter glutamate (via the intermediate 2-hydroxyglutarate), which 
then enters the citric acid cycle to yield ATP. Individuals with a damaging variant in L2HGDH 
may not be able to optimally yield energy from glutamate. Alpha-ketoglutarate is 
transaminated back to form glutamate, which can be used to form the inhibitory 
neurotransmitter GABA. Reduced GABA levels or a suboptimal balance of glutamate and 
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GABA levels would influence neuronal excitability and potentially prevent the KD-induced 
increased seizure threshold. As outlined in Chapter 1, it has been suggested that the KD 
reduces seizure frequency by increasing the availability of glutamate, leading to elevated 
levels of GABA to dampen hyperexcitability in the brain, and also that the KD replenishes 
citric acid cycle intermediates that are made deficient by seizures. Based on these theories, 
mutations that hinder the glutamate/alpha-ketoglutarate/glutamine/GABA cycle would 
thus likely lead to an unfavourable response to KD.  
XPO1 (which included a variant unique to 13 non-responders that was predicted to be 
damaging by all algorithms available) encodes exportin 1, which mediates nuclear export 
signal-dependent protein transport. This protein, first associated with nuclear export of 
human immunodeficiency virus Rev protein [1073], has been shown to be important for 
the stress response. Exportin 1 has since been implicated in recovery from stroke, as it 
enables HMGB1 (released from astrocytes in response to inflammatory cytokines) to 
translocate from nucleus to cytoplasm before release [1074]. MAPK ERK was also involved 
in the signalling process and its inhibition decreased HMGB1 upregulation in the stimulated 
astrocytes. The stress-induced translocation of MK5 (MAPK-activated protein kinase 5) 
from the nucleus to the cytoplasm has been shown to be dependent on exportin 1 [1075], 
as has localisation of PAPA1 (which activates expression of many genes induced by 
oxidative stress) in response to oxidative stress [1076]. Exportin 1 has also been shown to 
play a role in apoptosis: inhibition of XPO1-mediated nuclear export induced rapid 
apoptosis in leukemic CD34(+) progenitors [1077]; ablation of the nuclear export signal to 
which exportin 1 binds in the second SH3 domain of Crk II increases the proapoptotic 
activity of the Crk protein [1078]. 
Exportin 1 may influence glucose homeostasis via translocation of hepatic glucokinase (in 
the postprandial state, the simultaneous rise in glucose and insulin increases glucokinase 
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activity; in the fasting state, the combined decrease in glucose and insulin concentrations 
and increase in glucagon concentrations, stop glucokinase activity [1053]). It has been 
reported that, when intracellular glucose concentrations are high, glucokinase translocates 
from the nucleus to the cytoplasm via exposure of its active nuclear export sequence 
[1054]. Others have found that glucokinase regulatory protein mediates the nuclear export 
of glucokinase, as well as its import, which does not involve interaction with exportin 1 
[1079].  
The theme of glucose metabolism links with the functions of other genes of interest 
identified from single variant and gene-based tests. Genes may share similar functions and 
may (jointly or independently) influence KD response, even if they exert their effects in 
different areas of the body. For example, while XPO1 may influence glucose metabolism via 
an effect on glucokinase in the liver, GBF1 may exert an effect through activation of ARF5, 
which is thought to regulate insulin-stimulated translocation of GLUT1 to the cell 
membrane in adipocytes [1080]. TRPM5 is expressed in pancreatic β cells and is also 
thought to play a role in glucose-stimulated insulin secretion [1052, 1081]. As glucose 
enters pancreatic β cells and is metabolised, the ATP-to-ADP ratio is increased and KATP 
channels close. This depolarises the membrane and causes an influx of calcium through 
voltage-dependent calcium channels. In theory, this then leads to insulin release, although 
KATP channel closing alone has been found to be insufficient to depolarise the membrane to 
the extent needed for insulin release to occur [1082]. Activation of TRPM5 and subsequent 
depolarisation of the plasma membrane may help depolarise the membrane to an extent 
sufficient for insulin release. It is thus feasible that variation in TRPM5 that affects the role 
of the protein in glucose-stimulated insulin release may influence KD response; TRPM5 is 
also expressed in the brain and may influence neuronal glucose metabolism (for example, 
the preference of neurons to metabolise glucose or ketone bodies) or it may play a more 
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indirect role by affecting glucose uptake elsewhere in the body. The extent to which 
variation influences KD response may depend on other genetic variation, for example, in 
KCNJ11. An alternative theory is that variation in TRPM5 affects people’s food preferences 
(Trpm5 knockout mice of the strain are unable to detect sweet taste [1083]) and so certain 
individuals may be more or less likely to be non-adherent to the diet. Others have found 
that reduced glucose intake in Trpm5 knockout mice is independent of taste [1084]. As the 
TRPM5 channel is also present in the gastrointestinal tract, the authors suggested that a 
lack of preference for carbohydrate may be due to selective blockage of glucose utilisation 
and the subsequent dopamine reward signals.  
Other themes identified among the genes of most interest may also be relevant to KD 
response. GTP/GTPase-activating proteins and GTP-binding proteins have been shown to 
influence insulin signalling and glucose homeostasis [1085-1087] and apoptosis [1088-
1090]. The genes associated with Alzheimer’s disease (APBA2 and GBF1) are also involved 
in several processes, such as neurotransmitter release (APBA2) [1091], stabilisation of 
amyloid precursor protein (APBA2) [1092] and maintenance of Golgi structure and function 
(GBF1) [1093]. The latter function of GBF1 is impaired in situations of metabolic stress that 
deplete ATP, such as glucose deprivation [1094]. It is biologically plausible that such genes, 
which have multiple functions and/or are affected by various factors, influence KD 
response, but it is unknown exactly how. Genes may influence KD response via different 
mechanisms in different people, depending on other genetic and environmental factors.  
Protein binding/transport was another common theme amongst genes of interest, but the 
general nature of this term means that it does little to enhance understanding of how such 
processes influence KD response. 
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7.4.3.2 Pathway-based approach 
Despite the fact that several genes with the lowest p-values or the greatest difference in 
case-control alternative allele counts are of interest, an examination of allele counts 
reveals that extreme KD response in this cohort is not influenced by one single gene – not 
surprisingly, due to the complex nature of the trait. Thus, rather than looking at a list of 
genes of interest, it makes sense to concentrate more on pathways that may influence KD 
response. Some genes within these pathways may have more of an effect on the 
phenotypic trait than others. The pathway-based approaches have highlighted some 
common pathways and themes that may potentially influence KD response, namely stress 
response, neurological processes and lipid metabolism.  
The ERBB1 (human epidermal growth factor receptor) pathway was significantly associated 
with unfavourable KD response in the case-unique alleles test. ERBB1 lies on the cell 
surface and, when activated by ligand-binding, endocytosis occurs: the receptor 
internalises and moves to the early endosomal compartment of the cell. Depending on 
which ligand has bound to ERBB1, the receptor may be degraded or recycled and moved 
back to the cell surface [1124], and this has a downstream effect on several cascades 
(either diminishing or prolonging their signals [1125]), including the MAPK, AKT and stress-
activated protein kinase pathways, which lead to cell cycle progression, growth, survival 
and proliferation [1126]. Mutations that lead to ERBB1 overexpression have been 
implicated in the pathogenesis of many cancers [1127], potentially because this leads to 
constant activation of the receptor and thus uncontrolled cell division. ERBB1 is expressed 
in the brain, including in neurons and astrocytes, and mice with mutations in ERBB1 that 
survive display progressive neurodegeneration characterised by apoptosis and upregulation 
of c-fos, which is also though to act as a mediator of cell death [1128]. ERBB1 
overexpression has frequently been found in many tumours, including in the brain [1129] 
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and ERBB1 inhibitors (gefitinib and erlotinib) are used to treat non-small cell lung cancer. 
ERBB1 ligands, such as heparin-binding epidermal growth factor-like growth factor and 
transforming growth factor-α, have been shown to promote survival of neurons and axon 
regeneration in response to induced seizures or brain injury and have thus been proposed 
as neuroprotective agents [1130-1132]. Depending on which components of the pathway 
are affected (other ERBB1 ligands or other members of the ERB family may compensate for 
impaired function of ERBB1 or vice versa), KD response may be adversely affected by an 
impaired stress/apoptotic response to seizures. One may draw a parallel with response to 
gefitinib, which is thought to be mediated by AKT signalling, which has antiapoptotic 
properties: mutations in the ERBB1 pathway (not just ERBB1 itself) lead to reduced 
internalisation rates and unrestrained signalling of AKT, thus reducing apoptosis and 
allowing proliferation [1133]. It is also of interest that ERBB1 expression was found to be 
lower in adipose tissue of insulin-resistant or diabetic obese women, compared to those 
with normal insulin sensitivity, and that inhibition of ERBB1 prevented adipogenesis in 
human preadipocytes [1134]; the authors raised the possibility that reduced ERBB1 
expression is, akin to insulin resistance, a way of preventing further dyslipidaemia and 
insulin resistance by inhibiting lipolysis. An ERBB1 inhibitor induced an improvement in 
glucose tolerance and insulin sensitivity in mice, and a reduction in circulating levels of the 
cytokines IL6 and TNF-α, consistent with reduced inflammation [1135].   
The PTC1-signalling pathway reached suggestive significance in the case-unique alleles test, 
when testing for association with unfavourable KD response. PTC1 encodes patched 1, a 
sonic hedgehog (SHH) receptor that represses SHH cell signalling, affecting different phases 
of the cell cycle. When bound to SHH, patched 1 releases the transmembrane protein 
smoothened, which leads to activation of the GLI transcription factors, which control the 
transcription of hedgehog target genes, allowing progression to the G1 phase of the cell 
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cycle. The G2/M (Gap 2 – the last stage of interphase – to mitosis) transition phase of the 
cell cycle is also affected: when unbound, patched 1 binds to cyclin B1 and CDC2, which 
blocks M-phase promoting factor activity and progression through the G2/M transition 
phase; when bound to SHH, PTC1 is degraded and so cannot bind to cyclin B1; cyclin B1 
then enters into the nucleus 
(http://www.broadinstitute.org/gsea/msigdb/cards/BIOCARTA_PTC1_PATHWAY). Exportin 
1 is also involved in this pathway, as it mediates the localisation of the cyclin B1/CDC2 
complex and thus the entry of cells into mitosis [1095]; binding to exportin 1 causes nuclear 
export of the cyclin B1/CDC2 complex and disruption of this binding leads to an 
accumulation of this complex in the nucleus. 
Both PTC1 and SHH have been shown to play an important role in both prenatal and 
postnatal brain development through the proliferation of neural progenitors and 
determination of cell fate [1096]. For example, Shh was shown to maintain the survival of 
neuroepithelial cells by preventing Ptc1-induced apoptotic cell death [1097]. Mutations in 
SHH are the most common cause of holoprosencephaly, a disorder in which the embryonic 
forebrain does not divide into two cerebral hemispheres [1098, 1099]. Holoprosencephaly 
is associated with a spectrum of symptoms, ranging from serious malformations of the 
brain, facial abnormalities and epilepsy, to microcephaly, learning disabilities and motor 
impairments. Mutations in PTCH1 have also been associated with a holoprosencephaly-like 
phenotype [1100-1102], as well as Gorlin syndrome, characterised by developmental 
malformations and a high predisposition to skin basal cell carcinoma development [1103, 
1104]. Methylation of PTCH1 and loss-of-function mutations in the gene have been 
associated with tumour development [1105-1107]. Mutations in genes encoding several 
components of the SHH pathway, with the overall effect of increasing SHH activity, have 
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been associated with skin tumours [1108-1110]. It is predicted that mutations in this 
pathway that lead decreased SHH activity may cause holoprosencephaly [1111]. 
The SHH signalling pathway has been implicated in the process of hippocampal 
neurogenesis after injury and increased mRNA levels of Shh and Gli1 were found in 
hippocampus immediately after ischaemia [1112]. Hypoxia/ischaemia has also been 
demonstrated to induce expression of Shh in cardiomyoblasts, astrocytes, neurons, neural 
progenitor cells and testicular tissue [1113-1117]. The hypoxia-induced increased 
expression of SHH is dependent on hypoxia-inducible factor-1α (HIF1α) [1114, 1116]. It is 
unknown exactly how the PTC1/SHH signalling pathway exerts a neuroprotective effect, 
and there are several possibilities. SHH has been shown to activate the PI3K/AKT pathway, 
upregulate BAD expression and inhibit the ERK pathway, thus decreasing cell apoptosis in 
neurons [1118]. The inhibition of Smo and subsequent activation of Gli1 are thought to be 
involved in the neuroprotective mechanisms of SHH but it is unknown how they exert these 
effects [1119]. SHH has been shown to have neurotrophic effects in midbrain dopaminergic 
neurons but not in motor neurons [1120]. The authors found that this neurotrophic effect 
could not be attributed to the stimulation of proliferation by SHH, as the neurotrophic 
activity was on post-mitotic neurons rather than on dividing progenitor cells. Others have 
shown SHH gene expression to be induced by BDNF in rat neurons [1121] and it has been 
suggested to investigate whether SHH-mediated neuroprotection involves BDNF [1119]. 
Children with autism were found to have higher serum levels of SHH and BDNF compared 
to age- and sex-matched controls [1122].     
It is biologically feasible that mutations in the PTC1/SHH pathway adversely affect KD 
response as the neuroprotective response to seizures is impaired. This may be due to 
impaired regulation of cell apoptosis, neurotrophin release and/or response to oxidative 
stress. Considering that the starvation stress response has been correlated with the 
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oxidative stress response in yeast [1123], the KD may result in similar changes in gene 
expression as those caused by hypoxia (increased expression of components of the 
PTC1/SHH pathway, with a neuroprotective effect). Individuals without damaging variants 
in the various components of this pathway may respond better to the KD as this 
neuroprotective effect is not impaired. These mechanisms may not only mediate the 
antiseizure effects of the KD, but also the neuroprotective or anticarcinogenic effects of the 
KD for other neurological diseases and cancer.  
The pathway most closely associated with favourable KD response was triglyceride 
biosynthesis. This pathway consists of fatty acyl-CoA biosynthesis, conversion of fatty acyl-
CoA to phosphatidic acid, conversion of phosphatidic acid to diacylglycerol, and conversion 
of diacylglycerol to triacylglycerol. Fatty acids may be synthesised from dietary fat intake or 
de novo synthesis from acetyl CoA (mostly obtained from conversion of pyruvate [from 
glucose] to acetyl CoA in the mitochondria) [1136]. As part of the wider pathway, ‘Fatty 
acid, triacylglycerol, and ketone body metabolism’, genetic variation in the ‘triglyceride 
biosynthesis’ pathway may indirectly influence ketone body production and metabolism. 
Hydrolysis of triglycerides generates fatty acids for use as an energy substrate in muscles 
and other tissues, and for conversion into ketone bodies, as well as glycerol for 
gluconeogenesis. Variation affecting this pathway may impair or increase the amount of 
ketone bodies available for brain metabolism, which may influence seizure control 
(whether this is mediated by a direct or indirect effect, or both, is unknown).  
The effects of insulin on triglyceride turnover are also worth noting. Insulin stimulates cells 
to preferentially use glucose instead of fatty acids as an energy source and it controls 
triglyceride synthesis in adipose tissue and muscle by increasing glucose uptake and 
regulating its conversion to glycerol-3-phosphate via glycolysis [1137]. Both acutely and 
chronically elevated levels of free fatty acids cause reduced glucose uptake and increased 
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insulin secretion, ultimately leading to insulin resistance and potentially type II diabetes 
[1138]. Increased serum fatty acid levels are a hallmark feature of KD-feeding, which is 
needed for ketone body synthesis, to provide energy for the muscles and liver, and to avoid 
lean body mass breakdown. Severe insulin resistance would not be desirable when 
following a KD, as some glucose is still needed by the brain. An inability to esterify fatty 
acids back to triglycerides in the triglyceride-to-fatty-acid cycle would further exacerbate 
insulin resistance and may also cause excessive concentrations of ketone bodies and thus 
ketoacidosis.  
It is biologically feasible that variation in these pathways influence KD response, although 
the extent to which KD response is affected will be determined by how damaging the 
variants are, whether an individual is homozygous or heterozygous for the alternative 
allele, which genes the variants are present in and, potentially, other environmental 
factors. For example, the wide phenotypic variability in individuals with holoprosencephaly 
caused by heterozygous mutations in SHH suggests that the extent to which cortical 
development is impaired depends on other factors (these may be genetic or 
environmental) that interfere with the already impaired SHH signalling. Dietary intake of fat 
and carbohydrate may influence to what extent variation in the triglyceride biosynthesis 
pathway affects KD response. Depending on how many genes within a pathway harbour 
damaging variants, individuals may be able to synthesise enough triglycerides and obtain 
sufficient amounts of fatty acids and ketones for seizure control. 
 Conclusions and future work 7.4.4
A combination of single variant, gene-based and pathway-based tests have revealed 
several genes and biological pathways that could feasibly account for variability in KD 
response in this cohort. Predominant themes include apoptosis/stress response, glucose 
homeostasis and lipid metabolism. 
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The difficulty resides in translating these results into clinical practice. Given the complex 
nature of the trait, in the absence of SLC2A1 mutations, KD response may not be influenced 
by a single gene; it may not even be influenced by a single pathway. There may be a 
different genetic reason for (un)favourable response in different individuals and so no 
signal would be picked up in an underpowered association study. If this is the case, a larger 
sample size may indicate several pathways of interest, but only stringent stratification of 
the cohort (for example, by extent of KD response or presence of certain genetic variants) 
could help predict which mechanisms are relevant for which individuals. Furthermore, as 
demonstrated by XPO1, a single gene, or a single pathway, may not just influence one 
process. This overlapping complicates the interpretation of results and further investigation 
would be required in order to establish exactly how the variants/genes of interest influence 
KD response and whether the mechanisms differ between individuals.  
The problem with investigating the genetic basis to complex traits is that, if phenotypic 
variability is caused by a collection of variants or genes, one may be limited by the cost of 
follow-up studies, such as targeted sequencing of genes of interest, or functional studies of 
specific variants (such as c.T593G:p.V198G in L2HGDH or rs79074863 in XPO1) that would 
help elucidate the consequences of such variants on the gene and the exact mechanisms by 
which this affects KD response [945, 1033]. The first step would be to identify those 
variants of most interest (variants that are predicted to be damaging in genes with a 
feasibly relevant role, or several variants within feasibly relevant genes) and confirm them 
with Sanger sequencing, as is standard practice with variants identified from next-
generation sequencing. The variant/gene(s) in question may not be relevant for every 
individual in the cohort, but it may help to explain variability in KD response in a subset of 
patients.  
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8 Conclusions, study limitations and future work 
 
8.1 Conclusions 
The aim of this study was to determine whether genetic variation affects response to the 
KD, with the hope of identifying the biological underpinnings of the antiepileptic effects of 
the KD and potentially improving targeting of treatment. This is the first exploration of the 
genetic contribution to KD response and a range of approaches were adopted, including 
candidate gene sequencing, whole-genome SNP array genotyping and whole exome 
sequencing. Analyses were underpowered, but similar themes were identified from 
common and rare variant association analyses. Gene- and pathway-based analyses 
provided the opportunity to detect complementary information that would not have been 
easily observed from single SNP analyses alone.  
 Comments on phenotypic results  8.1.1
KD response can be defined in various different ways. Firstly, when used to treat drug-
resistant epilepsy, seizure reduction is commonly used as the primary measure of response. 
However, as demonstrated with this cohort, other benefits may be obtained from the KD 
that cause some individuals to continue treatment, despite no (or very little) reduction in 
seizure frequency. These include seizure-related benefits, such as reduced seizure severity 
and fewer hospital admissions, and non-seizure-related benefits, such as improved 
alertness, cognition and sleep. In this study, only seizure frequency was used to classify KD 
response, as this was the only factor that was systematically commented on in clinic letters 
and thus could be semi-quantified. A ≥50% reduction in seizure frequency is considered 
clinically meaningful in such drug-resistant cohorts, although other ‘stricter’ definitions may 
be adopted to define extreme response, such as ≥75 or ≥90% seizure reduction. Seizure 
diaries would likely have to be used in order to treat seizure frequency as a continuous 
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variable, or to very precisely define seizure reduction (for example, to differentiate 
between those individuals who achieved ≥90% seizure reduction and those who were 
seizure-free). 
Secondly, KD response may be classified at specific points in time or using longitudinal data. 
This is independent of whether multiple factors, or solely seizure frequency, are used to 
define response. As shown in this cohort, response is not always consistent over time 
(seizures may be temporarily exacerbated, for example, due to illness, or for unknown 
reasons) and so, by defining responders as those with a sustained reduction in seizure 
frequency, one can be more certain that seizure reduction was due to KD-feeding and not 
due to chance alone. How long seizure reduction should be maintained for is debatable. On 
the other hand, it may be useful to conduct analyses taking response at specific time 
points, as certain genes may have different effects in the short- and long-term. The 
difficulty with this approach is that it is unknown whether the KD induces different changes 
in gene expression at the follow-up points used in this study (3-, 6-, 12-, 18- and 24-
months+ from commencement of treatment). Obviously, changes associated with 
starvation have not been assessed for this time period; studies regarding prolonged calorie 
restriction (that is to say, over months/years rather than weeks) tend to concentrate on 
clinical measures, such as weight loss/maintenance, insulin sensitivity or lifespan, and 
studies that have examined gene expression changes focus on one particular time point, or 
do not specify for how long subjects/animals have followed a calorie-restricted diet. The 
benefit of the strategy employed with the rare variant array data and exome sequencing 
data is that results would be the same if analyses were conducted with 3-month response, 
as responders had sustained seizure reduction at every time point. 
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 Comments on genotypic results 8.1.2
Despite the fact that the recruited cohort was relatively small, several variants/genes were 
highlighted in this work as being potentially relevant to KD response. rs12204701 reached 
significance in the 3-month response GWAS, but did not even reach suggestive significance 
in the summary diet response GWAS. One can only presume that this variant influences its 
closest gene, CDYL, but, even if this were the case, it is unknown how this may influence KD 
response. rs12204701 may affect expression of other genes. CDYL was not one of the genes 
highlighted from gene-based analyses, either from the chip or exome sequencing, which 
assigns less credence to the importance of this gene.  
The significant association of ANKRD36C with extreme KD response in the c-alpha exome 
sequencing test seems to have been predominantly driven by specific variants, such as 
rs5005869 (present in 17 non-responders and 1 responder), rs1819101 (present in 12 non-
responders and 2 responders) and rs5005868 (present in 6 non-responders and 0 
responders). Many other variants within this gene had a lesser difference in non-
responder/responder alternative allele counts and, for several variants, more responders 
harboured the alternative allele than non-responders, which is why this gene did not 
generate a low p-value in the burden-based tests. The variants with the greatest difference 
in non-responder/responder alternative allele counts were not consistently predicted by 
various algorithms to be damaging and so it is difficult to know whether they are relevant 
or not. No variant typed on the SNP array was found to be present in ANKRD36C. 
Furthermore, only scarce information regarding ANKRD36C is present in the literature and 
so, even if these variants were to influence KD response, it is unknown exactly how this 
would occur. It is of interest that ANKRD36C is expressed in the brain and that it interacts 
with proteins that influence glucose and lipid metabolism and apoptosis.  
383 
 
XPO1 was the only gene that reached suggestive significance or generated the lowest p-
value in gene-based analyses from the chip (3-month response GWAS) and exome 
sequencing data. This suggests that it may be relevant for KD response, whether it be an 
extreme response or just ≥50% seizure reduction. rs79074863, present in XPO1, along with 
c.T593G:p.V198G in L2HGDH are of most interest from the exome sequencing data as they 
were predicted to affect gene function by all available algorithms, which assigns more 
credence to the relevance of these genes to KD response. L2HGDH did not generate as low 
a p-value as XPO1 in gene-based tests because L2HGDH also contained other variants that 
did not have such a differential distribution between responders and non-responders. 
Neither of these variants was typed on the chip, but the gene-based test indicated that 
other typed variants within XPO1 may also be relevant, or that these variants may tag a 
susceptibility variant (potentially rs79074863). As mentioned in the previous chapter, the 
biological functions of XPO1 and L2HGDH make them plausible candidates for influencing 
KD response, although, at least with XPO1, they may exert effects through several 
pathways.  
Even with a relatively small sample size, a gene that strongly influences KD response (for 
example, with variants in the majority of non-responders but few or no responders) should 
have been identified from association analyses, or examination of responder/non-
responder allele counts. However, with the exception of specific metabolic disorders where 
the genetic basis for KD response is known, the KD is a complex trait and is unlikely to be 
influenced by a single gene. Genes that influence KD response are likely to have a relatively 
small effect size – smaller than what the present analyses were powered to detect. This is 
precisely what this study has found: association analyses highlighted many variants or 
various variants within genes with a different distribution (some to a greater extent than 
others) between KD responders and non-responders, many of which could feasibly 
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influence KD response. It may be that, with a larger sample size, particular genes will be 
shown to be more relevant than others. For example, if more individuals were exome 
sequenced and more non-responders (and no or very few responders) were found to 
harbour damaging variants in XPO1 or L2HGDH, sequencing of these genes could be used 
as part of the screening criteria for contraindications to KD response. A larger cohort would 
assign more credence to the importance of these genes and increase confidence that 
certain results did not occur by chance alone. This could then be extended to other genes 
that, if their function were compromised (but individuals may still be asymptomatic), may 
be a contraindication for starting KD treatment, such as those involved in fatty acid 
oxidation.   
Due to the complex nature of KD response and the fact that many genes may account for 
phenotypic variability, it seems prudent to examine common themes highlighted from the 
genes of most interest, as well as from pathway analyses. Several common areas of interest 
were identified, both from common and rare variation analyses:  
i) cell cycle progression and apoptosis  
ii) glucose homeostasis 
iii) neurological processes  
iv) triglyceride biosynthesis 
At first sight, these themes appear diverse, supporting the premise that the KD relies on 
various mechanisms of action. However, these processes have a point of convergence: 
insulin/insulin-like growth factor 1 (IGF1) signalling and downstream effects on 
PI3/AKT/mTOR and MAPK/ERK pathways; they either begin with these signalling cascades 
or interact with one or more of their components downstream.   
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The PI3/AKT/mTOR and MAPK/ERK pathways are two major pathways controlling the 
metabolic and mitogenic roles of insulin/IGF1. Signalling through these pathways is 
initiated by stimuli from growth factors that bind receptors in the cell membrane, such as 
insulin-like growth factor 1 receptor (IGF1R), platelet-derived growth factor receptor 
(PDGFR), epidermal growth factor receptor (EGFR) and human epidermal growth factor 
receptor 2 (HER2) (http://www.sabiosciences.com/pathway, [1139]). As outlined in Figure 
8.1, activation of insulin-receptor substrate 1 (IRS1) (this may be from phosphorylation of 
IGF1R by IGF1 or insulin, or phosphorylation of the insulin receptor by insulin or IGF1, 
which allows the receptors to bind to IRS1) leads to a cascade of events that has many 
implications: via phosphorylation of RAS and then RAF and MEK, MAPK and ERK are 
activated, and subsequently ERK1 and ERK2; through activation of PI3K, AKT is activated; 
both ERK and AKT can activate mTOR; AKT can also inhibit AMPK, which further stimulates 
mTOR activity.   
 
Figure 8.1: Diagram of the insulin/insulin-like growth factor 1/insulin receptor substrate signalling 
cascade, taken from Tao et al. 2007 [1140] 
This has the following effects: 
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Activation of MAPK/ERK: mediates cell growth, survival and differentiation, predominantly 
through regulating transcription of genes such as c-fos. Whether activation of this pathway 
promotes or protects against neuronal apoptosis most likely depends on the stimulus, cell 
type and the duration of ERK activation [1141]. 
Activation of PI3/AKT: AKT regulates cell growth, survival and cell cycling through 
phosphorylation of a number of substrates. For example, by inhibiting the pro-apoptotic 
molecules BAD and FOXO, it mediates cell survival. AKT has been shown to regulate 
proteins involved in neuronal function, such as GABAA receptor, ataxin 1, and huntingtin 
(http://www.cellsignal.com/reference/pathway/Akt_PKB.html) and thus plays a role in 
synaptic plasticity and neurodegeneration. AKT is also involved in insulin signalling and 
glucose metabolism: for example, in the liver, FOXO1 activates transcription of genes 
encoding gluconeogenic enzymes and AKT suppresses this; AKT is also involved in the 
translocation of GLUT4 to the cell membrane in response to insulin [1142] and suppresses 
β-oxidation of fatty acids [1143]. 
Through activation of mTOR, either by ERK or AKT stimulation or lack of inhibition from 
AMPK, cell growth and proliferation are positively regulated through the promotion of 
protein and lipid synthesis, the upregulation of key glycolytic enzymes and the inhibition of 
catabolic processes such as autophagy [1144, 1145]. 
There is substantial cross-talk between kinases of the PI3K/AKT/mTOR and Raf/MEK/ERK 
pathways, and inhibition of one cascade activates the other [1139].  
Insulin/IGF1 and its downstream pathways have received much attention with regards to 
their role in cancer and the KD. Expression of IGF1R has been shown to be higher in cancer 
cells, compared to normal tissue [1146, 1147], and genetic variation in IGF1 has been 
associated with increased cancer risk and poor survival rates [1148-1150]. The insulin/IGF1 
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pathway influences many other pathways, such as epidermal growth factor receptor and 
HER2, which have both been targeted to enhance apoptosis and reduce cellular invasion 
and angiogenesis in tumours [1140, 1151]; resistance to drugs that target these molecules 
may be prevented by treatments that inhibit IGF1R signalling [1152-1155]. In light of this, it 
is feasible that these pathways underline the mechanisms of action of the KD for cancer. 
Plasma IGF1 levels reduce in correlation with plasma glucose levels and both are predictive 
of brain tumour growth [1156]. This is not surprising, considering that tumour cells cannot 
metabolise ketone bodies and so the KD (or indeed, starvation or calorie restriction), in 
effect, starves the tumour, and inhibits its growth. However, the effect of the KD may be 
wider than simply metabolically isolating tumours: it may enhance apoptosis (calorie 
restriction and the glycolysis inhibitor 2DG have been shown to enhance apoptosis [1157, 
1158]), reduce inflammation (calorie restriction reduced the expression and activity of pro-
inflammatory markers in brain tumours [1159]) and reduce angiogenesis (vascularity) 
[1158].  
These pathways have also been implicated in the beneficial effects of calorie restriction 
(without malnutrition) on ageing. Reduced insulin/IGF1 signalling through deletion of the 
insulin receptor, IGF1R or growth hormone has been associated with longevity in animal 
and human studies [1160]. It is thought that the metabolic shift associated with low 
glucose levels and thus a low insulin drive may influence longevity in various ways, many of 
which correspond to those implicated with cancer. These include suppression of NFΚB and 
subsequent reduced activation of COX2, TNFα and other pro-inflammatory genes and 
antiapoptotic molecules, upregulation of several antioxidant enzymes: and activation of 
PPGC1α (which leads to increased oxidative stress resistance), and increased mitochondrial 
biogenesis (which leads to less ROS production as mitochondrial workload is less) [1160, 
1161]. The degree of calorie restriction and diet quality are also likely to play a role [1162].  
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Might the KD alter insulin/IGF1 signalling and this is how it exerts its antiseizure effects? 
The KD has been shown to increase insulin sensitivity in animal studies and in humans [177, 
192, 416, 1163-1165] and so these pathways must be altered in some way. Genes and 
pathways related to cell cycle progression, apoptosis and glucose metabolism, which 
interact with or can be linked back to the insulin signalling cascade, were associated with 
unfavourable KD response in exome sequencing analyses (the direction of effect was 
unknown in GWAS analyses, although the same themes were highlighted); it is unknown 
whether variation inhibits or enhances the activity of certain genes. It is feasible that 
increased insulin/IGF1 signalling may reduce seizures, potentially due to the effects of 
downstream pathways involved in either cell survival/apoptosis or metabolism. Insulin and 
IGF1 receptors are present in most brain regions and increased expression of IGF1 and IGF 
binding proteins occurs in response to ischaemia in rats [1166]. Insulin has been found to 
reduce neuronal excitability, potentially by activating GABA channels [1167], and to inhibit 
hippocampal epileptiform-like activity by activating KATP and large-conductance, calcium-
activated-K+ channels via an MAPK-driven process [1168, 1169]; insulin and IGF1 regulate 
neurotransmitter release and receptors, glucose metabolism, they modulate membrane 
channels (such as K+, Ca2+ and Cl-) and stimulate neurogenesis [1170, 1171]; 
supplementation with blueberries increased hippocampal IGF1 and IGF1R levels and ERK 
activation in rats and these increases were significantly correlated with improved cognitive 
performance [1172] – this is of interest as the ERK pathway is activated by seizures and is 
thought to play in role in regulating neuronal excitability and synaptic plasticity [1173, 
1174]. Activation of AKT has also been shown to promote neuronal survival [1175]. 
Impaired activation of these pathways may increase vulnerability of neurons to excitotoxic 
damage [1176]. On the other hand, although IGF1 is commonly cited as a neuroprotective 
agent [1177]), it can increase neuronal excitability [1178], which could feasibly increase 
likelihood of a seizure.  
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One would expect the KD to down-regulate insulin/IGF1 signalling due to reduced glucose 
intake and the fact that increased responsiveness of the liver to insulin would lead to a 
decrease in gluconeogenesis, glycogenolysis and ketogenesis; these survival adaptations 
are necessary in order to reduce non-essential glucose utilisation and increase production 
of alternative energy sources (ketones), particularly for the brain. This is known as 
‘starvation diabetes’ [1179] and very-low calorie diets and prolonged fasting have been 
shown to cause insulin resistance and diabetes in humans [1180]. In support of this, it has 
been shown that dietary fat intake is positively associated with serum IGF1 levels, whereas 
carbohydrate intake has a negative association [1181], and rodents subjected to calorie 
restriction have reduced serum IGF1 levels [1182] and increased activated AMPK, with 
subsequent down-regulation of AKT and mTOR activity [1183]. However, in humans, long-
term calorie restriction was not associated with reduced serum IGF1 levels but did improve 
insulin sensitivity [1184]; in rat β cells, Igf1r expression was suppressed by both very high 
and very low glucose concentrations [1185]; KD-feeding in rats led to upregulation of brain 
Igf1r expression in rats, which did not occur with a carbohydrate-rich, calorie-restricted 
diet [411], and lead to increased AMPK signaling in the liver but not the brain [1186]; serum 
IGF1 has been shown to be decreased in children following the KD for three months, 
although levels did not decrease any further from this point onwards (follow-up of one 
year) [1187]. Increased insulin/IGF1 signalling may be a compensatory mechanism in 
response to chronic low glucose/insulin levels with the KD, which may involve PI3/AKT 
activation, SIRT1 and/or FOXO1: increased PI3/AKT activation and SIRT1 (which modulates 
transcription of some regulatory subunits of PI3K) have been implicated in the mechanisms 
of improved insulin sensitivity in skeletal muscle due to greater recruitment of GLUT4 to 
the cell membrane and thus greater glucose uptake [1188-1190]; calorie restriction-
induced increased insulin sensitivity may also be due to activation of FOXO1, which leads to 
increased transcription of the insulin receptor and IRS2 [1191]; the increased fat intake 
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could also be responsible as increased phosphorylation of ERK1/2 is associated with 
elevated plasma NEFA levels [1192]. There may be tissue-specific effects on these signalling 
pathways induced by the KD, as has been shown with calorie restriction in rats [1193].   
It may be the case that certain people respond well to the KD because their seizures are (at 
least partly) a result of impaired brain glucose utilisation and energy metabolism, which is 
overcome by high-fat, low-carbohydrate feeding. Impaired insulin sensitivity has been 
linked with neurodegeneration, in particular Alzheimer’s disease, potentially due to its 
reduced glucose utilisation, reduced activation of AKT and thus increased neuronal death 
(AKT inhibits apoptosis by phosphorylating and thus inactivating GSK-3β and BAD), 
increased oxidative stress, inflammation and hyper-phosphorylation of tau [1171, 1194, 
1195]. Impaired insulin sensitivity is also associated with cognitive dysfunction, potentially 
due to reduced expression of acetylcholine transferase, an enzyme responsible for 
acetylcholine synthesis, a critical neurotransmitter in cognitive function, or due to 
increased release and decreased degradation of amyloid β-peptide metabolism with 
increased amyloid deposition [1196, 1197]. There are few reports of insulin resistance 
being associated with seizures [1198, 1199] but it is of interest that children with drug-
resistant epilepsy have been shown to be more likely to be glucose intolerant, compared to 
those with epilepsy controlled by AEDs, independent of the AEDs being taken [1200]; the 
authors commented that the individuals with refractory epilepsy and abnormal oral glucose 
tolerance tests would be candidates for KD treatment. The most severe case of impaired 
brain glucose availability/metabolism linked with neurological disease (often with seizures) 
is GLUT1 deficiency secondary to SLC2A1 mutations but, considering the neuroprotective 
role of insulin/IGF1 pathways, it is feasible that genetic variation influencing any 
component of these pathways could lead to brain-resistance to insulin/glucose signalling 
and potentially seizures. In this way, individuals harbouring variants that impair the action 
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of these pathways (and this is the reason for their seizures) would be expected to respond 
well to the KD. Alternatively, if the cause of seizures in some individuals is due to impaired 
brain glucose metabolism (for whatever reason) and the KD exerts an antiseizure effect via 
insulin/IGF1 pathways, individuals harbouring variants that impair the action of these 
pathways would not be expected to respond well to the KD. It may, of course, be the case 
that individuals with variants in these pathways have an impaired ability to put in place the 
neuroprotective mechanisms induced by seizures and so they are resistant to any type of 
antiepileptic treatment.  
Variation in the triglyceride biosynthesis pathway was associated with favourable KD 
response in the exome sequencing analysis. Although not highlighted in analyses from the 
SNP chip, this process is closely related to insulin signalling and its downstream pathways. 
When activated by insulin, the transcription factor SREBP-1c stimulates lipogenesis 
(conversion of acetyl CoA, produced from the breakdown of excess carbohydrate, to fatty 
acids) and subsequently triglyceride synthesis (esterification of fatty acids with glycerol to 
form triglycerides). The effects of insulin on SREBP-1c are mediated by PI3-dependent 
pathways [1201]. Due to the high-fat content of the KD, free fatty acid levels inevitably 
increase and this is a sign of increased ketogenesis and use of ketone bodies as energy 
substrates. Too high levels of free fatty acids would lead to increased re-esterification of 
fatty acids and storage as triglycerides, once energy requirements have been met. Although 
high-fat diets have been found to stimulate lipogenesis [1202], due to the low-
carbohydrate nature of the KD (which limits lipogenesis), together with the enhanced 
disposal of fatty acids via ketogenesis and mitochondrial β-oxidation, a KD with the 
appropriate amount of calories should not result in a net accumulation of triglycerides. 
Increased triglyceride levels are a hallmark feature of insulin resistance and depositing of 
triglycerides in tissues, such as skeletal muscle and liver, further exacerbates insulin 
392 
 
resistance. Deletion of certain genes present in the triglyceride biosynthesis pathway has 
been shown to protect against insulin resistance. For example, in Elov16-knockout mice fed 
a high-fat, high-carbohydrate diet, insulin sensitivity was higher than wild types [1203]; this 
was thought to be due to recovery of the hepatic Irs2/Akt signalling pathway: hepatic Akt 
was still phosphorylated and this was accompanied by increased hepatic IRS2. Other genes, 
such as ACSL1, have not been shown to protect against insulin resistance in animal 
knockout models [1204]. It is possible that genetic variation that affects triglyceride 
biosynthesis favourably influences KD response due to putative effects on insulin 
sensitivity, but not every gene may have the same effect. It is unknown whether brain 
insulin sensitivity may be affected directly, but it is plausible that the systemic effects of the 
KD indirectly impact relevant pathways in the brain.     
8.2 Study limitations 
 Classification of KD response  8.2.1
Clinic letters and dietetic notes were the principal source of information used to classify KD 
response. These were not created for research purposes and so do not always provide 
consistent data. The clinic letters used to mine information were written by different 
consultants, many of which were from different hospitals, who have different ways of 
writing clinic letters: some may give more information than others. The amount of detail 
provided even varies amongst those composed by the same clinician. These disadvantages 
must be balanced against the ease of obtaining such data; using notes already collected as 
part of clinical monitoring is less burdensome than asking participants to complete seizure 
diaries and record other information. This study was not a clinical trial and so it would have 
been more difficult to obtain ethnical approval if such requirements were included in the 
protocol. Furthermore, the fact that the researcher was present in clinic appointments for 
many prospectively-recruited individuals meant that any information that was not 
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mentioned in clinic letters could still be used. Some individuals who followed the KD in the 
past and were recruited retrospectively, chose (or their parent/guardian(s) chose) to give 
details of their experience with the KD during recruitment, but such information was not 
systematic and could not be used to classify response at certain time points (it is highly 
unlikely that people remember exactly when seizure control was better or worse).  
It should be noted that any non-significant results in genetic analyses may have been due 
to misclassification bias, if some participants were placed in the incorrect response group. 
Taking seizure-freedom (for example, at the 3-month point or sustained over a 2-year 
period) as the phenotype may have resulted in less misclassification bias, as there is less 
margin for error with regards seizure frequency when reporting such an extreme response. 
The problem with such an approach is that, due to the rarity of achieving seizure-freedom 
with the KD, a much larger sample size would have been needed to have confidence in any 
results obtained; in the current cohort, only nine individuals were seizure-free at the 3-
month point and only two individuals maintained 100% seizure-freedom over a 2-year 
period. Furthermore, seizure-freedom whilst following the KD may be due to spontaneous 
remission, although one would encounter this problem when adopting any definition of 
response, due to the fluctuating nature of epilepsy. The genetic architecture of KD 
response is unknown and so it makes sense to start with a percentage seizure-reduction 
that is viewed as clinically useful in such a drug-resistant population; other phenotypes may 
subsequently be explored. 
 Compliance to treatment 8.2.2
Misclassification bias may also be present because some non-compliers were incorrectly 
classified as non-responders; this may have influenced genetic analyses. In clinical practice, 
the presence of ketones in urine and blood is often used as a sign of treatment compliance 
but these measures are subject to wide intra- and inter-individual variability. The 
394 
 
researcher tried to address this issue with the adapted MARS questionnaire but these data 
were not available for all participants and the questionnaire itself may not accurately 
reflect dietary compliance, as people aim to give socially-acceptable answers. The MARS 
measures intentional and unintentional non-adherence and there may have been inter-
individual variability in interpretation of the question ‘We alter the diet’; it may not have 
been clear whether or not this referred to changes prescribed by the dietitian. In this study, 
few changes were made in order to remain as close as possible to the validated versions of 
the questionnaire, but the MARS may have benefitted from further adaptation. Ideally, the 
adapted questionnaire should have been validated with more objective measures of 
compliance, such as weighed food records or doubly-labelled water. Accurate knowledge of 
food consumption may be obtained by patient surveillance and weighing of meals in future 
participants, as described in a previous case report18, but this may not be feasible on a 
large-scale out-patient basis. 
 Prospective versus retrospective recruitment 8.2.3
If all participants were recruited prospectively, completion of seizure diaries could have 
been stipulated as a requirement in Patient Information Sheets in order to improve the 
quality of KD response classification. Other tools could also have been used, such as quality 
of life and seizure severity questionnaires, which would have allowed more than one 
aspect to be taken into account when classifying KD response, although it is unknown 
whether this would have been viewed as acceptable by the Research Ethics Committee. As 
demonstrated by the phenotypic analyses in this work, other clinically relevant factors 
besides seizure frequency were lost to appraisal in this study because they were not 
systematically recorded or quantified. Due to limited clinic time, it may be a good idea to 
reserve a clinic room where patients could fill in such questionnaires whilst waiting for their 
appointments, with the researcher available to answer questions if needed. A balance 
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would have to be struck between obtaining as much data as possible and not over-
burdening the patient or his/her parent/guardian(s).  
Prospective recruitment would also have allowed better measures of compliance to be put 
in place. This is important as non-significant genetic results may be due to the fact that 
some non-compliers were incorrectly classified as non-responders. With prospective 
recruitment, the researcher could ensure that blood ketone levels are measured when 
patients attend clinics (this was done, where possible, but not for patients recruited 
retrospectively) or request recordings of daily ketone monitoring since the previous clinic 
visit. Completion of compliance questionnaires could be requested at various follow-up 
times from all participants, although this method does have its limitations (as noted in the 
previous section). Other methods, such as weighed food records or even short dietary 
recall interviews would provide further assurance that participants were actually following 
the KD. With a multi-centre study such as this, co-operation from colleagues at other 
centres would be required.   
The benefit of retrospective recruitment is that the sample size can be more easily 
increased in a shorter space of time. Many individuals who previously followed the KD are 
still under follow-up with the same neurology team, or at least within the same centre.  
The recruitment rate (whether prospective or retrospective) may have been greater if 
certain people at each site were involved from the very beginning. For example, dietitians, 
consultants or research assistants could have contributed to the protocol, giving them a 
sense of ownership. 
 Sample size 8.2.4
The size of the recruited cohort for this study was small, at least in terms of genetic analysis 
of a complex trait. This is the difficulty when the majority of cases are recruited by a single 
396 
 
person (despite putting systems in place for recruitment to occur elsewhere) and when the 
pool from which to recruit individuals in the first place is very limited - only several hundred 
people are thought to be following the KD during a year in the UK, and people who have 
followed the KD in the past are often lost to follow-up. The smaller the sample size, the less 
power there is to detect a significant genotypic-phenotypic association; although one can 
still examine the proportion of variants in responders and non-responders of the genes of 
most interest, rather than looking at p-values alone, other variants/genes/pathways with 
lesser effect sizes may also be relevant. The fact that some statistically significant results 
were obtained in this study, even with such a small sample size, is certainly encouraging. 
However, these results are largely dependent on which statistical test or definition of KD 
response is used. The more consistent the results and the larger the cohort, the more 
confident one can be that certain genes truly play a role in KD response. As it stands, 
caution is warranted when interpreting the reported results, given that this is a first report 
based on a relatively small sample. 
 Population structure 8.2.5
It is standard practice to adjust for population structure in genetic association studies. 
However, as shown in a study from the Wellcome Trust Case Consortium, population 
structure may only have a very small confounding effect: results from tests that adjusted 
for population structure were very similar to those from tests that did not adjust for 
population structure, and estimates of over-dispersion of the association statistics were 
close to 1 [573]. Individuals recruited for the KD study had a wide range of ethnicities, but 
the axes of variation explaining their genetic diversity was not correlated with the 
phenotype. λGC and quantile-quantile plots both showed that the least biased approach was 
a Fisher’s test, which does not adjust for population stratification; this was used for the 
single variant tests using genotyping array and exome sequencing data, and the gene- and 
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pathway-based tests using genotyping array data. This is likely to do with the fact that the 
Fisher’s test does not rely on an asymptotic distribution method: exact p-values are 
calculated based on the exact distribution of the test statistic (the dataset may, in fact, be 
unbalanced), rather than estimating p-values based on the assumption that the data 
conforms to a normal distribution (these approximations become more exact as the sample 
size nears infinity). With a larger sample size, population structure may become more of an 
issue. Circulating insulin levels and insulin sensitivity differs between ethnic populations – 
for example, African Americans tend to be hyperinsulinaemic and have an elevated insulin 
response and reduced insulin sensitivity compared to Caucasians [1205-1208]; this further 
strengthens the importance of examining the effect of population structure on KD response 
in future analyses and, if necessary, correcting for it.  
 Replicates and batch effect  8.2.6
Ideally, some individuals should have been genotyped or sequenced more than once. 
Although stringent quality-control criteria were adopted and performance metrics did not 
differ between batches, high concordance would provide further reassurance that call and 
error rates did not differ between batches. Further funding would have to be sought in 
order to do this in the future.  
Principal component analysis can be used to detect patterns in the data that reflect 
subgroups other than those defined by ethnicity, such as batch effect, and included as 
covariates if necessary. 
8.3 Future work 
 Continuing recruitment and further analyses 8.3.1
If possible, recruitment should be extended in order to obtain as large a sample size as 
possible – preferably ≥1000 participants. Further international collaboration and dedicated 
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research assistants, or at least somebody responsible for recruitment at each site, would 
greatly aid this effort.  
Ideally, recruitment would be prospective in order to allow systematic collection of data so 
that compliance could be more closely monitored, seizure frequency could be more 
accurately quantified and other components besides seizure frequency could be used when 
classifying KD response. This would require submission of an amendment to the Research 
Ethics Committee. If a large enough cohort was recruited, separate analyses could be 
conducted to determine whether the mechanisms that lead to, for example, increased 
alertness with the KD are different to those that lead to reduced seizure frequency.  
KD response data should be collected for as many time points as possible, as has been done 
with this cohort. This would allow future analyses to be conducted with response classified 
at specific time points, or accounting for longitudinal response. There may be a genetic 
reason why some individuals do not respond well at all to the KD, others respond well to 
the KD in the short-term but then relapse, whereas others have a sustained response.  
With a larger sample size, other approaches to analysing the genetic data could be taken. 
For example, it may be possible to look for the genetic cause of epilepsy in individuals for 
whom this is unknown (by identifying rare variants of putative functional consequence in 
genes that are known to be associated with epilepsy) and investigate whether this is 
correlated with KD response. This could feasibly be done with whole exome sequencing or 
with a genotyping array with additional epilepsy-specific markers. Association analyses 
could also be conducted with individuals with specific (non-genetic) causes of epilepsy; in 
this way, each sub-cohort, each with a specific diagnosis, would be more homogeneous 
than the present cohort, thus reducing potential ‘noise’. A large sample size would be 
needed for such analyses because individuals that commence dietary treatment for 
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epilepsy are very heterogeneous; one would require as many individuals as possible in each 
group, most or all with a similar response to the KD, in order to increase confidence that 
the genetic cause of their epilepsy is also correlated with KD response, or that the 
mechanism for KD response is distinct in individuals with certain epilepsy aetiologies.  
Other programmes could also be used to conduct gene- and pathway-based analyses, both 
with genotyping array and exome sequencing data, and overlapping results prioritised.  
 Gene expression analyses 8.3.2
In addition to overcoming the sample size limitation of the gene variant analyses, 
investigation into what gene expression changes occur in humans following the KD 
(Research question 3) would be of great interest. Comparing gene expression levels in 
individuals before they start the KD, when they have followed the KD for a certain length of 
time, and potentially soon after being weaned from the diet, could answer two questions:  
i) what changes in gene expression does the KD induce in humans? Do up- or 
down-regulated genes have a particular function in common or belong to a 
particular pathway? This may or may not be the same as changes induced by 
starvation/calorie restriction alone, or by KD-feeding in animal studies.   
ii) do KD responders have different gene expression changes compared to non-
responders? This could be examined both separately and alongside results 
from the SNP chip and/or exome sequencing. It may be that certain gene 
expression changes can be linked with specific gene variants.  
If RNA were to be collected at various time points, it may be determined whether certain 
gene expression changes are more correlated with short- or long-term response. If RNA 
was also collected after discontinuation of the KD, it may be determined how long KD-
induced changes in gene expression last. It may be the case that those who discontinue 
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treatment following a long period of sustained response (normally 2+ years) are more or 
less likely to maintain the benefits obtained from the KD, depending on these long-term 
expression changes. RNA from brain would be ideal, although this is relatively inaccessible. 
Gene expression in peripheral blood lymphocytes has been shown to moderately correlate 
with gene expression in the brain [1209]. Therefore, except for genes with tissue-specific 
expression, peripheral blood gene expression data may be used as a surrogate for CNS 
gene expression. It would be desirable to develop blood-based biomarkers for KD response 
due to the relative non-invasive nature of whole blood collection, or at least determine 
whether genes with certain functions are more likely to be differentially regulated in 
responders and non-responders.  
 Follow-up studies 8.3.3
If certain genes were highlighted as potentially relevant in higher-powered analyses with a 
larger sample size and, potentially, in another replication cohort, targeted genotyping or 
sequencing of the regions of interest could then be undertaken with future samples, rather 
than having to obtain whole genome or whole exome data. Gene knockout functional 
assays could help ascertain the phenotypic consequences of gene ablation, including 
general consequences, such as whether this leads to apoptosis or influences cell 
proliferation, or whether more specific features of the gene/protein, such as secreting a 
particular hormone, remain intact or not. It would be of interest to see whether organ-
specific gene knockout (for example, in the brain versus the liver or pancreas) had different 
effects. Functional studies could also help determine the effects of certain variants on 
gene/protein function.  
These approaches, however, are problematic when dealing with a complex trait: firstly, 
because there may be many genes of interest, which would increase cost of future analyses 
and, secondly, because investigation of individual genes does not account for the fact that 
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the KD is likely influenced by metabolic or cell signalling networks. Results have shown that 
one single gene may have various functions and influence various pathways that may 
feasibly be relevant to KD response. Genes that appear to have the largest effect size on 
the phenotypic trait should be identified for further analysis, whilst bearing in mind that no 
single gene is likely to fully explain the whole story.  
 Clinical translation 8.3.4
If one or more genes were found to have a large effect size on KD response, either from 
gene variant or expression analyses, results from targeted genotyping or sequencing 
(conducted in a clinically-accredited laboratory) could be used as an additional factor when 
deciding whether to commence KD treatment for an individual at a certain point in time. If 
abnormal function of these genes, or of the pathways within which they function, could be 
detected by specific biomarkers, this would greatly facilitate this process. This is unlikely, 
because no parameter that is routinely measured before or during KD treatment has been 
consistently shown to correlate with response. In light of the results obtained, I would be 
interested in assessing whether glucose tolerance or insulin sensitivity could be used as a 
biomarker to predict KD response.  
8.4 Final words 
Four themes have emerged from the various genetic analyses conducted, including variant-
, gene- and pathway-based analyses: cell cycle progression and apoptosis, glucose 
homeostasis, neurological processes and triglyceride biosynthesis. There was no evidence 
that common variation has a greater or lesser effect than rare variation on KD response, as 
these themes were identified from all analyses. It is of interest that the first three themes 
highlighted are also linked with the candidate genes KCNJ11 and BAD, although variants in 
other genes appeared to have a greater differential distribution amongst responders and 
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non-responders. These four themes can all be traced back in some way to the insulin 
signalling cascade. However, the implications of these pathways are wide (for example, 
insulin regulates the expression of over 100 genes [1210] and there are over 1000 
combinatorial possibilities only in the first steps of the insulin/IGF1 pathways [1211]), even 
if one just concentrates on the effects on the brain: neuronal survival, brain glucose 
metabolism, neurotransmitter release and so on. As such, genetic variation in many genes 
downstream of insulin/IGF1, PI3/AKT/mTOR and MAPK/ERK pathways may influence these 
diverse effects. Impaired function of certain components of a pathway may be 
compensated for by others, which hinders the use of loss-of-function strategies.  
One may claim that this work has done little to enhance understanding of the mechanisms 
underlying how the KD restores neuronal excitability homeostasis in some individuals but 
not others. Despite the study limitations, I would argue against this; the results obtained 
provide evidence that KD response is influenced by a web of factors, many of which are 
inter-related. In subsets of individuals, unfavourable KD response may be explained by a 
specific variant that, for example, influences glutamate or glucose metabolism; in other 
individuals, there may be many biologically feasible explanations for their favourable or 
unfavourable KD response but, when taken in isolation, no theory solely accounts for this 
variability. The major disadvantage of this is that, at this stage, these results have little 
clinical significance. Although it is likely that KD response is influenced by genetic variation, 
the mechanisms are too complex to be narrowed down to a single gene and are likely to 
involve multiple pathways. Certain genes may be more relevant than others and this study 
has highlighted several genes for further investigation. A larger sample size and additional 
studies are certainly needed to increase confidence in the importance of these genes. 
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10 Appendices 
Appendix 1.1 
Fig 3B from Bough et al., 2006 [291]. 
 
Relative expression levels of 24 energy metabolism genes that were upregulated by the KD. 
Each row corresponds to one gene. Genes associated with glycolysis, the tricarboxylic acid 
(TCA) cycle, or oxidative phosphorylation (Ox Phos) are grouped. 
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Appendix 1.2 
Taken from Supplemental Table 1, Bough et al., 2006 [291]. 
Access No. Symbol 
Log2 ratio 
(KD/Control) 
Gene Name 
CB717809 Ttc11_pr 0.39 Tetratricopeptide repeat domain 11    
AI172214 
 
Mrpl53_pr 0.19 Mitochondrial ribosomal protein L53    
AI599839 
 
LOC298684 0.66 Similar to Mrpl20 protein 
AI170683 
 
Oat 0.42 Ornithine aminotransferase 
XM_215897 Acas2l_pr 0.39 
Acetyl-Coenzyme A synthetase 2 (AMP forming)-
like    
AI177136 
 
Atpaf2_pr 0.66 
ATP synthase mitochondrial F1 complex assembly 
factor 2    
CV118235 Atp5d 0.45 
ATP synthase, H+ transporting, mitochondrial F1 
complex, delta subunit 
CR754443 Atp5c1 0.4 
ATP synthase, H+ transporting, mitochondrial F1 
complex, gamma 1 
D13127 
 
Atp5o 0.44 
ATP synthase, H+ transporting, mitochondrial F1 
complex, O subunit 
BI293306 
 
Atp6v1c1_pr 0.55 ATPase, H+ transporting, V1 subunit C, isoform 1    
AA874909 Atp6v1e1 0.27 ATPase, H+ transporting, V1 subunit E isoform 1 
AI599960 
 
Atp6v1f 0.21 ATPase, H+ transporting, V1 subunit F 
AA892167 Cox6a1 0.31 Cytochrome c oxidase, subunit VIa, polypeptide 1 
CV116832 Cyc1_pr 0.34 Cytochrome c-1    
AA892808 Idh3g 0.33 Isocitrate dehydrogenase 3, gamma 
AI010480 
 
Mor1 0.32 Malate dehydrogenase, mitochondrial 
AI171476 
 
Ndufa6_pr 0.22 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 6 (B14)  
CB725067 Ndufa8_pr 0.38 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 8    
CF976612 
 
Ndufb9_pr 0.34 
NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 9    
CF976253 
 
RGD:1303259 0.25 
Similar to CG6105-PA (component of ATP 
synthase, F0 complex) 
CB327643 Slc25a4 0.23 
Solute carrier family 25 (mitochondrial adenine 
nucleotide translocator 4) 
CA340524 Slc25a3 0.35 
Solute carrier family 25 (mitochondrial adenine 
nucleotide translocator 3) 
AW922020 Sdha 0.34 
Succinate dehydrogenase complex, subunit A, 
flavoprotein (Fp) 
BC059160 Sdhd 0.22 
Succinate dehydrogenase complex, subunit D, 
membrane protein 
   
0.26 
similar to NADH-ubiquinone oxidoreductase 18 
kDa subunit 
BC085339 RIS1 0.38 
Ubiquinol-cytochrome c reductase, Rieske iron-
sulfur polypeptide 1 
AI175483 
 
Ndufb11 0.43 
NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 11  
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AA800237 Acadm -0.39 
Acetyl-Coenzyme A dehydrogenase, medium 
chain 
BM390148 Acsl3 0.4 Acyl-CoA synthetase long-chain family member 3 
AI176264 
 
Dci 0.46 Dodecenoyl-coenzyme A delta isomerase 
CK840087 Gpam -0.41 
Glycerol-3-phosphate acyltransferase, 
mitochondrial 
AI102615 
 
Hadhb 0.35 
Hydroxyacyl-Coenzyme A dehydrogenase 
(trifunctional protein), beta  
BF285297 
 
— 0.31 Transcribed locus 
NM_080689 Dnm1 0.28 Dynamin 1 
AF019043 
 
Dnm1l 0.29 Dynamin 1-like 
BF282660 
 
Timm9 0.36 
Similar to Mitochondrial inner membrane 
translocase subunit TIM9 A 
NM_152935 Tomm20 0.3 
Translocase of outer mitochondrial membrane 20 
homolog (yeast) 
XM_215358 Mtch1_pr 0.2 Mitochondrial carrier homolog 1 (C. elegans)    
CB325437 Immt_pr 0.43 Inner membrane protein, mitochondrial    
AF095741 
 
Mg87 1.04 Mg87 protein 
BM383379 RGD:1303219 0.34 Similar to Protein CGI-51 
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Appendix 2.3 
 
The National Hospital for Neurology & Neurosurgery  
Queen Square  
London  
WC1N 3BG  
Telephone: 0845 155 5000 
Web-site: www.uclh.nhs.uk 
ADULT PATIENT INFORMATION SHEET  
Genetics of Response to Ketogenic Diet 
 
You are invited to participate in a study that is being carried out at the National 
Hospital for Neurology and Neurosurgery in collaboration with Great Ormond Street 
Hospital, the National Centre for Young People with Epilepsy, Evelina Children’s 
Hospital and Birmingham Children’s Hospital.  Before you decide, it is important for 
you to understand why the research is being done and what it will involve.  Please 
take time to read the following information carefully.  One of our team will go 
through the information sheet with you and answer any questions you have. There 
will be the opportunity to ask questions if anything is not clear, or if you would like 
further information. 
 
PART 1 
What is the purpose of this study? 
The aim of this study is to see whether there is a genetic basis to treatment 
outcome with the Ketogenic diet and whether the genetic basis might be because 
the diet causes changes in gene expression.  
 
Why have I been invited? 
As will have been discussed with you in clinic, we still do not understand why some 
people respond well to the Ketogenic diet and others do not. The purpose of this 
study is to collect together some patients who have received, or are currently 
receiving the Ketogenic diet and look at their genetic material to see whether there 
are any similarities in those who have responded well to treatment and those who 
have not. We will also look at whether the Ketogenic diet causes changes in 
patients’ genes. By looking at a group of people treated with the d iet, we hope that 
we will find some common genetic changes and improve our understanding of how 
the Ketogenic diet works. 
 
Do I have to take part? 
You do not have to take part in the study if you do not wish to. If you decide to take 
part, you may withdraw your information at any time without having to give a reason. 
The decision about whether to take part or not will not affect your care and 
management in any way. If you decide to take part, you will be given a copy of this 
information sheet to keep and be asked to sign a consent form, a copy of which you 
will also be given to keep.  If you decide to take part, you are still free to withdraw 
your data at any time, without giving a reason 
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What will happen to me if I take part? 
If you have not yet started the diet, we will take two or three blood samples from 
you. The first blood sample will be taken before you start the diet; the second 
sample will be taken at one point while you are on the diet. If you are weaned off the 
diet while the study is still in operation, a third blood sample will be taken. 
 
If you are already on the diet, we will take one or two blood samples from you. The 
first blood sample will be taken at one point while you are on the diet. If you are 
weaned off the diet while the study is still in operation, a second blood sample will 
be taken. 
 
If you are no longer following the diet, we will take a single blood sample from you. 
  
On all occasions, it is likely that we will take the blood at the same time as blood 
taken for routine clinical monitoring (this means that an extra blood sample will be 
taken).  We will require a very small amount of blood – 10mls. The procedure will be 
like any previous blood sample that has been undertaken. The blood will be taken 
by an experienced blood taker.  The procedure should not cause any problems, but 
very occasionally it can result in mild bruising or discomfort.  The blood sample will 
be sent to the laboratory to isolate genetic material (DNA and RNA) from the blood.  
Tests will then be performed when we have a collection of samples to see if there 
are any changes in the genes that are common to people with similar types of 
epilepsy.  We will not be able to return any individual results. However, at the end of 
the study we will make the overall results available to all those who participated.  
 
Seizure frequency data will be obtained from that already collected as part of the 
monitoring for the KD service provision. 
 
All the information we gather will be held on a computer at the Institute of 
Neurology. Only Professor Sisodiya, his collaborator at Great Ormond Street 
Hospital, Professor Cross, and the research team undertaking this study will have 
access to it.  Professor Sisodiya and Professor Cross will have sole responsibility 
for access to this information.  At the end of the study the sample will be kept for 20 
years for future ethically approved projects. The nature of any further research will 
depend on our initial findings. The information and results we collect will remain 
confidential forever to uphold good research practice. The information you give will 
only be used for medical research and will be stored and disposed of securely.   
 
What will I have to do? 
As outlined above, this research involves taking one, two or three blood tests from 
which genetic material will be extracted and analysed. No extra visits to the hospital 
will be required. 
 
What are the possible disadvantages and risks of taking part? 
Taking part in this research will not affect the management of your epilepsy. The 
only risk is in minor bruising from the blood test. You may ask for all information 
collected for this study to be destroyed at any time.  All information regarding your 
medical records will be treated as strictly confidential and will only be used for 
medical and research purposes.  Your medical records may be inspected by 
constant authorities and properly authorised persons, but if any information is 
released this will be done so in a coded form so that confidentiality is strictly 
maintained.   
 
What are the possible benefits of taking part? 
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The results of this research are unlikely to help you specifically. However, in the 
long term, it may influence treatment choices in individuals with a similar epilepsy. 
 
What if there is a problem? 
Any complaints about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. The detailed information 
concerning this is given in Part 2 of this information sheet. 
 
Will my taking part in the study be kept confidential? 
All information about the study will be kept strictly confidential; we will follow ethical 
and legal practice. The details are included in part 2.  
 
 
PART 2  INFORMATION YOU NEED TO KNOW IF YOU WANT TO TAKE PART 
 
What will happen if I don’t want to carry on with the study? 
If you wish to withdraw from the study at any time, we will destroy all identifiable 
samples, but we will need to use the data collected up to the time of your 
withdrawal. 
 
What if there is a problem? 
Every care will be taken in the course of this study. However, in the unlikely event 
that you are injured by taking part, compensation may be available. 
 
If you suspect that the injury is the result of the Sponsor’s (University College 
London) or the hospital's negligence then you may be able to claim compensation. 
After discussing with your research doctor, please make the claim in writing to 
Professor Sanjay Sisodiya, who is the Chief Investigator for the research and is 
based at the Institute of Neurology, 33 Queen Square, London WC1N 3BG; 
telephone number: 020 3448 8612; fax number: 020 3448 8615; email address: 
s.sisodiya@ucl.ac.uk. The Chief Investigator will then pass the claim to the 
Sponsor’s Insurers, via the Sponsor’s office. You may have to bear the costs of the 
legal action initially, and you should consult a lawyer about this. 
 
Regardless of this, if you wish to complain, or have any concerns about any aspect 
of the way you have been approached or treated by members of staff or about any 
side effects (adverse events) you may have experienced due to your participation in 
the research, the normal National Health Service complaints mechanisms are 
available to you. Please ask your research doctor if you would like more information 
on this. Details can also be obtained from the Department of Health website: 
http://www.dh.gov.uk. 
 
Will my taking part in this study be kept confidential? 
This information will be held on a computer at the Institute of Neurology and only 
Professor Sisodiya, his collaborator at the Institute of Child Health, Professor Cross, 
and the research team undertaking this study will have access to it. Professor 
Sisodiya and Professor Cross will have sole responsibility for access to this 
information. At the end of the study, the information will be kept for further research.  
The nature of which will depend on our initial findings. 
 
In line with current practice in the field of genetics, we plan to make overall results 
which cannot be related back to individual people, openly available upon publication 
of the main findings from the study. There is no way anybody will be able to identify 
you from the study. Coded individual genetic results, which also cannot be traced 
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back to individual people, will be made available only to qualified researchers with 
strict agreements on use of the information in due course.  This is to further 
enhance the value of the research and to maximise the potential of the findings for 
research and epilepsy. 
 
Involvement of the General Practitioner 
Your GP will be informed of your participation in the study. No information will be 
released without your consent. 
 
What will happen to any samples taken from me? 
One, two or three blood samples will be taken. These will go to the laboratory where 
genetic material (DNA and RNA) will be extracted. Information will be held on a 
computer at the Institute of Neurology and only Professor Sisodiya, his collaborator 
at the Institute of Child Health, Professor Cross, and the research team undertaking 
this study will have access to it. Professor Sisodiya and Professor Cross will have 
sole responsibility for access to this information.  At the end of the study the sample 
will be kept for further research. Samples will be stored for 20 years. The nature of 
any further research will depend on our initial findings.  They will not be used for 
other research without your consent.  
 
In the unlikely event of a loss of capacity, the research term would retain blood and 
personal data collected and continue to use it confidentially in connection with the 
purposes for which consent is being sought. 
 
What will happen to the results of the research study? 
On the whole, results will not be available on an individual basis. In some cases a 
significant genetic result may be found. If this is the case, we will arrange to discuss 
this with you and your consultant, and arrange further investigations as necessary. 
The overall results at the end of the study will be made available to all participants. 
Results will be published in medical journals. No patient will be identified in any 
report or publication unless consent has been obtained. 
 
Who is organising and funding the research? 
The research is being organised through UCL-Institute of Neurology in collaboration 
with Great Ormond Street Hospital for Children NHS Trust. It is being funded by The 
Epilepsy Society and UCL. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people called a 
Research Ethics Committee, to protect you and your child’s interests. This study 
has been reviewed and given a favourable opinion by East Central London 
Research Ethics Committee 1. 
 
Further information and contact details 
 
1. For general information about research please review the UKCRN website: 
www.UKCRN.org.uk 
2. If you require specific information about this research project, or are 
unhappy with the study, please contact Professor Sanjay Sisodiya at the 
Institute of Neurology, 33 Queen Square, London WC1N 3BG; telephone 
number: 020 3448 8612; fax number: 020 3448 8615; email address: 
s.sisodiya@ucl.ac.uk  
3. For advice about whether to participate please consult with your consultant 
at the National Hospital for Neurology and Neurosurgery.  
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The National Hospital for Neurology & Neurosurgery  
Queen Square  
London  
WC1N 3BG  
Telephone: 0845 155 5000 
        Web-site: www.uclh.nhs.uk 
ADULT PATIENT CONSENT FORM       
Title of the Research project: Genetics of Response to Ketogenic Diet 
Study Protocol No: 10/0427  
Researchers:  Professor Sanjay M. Sisodiya, Professor Josemir Sander, 
Professor J. Helen Cross, Miss Natasha Payne  
Contact details:  020 3448 8612:  email: s.sisodiya@ucl.ac.uk 
Patient Identification No for this trial:  
Please initial box to indicate agreement: 
 
1 
 
I confirm that I have read and understand the information sheet for the above study 
(Version 1.2 dated 05/10/11). I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
 
2 
 
I understand that my participation is voluntary and that I am free to withdraw at  
any time, without giving any reason, without my medical care or legal rights being affected. 
 
 
3 
 
I understand that relevant sections of any of my Medical Notes and data collected during 
the study may be looked at by employees from Regulatory Authorities or from National 
Hospital for Neurology and Neurosurgery, Great Ormond Street Hospital/ Institute of 
Child Health, National Centre for Young People with Epilepsy, Evelina Children’s 
Hospital or Birmingham Children’s Hospital, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my records.  
 
 
4 
 
I agree to my GP and/or neurologist being informed of my participation in the study. 
 
 
5 
 
I agree for my blood and DNA/RNA sample to be taken once, twice or three times at a 
routine clinic visit and stored with my medical records for the purpose of this study. 
 
6 
I agree for my blood and DNA/RNA sample to be stored for future ethically approved 
research. 
 
7 I agree to take part in the above study.  
                     
__________________________________         ___________                    ______________ 
Name of Patient                Date    Signature 
_________________________________          ___________                   ______________ 
Name of Person taking consent              Date   Signature 
(if different from Investigator) 
__________________________________          ___________            ______________ 
Investigator                Date   Signature 
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PARENT/GUARDIAN INFORMATION SHEET 
 
Genetics of Response to Ketogenic Diet 
Your child is invited to participate in a study that is being carried out at Great 
Ormond Street Hospital in collaboration with the National Hospital for Neurology and 
Neurosurgery, The National Centre for Young People with Epilepsy, Evelina 
Children’s Hospital and Birmingham Children’s Hospital.  Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully.  One of our 
team will go through the information sheet with you and answer any questions you 
have. There will be the opportunity to ask questions if anything is not clear, or if you 
would like further information. 
 
PART 1 
What is the purpose of this study? 
The aim of this study is to see whether there is a genetic basis to treatment 
outcome with the Ketogenic diet and whether the genetic basis might be because 
the diet causes changes in gene expression.  
 
Why has my child been invited? 
As will have been discussed with you and your child in clinic, we still do not 
understand why some people respond well to the Ketogenic diet and others do not. 
The purpose of this study is to collect together some patients who have received, or 
are currently receiving the Ketogenic diet and look at their genetic material to see 
whether there are any similarities in those who have responded well to treatment 
and those who have not.  We will also look at whether the Ketogenic diet causes 
changes in patients’ genes. By looking at a group of people treated with the diet, we 
hope that we will find some common genetic changes and improve our 
understanding of how the Ketogenic diet works 
 
Does my child have to take part? 
Your child does not have to take part in the study if he or she does not wish to.  We 
are also releasing information to your child for them to also make the decision. If 
your child decides to take part you may withdraw your child’s information at any time 
without having to give a reason. The decision about whether to take part or not will 
not affect your child’s care and management in any way. If your child decides to 
take part you will be given a copy of this information sheet to keep and be asked to 
sign a consent form, a copy of which you will also be given to keep.  We also have 
an assent form for your child to sign if he or she so wishes.  If your child decides to 
take part you are still free to withdraw your child’s data at any time and without 
giving a reason 
 
What will happen to my child if he or she takes part? 
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If your child has not yet started the diet, we will take two or three blood samples 
from your child. The first blood sample will be taken before your child starts the diet; 
the second sample will be taken at one point while he/she is on the diet. If your child 
is weaned off the diet while the study is still in operation, a third blood sample will be 
taken. 
 
If your child is already on the diet, we will take one or two blood samples from your 
child. The first blood sample will be taken at one point while your child is on the diet. 
If your child is weaned off the diet while the study is still in operation, a second 
blood sample will be taken. 
 
If your child is no longer following the diet, we will take a single blood sample from 
your child. 
  
We will require a very small amount of blood: 2-5mls. On all occasions, it is likely 
that we will take the blood at the same time as blood taken for routine clinical 
monitoring (this means that an extra blood sample will be taken). The procedure will 
be like any previous blood sample that has been undertaken in your child.  We will 
use anaesthetic spray if you and your child so wish, and the blood will be taken by 
an experienced blood taker.  The procedure should not cause any problems, but 
very occasionally it can result in mild bruising or discomfort. The blood sample will 
be sent to the laboratory to isolate genetic material (DNA and RNA) from the blood. 
Tests will then be performed when we have a collection of samples to see if there 
are any changes in the genes that are common to children with similar types of 
epilepsy. We will not be able to return any individual results, however at the end of 
the study we will make the overall results available to all those who participated. 
Seizure frequency data will be obtained from that already collected as part of the 
monitoring for the KD service provision. 
All the information we gather will be held on a computer at the Institute of Neurology 
and only Professor Cross, her collaborator at the Institute of Neurology, Professor 
Sisodiya, and the research team undertaking this study will have access to it.  
Professor Cross and Professor Sisodiya will have sole responsibility for access to 
this information. At the end of the study the sample will be kept for 20 years for 
future ethically approved projects. The nature of any further research will depend on 
our initial findings. The information and results we collect will remain confidential 
forever to uphold good research practice. The information you give will only be used 
for medical research and will be stored and disposed of securely.   
 
What will my child have to do? 
As outlined above, this research involves taking one, two or three blood tests from 
which genetic material will be extracted and analysed. No extra visits to the hospital 
will be required. 
 
What are the possible disadvantages and risks of taking part? 
Taking part in this research will not affect the management of your child’s epilepsy. 
The only risk is in minor bruising to your child from the blood test. You may ask for 
all information collected for this study to be destroyed at any time.  All information 
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regarding your child’s medical records will be treated as strictly confidential and will 
only be used for medical and research purposes.  Your child’s medical records may 
be inspected by constant authorities and properly authorised persons, but if any 
information is released this will be done so in a coded form so that confidentiality is 
strictly maintained.   
 
What are the possible benefits of taking part? 
The results of this research are unlikely to help your child specifically. However, in 
the long term, it may influence treatment choices in individuals with a similar 
epilepsy. 
 
 
What if there is a problem? 
Any complaint about the way your child has been dealt with during the study or any 
possible harm he or she might suffer will be addressed. The detailed information 
concerning this is given in Part 2 of this information sheet. 
 
Will my child’s taking part in the study be kept confidential? 
All information about the study will be kept strictly confidential; we will follow ethical 
and legal practice. The details are included in part 2.  
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PART 2  INFORMATION YOU NEED TO KNOW IF YOU WANT TO TAKE PART 
 
What will happen if my child doesn’t want to carry on with the study? 
If your child wishes to withdraw from the study at any time, we will destroy all 
identifiable samples, but we will need to use the data collected up to the time of your 
withdrawal. 
 
What if there is a problem? 
Every care will be taken in the course of this study. However, in the unlikely event 
that you are injured by taking part, compensation may be available. 
 
If you suspect that the injury is the result of the Sponsor’s (University College 
London) or the hospital's negligence then you may be able to claim compensation. 
After discussing with your research doctor, please make the claim in writing to 
Professor Sanjay Sisodiya, who is the Chief Investigator for the research and is 
based at the Institute of Neurology, 33 Queen Square, London WC1N 3BG; 
telephone number: 020 3448 8612; fax number: 020 3448 8615; email address: 
s.sisodiya@ucl.ac.uk. The Chief Investigator will then pass the claim to the 
Sponsor’s Insurers, via the Sponsor’s office. You may have to bear the costs of the 
legal action initially, and you should consult a lawyer about this. 
 
Regardless of this, if you wish to complain, or have any concerns about any aspect 
of the way you or your child have been approached or treated by members of staff 
or about any side effects (adverse events) you may have experienced due to your 
participation in the research, the normal National Health Service complaints 
mechanisms are available to you. Please ask your research doctor if you would like 
more information on this. Details can also be obtained from the Department of 
Health website: http://www.dh.gov.uk. 
 
Will my child’s taking part in this study be kept confidential? 
This information will be held on a computer at the Institute of Neurology and only 
Professor Cross, her collaborator at the Institute of Neurology, Professor Sisodiya, 
and the research team undertaking this study will have access to it.  Professor 
Cross and Professor Sisodiya, will have sole responsibility for access to this 
information. At the end of the study, the information will be kept for further research.  
The nature of which will depend on our initial findings. 
 
In line with current practice in the field of genetics we plan to make overall results 
which cannot be related back to individual people, openly available upon publication 
of the main findings from the study. There is no way anybody will be able to identify 
your child from the study.  Coded individual genetic results which also cannot be 
traced back to the individual people will be made available only to qualified 
researchers with strict agreements on use of the information in due course.  This is 
to further enhance the value of the research and to maximise the potential of the 
findings for research and epilepsy. 
 
Involvement of the General Practitioner 
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Your child’s GP will be informed of your child’s participation in the study. No 
information will be released without your consent. 
 
What will happen to any samples from my child? 
Either one, two or three blood samples will be taken. These will go to the laboratory 
where genetic material (DNA and RNA) will be extracted. Information will be held on 
a computer at the Institute of Neurology and only Professor Cross, her collaborator 
at the Institute of Neurology, Professor Sisodiya, and the research team undertaking 
this study will have access to it. Professor Cross and Professor Sisodiya, will have 
sole responsibility for access to this information.   At the end of the study the sample 
will be kept for further research. Samples will be stored for 20 years. The nature of 
any further research will depend on our initial findings.  They will not be used for 
other research without your consent.  
 
In the unlikely event of a loss of capacity, the research term would retain blood and 
personal data collected and continue to use it confidentially in connection with the 
purposes for which consent is being sought.  
 
What will happen to the results of the research study? 
On the whole, results will not be available on an individual basis. In some cases a 
significant genetic result may be found. If this is the case in your child, we will 
arrange to discuss this with you and your consultant, and arrange further 
investigations as necessary. The overall results at the end of the study will be made 
available to all participants. Results will be published in medical journals. No patient 
will be identified in any report or publication unless consent has been obtained. 
 
Who is organising and funding the research? 
The research is being organised through Great Ormond Street Hospital for Children 
NHS Trust in collaboration with the UCL- Institute of Neurology. It is being funded by 
The Epilepsy Society and UCL. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people called a 
Research Ethics Committee, to protect you and your child’s interests. This study 
has been reviewed and given a favourable opinion by East Central London 
Research Ethics Committee 1. 
 
Further information and contact details 
1. For general information about research please review the UKCRN website: 
www.UKCRN.org.uk 
2. If you require specific information about this research project, or are 
unhappy with the study, please contact Professor Helen Cross, c/o Mrs 
Anne Brown, Neurosciences Unit, UCL Institute of Child Health, 4/5 Long 
Yard, London WC1N 3LU; Telephone number: 0207 599 4105; email 
a.brown@ucl.ac.uk 
3. For advice about whether to participate please consult with your child’s 
consultant at Great Ormond Street Hospital for Children 
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.   
INFORMATION SHEET for young people age 11-16 years 
Genetics of Response to Ketogenic Diet 
 
You are being asked to take part in a research study. This is because you have 
been treated with the Ketogenic diet, and we are still trying to find out why this 
treatment works with some people but not others. This study is trying to find out 
whether a change in the genetic building blocks of your body has affected whether 
the Ketogenic diet works in your case. Before you decide if you want to join in, it’s 
important to understand why the research is being done, and what it will involve for 
you. So please consider this leaflet carefully. Talk to your family, friends, doctor or 
nurse if you want to. 
 
PART 1 
Why are we doing this research? 
As your doctor will have explained, we still do not understand why some people 
respond well to the Ketogenic diet and others do not. We want to look at the genetic 
makeup of lots of patients with epilepsy treated with the Ketogenic diet to see 
whether we can find a common link. We also want to see if the Ketogenic diet 
causes changes in your genes. If this research is successful, we may understand 
better how the Ketogenic diet works. 
 
Why have I been invited to take part? 
You have come to the epilepsy clinic at Great Ormond Street Hospital to talk about 
your epilepsy. You and your parents will have discussed this with the consultant. As 
we do not know what makes the Ketogenic diet work in some people but not in 
others, your consultant has suggested we use some genetic material from you 
(taken from your blood) for this study. We hope 100 children and other people like 
you will participate. 
 
Do I have to take part? 
No, you don’t have to take part. It’s up to you. We will ask for your assent and then 
ask if you would sign a form. We will give you a copy of this information sheet and 
your signed form to keep. You are free to stop taking part at any time during the 
research without giving a reason. If you decide to stop this will not affect the care 
you receive. 
 
What will happen to me, and what will I be asked to do if I take part? 
If you have not yet started the diet, we will take two or three blood samples from 
you. The first blood sample will be taken before you start the diet; the second 
sample will be taken at one point while you are on the diet. If you are weaned off the 
diet while the study is still in operation, a third blood sample will be taken. 
 
If you are already on the diet, we will take one or two blood samples from you. The 
first blood sample will be taken at one point while you are on the diet. If you are 
 
480 
 
weaned off the diet while the study is still in operation, a second blood sample will 
be taken. 
 
If you are no longer following the diet, we will take a single blood sample from you. 
 
We can use anaesthetic spray or cream if you wish. The blood sample will go for 
further analysis in the laboratory. We will also record some details about your 
epilepsy from talking with you and your parents, as well as your hospital notes. All 
the details we collect will be recorded on a database but they will be coded so that 
they cannot be traced back to you. It will not affect your treatment in any way. 
 
What are the possible benefits of taking part? 
We cannot promise the study will help you but the information we get might help 
treat people with epilepsy in the future. 
 
What if I don’t want to do the research anymore? 
If at any time you don’t want to do the research anymore, just tell your parents, 
doctor or nurse. They will not be cross with you. We will destroy all identifiable 
samples, but we will need to use the data collected up to the time of your 
withdrawal.   
 
Contact details 
If you have any further questions please get in touch with Professor Helen Cross at 
the Neurosciences Unit, UCL Institute of Child Health, 4/5 Long Yard, London 
WC1N 3LU;Telephone number: 0207 599 4105. 
 
 
PART 2  INFORMATION YOU NEED TO KNOW IF YOU WANT TO TAKE PART 
 
What if there is a problem or something goes wrong? 
If there is a problem, please get in touch with Professor Sanjay Sisodiya at the 
Institute of Neurology, 33 Queen Square, London WC1N 3BG; telephone number: 
020 3448 8612; fax number: 020 3448 8615; email address: s.sisodiya@ucl.ac.uk. If 
you are unhappy then please talk with your parents; there is a way to formally 
complain if you want to. 
 
Will anyone else know I’m doing this? 
We will keep your information in confidence. This means we will only tell those who 
have a need or right to know.  
 
What will happen to any samples I give? 
One, two or three blood samples will be taken. These will go to the laboratory where 
genetic material (DNA and RNA) will be extracted. Information will be held on a 
computer at the Institute of Neurology and only Professor Cross, her collaborator at 
the Institute of Neurology, Professor Sisodiya, and her research team undertaking 
this study will have access to it. Professor Cross and Professor Sisodiya, will have 
sole responsibility for access to this information.   At the end of the study the sample 
will be kept for further research.  The samples will be kept for 20 years.  The nature 
of any further research will depend on our initial findings.  They will not be used for 
other research without your consent. 
 
Who is organising and funding the research? 
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The research is being organised by Great Ormond Street Hospital for Children NHS 
Trust with the National Hospital for Neurology and Neurosurgery. The research is 
being funded by The National Society for Epilepsy and UCL. 
 
Who has reviewed the study? 
Before any research goes ahead it has to be checked by a Research Ethics 
Committee. They make sure that the research is fair. Your project has been 
checked by East Central London Research Ethics Committee 1. 
 
Thank you for reading this. Please ask any questions if you need to. 
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INFORMATION SHEET FOR CHILDREN AGE 6-10 
YEARS 
GENETICS AND THE KETOGENIC DIET  
 
Why is the research being done? 
Research is a way we try to find out the answers to 
questions. In this research we are trying to find out 
the reasons why some people get better with the 
Ketogenic diet and some people don’t.  
 
Why have I been asked to take part? 
You have come to Great Ormond Street Hospital to 
talk about your epilepsy and a special diet - the 
Ketogenic diet. We are not sure exactly why some 
people get better with the Ketogenic diet and some 
people don’t. We think we can find out more by looking 
at your blood and that of other people on the 
Ketogenic diet. 
 
Did anyone else check the study is ok to do? 
Before any research is allowed to happen, it has to be 
checked by a group of people called a Research Ethics 
Committee. They make sure that the research is fair. 
This project has been checked by the East Central 
London Research Ethics Committee 1. 
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Do I have to take part? 
You do not have to take part if you don’t want to. If 
you don’t want to it will not affect your treatment in 
any way. Your doctor will still continue to see you. 
 
What will happen to me if I take part in the 
research? 
You will have one, two or three blood tests. We can 
use magic spray if you want us to.  
 
Will joining in help me? 
Joining in will not immediately help you, but may help 
other people in the future. 
 
Will my medical details be kept private? Will 
anyone else know I’m doing this? 
All your medical records will be kept completely 
private; we will tell your GP that you have taken part 
but no-one else will know. 
 
What if I don’t want to do the research anymore? 
If at any time you don’t want to do the research 
anymore, just tell your parents, doctor or nurse. They 
will not be cross with you.  We will destroy all samples 
that have been taken. 
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PARENT/GUARDIAN CONSENT FORM     
Title of the Research project: Genetics of Response to Ketogenic Diet 
Study Protocol No: 10/0427      
Researchers:  Professor J. Helen Cross, Professor Sanjay M. Sisodiya, 
Professor Josemir Sander, Miss Natasha Payne  
Contact details:  : 0207 599 4105  PA: a.brown@ucl.ac.uk 
Patient Identification No for this trial:  
Please initial box to indicate agreement: 
 
1 
 
I confirm that I have read and understand the information sheet for the above study 
(Version 1.2 dated 05/10/11). I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
 
2 
 
I understand that my child’s participation is voluntary and that he/she is free to withdraw at  
any time, without giving any reason, without his/her medical care or legal rights being 
affected. 
 
 
3 
 
I understand that relevant sections of any of my child’s Medical Notes and data collected 
during the study may be looked at by employees from Regulatory Authorities or from 
Great Ormond Street Hospital/ Institute of Child Health, the National Centre for Young 
People with Epilepsy, the National Hospital for Neurology and Neurosurgery, Evelina 
Children’s Hospital, or Birmingham Children’s Hospital where it is relevant to my child’s 
taking part in this research. I give permission for these individuals to have access to my 
child’s records.  
 
 
4 
 
I agree to my child’s GP, paediatrician and/or neurologist being informed of his/her 
participation in the study. 
 
 
5 
 
I agree for my child’s blood and DNA/RNA sample to be taken once, twice or three times 
at a routine clinic visit and stored with his/her medical records for the purpose of this 
study. 
 
6 
I agree for my child’s blood and DNA/RNA sample to be stored for future ethically 
approved research. 
 
7 I agree to my child taking part in the above study.  
                       
__________________________________ 
Name of Child                                         
 
__________________________________         ___________                    ______________ 
Name of Parent/Guardian              Date    Signature 
 
_________________________________          ___________                   ______________ 
Name of Person taking consent              Date   Signature 
(if different from Investigator) 
__________________________________          ___________            ______________ 
Investigator                Date   Signature 
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YOUNG PERSON CONSENT FORM (AGE 11-16)  
Title of the Research project: Genetics of Response to Ketogenic Diet 
Study Protocol No: 10/0427       
Researchers:  Professor J. Helen Cross, Professor Sanjay M. Sisodiya, 
Miss Natasha Payne  
Contact details:  : 0207 599 4105 PA: a.brown@ucl.ac.uk 
Patient Identification No for this trial:  
      
Please initial box to indicate agreement: 
 
1 
 
I confirm that I have read and understand the information sheet for the above study 
(Version 1.2 dated 05/10/11). I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
 
2 
 
I understand that my participation is voluntary and that I am free to withdraw at  
any time, without giving any reason, without my medical care or legal rights being affected. 
 
 
3 
 
I understand that relevant sections of any of my Medical Notes and data collected during 
the study, may be looked at, by employees from Regulatory Authorities or from Great 
Ormond Street Hospital/ Institute of Child Health, the National Centre for Young People 
with Epilepsy, the National Hospital for Neurology and Neurosurgery, Evelina Children’s 
Hospital, or Birmingham Children’s Hospital where it is relevant to my taking part in this 
research.  I give permission for these individuals to have access to my records.  
 
 
4 
 
I agree to my GP, paediatrician and/or neurologist being informed of my participation in 
the study. 
 
 
5 
 
I agree for my blood and DNA/RNA sample to be taken once, twice or three times at a 
routine clinic visit and stored with my medical records for the purpose of this study. 
 
6 
I agree for my blood and DNA/RNA sample to be stored for future ethically approved 
research. 
 
7 
I agree to take part in the above study. 
 
 
   
               
__________________________________         ___________                    ______________ 
Name of Patient               Date    Signature 
 
_________________________________          ___________                   ______________ 
Name of Person taking consent              Date   Signature 
(if different from Investigator) 
 
__________________________________          ___________            ______________ 
Investigator                Date   Signature 
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ASSENT FORM FOR CHILDREN (AGE 6-10) 
 
Title of project: Genetics of Response to Ketogenic Diet 
Study Protocol Number: 10/0427 
Researchers:  Professor J. Helen Cross, Professor Sanjay M. Sisodiya, 
Professor Josemir Sander, Miss Natasha Payne 
Contact details: : 0207 599 4105  PA: a.brown@ucl.ac.uk 
Patient Identification Number for this trial:  
 
Child (or if unable, parent on their behalf) / young person to circle all they 
agree with:  
 
Have you read (or had read to you) about this work (Version 1.1 dated 
05/10/11)?  
Yes/No 
Has somebody else explained this work to you?  Yes/No 
Do you understand what this work is about?  Yes/No 
Have you asked all the questions you want?  Yes/No 
Have you had your questions answered in a way you understand?  Yes/No 
Do you understand it’s OK to stop taking part at any time?  Yes/No 
Are you happy to take part?  Yes/No 
If any answers are ‘No’ or you don’t want to take part, don’t sign your name!  
 
If you do want to take part, you can write your name below:  
 
Your name ___________________________  
 
Date ___________________________  
 
The doctor who explained this project to you needs to sign too:  
 
Print Name ___________________________  
 
Sign ___________________________  
 
Date ___________________________  
 
Thank you for your help 
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Appendix 2.4 
Ketogenic Dietary Therapies 
 
People may find a way of following Ketogenic Dietary Therapies that suits 
them. This may differ from what their doctor or dietitian has said. Here are 
some ways in which people may follow Ketogenic Dietary Therapies. For 
each statement, please circle which best applies to you.  
 
All questions refer to your prescribed Ketogenic Dietary Therapy. 
 
I alter my diet  
Never  rarely   sometimes   often   very often  
 
I forget to follow the diet  
Never  rarely   sometimes   often   very often  
 
I stop following the diet for a while  
Never  rarely   sometimes   often   very often  
 
I decide to miss a meal 
Never  rarely   sometimes   often   very often  
  
Do you ever eat foods that are not allowed on the diet? 
Never  rarely   sometimes   often   very often  
 
I avoid following the diet if I can  
Never  rarely   sometimes   often   very often  
 
 
 
 
Thank you very much for your cooperation! 
 
 
 
 
 
 
 
 
488 
 
Ketogenic Dietary Therapies 
 
People may find a way of following Ketogenic Dietary Therapies that suits 
them. This may differ from what their doctor or dietitian has said. Here are 
some ways in which people may follow Ketogenic Dietary Therapies. For 
each statement, please circle which best applies to you and your child. 
 
All questions refer to your child’s prescribed Ketogenic Dietary 
Therapy. 
 
We alter the diet  
Never  rarely   sometimes   often   very often  
 
We forget to follow the diet  
Never  rarely   sometimes   often   very often  
 
My child stops following the diet for while  
Never  rarely   sometimes   often   very often  
 
My child misses a meal 
Never  rarely   sometimes   often   very often  
  
My child eats eat foods that are not allowed on the diet 
Never  rarely   sometimes   often   very often  
 
My child avoids following the diet if he/she can  
Never  rarely   sometimes   often   very often  
 
 
 
Thank you very much for your cooperation! 
 
 
 
 
 
 
 
 
 
489 
 
Appendix 4.1 
Table 4.9: Results of association analysis, not accounting for ethnicity: common and intermediate variation in KCNJ11 and BAD in Ketogenic diet overall responders and 
non-responders (summary KD response, n=216) 
 
 
 
 
 
 
Gene SNP rs number 
Minor allele 
(in Ketogenic 
diet cohort) 
Frequency of minor 
allele in non-
responders 
Frequency of minor 
allele in responders 
Unadjusted p-
value 
Odds ratio [95%CI] 
P-value (100,000 
permutations) 
KCNJ11 
rs8175351 A 0.02857 0.004505 0.0615 2.085 [0.908-4.786] 0.3306 
rs1800467 G 0.08095 0.04054 0.1044 0.6757 [0.3911-1.167] 0.5055 
rs5219 (same for 
rs5215) 
A 0.3143 0.3514 0.4749 1.99 [0.7225-5.481] 0.9842 
rs5218 T 0.2714 0.3063 0.4581 0.8462 [0.5666-1.264] 0.9782 
rs5216 G 0.01905 0.03604 0.3832 0.5194 [0.1541-1.751] 0.9463 
BAD 
rs34882006 A 0.05238 0.02703 0.2186 0.8437 [0.556-1.28] 0.764 
rs2286615 T 0.119 0.1667 0.1716 0.8462 [0.5666-1.264] 0.7052 
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Appendix 4.2 
Table 4.10: Results of association analysis, including ethnicity as a covariate: common and intermediate variation in KCNJ11 and BAD in Ketogenic diet overall 
responders and non-responders (summary KD response, n=216) 
Gene SNP rs number Unadjusted p-value Odds ratio [95%CI] 
P-value (100,000 
permutations) 
KCNJ11 
rs8175351 0.05897 6.327 [0.7137-56.09] 0.4623 
rs1800467 0.0901 2.06 [0.8865-4.788] 0.527 
rs5219 0.7765 0.9421 [0.6245-1.421] 1 
rs5218 0.4147 0.8375 [0.5475-1.281] 0.9803 
rs5216 0.3097 0.5361 [0.1585-1.814] 0.9537 
BAD 
rs34882006 0.1521 2.075 [0.7504-5.74] 0.6971 
rs2286615 0.1743 0.678 [0.388-1.185] 0.7334 
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Appendix 4.3 
Table 4.11: Top 10 most significant results for haplotype association analysis: variation in KCNJ11 and BAD in Ketogenic diet overall responders and non-responders 
(summary KD response, n=216) 
SNPs in haplotype Haplotype 
Frequency in 
non-responders 
Frequency in 
responders 
P-value 
rs41282930|rs8175351|rs1800467|rs5219|rs5218|rs5216
|rs5215|rs5214|rs75052600|rs59283629|rs34882006|rs2
286616 
CACGCCAACCGC 0.03006 0 0.01004 
rs41282930|rs8175351|rs1800467|rs5219|rs5218|rs5216
|rs5215|rs5214|rs75052600|rs59283629|rs34882006 
CACGCCAACCG 0.02992 0 0.01005 
rs41282930|rs8175351|rs1800467|rs5219|rs5218|rs5216
|rs5215|rs5214|rs75052600|rs59283629 
CACGCCAACC 0.02969 0 0.01027 
rs112070496|rs41282930|rs8175351|rs1800467|rs5219|r
s5218|rs5216|rs5215|rs5214|rs75052600|rs59283629|rs
34882006 
GCACGCCAACCG 0.03023 0 0.01034 
rs8175351|rs1800467|rs5219|rs5218|rs5216|rs5215|rs52
14|rs75052600|rs59283629|rs34882006|rs2286616 
ACGCCAACCGC 0.02975 0 0.01043 
rs8175351|rs1800467|rs5219|rs5218|rs5216|rs5215|rs52
14|rs75052600|rs59283629|rs34882006 
ACGCCAACCG 0.02961 0 0.01044 
rs112070496|rs41282930|rs8175351|rs1800467|rs5219|r
s5218|rs5216|rs5215|rs5214|rs75052600|rs59283629 
GCACGCCAACC 0.02999 0 0.01049 
rs8175351|rs1800467|rs5219|rs5218|rs5216|rs5215|rs52
14|rs75052600|rs59283629 
ACGCCAACC 0.0294 0 0.01065 
rs41282930|rs8175351|rs1800467 CGC 0.8894 0.955 0.01074 
rs112070496|rs41282930|rs8175351|rs1800467 GCGC 0.8894 0.955 0.01074 
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Appendix 5.1 
Table 5.2: Known regions of long-range linkage disequilibrium (identified by Price et al [687]) 
excluded from Identity-by-State calculations  
Chromosome Start position (NCBI build 37) End position (NCBI build 37) 
1 48287980 52287979 
2 86088342 101041482 
2 134666268 138166268 
2 183174494 190174494 
3 47524996 50024996 
3 83417310 86917310 
5 97972100 100472101 
5 128972101 131972101 
5 135472101 138472101 
6 25392021 33392022 
6 139958307 142458307 
8 7962590 11962591 
8 111930824 114930824 
11 87860352 90860352 
12 111037280 113537280 
20 32536339 35066586 
3 88917310 96017310 
5 44464243 50464243 
6 56892041 63942041 
7 55225791 66555850 
8 42880843 49837447 
10 36959994 43679994 
11 46043424 57243424 
12 33108733 41713733 
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